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Resumo 
 
O tratamento e decisão clínica no cancro de bexiga avançado permanecem críticos, 
principalmente devido à sua grande heterogeneidade molecular. Assim, urge identificar novos 
biomarcadores e criar novas ferramentas para estratificar com maior precisão o risco de 
progressão e o prognóstico. Adicionalmente, é importante criar um racional molecular que 
permita definir seletivamente as células estaminais tumorais de bexiga, que fenotipicamente 
se caracterizam pela grande agressividade, quimioresistência e indução de disseminação da 
doença. 
Este trabalho descreve a sobre-expressão de O-glicanos sialilados de cadeia curta 
(sialil-Tn e (di)sialil-T), em tumores avançados de bexiga, em comparação com os seus 
homólogos neutros (Tn e T). O antigénio sialil-Tn (STn) foi o mais relevante sob o ponto de 
vista da sua associação com mau prognóstico em tumores de bexiga musculo-invasivos e não 
musculo-invasivos. Além disso, a sua ausência ou expressão marginal no uretélio saudável 
confirma a sua natureza cancro-específica. Cumulativamente, o antigénio STn foi encontrado 
em tumores quimioresistentes e caracterizados pela expressão de marcadores estaminais. A 
possível associação entre a expressão de STn, fenótipos estaminais e quimioresistência foi 
ainda reforçada através de estudos in vitro utilizando modelos celulares representativos das 
diferentes vias de carcinogénese da bexiga (linha celular de cancro de bexiga T24, 
FGFR3/CCND1; linha celular de cancro de bexiga HT1376, E2F3/RB1). De modo 
concordante, o antigénio STn foi encontrado em lesões basais, fenotipicamente caracterizadas 
pela sobre-expressão de KRT14 e/ou KRT5 em comparação com a KRT20, descritas como 
sendo maioritariamente compostas por células estaminais quimioresistentes. A presença de 
células STn-positivas em lesões luminais (KRT14
-
 e/ou KRT5
-
 e KRT20
+
) menos agressivas 
também foi associada com pior sobrevivência dos doentes. Estes dados foram posteriormente 
utilizados para melhorar a capacidade preditiva de um modelo de estratificação baseado na 
expressão de citoqueratinas em cancro de bexiga. Verificou-se ainda que o antigénio STn 
estava presente nas metástases de tumores de bexiga, sugerindo um papel na dessiminação da 
doença. Assim, explorou-se a expressão de STn em células tumorais circulantes (CTC) 
através de uma plataforma de microfluídica, tendo-se demonstrado uma elevada frequência 
de CTCs de bexiga a expressar este antigénio com características basais, à semelhança dos 
tumores primários e metástases. Estes dados suportam que a expressão de STn nas células 
tumorais de bexiga poderá possuir um papel na disseminação da doença e no estabelecimento 
xii 
 
de metástases. Com base nestas observações, desenvolveu-se um dispositivo de microfluídica 
com afinidade para glicanos para capturar seletivamente STn
+
CTC, tendo em vista a sua 
aplicação num contexto de medicina de precisão. 
Em conclusão, este trabalho demonstra uma relação entre a expressão de STn, mau 
prognóstico e fenótipos estaminais, caracterizados pela resistência à quimioterapia e, 
potencialmente, pela capacidade de regenerar a heterogeneidade tumoral. Além disso, a 
natureza disseminada das STn
+
CTC e a sua prevalência nas metástases suporta o seu papel na 
propagação da doença, o que exige confirmação futura. O racional clínico está agora 
estabelecido para explorar o glicoproteoma associado ao STn, tendo em vista desenvolver 
ligandos novos e mais específicos para cancro de bexiga, com intuito terapêutico. O STn é 
apresentado como um biomarcador de CTC que deve suscitar interesse da comunidade 
médica e científica com o propósito de melhorar a abordagem dos indivíduos com doença 
avançada. 
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Abstract 
 Advanced bladder cancer management remains critical, due to its high molecular 
heterogeneity. Therefore, it is urgent to identify novel biomarkers and molecular tools to 
stratify patients facing worst prognosis and at higher risk of rapid disease progression. 
Moreover, it is important to generate the molecular rationale for targeting bladder cancer 
stem-cells, phenotypically characterized by aggressiveness, chemoresistance and involvement 
in dissemination of disease.  
Here, we observed that advanced bladder tumours overexpress sialylated short-chain 
O-glycans (sialyl-Tn and (di)sialyl-T) in comparison to their neutral counterparts (Tn and T 
antigens). The sialyl-Tn (STn) antigen was the most relevant in terms of association with 
poor prognosis in both non-muscle and muscle invasive bladder tumours. Noteworthy, STn 
was not detected in healthy urothelium, demonstrating its cancer-specific nature. In addition, 
this antigen was found in chemoresistant tumours enriched for a panel of epithelial-to-
mesenchymal transistion and stem-cell markers. A possible association between STn, stem-
cell molecular phenotypes and chemoresistance was further reinforced using in vitro studies 
in cell models representative of different invasion pathways (T24 bladder cancer cell line, 
FGFR3/CCND1 pathway; HT1376 bladder cancer cell line, E2F3/RB1 pathway). Likewise, 
the STn antigen was found in basal-like lesions, phenotypically characterized by the 
overexpression of KRT14 and/or KRT5 in relation to KRT20, which have been described as 
enriched for chemoresistant cancer stem cells. Nevertheless, the presence of STn-positive 
cancer cells subpopulations has also been associated with worst survival of patients 
exhibiting less aggressive luminal lesions (KRT14
-
 and/or KRT5
-
 and KRT20
+
 phenotype). 
Such findings were subsequently used to improve on the prognostication capacity of this 
KRT-based stratification model for bladder cancer. Finally, we have explored STn expression 
using microfluidic-isolated circulating tumour cells (CTC). Accordingly, it was demonstrated 
that the majority of bladder cancer CTC express the STn antigen and possess a basal-like 
character, mimicrying the primary tumour and metastasis. These findings support STn-
expressing bladder cancer cells may have a key role in disease dissemination and metastases 
development. Based on these observations, we have specifically developed a glycan-affinity 
microfluidics device to target STn
+
CTC, envisaging precision medicine applications.  
In conclusion, this work presents a more definitive clinical link between STn 
expression, poor prognosis and stem-cell phenotypes, characterized by resistance to 
chemotherapy and capability of regenerating tumour heterogeneity. Moreover, the 
widespread nature of STn
+
CTC and its prevalence in the corresponding metastasis supports a 
xv 
 
role in disease dissemination, warranting future confirmation. The clinical rationale is now 
set to comprehensively address the STn-glycoproteome envisaging novel and highly specific 
bladder cancer ligands for novel therapeutics. STn is presented as a relevant CTC biomarker 
that should be carefully exploited envisaging to improve the management of advanced stage 
patients. 
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Introduction 
 
1. Bladder cancer epidemiology 
 
Bladder cancer (BC) is the ninth most common cancer worldwide, being in the top fifteen 
causes of death(1). Bladder cancer incidence increases with age, reaching a peak between 60 and 70 
years, and is three-to-four times more common in men than in woman(2). Factors involved in 
urothelial carcinogenesis may contribute to explain these demographic trends, including disparate 
activity of sex steroid hormone pathways, different metabolism of carcinogens by hepatic enzymes, 
resulting in differential exposure of the urothelium to carcinogens, gender- associated differences in 
exposures to risk factors, and delay of diagnosis in woman compared to men(2). 
Environmental risk factors play a key role in BC initiation. In western world, cigarette smoking 
is the most relevant hazard factor, accounting for approximately 50% of BC cases and tripling BC risk 
compared to non-smokers(3). Occupational exposure to chemical compounds, e.g. aromatic amines, 
aniline dyes, nitrites, nitrates, acrolein, coal and arsenic, as well as chronic irritation, indwelling 
catheters, Schistosoma haematobium infection, and pelvic irradiation, have all been established as 
causal factors for BC(4-6). The inherited genetic background is also believed to play a role in BC 
carcinogenesis, particularly modulating the aptho physiological burden resulting from gene-
environmenta interactions, such as  the slow acetylator N-acetyltransferase 2(NAT2) genetic variant 
and glutathione S-transferase mu 1(GSTM1)–null genotypes(7). Somatic genetic alterations that 
associate with BC include mutations in oncogenes, such as TP63, the epidermal growth factor receptor 
(EGFR), and Ras p21 proteins, as well as in tumour suppressor genes TP53 and RB1(8). 
 
2. Bladder cancer pathophysiology, progression and management 
 
Bladder cancer has a complex and multifactorial etiopathogeny, where multiple steps are 
involved in the development of urothelial cell carcinomas. Particularly, BC cells and their surrounding 
partners (tumour microenvironment) undergo several genetic and molecular alterations in order to 
achieve a characteristic phenotype that resembles the “hallmarks of cancer”, which include sustaining 
proliferative signalling, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, reprogramming energy metabolism, evading immune destruction 
and activating invasion and metastasis(9). These alterations further affect downstream pathways 
through loss of cell cycle control, telomere dysfunction, genomic instability, and growth 
advantages(10). Low-grade non-muscle-invasive bladder cancer (NMIBC) and high-grade muscle-
Identification and Characterization of Glycobiomarkers in Bladder Cancer Stem Cells 
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invasive bladder cancer (MIBC) are two types of bladder cancers that are divided into different 
oncogenic pathways (Figure 1). Well-differentiated, non-invasive papillary urothelial cancers are 
derived from benign lesions through a process called urothelial hyperplasia, whereas poorly 
differentiated muscle-invasive cancers are derived from carcinoma in situ (Cis or Tis), urothelial 
dysplasia, or high-grade papillary bladder lesions. Although just a small fraction of superficial lesions 
progress to muscle invasive tumors, this process is highly dependent on genetic instability and 
accumulation of genetic alterations(11, 12) that correlate well to the clinicopathological phenotype(13, 
14). Moreover, the occurrence of NMIBC and MIBC may depend on their originating site and 
aberrations in specific signalling pathways. As such, NMIBC exhibits frequent mutations of FGFR3 
(75%)(15-17), and HRAS (30-40%)(18), affecting MAPK and PI3K pathways (PI3K3CA 25-48% (19-
21); PTEN 50% (22, 23); TSC1 50% (24)) in differentiated (uroplakin+ and KRT-20+) or intermediate 
(KRT-18+, p63+/−, cytokeratin-5+/−, and CD44+/−) urothelial cells, whereas MIBC exhibits 
mutations of the tumor suppressor genes p53 (>50%) (25, 26), Rb (25-30%)(27), and PTEN in basal 
cells (KRT-14+, KRT-5+/−, KRT-17+, CD44+/−, and p63+)(28-30). 
 
 
Figure 1. Schematic representation of bladder cancer stage and grade. The stage of the primary tumour 
(T) is based on the extent of invasion into the bladder wall. Regarding tumour grading, bladder lesions can 
be classified as urothelial papilloma (a benign lesion), papillary urothelial neoplasm of low malignant 
potential (PUNLMP), low-grade papillary urothelial carcinoma and high-grade papillary urothelial 
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carcinoma. Noteworthy, PUNLMP lesions do not have cytological features of malignancy and have a very 
low risk of progression, despite having a high tendency to recur. Tis, Tumour in situ: ‘‘flat tumour’’; Ta, 
Non-invasive papillary carcinoma; T1, Tumour invades sub-epithelial connective tissue; T2, Tumour 
invades muscle; T2a, Tumour invades superficial muscle (inner half); T2b, Tumour invades deep muscle 
(outer half); T3, Tumour invades perivesical tissue; T4, Tumour invades any of the following: prostate, 
uterus, vagina, pelvic or abdominal wall. The genes associated with urothelial dysplasia and CIS 
progression, as well as associated with invasive bladder tumors and metastasis are shown in the figure. 
 
Histologically, more than 90% of diagnosed bladder tumours are urothelial cell carcinomas, 
with the remaining 5-10% comprising mesenchymal neoplasms and epithelial tumors of other 
types(31). At the time of diagnosis, 70-80% are NMIBC, of which 50-70% will recur and 10-20% will 
progress to MIBC(32). Non-muscle invasive bladder tumour patients are endoscopically treated using 
complete transurethral resection (TUR) and adjuvant intravesical therapies, such as Mitomicin C 
(MMC) or Bacillus Calmette–Guérin (BCG) depending on disease severity (33). However, only two 
thirds of patients respond to BCG, with one third of the responders facing recurrent disease with poor 
prognosis(34). Particularly, high-grade NMIBC presents strikingly high recurrence and progression to 
muscle invasive disease(33); as such additional therapies are needed for BCG non-responders. 
Conversely, 25% of newly diagnosed patients have MIBC or metastatic disease are currently treated 
with radical cystectomy and cisplatin-based chemotherapeutic regimens(35), which still have a high 
rate of tumour relapse and disease progression. In patients with disease progression following 
chemotherapy, some promising second line options are now available such as systemic 
immunotherapy with checkpoint inhibitors like atezolizumab (a programmed cell death protein 1 
(PD1) inhibitor)(36, 37). Therefore, bladder cancer patients represent a significant management hurdle 
due to high recurrence rates, rapid progression, dissemination and poor response to chemotherapy, 
associated with a larger lag in the time-to-availability of novel targeted therapeutics in comparison 
with other solid tumours(38, 39). In addition, the high molecular heterogeneity of bladder tumours of 
apparently similar histology seems to be responsible for significant variations in disease course, 
inconsistency in therapeutic responses and prognostic uncertainty(40), thus urging for individualized 
disease management. Prognostication difficulties are often aggravated by the lack of efficient follow-
up strategies, especially of non-invasive nature, for early detection of imagiological occult 
micrometastasis, real-time monitoring of therapy response and metastatic risk assessment, which 
would enable timely and eventually life-saving interventions. Taken together, these insights ultimately 
suggest that improving bladder cancer survival will require earlier detection, more effective local 
control and new therapies for metastatic disease. 
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3. Tumor Heterogeneity and Cancer Stem Cells (CSCs)  
 
Advanced stage BC is a highly heterogeneous, recurrent metastatic disease, which results in 
poor prognosis(41). Despite the latest advances in diagnosis and therapeutics, both chemo and surgical, 
the survival rate of MIBC patients remains low at 5-year, current strategies often fail to prevent tumour 
relapse and/or progression. According to the CSC theory, the majority of bladder non-CSCs are 
eliminated in response to systemic chemotherapy, even though a small population of bladder CSCs 
(BCSCs) resists, ultimately resulting in tumor recapitulation and disease recurrence from BCSC 
clones.  
The recent establishement of novel molecular targets for BC (e.g. EGFR, FGFR, VEGFR, 
PI3K-Akt-mTOR, PD-1, COX-2, Aurora kinase A, and several miRNAs) with corresponding 
investigation of targeted therapies in clinical trials(42) has yielded only modest improvement in 
survival, thereby supporting a role for BCSCs, contributing to explain clinical observations such as 
tumor heterogeneity, chemoresistance, recurrence, and metastasis(43, 44). Thus, understanding CSCs’ 
role in BC will add significantly to our comprehension of recurrence and metastasis, and facilitate the 
development of novel therapeutic strategies. 
The origin of cancer stem cells remains controversial(45, 46); still, the bladder possesses many 
types of stem cells, such as urothelial stem cells, adipose-derived stem cells, bone marrow-derived 
mesenchymal stromal cells, mesenchymal stem cells, and urine-derived stem cells(47, 48). Bladder 
tumours may develop from some of these populations or from more differentiated progenitor cells as a 
result of random mutations, chromatin modifications, epigenetic reprogramming, and 
microenvironmental cues(49). Nevertheless, generation of BCSCs may also be a late event in 
tumorigenesis, after transformation of early BC cells into BCSCs through epithelial-to-mesenchymal 
transition (EMT), de-differentiation, tumour-associated cytokines, and cancer cell fusion (45, 50). In 
EMT, while tumour progresses cancer cell lose its epithelial features and acquire a mesenchymal 
phenotype (51). Moreover, during EMT cells gain the expression of stemness markers, and the ability 
to form spheres(52, 53). Further data concurring to BCSCs’ role, demonstrate that activation of 
hypoxia inducible factor (HIF) and transforming growth factor β (TGF-β) pathways, which contribute 
to EMT and self-renewal, are also activated in BC (54-57). As found in other tumours, the stemness of 
BCSCs might be regulated by cytokine networks(58). Noteworthy, circulating interleukin-6 (IL-6) 
levels are elevated in BC patients compared to healthy controls, and its downstream signalling 
pathway Jak2-Stat3 is upregulated in tumours, resulting in malignancy growth and aggressiveness(59, 
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60). Importantly, MIBC driven through Stat3 signaling was predominantly composed of stem cells, 
which were characterized by KRT14 positive staining and enhanced tumor sphere-forming ability; 
thereby confirming the Stat3-induced stem cell expansion model(61). Cyclooxygenase-2 (COX-2) is 
another protein overexpressed in BC compared to normal urothelium(62), and its major bioproduct, 
prostaglandins (PGs), has been reported to be involved in BC biology, including its role in 
inflammation and carcinogenesis(63). Nuclear COX-2 is significantly associated with the upregulation 
of the stemness markers Oct3/4 and CD44v6, suggesting that COX-2 activation might be involved in 
inflammation-mediated bladder CSC proliferation(64). Notably, a wide variety of stem cell markers is 
up-regulated in CSCs obtained from MIBC cell lines(65). Moreover, most BCSCs were identified in 
metastatic MIBC but not in NMIBC(66-71). 
Pathological dedifferentiation is observed in BC, especially in MIBC. Approximately 10% of 
BC contains glandular differentiation, and up to 60% contains squamous differentiation(72, 73). 
Moreover, rarely, BC cells can dedifferentiate into other aggressive and prognostically unfavourable 
variants, including sarcomatoid, lymphoepithelioma-like, and small cell carcinoma(74-77). 
Remarkably, the gene expression profile of MIBC reveals that squamous or sarcomatoid 
differentiation is enriched in the basal-type of MIBC, which displays a CSC phenotype(30, 75).  
Cancer cell fusion also promotes BC aggressiveness and stemness(78, 79), resulting in 
premature chromosome condensation (PCC)(80, 81), nuclear reprogramming(82) and CSC 
generation(83). This process requires fusogens such as the BCSC marker CD44(45, 84) to allow the 
fusion of tumour cells with stem cells, macrophages(85), or bone marrow-derived cells (BMDCs)(80, 
86). Several mechanisms of cancer cell fusion have been proposed, but oncogenic viruses are the most 
likely candidate(87). Human endogenous retroviruses (HERVs) may have oncogenic potential, and 
HERVW-1 is reportedly overexpressed in 75.6% of BC, whereas it is overexpressed in only 6.1% of 
matched non-cancer tissues(88). Interestingly, smoking increases HERV transcription in the 
urothelium(89). Apoptosis is another mechanism of cancer cell fusion, resulting in hybrids with an 
enhanced migratory capacity that may enable dissemination and metastasis (45). 
As previously described, recurrent BC is usually chemoresistant, even if initially apparently  
chemotherapy-sensitive(90). Besides unfavourable drug pharmacokinetics and abnormal tumor 
vasculature that result in suboptimal delivery of cytotoxic agents to the tumor (44, 91), emerging data 
supports a direct effect of BCSCs in chemoresistance(90-92). Actually, chemotherapy combined with 
stem cell-targeted therapy would be the ideal strategy for advanced stage BC patients. Therefore, it is 
important to identify BCSCs chemoresistance mechanisms and uncover ways to circumvent it. 
Hitherto, the mechanisms behind BCSCs chemoresistance reside in favourable alterations in drug 
transport and metabolism, enhanced DNA repair mechanisms, alterations in cell cycle regulation,  
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inhibition of apoptosis and regulation of cytokines and other immune mediators that decrease 
immunosurveillance (91). Studies have brought glycosylation into the spotlight by demonstrating that 
selective inhibition of N-glycosylation pathways may constitute an important therapeutic strategy to 
overcome cancer cells’ chemoresistance. Additional and novel findings now pinpoint that the influence 
of glycosylation might extend beyond these events, given its pivotal role in the activation of several 
oncogenic pathways that sustain chemoresistance (reviewed by JA Ferreira, Peixoto A, Neves M et al) 
(Annex A)(91). 
Increasing evidence suggests that a presumably small subset of cancer stem cells has the 
functional plasticity for transitioning between mesenchymal-like and epithelial-like states through 
EMT and cellular dedifferentiation; these cells are indeed a relevant source for metastasis at distant 
sites and are commonly termed circulating cancer stem-cells (CCSCs)(93, 94). As compared to non-
tumorigenic/metastatic bulk circulating tumour cells (CTCs), CCSCs may not only be capable of 
evading from primary tumor, but also escape from immune surveillance, survive in circulation and 
subsequently metastasize to distant organs(95). Thus, CCSCs seem to represent a subset of exclusively 
tumorigenic cancer stem cells characterized by their invasive characteristics. 
 
3.1. Bladder cancer stem cell (BCSC) markers  
 
Bladder cancer stem cells were identified in 2009 using normal stem cells surface markers (71). 
Since then, additional cell surface markers, such as CD44(71), CD44v6(64, 70), laminin receptor 
(67LR)(66), Aldehyde dehydrogenase 1 family, member A1 (ALDH1A1)(69), CD133(96, 97), 
CD47(71), CD49(98), and keratin 14 (KRT14)(99) have been used to isolate BCSCs. Cancer stem 
cells can also be sorted by Fluorescence Assisted Cell Sorting (FACS) based on their ability to 
efficiently efflux the DNA fluorescent dye Hoechst 33342 through ATP-binding cassette transporters, 
demonstrating enhanced colony formation, self-renewal and multi-directional differentiation, which 
are features typical of CSCs(67). The sequential transplantation of xenograft tumors is increasingly 
required for the confirmation of CSCs isolation(100-102). To rise isolation specificity, most of these 
markers are used with mutually exclusive indicators, such as cytokeratins (CD44+ KRT5+ 
KRT20−)(71). Importantly, a molecular model has been recently proposed to improve patient 
stratification and prognosis based on the sub-classification of bladder tumours as luminal or basal-
like(75, 99, 103). Accordingly, well differentiated and prognostically favourable luminal tumours 
(KRT14- , KRT5- and KRT20+) were distinct from basal-like lesions (KRT14+ or KRT5+, or both 
and KRT20-), characterized by reduced survival and higher chemoresistance(75, 99, 103). Albeit only 
50% of MIBC could be subtyped through this approach, it may provide the premise for molecular-
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based clinical decision. The introduction of novel biomarkers capable of further refining patient 
stratification seems now warranted. Exploring cancer-associated glycans, which are often of oncofetal 
nature, presents a unique and highly specific opportunity to target CSCs. In fact, several studies 
reported alterations in the glycopatterns of CSC of tissue from different origins compared to other 
cancer cells. Many of these findings are related with the overexpression of glycans commonly found in 
glycolipids (CD60a, CD77, GD2, Gb4) and proteins (CD147 or Le
y
, CD15 or Le
x
)(104). More 
recently, data confirmed that CSC resistant to gemcitabine(105) and doxorubicin(106) present distinct 
glycosylation patterns when compared to drug sensitive parental cell lines. Terao et al. described that 
CSC derived from the gemcitabine chemoresistant pancreatic cancer cell line Panc1 display significant 
overfucosylation and upregulation of fucosyltransferases, GDP-fucose synthetic enzymes, and GDP-
fucose transporters(105). However, knockdown of GDP-fucose transporters did not improve 
gemcitabine response, suggesting that overfucosylation is a result of CSC transformation with little 
influence on chemoresistance. Moreover, increased fucosylation has been associated with invasive and 
metastatic properties of cancer cells(107). A recent study by Desiderio et al. investigated the role of 
fucosylation in cancer stem cells and found that inhibition of fucosylation affected sphere formation 
and invasion ability of cancer stem cells (108), whereas in another report, inhibition of fucosylation 
was found to affect E-selectin binding and cell extravasation(109), all crucial features for the 
metastatic process(110). Thus, fucosylation may be a novel mechanism exploited by cancer stem cells 
to acquire invasive and metastatic features in order to generate metastatic cancer stem cells, although 
simultaneously amendable for therapeutic intervention. Conversely, Azuma et al. explored the 
oversialylation of doxorubicin-resistant hepatocellular CSC and identified highly specific glycoprotein 
species(106). Taken together, these findings contributed to underline the need for an in-depth glycome 
and glycoproteome assessment of CSC populations towards the development of more specific 
biomarkers. 
 
4. Protein glycosylation in bladder cancer 
It has long been known that advanced stage bladder tumours present severe dysregulations in 
glycosylation pathways, translated by the loss of terminal ABO (H) blood group determinants at the 
cell-surface of ABH secretor individuals(111), over- and/or de novo expression of short-chain O-
GalNAc glycans(112), Lewis blood group related antigens, and their sialylated counterparts(113, 114), 
as well as oversialylation and fucosylation of glycan chains(115) (Figure 2). Gycosylation patterns 
dynamically change with the course of disease (a nossa revisão do oncotarget)as a result of: i) altered 
glycogenes expression(116, 117); ii) impaired glycosyltransferases’ chaperone function(118); iii) 
altered glycosidase/glycosyltransferase activity(117); iv) reorganization of glycosyltransferases 
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topology(119, 120); v) bioavailability of sugar nucleotide donors and cofactors(121); and vi) 
alterations on the conformation of peptide backbone or on the nascent glycan chain structure(121). The 
resultant aberrant and cancer-associated glycans seem to be implicated in the activation of oncogenic 
pathways(121), establishment of tumour-tolerogenic immune responses(122), and in epithelial-to-
mesenchymal transition (EMT), towards invasion and metastasis(123, 124). Thus, many 
glycoepitopes, and their related glycosidases/glycosyltransferases, can be considered relevant tumour-
associated antigens(125, 126), with possible clinical significance in bladder cancer. Those found at the 
cell surface are easily accessible to antibodies and lectins to selectively target specific tumour cells, 
while those secreted or shed into bodily fluids can be explored for non-invasive cancer detection 
through serological assays. As such, cancer-specific alterations in protein glycosylation might provide 
a unique opportunity for clinical intervention. Accordingly, the majority of glycobiology studies in 
bladder cancer describe alterations in terminal stuctures shared by both N-glycans (in Asn residues of a 
glycoprotein chain) and O-glycans (in Ser and/Thr residues) of membrane and secreted glycoproteins 
as well as glycolipids, mostly based in immunohistochemistry results(127). Other commonly reported 
alterations are related with the overexpression of short-chain O-glycan chains(127). Noteworthy, very 
few studies have undergone a comprehensive mass spectrometry-based glycomic characterization of 
bladder tumours(127). 
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Figure 2. The figure represents specific N-linked and O-linked glycan structures, as well as terminal 
Lewis and sialylated Lewis structures that have biological significance in bladder cancer. Key enzymes 
mediating the addition of specific sugars are also shown. Protein N-glycan alterations include the β1-6 
branching of N-glycans in result of GlcNAcT-V (GnT-V) overexpression, and the addition of bisecting GlcNAc 
branches by GlcNAcT-III (GnT-III) glycosyltransferases. Alterations in O-glycosylation pathways are also a 
common hallmark of malignant transformations of the bladder. Herein, we represent the overexpression of 
simple mucin-type O-glycans and their sialylated counterparts, T, sialyl T (ST), Tn and sialyl Tn (STn) 
antigens. Altered expression of terminal structures is also a common feature of bladder tumours. Namely, the 
abnormally low or absent expression of ABO(H) blood group determinants are frequently found in high grade 
and invasive disease. Carbohydrate terminal Lewis antigens are significantly under-expressed in healthy 
urothelium when compared to bladder tumours and are also highlighted here. Lewis type 1 antigens includes 
Lewis a (Le
a
), and sialyl Lewis a (SLe
a
), while the type 2 group includes Lewis x (Le
x
) and sialyl Lewis x (Sle
x
). 
 
Alterations in N- and O-glycans terminal structures 
The loss of ABO(H) blood group determinants in secretor individuals and the overexpression 
or expression de-novo of Lewis (Le) blood group related antigens are amongst the most common 
alterations in terminal epitopes of N- and O-glycans in glycoproteins and glycolipids in bladder cancer. 
Particularly, ABO(H) blood group antigens are present on normal bladder urothelium but not on some 
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low grade and early stage urothelial carcinomas(128), with its loss being associated with higher grade 
and recurrent bladder cancer(129-131). Moreover, the absence of ABO(H) antigens in the initial 
biopsy of bladder carcinomas is predictive of increasing chance of subsequent invasion compared to 
tumours in which these antigens are detectable(132). However, a significant number of patients whose 
initial tumours were reported as blood group antigen negative failed to develop an invasive 
tumour(132). These conflicting results may, at least in part, be explained by differences in 
methodology, interpretation, or both. Furthermore, the loss of activity of the A and B gene-encoded 
transferases(128), ABO(H) gene, and/or its promoter hypermethylation(133) have been proposed to 
drive the deletion of these antigens in bladder tumours. 
The A, B, H antigens have biosynthetic and structural similarities with the Lewis antigens, 
including the type 1 lewis a (Le
a
) and type 2 Lewis
x
 (Le
x
) antigens and their sialylated counterparts 
sialyl-lewis a (SLe
a
) and sialyl-lewis x (SLe
x
). Several authors associated patterns of Le
a
 expression 
with malignant transformations, reporting significantly lower expression of this antigen in healthy 
urothelium and non-invasive tumours compared to invasive tumours(134). As such, the expression of 
Le
a
 may be associated with worse bladder cancer phenotypes. Moreover, Le
a
 antigen expression 
patterns change at an early neoplastic stage, suggesting that Le
a
 determination might be useful in the 
diagnosis of very early premalignant changes in the urothelium(134). In addition, the employment of 
Le
a
 staining scores allows the sub-classification of histologically identical tumours into prognostically 
different groups, pointing to a relationship between the pathological grade and stage of the evaluated 
tumours and a morphological and functional dedifferentiation(134). Given this, Le
a
 antigen is a 
valuable functional marker of the malignant potential in superficial bladder cancer. In turn, the Le
x
 
antigen is not expressed in normal urothelium, except for occasional umbrella cells, but it is 
demonstrated in most invasive tumours, regardless of blood type and secretor status of the individuals 
studied(135). Overall, despite the few reports on Le antigens expression in BC, most studies point to 
an association with malignant potential of cancer cells towards more invasive phenotypes(135, 136). 
Oversialylation of Le antigens originates selectin ligands SLe
a
 and SLe
x
 Both terminal epitopes present 
high affinity for E- and P-selectin, mediating cancer cells adhesion to endothelium and subsequent 
extravasation into the blood stream, thereby favouring the metastatic process in several 
malignancies(115, 137, 138), including bladder cancer(136). Besides metastasis, these glycans have 
been shown to mediate tumour growth, invasion and angiogenesis in BC(113, 139) and numerous 
other tumour types(140-142). Specifically, it has been demonstrated that loss/reduction of SLe
a
 
expression is associated with higher atypia grade(136), while SLe
x
 has been closely linked to invasive 
and metastatic potential of primary bladder tumours(113). Nonetheless, another study demonstrated no 
associations between SLe
x
, grade or stage in urothelial carcinoma of the renal pelvis, ureter, and 
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urinary bladder(136). Notwithstanding, the overall overexpression of sialoglycans (SLe
a/x
) correlates 
with tumor aggressiveness, capacity to invade surrounding tissue and metastasis, and the EMT process 
is characterized by the overexpression of these sialoglycans due to ST3Gal-I, -III, and -IV expression 
(143). This indicates that the upregulation of sialyltransferases and subsequent expression of 
sialoglycans during EMT represents an important step underlying the migratory phenotype of 
metastasizing cancer cells. Moreover, downregulation of the lysosomal sialidases NEU1 and NEU4 
favours tumor metastasis through enhanced signalling of the laminin receptor β4-integrin(144), and 
reduced hydrolysis of SLe
x 
antigens(145). Moreover, the overall increase in cell-surface sialic acid 
content was shown to reduce the attachment of metastatic tumour cells to the extracellular matrix, 
possibly protecting them from recognition by the alternative pathway of complement activation, 
favouring metastatic spread(146). Nevertheless, these processes need to be explored in the context of 
BC in order to understand the contribution of sialyltransferases and sialidases in cancer cell 
aggressiveness and ability to metastasize. 
Sulfation has also been found as an important mediator of SLe epitopes functional and clinical 
role. Namely, sialyl-6-sulfo Lewis
x
, is preferentially expressed in normal epithelial cells compared to 
cancer cells(147). Essentially all genes involved in the synthesis of SLe
x
 are predicted to be the same 
as those governing the synthesis of sialyl-6-sulfo Lewis
x
, except for the genes engaged in its sulfation. 
This finding supports the hypothesis that reduced expression of sialyl-6-sulfo Lewis
x
 induces SLe
x
 
expression in cancers(148). Sialyl-6-sulfo Lewis
x
 antigen is expressed in bladder urothelial 
carcinomas, promoting its progression through E-selectin-mediated tumour cell adhesion to vascular 
endothelial cells, which is potentially associated with metastasis, while aiding lymphocyte recruitment 
to enhance anti-tumour immune responses(149).  
The O-6 sialylation of LeA originating disialyl-LeA also provides means to distinguish non-
malignant cells from malignant urothelium, and is useful as a marker for tissue injuries occurring in 
benign diseases(150, 151). It has been suggested that the α-2-6 sialylation of the GlcNAc moiety is 
impaired in cancer cells compared to non-malignant. Moreover, this event has been associated with the 
epigenetic silencing of the ST6GalNAcIV gene, responsible for the α2-6 sialylation of the βGlcNAc 
moiety in cancer cells(150). 
 
Alterations in O-GalNAc glycans  
Significant amount of evidences support that bladder cancer progression and dissemination is 
also accompanied by profound remodelling of O-GalNAc glycans(127). This type of glycosylation 
inititates with the transfer of a GalNAc residue from UDP-GalNAc to either serine or threonine in a 
polypeptide chain, originating the monosaccharide Tn antigen. This reaction is catalysed by several 
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UDP-GalNAc:polypeptide N-acetylgalactosaminyl transferases (ppGalNAc-Ts) in the ER, in a 
substrate dependent manner (152). Further extension originates the T antigen (Gal-β1-3GalNAc-α1-
Ser/Thr), catalysed by C1Gal-T1 and its molecular chaperone Cosmc(153). Both Tn and T antigens 
can be sialylated, giving rise to sialyl-Tn (STn), sialyl-T (ST) and disialyl-T antigens (dST), which 
generally stops further O-glycosylation extension (Figure 3). Alternatively, the Tn antigen can be the 
precursor of more extended glycans (cores 2-4), which may be further extended and present terminal 
structures similar to those found in N-glycans and glycolipids despicted in the previous section (Figure 
1, Chapter 1).  
 
 
Figure 3: Schematic representation of short-chained O-linked glycan structures. The addition of specific 
sugar monomers to Ser/Thr residues of a protein backbone begins with the action of polypeptide 
N-acetylgalactosamine transferases (ppGalNAc-Ts; a family of 20 enzymes, including GalNAc-T1, 
GalNAc-T2, GalNAc-T3, GalNAc-T4, GalNAc-T5 and GalNAc-T6) given rise to the Tn antigen, which is 
generally extended with a Gal residue by C1Gal-T1, originating the Thomsen-Friedenreich or T antigen (core 
1). Alternatively, Tn and T antigens can be sialylated by α2,3-sialyltransferases (ST3Gal-Ts) and α-GalNAc 
ST6Gal-I (ST6GalNAc-I), forming the sialyl-Tn (STn), and sialyl-T antigens. On the other hand, core 1 may be 
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extended originating cores 2-4 by the action of N-acetylglucosamine (GlcNAc) transferases (GnTs; such as 
GnT-III, GnT-V, core 2 GnTs (C2GnTs) and β3GnT). 
 
Main structural alterations in O-GalNAc glycans include glycan chains shortening and 
oversialylation. The simplest O-GalNAc glycoforms, including the Tn and T antigens and its sialylated 
counterparts, are absent or marginally expressed in healthy urothelium, and their overexpression is 
strictly associated with higher bladder tumour stage and poor prognosis, making them ideal 
theragnostic targets in bladder cancer management (more extensive reading in Azevedo R and Peixoto 
A et al, 2017), annex B(127, 154). Several reports associated the presence of Tn and T antigens with 
recurrence and metastization in BC, suggesting that these antigens may be surrogate markers of 
profound cellular alterations(155-157). Furthermore, there are growing evidences linking the 
overexpression of the sialyl-T antigen and ST3Gal.I, the enzyme responsible by T antigen sialylation, 
with BC aggressiveness, recurrence, poor prognosis, and tumour grade(155, 158). Moreover, the 
expression of T antigen is significantly associated with higher risk for subsequent recurrences with 
deep muscle invasion and metastatic involvement of regional lymph nodes(155). In addition, there is a 
predominance of truncated sialoglycans over neutral glycoforms (Tn and T antigens) in advanced stage 
bladder tumors(159). In particular, the overexpression of ST6GalNAc-I has been found to promote the 
premature sialylation of the Tn antigen and consequent formation of the STn antigen in bladder 
cancer(160). Specifically, the STn antigen is absent in the healthy urothelium, while present in more 
than 70% of high-grade NMIBC and MIBC, denoting a cancer specific nature(160). This 
posttranslational modification of cell surface proteins is mostly expressed in non-proliferative tumour 
areas, known for their high resistance to cytostatic agents currently used to improve the overall 
survival of advanced stage BC patients(160). Recently, a novel STn-dependent mechanism for 
chemotherapeutic resistance of gastric cancer cells to cisplatin has been described, in which STn 
protects cancer cells against chemotherapeutic-induced cell death by decreasing the interaction of cell 
surface glycan receptors with galectin-3 and increasing its intracellular accumulation(161). The 
relationship between chemoresistance and STn overexpression remains to be fully explored in bladder 
cancer. Furthermore, STn expression is significantly higher in MIBC when compared to NMIBC, 
denoting its association with muscle invasion and poor prognosis(160). Furthermore, STn-expressing 
BC cells have shown the ability to induce a tolerogenic microenvironment by impairing dendritic cells 
maturation, allowing cancer cells to evade innate and adaptive immune system responses(162). 
Interestingly, the tolerogenic effect of short-chained O-glycans has also been correlated with bladder 
tumor metastasis through a mechanism in which MUC1 carrying core 2 O-glycans functions as a 
molecular shield against NK cells attack, thereby promoting metastization(163). In addition, STn 
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expression in BC tissues has been used in combination with other surrogate markers of tumour 
aggressiveness envisaging patient stratification regarding disease stage and therapeutic benefit. 
Specifically, STn and sialyl-6-T (s6T), an STn-related antigen, expression are independent predictive 
markers of BCG treatment response and were found useful in the identification of patients who could 
benefit more from this immunotherapy(164). 
In agreement with their vital role in many physiologic processes, several reports imply that 
aberrant expression of sialic acids confers major advantages to tumor cells, such as inhibition of 
apoptosis(165) and anoikis(166), as well as resistance to chemotherapy(167, 168), including cisplatin-
based schemes(161, 169). Overexpression and/or altered activity of sialyltransferases is a major 
mechanism underlying modifications in the sialome of cancer cells, partially due to the impact in 
proto-oncogenes overexpression (e.g. Ras and c-Myc) (143, 170), hypoxia(91, 171) and high hormone 
levels(172). Alternatively, increased substrate availability or overexpression of genes involved in sialic 
acid biosynthesis also contribute to hypersialylation in tumour cells, mostly in glycoproteins associated 
with extracellular matrix interactions and cell migration(173). Finally, downregulation of endogenous 
sialidases (NEU1, 2, and 4) can also lead to accumulation of sialoglycans in tumour cells(174). 
Although the molecular mechanisms responsible for the sialome modulation are starting to be 
unravelled, there is a lack of clarification of these processes in bladder cancer. Also, urges to elucidate 
if the hypersialylation of glycoproteins alters their intrinsic function, thereby contributing to 
tumorigenesis, or if overexpression of sialoglycans is a bystander consequence of malignant 
transformation. Moreover, the selective blocking of aberrant sialylation has antagonized tumor growth 
and metastasis formation by using sialyltransferase inhibitors(175, 176), advocating for the application 
of these inhibitors in preclinical models for cancer therapy development. Furthermore, these truncated 
structures are observed in heavily O-glycosylated proteins relevant in BC, such as CD44, β1-integrin, 
and mucins(91, 159, 177, 178). Importantly, and similarly to other malignancies, BC patients serum O-
glycomics has uncovered that both ST and dST antigens are significantly increased in whole serum 
glycoproteins compared to controls, suggesting its probable non-invasive biomarker potential(179). 
Nevertheless, larger-scale glycomics studies are needed to confirm whether the detected glycoform 
changes are directly reflected from those in BC cells/tissue or are derived from other homeostatic 
alterations affecting glycoprotein metabolism during tumor proliferation. However, despite promising 
results, glycans failed implementation in clinical practice for BC non-invasive detection, mostly due to 
small patient cohorts, biased patient series, variations in detection and processing methods, lack of 
endpoint standardization and use of samples from different origins. As such, future studies should 
consider comprehensive functional glycomics approaches where glycans are incorporated in broader 
biomarker panels, envisaging highly sensitive detection methods. Moreover, current data will foster 
Identification and Characterization of Glycobiomarkers in Bladder Cancer Stem Cells 
17 
 
glycobiomarkers validation in larger patient series, reinforcing their potential as novel therapeutic 
targets for BC therapy. 
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Aims and study outline 
 
This work was grounded on previous knowledge about bladder cancer glycobiology and sought 
to expand on the potential of the cancer-associated O-GalNAc glycan sialyl-Tn (STn) as biomarker, in 
the context of advanced stage BC and response to chemotherapy. Additionally, it was designed to 
identify putative targets and scheming highly specific targeted therapeutics against bladder cancer stem 
cells. 
 
This work comprehends the following specific aims: 
 
i) Define the role of the STn antigen in the prognostication of muscle-invasive bladder 
cancer; 
ii) Define the role of the STn antigen as a chemoresistant and stem-like cell biomarker; 
iii) Include STn expression in a recently proposed molecular model for bladder cancer 
prognostication based on the degree of tumour differentiation, towards precision medicine 
settings; 
iv) Explore STn expression in CTCs; 
v) Development of a target-directed microfluidics device for the isolation STn+CTC. 
 
Preliminary observations from our group supported the hypothesis that STn expression may play 
a key role in disease outcome, thereby fostering current investigation. In addition, solid tumours often 
express the T antigen and its sialylated form ST, whose overexpression has been associated with poor 
prognosis. However, the ST antigen comprises a heterogeneous group of mono- (sialyl-6-T: S6T; 
sialyl-3-T: S3T) and disialylated glycoforms that remained to be individually evaluated in cancer.  
Building on these insights, chapter 1 addresses the first specific aim of this work. Accordingly, 
bladder tumours were screened for the above-mentioned cancer associated glycans and special 
emphasis was given to STn, which was shown to be a key cancer-associated antigen highly linked with 
advanced disease and poor prognosis in bladder cancer. 
Chapter 2 addresses the second specific aim of this project. Hence, two MIBC cell lines (T24 and 
HT1376) were exposed to an IC50 dosage of cisplatin and evaluated according to the expression of 
STn and CD44, a typical BCSC-associated glycoprotein usually related with drug resistant phenotypes 
and poor prognosis. Both, chemotherapy-challenged cell lines and muscle-invasive bladder tumours, 
were submitted to transcript quantification of a gene panel reflecting stem, mesenchymal, epithelial-to-
mesenchymal (EMT), and epithelial markers, as well as cytokeratins (KRT) to assess cellular 
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differentiation states. Overall, data suggested that chemotherapy acts a selective pressure, creating 
tumour niches composed of undifferentiated stem-like cells characterized by the expression of CD44-
STn
+
 glycoforms. Moreover, results reinforce that STn is a biomarker of aggressiveness and resistance 
to chemotherapy in bladder tumours. 
Chapter 3 addresses the third and fourth specific objectives. Therefore, a retrospective series of 
80 muscle-invasive primary bladder tumors and associated metastasis were screened for KRT14, 5, and 
20 as well as STn by real-time polymerase chain reaction and immunohistochemistry. Concomitantly, 
peripheral blood was collected from a subset of patients and CTCs isolated through a size-based 
microfluidic chip and screened for KRTs and STn expression. Notably, basal-like lesions presented 
worse cancer-specific and disease-free survival compared to luminal tumor, and inclusion of STn 
discriminated patients with worst survival in each subgroup (P= 0.047 for luminal; P= 0.027 for basal-
like tumors). In addition, STn expression in CTCs and distant metastasis was also demonstrated. 
Overall, this chapter reinforces the potential of the KRT-based model for bladder cancer management 
and the association of STn with aggressiveness. Likewise, it was described for the first time that CTCs 
and the metastasis present a basal phenotype and express the STn antigen.  
Chapter 4 addresses the last specific aim of this work. As such, the overexpression of the cell-
surface STn antigen in advanced bladder and colorectal tumours, but not in blood cells, was explored 
to propose a novel CTC isolation technology. Using a size-based microfluidic device, it was shown 
that the majority of CTC (>90%) isolated from the blood of metastasized bladder and colorectal 
cancers expressed the STn antigen, reinforcing its pan-carcinoma link with metastization. More 
importantly, STn
+
CTC counts were significantly higher compared to EpCAM-based detection in 
colorectal cancer, providing a novel and more efficient cell-surface biomarker for CTC isolation. 
Exploring this concept, a glycan affinity-based microfluidic device was built for selective isolation of 
STn
+
CTC and an enzymatic-based strategy for the recovery of viable cancer cells for downstream 
biomedical research was proposed. Here, clinically relevant cancer biomarkers (transcripts and 
mutations) in bladder and colorectal tumours were identified in microfluidic-isolated cells, confirming 
their malignant origin and highlighting the potential of this technology in the context of precision 
oncology. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 | Sialyl-Tn as a biomarker of 
bladder cancer aggressive phenotypes    
 
Part of the data presented in this chapter has been published in Molecular Oncology (2017; 
Annex C) and Plos One (2015, annex D) 
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Sialyl-Tn as a biomarker of bladder cancer aggressiveness phenotypes 
 
1. Abstract 
 
Advanced stage bladder cancer (BC) is the second deadliest genitourinary cancer, being 
accompanied by profound deregulations on cell surface protein glycosylation.  Envisaging the 
discovery of novel prognosis biomarkers and therapeutic targets, two series of bladder tumours with 
variable clinicopathological features was screened by immunohistochemistry to uncover cancer-
associated short-chain O-glycans, which included the Tn and T antigens, as well as their sialylated 
counterparts sialyl-Tn (STn) and sialyl-T(ST). T antigen sialylation was also explored using enzymatic 
treatments. Overall, a predominance of sialoglycans over neutral glycoforms was observed, with the 
STn antigen being associated with high-grade disease and muscle invasion, in accordance with our 
previous observations. Moreover, both S3T and S6T antigens were detected for the first time in 
bladder tumours, but not in healthy urothelium, highlighting their cancer-specific nature. Using a 
dataset composed by 47 NMIBC and 49 MIBC patients, the impact of STn on cancer-specific survival 
(CSS) was assessed. Of note, STn was an independent prognostic marker for CSS in bladder cancer 
patients, irrespective of tumour stage. In summary, it was demonstrated that STn is a biomarker for 
aggressive BC disease, associated with poorer prognosis.  
 
2. Introduction 
 
Bladder cancer is the fifth most common cancer in Western society, and the second most 
deadly genitourinary tumour(1). Approximately 20–30% of the newly diagnosed cases are muscle 
invasive (MIBC; T2-T4 stage), while 50% are non-muscle invasive bladder tumours (NMIBC) with 
high potential to progress and invade. MIBC treatment includes cystectomy and (neo)adjuvant 
cisplatin-based chemotherapy regimens, which often fail to avoid tumour relapse and disease 
dissemination, urging the introduction of predictive biomarkers and novel therapeutics(2-4). However, 
significant variations in the natural disease course and treatment responses can be observed in 
apparently identical tumours, reflecting its high molecular heterogeneity (5, 6). Noteworthy, 
approximately 50% of cases develop distant metastatic disease within 5 years, urging the identification 
of biomarkers to assist prognostication and the development of more effective targeted therapeutics(7). 
Malignant transformation is often accompanied by profound changes in glycosylation patterns, 
which play key roles in tumour progression and dissemination(8, 9). Moreover, alterations in 
glycosylation often produce protein glycoforms holding potential for targeted therapy(4, 10). In this 
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context, it has been long known that advanced stage bladder tumours present severe dysregulations in 
glycosylation pathways, translated by the loss of terminal ABO (H) blood group determinants at the 
cell-surface of ABH secretor individuals(11, 12), over- and/or de novo expression of short-chain O-
GalNAc glycans(13), Lewis blood group related antigens, and their sialylated counterparts(14, 15), as 
well as oversialylation and fucosylation of glycan chains(16). Special emphasis has been given to the 
overexpression of short-chain O-GalNAc glycans, which alter cellular adhesive properties while 
promoting invasion, metastasis, angiogenesis, and immune scape, often through oncogenic pathways 
signalling activation(17-19). Moreover, it has been previously demonstrated that, unlike healthy 
urothelium and superficial tumours, 70% of advanced-stage bladder tumours express the cancer-
associated carbohydrate antigen sialyl-Tn(19), whose expression favours cell invasion, motility, and 
immune tolerance(18-20). These observations support the hypothesis that STn expression may play a 
key role in disease outcome, therebywarranting further investigation. In agreement, also solid tumours 
often express the T antigen and its sialylated form ST, whose overexpression has been associated with 
poor prognosis(21, 22). However, the ST antigen comprises a heterogeneous group of mono- (sialyl-6-
T: S6T; sialyl-3-T: S3T) and disialylated glycoforms that remain to be individually evaluated in 
cancer. Building on these insights, bladder tumours were screened for the above-mentioned cancer 
associated glycans, envisaging a molecular rationale for the development of novel non-invasive 
diagnostic tools and highly specific targeted therapeutics towards precision medicine. Special 
emphasis was given to STn which was shown to be a key cancer-associated antigen highly linked with 
advanced disease and poor prognosis in bladder cancer. 
 
3. Methods 
 
3.1. Patients and samples 
 
For the screening of cancer-associated short-chain O-glycans (Tn, STn, T, S3T, S6T and dST), 
formalin-fixed paraffin-embedded tissue sections (FFPE) were prospectively obtained from 47 patients 
with urothelial bladder carcinomas who underwent bladder surgery in the Portuguese Institute of 
Oncology of Porto (IPO-Porto, Portugal). Tissues were collected from 37 male and 10 female patients 
(n=17 low-grade NMIBC, n=12 high-grade NMIBC, n=18 MIBC), mean age of 70 years (ranging 45–
89 years old). Also, FFPE with healthy urothelium was obtained from six necropsies from male 
individuals. The assessment of the influence of the most promising glycans in the survival of BC 
patients was performed on FFPE from a larger retrospective cohort study composed of 96 patients (47 
NMIBC and 49MIBC), 82 men and 14 women, ranging in age from 38 to 92 years (median of 69.5 
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years). Sixteen cases were low grade and 80 were high-grade tumours. Furthermore, carcinoma in situ 
(Cis) was concomitantly found in 20.8% of the patients. Cystectomy was performed in 64 patients 
(66.7%) while the other 32 (33.3%) were submitted to transurethral resection. Lymphadenectomy was 
performed in approximately 47% of the patients, of which 37% presented metastasis. Fifty-four cases 
(56.3%) were primary tumours and 42 (43.7%) were recurrent tumors. From the recurrent tumours, 
38% had no prior treatment, 27% were treated with Mitomicin C, 11% were treated with Bacillus 
Calmette-Guérin,19% were submitted to both treatments, and 5% were treated with neoadjuvant 
chemotherapy prior to the cystectomy. 
All tumour samples were colected between July 2011 and May 2012 and revised by a 
pathologist (TA) according to the 2004 World Health Organization criteria(23). All procedures were 
performed under the approval of the Ethics Committee of IPO-Porto after informed patient’s consent. 
All clinicopathological information was obtained from patient´s clinical records.  
 
3.2. Immunohistochemistry 
 
The screening of cancer-associated short-chain O-glycans (Tn, STn, T, S6T, S3T and dST) was 
performed using the avidin/streptavidin-peroxidase method, as described by Ferreira et al.(19). The 
expression of the Tn, STn and T antigens was directly evaluated using in-house mouse monoclonal 
antibodies 1E3, TKH2 and 3C9, respectively. For more information about these antibodies consult the 
following database of anti-glycan reagents: 
https://ccr2.cancer.gov/resources/Cbl/Tools/Antibody/About.aspx. Because there are no commercially 
available antibodies for S3T, S6T and dST antigens, enzymatic assays were performed to indirectly 
analyze the expression of these epitopes in T antigen negative tumour samples. Specifically, the 
expression of dST antigen was determined by comparing histological sections probed for the T antigen 
before and after digestion with an α-neuraminidase from Clostridium perfringens (Sigma Aldrich, St. 
Louis, MO, USA). The S3T antigen expression was determined by comparing histological sections 
probed for the T antigen before and after digestion with an α-(2,3)-neuraminidase from Streptococcus 
pneumonia (Sigma-Aldrich, Missouri, USA). The S6T antigen expression was accessed by comparing 
histological sections probed for STn before and after digestion with a recombinant β-(1,3)-
Galactosidase from Xanthomonas campestris (R&D systems, Minnesota, USA). The chromogen 3,3-
diaminobenzidine tetrahydrochloride (ImmPACT DAB; Vector Laboratories, California, USA) was 
used to visualize antibody binding sites and sections were counterstained with Harris’s hematoxylin. 
Negative controls were performed by replacing the primary antibody with 5% bovine serum albumin 
(BSA). Positive controls were known positive tissues for the antigens under study. The 
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immunoreactive tissue sections were assessed by light microscopy by two independent observers and 
validated by an experienced uropathologist. Although the interobserver agreement was high (k = 
0.961, P < 0.001), discordant readings were re-analysed using a double-headed microscope (Olympus 
BX46; Olympus Corporation,Tokyo, Japan), and consensus attained. A semi-quantitative measurement 
was established to score immunohistochemical labelling based on the percentage of positively stained 
cells, and  categorized as: negative (-),no staining was observed; positive (+), 1-19% of positive cells; 
positive (++), 20-49% of positive cells; positive (+++), 50-79% of positive cells; positive (++++), 80-
100% of positive cells.  
 
3.3. Statistical methods 
 
Statistical analysis of data was performed with IBM Statistical Package for Social Sciences - 
SPSS for Windows (version 20.0; IBM, New York, USA). Chi-square analysis was used to compare 
categorical variables, while Student’s t-test was used to compare normally distributed continuous 
variables. Kaplan-Meier survival curves were employed to evaluate correlations between STn 
expression and cancer-specific survival (CSS). Multivariate Cox regression analysis was performed to 
assess the individual effect of the evaluated markers on patient’s survival while adjusting for 
covariables (variables that could affect cancer-specific survival of NMIBC and MIBC patients). 
Cancer-specific survival was defined as the time frame between surgery and death from cancer. 
 
4. Results and discussion 
 
4.1. Screening of short-chain O-glycans in bladder cancer tissues 
 
Forty-seven FFPE bladder tumours and 6 healthy controls were analysed by 
immunohistochemistry to detect the expression of short-chain O-glycans (Tn, STn, T and ST). 
Emphasis was given to the expression of T antigen monosialylated forms S3T and S6T, which had 
been so far less studied due to the inexistence of commercially available specific monoclonal 
antibodies to these epitopes and limitations in glycomics approaches. To address the possibility of O-6 
GalNAc sialylation (S6T) of the T antigen, bladder tumour sections were digested with a β-(1-3)-
galactosidase to remove α-3 linked Gal residues from S6T antigens prior to incubation with the anti-
STn monoclonal antibody (Figure 1A). Similarly, incubation with an α-neuraminidase specific for 
cleaving O-3 linked sialic acids from S3T, allowed T antigen detection in previously T antigen 
negative tissues (Figure 1B). For detecting dST, bladder tumour sections were digested with an α-
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neuraminidase to remove α-3 and α-6 linked sialic acids, allowing T antigen detection in T, S3T and 
S6T negative tissues.  
 
 
Figure 1. Schematic representation of the analytical strategy for S6T and S3T detection by 
immunohistochemistry. A) The S6T antigen may be considered structurally related with STn, since it presents 
an O-6 sialylation of its GalNAc residue. As such, STn negative tumour sections were digested by an β-(1,3)-
galactosidase to remove the Gal residue of S6T; thereby exposing the STn antigen for recognition by TKH2 
monoclonal antibody. In addition, after enzymatic digestion of several STn positive tumours, a significant 
increase in STn staining was achieved (data not shown). B) Envisaging to evaluate S3T antigen expression in 
bladder tumours, an α-(2,3)-neuraminidase was used to remove the O-3 Gal sialylation of this epitope to expose 
the T antigen for recognition by the anti-T antigen monoclonal antibody 3C9. The presence of S3T was 
determined by comparing T antigen expression in T antigen negative tumours sections prior and after enzymatic 
digestion.  
 
Figure 2 summarizes the expression of these glycans in tissue samples representative of several 
BC stages and grades. Notably, we observed that none of the short-chain glycans was expressed in 
healthy urothelium, demonstrating the cancer specific nature of these molecular alterations, while Tn 
and T antigens were poorly expressed in bladder tumours (20–50% of total cases) in comparison with 
their sialylated counterparts STn and mono- and/or disialyl- ST (62% and 100%, respectively), 
irrespectiveof grade and invasion. The number of T antigen-positive cases largely exceeds the Tn-
positive cases (53% vs 23%), which was particularly seen in advanced tumours when compared to 
low-grade superficial lesions. This could be due to overexpression of C1GalT1 (core 1 synthase, T-
synthase) or downregulation of other glycosyltransferases, such as C2GnT, involved in O-glycan 
extension, as previously demonstrated in BC cells exposed to hypoxia(20). Moreover, these results 
reinforce previous work associating T antigen expression and tumour invasion(24). Notewithstanding, 
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in agreement with previous reports the STn antigen was observed in high-grade and invasive tumours 
(75 and 89%, respectively), whereas only 24% of low grade cases were positive.  
 
 
 
Figure 2. Expression of short-chain O-GalNAc glycans in bladder tumours of different clinicopathological 
natures and healthy urothelium determined by immunohistochemistry. 
 
Most STn-positive cases presented low extension of expression (< 20%), focal and 
polydisperse, throughout the tumour. STn was mostly found in cells of the basal layer, yet it could also 
be detected in tumour areas presenting extensive staining (> 50%), in papillary urothelium and 
invasive fronts (Figure 3A)(18). Moreover, whenever present in the tumour, STn was also detected in 
the adjacent but not in the distal mucosa(18). Furthermore, the sialylated forms of the T antigen, 
including mono- and/or disialylated glycans, were diffusely expressed by all studied bladder tumours. 
The S6T antigen was found in approximately 80% of the studied tumours, with similar percentage of 
positive cases between NMIBC and MIBC, despiteincreased extension of expression could be 
observed in advanced (Figure 1). In contrast with the ubiquitous nature of S6T, the S3T antigen was 
primarily found in high-grade NMIBC (41% low-grade NMIBC; 71% high-grade NMIBC; 61% 
MIBC), although we should note that many high-grade tumours co-expressed both T sialylated forms. 
These observations support previous associations between the overexpression of both sialyl-T and 
ST3Gal-I, the sialyltransferase responsible for T antigen O-3 sialylation, in high-grade tumours(22) 
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Figure 3. STn clinical significance and expression across different bladder tumor stages. A) Representative 
immunohistochemistry images of STn antigen patterns of expression in NMIBC (left) and MIBC (right) cases. 
In high-grade NMIBC cases STn positive cells are seen mostly in the basal layer, while MIBC cases present 
extensive staining and cells expressing STn are seen invading the muscle layer. B) Percentage of cases 
expressing STn throughout disease stages in the studied cohort of 96 patients. C. Effect of STn expression in 
cancer-specific survival of patients regardless of tumour stage. D. Effect of STn expression in cancer-specific 
survival of NMIBC patients. Kaplan–Meier analysis shows the association between STn expression and 
decreased CSS of BC patients. Comparison performed by log-rank test (p = 0.024); + censored STn negative 
tumours; ♦ censored STn positive tumours. 
 
In summary, results herein presented reinforce the cancer-specific nature of short-chain O-
glycans, as well as the up-until now neglected expression of T antigen sialylated glycoforms in bladder 
tumours. Moreover, the co-expression of non-sialylated and sialylated glycoforms was demonstrated in 
a minor subset of advanced-stage tumours. Finally, and given the prevalence of the STn antigen in 
increasingly aggressive high-grade and invasive tumours, its prognosticator role was shown in a larger 
patients’ set, demonstrating the promising clinical value of this glycan in bladder cancer. 
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4.2. Biological and clinical relevance of sialyl-Tn in bladder cancer 
 
The expression and staining patterns of STn antigen were confirmed in a larger retrospective 
subset of 96 BC patients. Particularly, STn was expressed in approximately 60% of all bladder 
tumours studied, mostly in MIBC (60-76%, p < 0.05), with the same staining patterns as previously 
observed. Figure 3B represents STn expression throughout BC stages. These findings further support 
STn’s  role in tumour invasion, as evidenced by in vitro studies(8). Accordingly, advanced stage 
bladder tumours were previously described to overexpress ST6GalNAc-I, an enzyme responsible for 
Tn antigen sialylation at the α2,6 position, originating STn(19). Notwithstanding, it is still necessary to 
disclose the expression of ST6GalNAc-II and possibly ST6GalNAc-IV, also known to be involved in 
the O-6 sialylation of the Tn antigen(25), as well as the expression of C1GALT1 and C2GnT1 in BC 
tissues. Moreover, the molecular mechanisms underlying glycomic alterations, including events 
modulating the expression, activity and distribution throughout secretory organelles of 
glycosyltransferases and glycosidases, as well as the mutational patterns of key enzymes involved in 
O-glycans biosynthesis and their functional impact also require further analyses.  
To evaluate the association between STn antigen expression and cancer-specific survival 
(CSS), a Kaplan-Meier analysis of 96 BC patients was conducted. Particularly, patients with STn 
positive tumours had lower CSS, after adjustment for tumour stage (p=0.024; Figure 3C). This was 
also observed when evaluating NMIBC alone (p = 0.020; Figure 3D). Importantly, among NMIBC, 
STn expressing T1 tumours presented lower CSS than negative tumours (p <0.05). After multivariate 
Cox regression analysis adjusting for relevant covariates (age, gender, stage, grade, recurrence status 
and presence of concomitant CIS) STn remained an independent prognostic marker of worst cancer-
specific survival (HR=11.836; 95%CI: 1.063–131.7; p=0.044).  
In summary, STn constitutes a cancer-specific antigen associated with advanced disease and 
poor prognosis in bladder cancer.  
 
5. Conclusions  
This work highlights that advanced bladder tumours overexpress an array of short-chain O-
glycans resulting from a premature arrest of glycosylation extension in membrane and secreted 
proteins, demonstrating a predominant sialylated over neutral glycoform, with emphasis on sialylated 
Tn and T antigens. Here, for the first time, insights on the nature of the T antigen sialylation are 
provided, which might be crucial for guiding future glycomics and glycoproteomics studies and for 
designing specific ligands against BC cells. Moreover, a significant increase in O-6 sialylation in 
bladder tumours is evidenced, particularly the overexpression of the STn antigen. 
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The altered protein glycosylation translated into STn overexpression in advanced stage tumours  
was reinforced by present work through O-glycans screening in larger patient sets that revealed  STn 
expression association with muscle-invasive, suggesting a role for sialylation in stopping protein 
glycosylation in advanced stage bladder tumours. Furthermore, new insights regarding its correlation 
with decreased CSS, as previously observed for digestive track tumours(26-28), were provided, 
demonstrating that STn antigen is a biomarker of poor prognosis, particularly in MIBC. 
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pressure for Sialyl-Tn expressing stem-like cells: 
A proof of concept study 
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1. Abstract 
 
Muscle invasive bladder cancer (MIBC) constitutes the second most deadly genitourinary 
cancer. Currently, the standard-of-care includes surgery and cisplatin-based chemotherapeutic 
schemes, which often fail to avoid tumour relapse and disease progression. Recently discovered 
bladder cancer stem cells (BCSCs) now help to explain observations in the clinical setting, including 
tumor heterogeneity, chemoresistance, recurrence, and metastasis. Therefore, novel biomarkers to aid 
prognostication and targeted therapeutics are warranted to improve patient management. 
In this work two established MIBC cell lines (T24 and HT1376) were exposed to an IC50 
dosage of cisplatin and evaluated according to the expression of the cancer-associated O-GalNAc 
glycan sialyl-Tn (STn) and CD44, a typical BCSC-associated glycoprotein also associated with drug 
resistant phenotypes and poor prognosis. Both chemotherapy challenged cell lines and muscle-invasive 
bladder tumours were submitted to transcriptional analyses of a panel of genes characteristic of stem, 
mesenchymal, epithelial-to-mesenchymal (EMT), and epithelial cell phenotype, as well as cytokeratins 
(KRT), to assess cellular differentiation states. 
Taken together, data suggest that chemotherapy acts as a discriminatory pressure, selecting 
tumour niches with undifferentiated stem-like cells characterized by the expression of CD44-STn+ 
glycoforms. These results reinforce that STn is a biomarker of aggressiveness and resistance to 
chemotherapy in bladder tumours. 
 
2. Introduction 
 
Bladder cancer (BC) is one of the most common malignancies of the urinary tract and the 
second deathliest amongst genitourinary cancers(1). At diagnosis, most patients present non-muscle 
invasive bladder cancer (NMIBC), conservatively treated by complete transurethral resection and 
intravesical therapies(2). Notwithstanding, high-grade NMIBC is characterized by high recurrence 
rates and elevated risk of progression to muscle invasion(2). In addition, 25% of new cases display 
muscle-invasive bladder cancer (MIBC) or metastatic disease, currently treated by radical cystectomy 
and cisplatin-based chemotherapeutic regimens, which often fail to avoid tumour relapse and disease 
progression(3). Therefore, BC patients present a significant management hurdle due to high recurrence 
rates, rapid progression, dissemination and poor response to chemotherapy, accompanied by a 
significant lag in the introduction of novel targeted therapies when compared to other solid tumours(4, 
5). Moreover, the lack of efficient follow-up strategies, especially non-invasive, for early detection of 
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occult micrometastasis, real-time monitoring of therapy response and metastatic risk assessment, 
further aggravates prognostication in bladder cancer(6). Thus, improving BC survival will require 
earlier detection, more effective local control and new therapies for metastatic disease. Importantly, 
tumour heterogeneity as been regarded to drive from minor subpopulations of cells within the tumour 
population endowed with distinct proliferative and differentiation capacities, termed cancer stem-cells 
(CSC). The CSC model supports that these cells are responsible for sustaining growth with significant 
clinical implications, as CSCs have been shown to be resistant to chemo and radiotherapy, especially 
when in quiescent state(7, 8). Particularly, recurrent BC is usually chemoresistant, even if the primary 
tumour is chemotherapy-sensitive(9), which might be explained either as a consequence of 
unfavourable drug pharmacokinetics and abnormal tumor vasculature delivering suboptimal 
concentrations of cytotoxic agents to the tumor (10, 11), or as a consequence of bladder cancer stem-
cells (BCSCs) chemoresistance(9, 11, 12). In fact, chemotherapy’s selective pressure results in 
enriched BCSCs populations capable of recapitulate residual tumours between chemotherapy cycles in 
human bladder cancer xenografts(13). Moreover, it has been shown that CSC-like cells can be isolated 
after chemotherapy in cancer cell lines, reinforcing the growth advantage of CSC-like cells upon 
therapeutic challenges(14). As such, chemotherapy in combination with CSC-targeted therapy would 
be ideal for advanced stage BC patients. Importantly, BCSCs were first isolated using cell-surface 
markers present on normal stem cells(15). Since then, superficial markers as CD44(15), CD44v6(16, 
17), laminin receptor (67LR)(18), Aldehyde dehydrogenase 1 family, member A1 (ALDH1A1)(19), 
CD133(20, 21), CD47(15), CD49(22), and keratin 14 (KRT14)(23) have been used, alone or in 
combination,to identify and isolate BCSCs. More recently, basal-like lesions presenting the KRT14+ 
and/or KRT5+ and KRT20- phenotype were found enriched for BCSCs and presented higher resistance 
to chemotherapy and decreased survival(25). This constrasted with well differentiated luminal lesions 
(KRT14- , KRT5- and KRT20+) with favourable prognosis (23-25). Nevertheless, despite these 
evidences, bladder CSC specific biomarkers for therapeutic targeting remain to be identified.   
Malignant transformation is often accompanied by profound changes in glycosylation patterns, 
which play key roles in tumour progression and dissemination(26, 27). As such, exploring cancer-
associated glycans, which are often of oncofetal nature, presents a unique and highly specific 
opportunity to target CSCs. Particularly, overexpression of the cancer-associated O-GalNAc glycan 
Sialyl-Tn (STn) has been demonstrated to be a salient feature of advanced stage bladder tumours(28, 
29, chapter 2-results), being a biomarker of poor prognosis, particularly in MIBC(30; chapter 2 
results). Moreover, it is also absent or marginally present in the normal urothelium, reinforcing its 
cancer-specific nature, while promoting cancer cell motility and invasion, as well as immune 
escape(29, 31, 32). Preliminary data also suggest that the STn antigen may be expressed by 
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chemoresistant cells in non-proliferative tumour areas (28); however its association with BCSCs 
phenotypes has not yet been disclosed and may provide the necessary means to improve on its 
indentification and targeting.  
 
3. Material and Methods 
 
3.1. Patients and tissue samples 
 
A subset of 10 MIBC patients, attending the Portuguese Institute of Oncology of Porto (IPO-
Porto; Portugal) and treated with neoadjuvant cisplatin-based chemotherapy, were included in this 
study. A total of 20 formalin-fixed paraffin-embedded (FFPE) tissue sections were analysed, 10 from 
prior chemotherapy transurethral resections (TUR) and 10 from post-chemotherapy cystectomies. All 
procedures were performed under the approval of the institution ethics committee and upon patients’ 
informed consent. All clinicopathological information was obtained from patients’ clinical records. 
 
3.2. Cell lines and cell culture conditions 
 
The T24 (grade III) and HT1376 (grade III) urothelial cancer cell lines used in this work were 
acquired from DSMZ (Düsseldorf, Germany) and recently characterized from the genetic standpoint 
by our group(34). Accordingly, the T24 cell line is representative of the FGFR3/CCND1 carcinogenic 
pathway, presenting a mutated HRAS and overexpression of CCND1, while the HT1376 cell line 
corresponds to the E2F3/RB1 pathway with loss of one copy of RB1 and mutation of the remaining 
copy. Additionally, HT1376 cells exhibit deletion of the Phosphatase and tensin homolog (PTEN) 
gene and no alteration of Phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA), which in 
combination with the inactivation of p53, translates into a more invasive and metastatic potential. The 
cells were cultured in RPMI 1640+GlutaMAXTM medium (Gibco, Life Technologies) supplemented 
with 10% heat-inactivated FBS (Gibco, Life Technologies) and 1% penicillin-streptomycin (10,000 
Units/mL P; 10,000 μg/mL S; Gibco, Life Technologies). Cell lines were cultured as a monolayer at 
37˚C in a 5% CO2 humidified atmosphere, and were routinely subcultured after trypsinization. 
 
3.3. Cell Viability Assay 
 
To assess the chemosensitivity of the UBC cell lines to cisplatin (CDDP, cis-
diamminedichloroplatinum-[II]), 1x106cells were seeded in triplicate into 6-well plates and incubated 
with increasing concentrations of cisplatin. Stock solutions of 1 mg/ml cisplatin in 10% NaCl were 
kindly provided by the Pharmaceutical Services of the Portuguese Institute of Oncology, Porto, 
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Portugal, from which the working solutions were prepared. The effect of cisplatin exposure on cell 
viability was determined at 72 h by the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide) assay (M6494, ThermoFisher Scientific) according to the manufacturer’s instructions. The 
IC50 values (cisplatin concentration that corresponds to 50% of cell growth inhibition) were estimated 
from at least three independent experiments, using GraphPad Prism Software. Estimated IC50 values 
for both cell lines were 3μg/mL. 
 
3.4. Gene expression 
 
Gene expression was assessed by quantitative polymerase chain reaction (qPCR). These assays 
included a group of genes associated with stem (NANOG, LIN28A, POU5F1, KLF9, KLF4, SOX2), 
epithelial (CDH1, DSP, EpCAM), Epithelial-to-mesenchymal transition (SNAI1, SNAI2, TWIST1, 
TWIST2, ZEB1, ZEB2, RUNX1, RUNX2, FN1), and mesenchymal (CDH2, VIM, SPARC) phenotypes, 
as well as CD44 and cytokeratins (KRT 5, KRT14, KRT20) described in Table 1. Briefly, total RNA 
from cultured cells was isolated using TriPure isolation Reagent (Roche) and from FFPE tissue 
samples using “Absolutely RNA FFPE Kit” (Stratagene, La Jolla, CA), according to the vendor’s 
instructions. The RNA quantity and its purity were determined based on the A260/A280 using a 
Nanodrop Lite Spectrophotometer (Fisher Scientific). Only samples with ratios between 1.9 and 2.1 
were considered for downstream molecular studies. RNA conversion and gene expression analysis was 
performed as previously described(35). All reactions were run in duplicates and experiments 
performed in triplicate. The mRNA levels were normalized to the expressions of B2M and HPRT, 
which were found to be the most stable genes for the cell lines(36). The relative mRNA levels were 
calculated using the formula 2−ΔΔCt described by Livak et al.(37). The efficiency of each 
primer/probe was above 95% as determined by the manufacturer. Interpretation of biological functions 
translated by alterations in gene expression was done using ClueGO version 2.3.2(38) and CluePedia 
plugins version 1.3.2(39) for cytoscape version 3.4.0(40). 
 
Table 1 – Taqman gene expression assays  
Gene 
TaqMan Gene Expression 
Assay ID 
KRT5 Hs00934200_g1 
KRT14 Hs00559328_m1 
KRT20 Hs00300643_m1 
CD44 Hs01075864_m1 
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NANOG Hs04260366_g1 
LIN28A Hs01552405_g1 
POU5F1 Hs04260367_g1 
KLF9 Hs00230918_m1 
KLF4 Hs00358837_g1 
SOX2 Hs01053049_s1 
CDH1 Hs01023894_m1 
DSP Hs00950591_m1 
EpCAM Hs00901885_m1 
SNAI1 Hs00195591_m1 
SNAI2 Hs00950344_m1 
TWIST1 Hs01675818_s1 
ZEB1 Hs01566410_m1 
ZEB2 Hs00207691_m1 
RUNX1 Hs01021971_m1 
RUNX2 Hs01047973_m1 
FN1 Hs00365052_m1 
CDH2 Hs00983056_m1 
VIM Hs00185584_m1 
SPARC Hs00234160_m1 
B2M Hs00984230_m1 
HPRT Hs99999909_m1 
 
 
3.5. Immunoprecipitation for CD44 and western blot conditions 
 
CD44 was immunoprecipitated from total protein extracts (IP) with anti-CD44 (EPR1013Y; 
Abcam) monoclonal antibodies using Pierce Direct IP Kit (Thermo Scientific) according to the 
supplier’s instructions. Protein samples were separated in reducing SDS/PAGE gels, transferred to 
0.45-mm nitrocellulose membrane (GE Healthcare Life Sciences, Uppsala, Sweden) and blotted for 
the CD44 and for STn with TKH2 hybridoma-derived monoclonal antibody. Protein extracts treated 
with α-neuraminidase (Sigma Aldrich) were used as controls. β-actin was used as loading control. 
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3.6.Immunohistochemistry 
 
Formalin-fixed, paraffin-embedded tissue sections (FFPE) were screened for CD44 by 
immunohistochemistry using the strepavidin/biotin peroxidase method. Briefly, 3 μm sections were 
deparaffinized with xylene, rehydrated with graded ethanol series, microwaved for 15 min in boiling 
citrate buffer (10mM Citric Acid, 0.05% Tween 20, pH 6.0, Sigma-Aldrich), and exposed to 3% 
hydrogen peroxide for 25 min. CD44 was detected using a recombinant polyclonal antibody (anti-
CD44, 1:4000 in PBS; ab157107; Abcam, Cambridge, UK) after incubation overnight at 4°C. The STn 
antigen was evaluated using a B72.3 monoclonal antibody (Abcam) 0.5ug/mL overnight at 4°C. The 
antigens were identified with UltraVision HRP Detection System Kit (Thermo Fisher Scientific, 
Waltham, MO, USA) followed by incubation with 3,3-diaminobenzidine tetrahydrochloride (Impact 
Dab, Vector Laboratories) for chromogenic development. Finally, the slides were counterstained with 
Harris’s haematoxylin for 1 min. Negative control sections were performed by adding BSA (5% in 
PBS) devoided of primary antibody. The immunoassayed sections were blindly assessed using light 
microscopy by two independent observers and validated by an experienced pathologist. Briefly, a 
semi-quantitative approach was established to score immunoreactivity based on the intensity and 
extension of the staining. The extension of staining was rated in cut-offs of 10%, and staining intensity 
was rated as follows: negative-0, weak-1, moderate-2, strong-3. The tumours were then classified as a 
score based on the product of extension with intensity. Readings not concordant were re-analysed 
using a double-headed microscope and consensus was reached. 
 
3.7. In situ proximity ligation assays on tissue sections 
 
The detection of CD44-STn+ glycoforms was achieved by in situ proximity ligation assays 
(PLA), using the Duolink in situ detection reagent Red (Olink Bioscience, Uppsala, Sweden), 
according to the manufacturer’s instructions. FFPE tissues were deparaffinized, rehydrated and 
subjected to acid- and heat-induced antigen retrieval, followed by incubation with 3% hydrogen 
peroxide. Then, tissue sections were incubated with blocking solution in a humidified atmosphere 
chamber. CD44 and STn were detected by indirect PLA using the polyclonal antibody anti-CD44 
1:2000 overnight at 4°C (clone ab157107; Abcam, Cambridge, UK) and the hybridoma-derived 3F1 
antibody 1:4 overnight at 4°C, respectively. The PLA probes anti-rabbit MINUS and anti-mouse PLUS 
were both added and sections were incubated at 37°C for 1 h. Next, ligation was performed for 30 min 
at 37 °C, and amplification was carried out for 120 min at 37°C to produce rolling circle products, 
followed by incubation with 4’,6-diamidino-2-phenylindole for 10 min at room temperature and 
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sample mounting for fluorescence microscopy. PLA results were evaluated by two distinct observers 
and validated by an experienced pathologist, who independently registered colocalization of staining’s. 
 
3.8.Statistical analysis  
 
Statistical analysis was performed using the Student’s T-test for unpaired samples. Differences 
were considered significant when p < 0.05. A chi-square test was used to analyse associations between 
variables and clinicopathological features. 
 
4. Results 
 
4.1.Expression of Sialyl-Tn and CD44 in urothelial cell lines exposed to cisplatin 
 
Muscle-invasive urothelial cell lines T24 and HT1376 were submitted to one IC50 dosage of 
cisplatin, a common agent in BC treatment schemes, resulting in a 50% reduction in tumour cell 
viability. Remain cells were maintained in culture for more than two month; however expansion in 
vitro was not observed under standard culture conditions presented in the material and methods. In 
order to evaluate the remaining clones, whole cell lysates were blotted for cancer-specific O-GalNAc 
glycan STn and the stem-cell marker CD44. Contrasting with the significant reduction in tumour cell 
viability, both STn and CD44 levels remained mostly unchanged before treatment, suggesting the 
selection of STn and CD44-expressing clones (Figure 1A and 1B). The specificity of slot blot signals 
was reinforced through its decay after sialidase treatment. To validate the existence of CD44-STn+ 
glycoforms, we have immunoprecipitated CD44 in these samples and confirmed the expression of STn 
by western blot (Figure 1C).  
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Figure 1. Expression of STn and CD44 in T24 and HT1376 cells after cisplatin exposure. A) 
Representative slot blot analysis of STn antigen in protein extracts from T24 and HT1376 remaining clones. 
This was a sialidase-sensitive signal, confirming the presence of the antigen. B) Western bot for the CD44 
glycoprotein in T24 and HT1376 cell lines exposed to cisplatin. CD44 levels are significantly higher in the T24 
cell line compared to HT1376 cell line. Nevertheless, CD44 levels did not vary for any cell line after exposure 
to IC50 doses of Cisplatin. C) Identification of CD44-STn+ glycoforms in whole cell lysates of treatment-
reminiscent cells by immunoprecipitation. CD44 was immunoprecipitated from protein extracts using antibody-
immobilized agarose beads and blotted for CD44 and STn thereafter.  
 
4.2. Cisplatin modulation of gene expression in urothelial cancer cell lines 
 
 After cisplatin exposure, both T24 and HT1376 cell lines were submitted to transcripts analysis 
regarding a panel of genes involved in stem, epithelial, epithelial-to-mesenchymal (EMT) and 
mesenchymal phenotypes. Moreover, to explore the differentiation patterns of the remaining clones the 
cytokeratin profile was also evaluated. Overall, the HT1376 cell line overexpresses stem-associates 
genes, as KLF4, as well as EMT-related genes as TWIST1 and ZEB2. In turn, T24 clones mostly 
overexpress EMT promoting genes such as TWIST1 and SNAI1. Importantly, both cell lines strikingly 
overexpress KRT14, denoting a very pronounced undifferentiated phenotype of the residual cells. In 
addition, as previously described, CD44 transcript levels remain mostly unchanged (Figure 2A). The 
integrative analysis of transcript modulation by cisplatin in both cell lines through Cytoscape Software 
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has evidenced the activation of pathways promoting the maintenance of stem cell populations, as well 
as the negative regulation of DNA damage response through p53, and modulation of cellular adhesion 
(Figure 2B).  
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Figure 2. Cisplatin modulation of gene expression. A) cisplatin-modulated under and overexpression of 
cytokeratins as well as stem, EMT, epithelial, and mesenchymal phenotype genes. B) Functional interaction 
network obtained through Cytoscape Software using ClueGO and CluePedia plugins for single cluster analysis 
and comparison of gene clusters to explore cellular processes and their dynamics. 
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4.3. Chemotherapy modulation of gene expression in bladder tumours 
 
 FFPE tumours sections from a subset of 10 MIBC patients treated with neoadjuvant cisplatin-
based chemotherapy were screened for STn and CD44 expression. CD44 and STn staining patterns 
and intensities do not significantly vary before and after chemotherapy (Figure 3A). However, to 
validate colocalization and the existence of abnormally glycosylated CD44, the same tumour sections 
were screened by in situ proximity ligand assay (PLA), which allowed the simultaneous detection of 
both CD44 and STn when in close proximity (Figure 3B). These findings support the existence of 
CD44 carrying cancer-associated STn glycoforms in bladder tumours after chemotherapy. 
Furthermore, the transcript levels of some stem gene, including CD44, and cytokeratins were also 
evaluated in these tumours. Of note, all evaluated stem markers were upregulated post-chemotherapy, 
as well as cytokeratin 14 (KRT14). Denoting a chemotherapy-mediated enrichment for stem and 
undifferentiated cells (Figure 3C). 
 
 
 
Figure 3. Chemotherapy modulation of bladder tumour phenotypes. Two complementary validation 
strategies were applied: A) first consecutive tumour tissues were screened for CD44 and the cancer-associated 
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O-glycan STn by immunohistochemistry; B) second, the same tumour sections were screened for CD44 and the 
targeted glycan STn by in situ proximity ligand assays, which allowed the simultaneous detection of both targets 
when in close proximity. Results showed the co-expression of CD44 STn in the same tumour areas and support 
the existence of CD44 carrying cancer-associated glycosylation in bladder tumours. C) Stem markers and 
cytokeratin transcript evaluation. 
 
5. Discussion 
 
In this work two MIBC cell lines (T24 and HT1376) were submitted to a dose IC50 of cisplatin 
and evaluated according to the expression of the cancer-associated O-GalNAc glycan sialyl-Tn (STn) 
and CD44, a glycoprotein commonly used in BCSCs identification panels. Interestingly, upon 
chemotherapeutic challenge, the remaining clones of both cell lines retain CD44 and STn expression. 
Both CD44 and STn have been shown to predict poorer prognosis in BC(30, 41). Moreover, while 
CD44 had been already associated with drug resistance in BC(42), this is the first report demonstrating 
the involvement of STn in the pharmacological response of BC cells. These results are strengthened by 
similar observations in gastric cancer where STn expression was described to induce tumor cell’s 
resistance to chemotherapeutic drugs(43). Moreover, the reminiscent cells were submitted to 
transcriptional analysis of a panel of genes including stem, mesenchymal, epithelial-to-mesenchymal 
(EMT), and epithelial phenotypes, as well as cytokeratins (KRT) to assess cellular differentiation 
states. Of note, both stem- and EMT-associated were consistently overexpressed, which accompanied 
cytokeratin modulation toward KRT14 overexpression leading to more undifferentiated and plastic 
phenotypes. In accordance with protein levels, CD44 transcript levels were also sustained. The 
integration of transcriptomic data through Cytoscape Software evidenced the activation of pathways 
promoting the maintenance of stem cell populations, as well as the negative regulation of DNA 
damage response through p53, and modulation of cellular adhesion, conceptually corroborating the 
molecular adaptation of cells to the imposed stress.  
In vitro results were validated using muscle-invasive bladder tumour sections of patients treated 
with neoadjuvant cisplatin-based chemotherapy. Particularly, both immunohistochemistry and PLA 
assays corroborate the preservation of STn and CD44 expression, as well as co-localization of CD44 
and STn antigens, supporting the existence of cancer-associated CD44-STn+ glycoforms. 
Transcriptional analysis also demonstrated stem-cell markers and KRT14 upregulation, suggesting a 
similar enrichment of cells in vivo towards more stem and basal-like cells. 
In summary, we demonstrated in both MIBC cell lines and MIBC tumour sections that 
chemotherapy acts as a selective pressure for undifferentiated stem-like cells characterized by the 
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expression of CD44-STn+ glycoforms. Future studies should devote to confirming these preliminary 
findings in larger patient series. Particular emphasis should also be set on the isolation of CD44-STn+ 
cells and evalution of its capacity to recapitulate tumour heterogeneity and chemoresistance. 
Noteworthy, CD44 is expressed by most human tumour. The identifications of specific isoforms will 
be required to improve on cancer specificity and specificity and possibly off-target effects envisioning 
therapeutic development.  
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Chapter 3 | Sialyl-Tn identifies muscle-invasive 
bladder cancer basal and luminal subtypes 
facing decreased survival, being expressed by 
circulating tumor cells and metastases 
 
This chapter has been published in Urologic Oncology (2017) 
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Abstract 
 
Objectives: To evaluate the potential of sialyl-Tn (STn), a cancer-associated glycan antigen 
present in membrane glycoproteins, to improve a recent molecular model for stratification and 
prognostication of advanced stage bladder tumors based on keratins (KRT14,5, and 20) expression. In 
addition, determine the association between STn and disease dissemination based on the evaluation of 
circulating tumor cells(CTCs) and the metastasis, which is a critical matter to improve patient 
management. 
Patients and methods: A retrospective series of 80 muscle-invasive primary bladder tumors and 
associated metastasis were screened for KRT14, 5, and 20 and STn by real-time polymerase chain 
reaction and immunohistochemistry. Peripheral blood was collected in a patients’ subset, CTCs were 
isolated through a size-based microfluidic chip and screened for KRTs and STn. 
Results: Basal-like lesions presented worse cancer-specific and disease-free survival compared to 
luminal tumors. STn antigen inclusion discriminated patients with worst survival in each subgroup (P= 
0.047 for luminal; P= 0.027 for basal-like tumors). STn expression in CTCs and distant metastasis was 
also demonstrated. 
Conclusion: This work reinforces the potential of the KRT-based model for bladder cancer 
management and the association of STn with aggressiveness, supporting its inclusion in predictive 
molecular models toward patient-tailored precision medicine. Moreover, we describe for the first time 
that CTCs and the metastasis present a basal phenotype and express the STn antigen, highlighting its 
link with disease dissemination. Future studies should focus on determining the biological and clinical 
significance of these observations in the context of liquid biopsies. Given the membrane nature of STn, 
highly specific targeted therapeutics may also be envisaged. 
 
Keywords: Bladder cancer subtypes; Sialyl-Tn; Predictive profile; Glycosylation; Circulating tumor 
cells 
__________________________________________________________________________________ 
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1. Introduction 
 
 Muscle-invasive Bladder Cancer (MIBC, stage >T2) constitutes the second most 
common cause of death among genitourinary cancers. Of note, significant variations in the clinical 
outcome are observed for histopathologically similar tumours subjected to identical treatments, mostly 
due to molecular heterogeneity[1]. 
A molecular model has been recently introduced to improve patient stratification and prognosis 
based on sub-classification of bladder tumours as luminal and basal-like[2-4]. Accordingly, well 
differentiated and prognostically favourable luminal tumours, with KRT14 and/or KRT5 
downregulation and KRT20 (KRT14
-
KRT5
-
KRT20
+
) upregulation, were distinguishable from basal-like 
lesions (KRT14
+
 and/or KRT5
+
 and KRT20
-
), characterized by reduced survival and higher resistance to 
chemotherapy[2-4]. Even though only 50% of MIBC could be subtyped using this approach, the notion 
that it may provide the premise for molecular-based clinical decisions prevails. The introduction of 
novel biomarkers capable of further refining patient stratification seems now warranted. 
This work is built upon our background in bladder tumour glycobiology to propose a strategy 
capable of further enhancing the KRT-based discriminatory potential in advanced stage tumours. 
Namely, we have described that bladder tumours overexpress membrane glycoproteins yielding the 
cancer-associated glycoantigen sialyl-Tn (STn)[5-7]. The STn antigen is a simple O-glycan 
(Neu5Acα2-6GalNAc-O-Ser/Thr residues in membrane and secreted glycoproteins) that is mainly 
associated with high-grade lesions and decreased survival, irrespective of grade and stage of 
disease[5,6,8,9]. It is also absent or marginally detectable in healthy urothelium, suggesting a 
malignant-specific nature. Its biosynthesis is triggered by high levels of hypoxia[8] and modulates 
protein functions in ways that favour motility and invasion[5,8], while promoting immune escape[10]. 
Such rationale supports STn as surrogate biomarker of poor prognosis, particularly in MIBC. 
Moreover, STn expression may be part of an array of molecular alterations favouring disease 
dissemination; nevertheless, its incorporation in multiplex biomarker models for improved 
prognostication a patient management has not yet been accomplished. Moreover, its link with 
metastatic progression remains to be demonstrated, which is a critical matter to improve patient 
management. 
 
3. Materials and methods 
 
3.1. Population and ethics statement 
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This study was performed retrospectively in a series of 80 formalin-fixed paraffin-embedded 
bladder tumours obtained from archived paraffin blocks at the Portuguese Institute of Oncology—
Porto (IPO-Porto), Portugal. Bladder tumors were surgically removed from 68 men and 12 women, 
ranging from 44 to 86 years of age (median, 74 years), admitted and treated at the IPOP between 2005 
and 2007. The time of follow-up was on average 31 months (1–104 months). All patients had 
cystectomy has primary therapy. From all cases included, 24% presented lymph node metastasis at the 
time of surgery. Table 1 summarizes clinicopathological information. Cancer-specific survival (CSS) 
was defined as the period between the date of surgery and date of patient death by cancer or date of 
last clinical visit. In a subset of patients (n=6) with metastatic muscle invasive bladder tumours, blood 
was collected in order to analyze circulating tumour cells. Blood donors matched in age and gender 
without known neoplasias were included as controls. All procedures were performed under patient’s 
informed consent to participate and after approval by the Ethics Committee at IPO-Porto. 
Clinicopathological information was obtained from patient’s clinical records. 
 
Table 1- Clinicopathological data of patients included in this study (n=80). 
  
n (%) 
 
Stage 
T2 22 (27.8) 
T3 36 (45.6) 
T4 21 (26.6) 
Lymph-node 
metastasis 
N0 27 (34.2) 
N1 19 (24.0) 
Nx 33 (41.8) 
 
Recurrence 
No 28 (49.1) 
Yes 29 (50.9) 
ND 23 
Type of 
recurrence 
Loco-regional 7 (25.9) 
Systemic 20 (74.1) 
Distant 
metastasis  
No 38 (47.5) 
Yes 42 (52.5) 
Type of 
Loco-regional 17 (40.5) 
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metastasis 
Systemic 25 (59.5) 
ND: not determined 
 
3.2. Immunohistochemistry 
 
Formalin-fixed, paraffin-embedded tissue sections (FFPE) were screened for Keratins 5, 14 and 
20 and cancer-associated O-glycan sialyl-Tn (STn) by immunohistochemistry using the 
strepavidin/biotin peroxidase method. Briefly, 3 μm sections were deparaffinized with xylene, 
rehydrated with graded ethanol series, microwaved for 15 min in boiling citrate buffer (10mM Citric 
Acid, 0.05% Tween 20, pH 6.0), and exposed to 3% hydrogen peroxide for 20 min. STn expression 
was performed using clone B72.3 mouse monoclonal antibody (Abcam, Cambridge UK) at a dilution 
of 1:100 in PBS, after overnight incubation at 37°C. Keratin 5 expression was performed with KRT5 
antibody (Monoclonal Rabbit Anti-Human Anti-Cytokeratin 5 antibody; Clone EP1601Y; Abcam) at a 
dilution of 1:100 in PBS, after 1h incubation at 37°C. Expression of keratin 14 was assessed with the 
KRT14 antibody (Monoclonal Rabbit Anti-Human Anti-Cytokeratin 14 antibody; Clone EP1612Y; 
Abcam) at a dilution of 1:50 in PBS, after overnight incubation at 4°C. The expression of Keratin 20 
was evaluated using KRT20 antibody (Monoclonal Rabbit Anti-Human Anti-Cytokeratin 20 antibody; 
Clone EPR1622Y; Abcam) at a dilution of 1:100 in PBS, after 1h incubation at 37°C.After blockage 
with BSA (5% in PBS). The antigens were identified with UltraVision HRP Detection System Kit 
(Thermo Fisher Scientific, Waltham, Massachusetts, USA) followed by incubation with 3,3-
diaminobenzidine tetrahydrochloride (Impact Dab, Vector Laboratories, Burlingame, CA, USA) for 
color development. Finally, the slides were counterstained with haematoxylin for 1 min. Negative 
control sections were performed by adding BSA (5% in PBS) devoid of primary antibody. The 
immunostained sections were blindly assessed using light microscopy by two independent observers 
and validated by an experienced pathologist. Disaccording readings were re-analysed using a double-
headed microscope and consensus was reached. Given the absence of STn in the healthy urothelium 
(160), tumors were classified as positive for these antigens when membrane and/or cytoplasmic 
immunoreactivity were observed in more than 5% of the tumour. 
3.3. Real-time polymerase chain reaction for KRT14, 5 and 20 expressions 
 
 Total RNA was extracted from FFPE for KRT expression analysis and from cell lines for the 
genes indicated in Table 2. RNA extraction from FFPE sections was performed using AbsolutelyRNA 
FFPE kit (Stratagene, La Jolla, CA, USA) according to the vendor’s instructions. Total RNA from 
cultured cells was isolated using TriPure isolation Reagent (Roche Diagnostics GmbH, Mannheim, 
Identification and Characterization of Glycobiomarkers in Bladder Cancer Stem Cells 
 
61 
 
Germany). The purity and quantity of RNA extracts were determined based on the A260/A280 ratio 
using Nanodrop ND1000 (Nano Drop Technologies Inc. Wilmington, DE, USA). Only samples with 
ratios between 1.9 and 2.1 were considered for downstream molecular studies. Up to 2µg total RNA 
from tissue sections and total RNA from cultured cells was reverse transcribed with random primers, 
using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, 
USA). The amplification conditions were the following: 25ºC for 10 min, 37ºC for 120 min and RT 
inactivation at 85°C for 5 min. Two non-template negative controls were used. The products were 
amplified in a Mycycler Thermal cycler (BioRad, Hercules, CA, USA). Gene expression levels, 
including three reference genes (B2M, HPRT and ActB) were analysed using TaqMan assays (Applied 
Biosystems; assays IDs indicated in Table 2). Real-time PCR amplification of cDNA samples was 
performed in a StepOne Real-Time PCR System (Applied Biosystems) using TaqMan Gene 
Expression Master Mix, primers and probes provided by Applied Biosystems. Thermal cycling 
conditions were 10 min at 95°C followed by 45 cycles of 15 sec at 95ºC and 1 min at 60°C. All 
samples were run in duplicate. Relative mRNA gene expression was calculated with the 2
-ΔCt
 formula.  
 
Table 2 – Taqman gene expression assays  
Gene 
TaqMan Gene Expression 
Assay ID 
KRT5 Hs00934200_g1 
KRT14 Hs00559328_m1 
KRT20 Hs00300643_m1 
B2M Hs00984230_m1 
HPRT Hs99999909_m1 
ActB Hs99999903_m1 
 
3.4. Circulating tumour cells isolation and molecular characterization  
 
 An innovative microfluidics device under patenting by our group was used for CTCs isolation 
based on their higher dimensions in comparison to blood cells[11]. Peripheral blood from metastatic 
bladder cancer patients was collected in EDTA tubes and unprocessed samples were run within two 
hours of collection through size-based microfluidic CTC isolation chips. These devices were fabricated 
in polydimethylsiloxane (PDMS) and comprise several isolation areas containing size exclusion filters 
which allow CTC enrichment just based on their size and deformability, irrespectively of their 
phenotype. After surface passivation, 5 to 8 ml of unprocessed blood samples were injected though the 
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system at a constant flow rate, followed by and a final washing step with PBS performed. Trapped 
cells were then fixed with formalin (approx. 4% paraformaldehyde) during 20 min at RT, washed 
again with PBS and incubated overnight at 4ºC with anti-STn clone B72.3 mouse monoclonal antibody 
(Abcam; 1:33 in PBS-2% BSA), followed by labelling with a secondary goat anti-mouse IgG-TRITC 
antibody (Thermo scientific; 1:500 in PBS-2%BSA) for 1h at RT. Cells were further stained for 1h 
with DAPI (1:1000), anti-pan KRT-FITC (Sigma-Aldrich, St. Louis, MO, USA; 1:50 in PBS-2% 
BSA) and anti-CD45-CY5 (Abcam; 1:50 in PBS-2%BSA) antibodies used as nuclear, epithelial and 
hematopoietic markers, respectively. Fluorescence microscopy analysis was performed using a Nikon 
Ti-E inverted fluorescence microscope equipped with a sCMOS camera (Andor Neo scc-01633). Cells 
presenting DAPI
+
/CK
+
/CD45
-
 our CD45
+
 were considered CTC while those presenting a DAPI
+
/CK
-
/CD45
+
 phenotype where regarded as blood cells[12, 13]. CTC entrapped in the microfluidics device 
were then lysed with Tripure (Roche) and RNA was purified with absolutely RNA FFPE kit (Agilent 
technologies, Santa Clara, CA, USA) and screened for KRT14, KRT5 and KRT20 as described in the 
previous section.  
 
3.5. Statistical analysis 
 
Statistical data analysis was performed with IBM Statistical Package for Social Sciences—
SPSS for Windows (version 20.0). Chi-square analysis was used to compare categorical variables. 
Kaplan-Meier curves were used to analyse the influence of STn expression in the time-to-event 
(death). Comparison of estimates was done using Log-rank test.  
 
4. Results 
 
In this study, we have screened 80 MIBC tissue samples from patients treated solely with 
cystectomy, 24% of which presenting with metastatic disease at the time of surgery. Table 1 shows the 
demographic characteristics and pathological findings. Tumours were first categorized by qPCR 
according with their differentiation state in either luminal (KRT14
-
KRT5
-
KRT20
+
; 34%) or basal-like 
(KRT14
+
/KRT5
+
KRT20
-
, 66%). A predominance of the basal-like tumour subtype in relation to luminal 
lesions could be found (data not shown), and these results were further validated by 
immunohistochemistry (Figure 1A). Approximately 75% of tumours could be sub-classified based on 
this approach, while the remaining could not be addressed due to analytical constrains related with low 
abundance of RNA. Nevertheless, the basal-like phenotype was further associated with recurrence 
(p=0.045). Furthermore, patients with basal-like tumours presented a decreased cancer-specific 
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survival when compared with patients presenting luminal tumours (mean 29 months vs. 69 months; log 
rank, p=0.019, Figure 1B). The majority of the metastases presented a basal-like profile in correlation 
with primary tumour. These insights reinforce the association of basal-like subtypes with worst 
prognosis in a Southern Europe population as well as the clinical potential of this stratification.  
 
 
Figure 1. (A) Immunohistochemical staining showing the differential expression of keratins in bladder 
tumours (x100). Columns represent staining of the antigen for each keratin (KRT5, KRT14 and KRT20) and 
lines depict the different subtypes studied. (B) Effect of bladder cancer subtypes in Cancer-specific survival 
(CSS) Kaplan-Meier analysis to evaluate the association between CSS and the basal-like and luminal subtypes. 
Log rank test (p=0.019), + censored luminal tumours; ⧫ censored basal-like tumours. 
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In parallel, 70% of the studied bladder tumours stained positive for the STn antigen, in 
accordance with our previous report[5]. STn was mainly expressed at the membrane and, to some 
extent, in the cytoplasm of dedifferentiated cells, mostly in areas of invasion (Figure 2A). STn 
positive cells were also observed at the invasive front and/or inside blood vessels, suggesting a 
possible role for this glycan in disease dissemination. Reinforcing these observations, STn 
overexpression was more frequent in primary tumours of patients with lymph-node metastasis when 
compared with tumours without metastasis (95% vs. 63%, p=0.013). In addition, STn was present in 
approximately 90% of the correspondent metastases (Figure 2B and C).  
 
Figure 2. Expression of STn in muscle invasive primary tumours, lymph node and distant metastasis. (A) 
Representative image of a MIBC tumour showing STn positive cells (brown) in the tumor invasion front and 
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inside blood vessels, suggesting possible involvement of STn in the metastatic process. (B) Representative 
image of a STn positive lymph node metastasis of a STn positive MIBC. (C) Representative image of a STn 
positive distant metastasis (pelvic) of a STn positive MIBC. Accordingly, over 90% of the metastasis from STn 
positive MIBC also expresses the antigen.  
 
We have then used an innovative microfluidic system to address the expression of the STn 
antigen in circulating tumour cells (CTCs) present in the blood of metastatic patients. This lab-on-a-
chip device acts as a cell sorter, allowing the retention of cancer cells presenting higher dimensions, 
irrespectively of their molecular profile, while removing lower dimensions blood cells. Accordingly, 
entrapped CTCs showing a DAPI
+
/CK
+
/CD45
-
 or CD45
+ 
phenotype were clearly distinguishable from 
residual levels of blood cells (DAPI
+
/CK
-
/CD45
+
) also present in the device (Figure 3). All cases 
presented CTC in concentrations that varied from 46-108 cells/mL of blood; moreover, no CTCs could 
be found in the blood of healthy blood donors used as controls.  In addition, the majority of isolated 
CTC (>90%) also express STn, mimicking the primary tumour and the metastasis (Figures 3 and 4).  
 
 
Figure 3. Expression of STn in circulating tumour cells (CTCs). (A)  Schematic representation of the 
microfluidic device used to isolate and characterize circulating tumour cells from peripheral blood of metastatic 
MIBC patients. Briefly, whole blood was run through a size-based microfluidic device composed of an array of 
micropillars that act as a molecular sorter. CTC, which are larger than blood cells, are expected to be retained in 
situ while blood cells flow through and exit the device. (B) Immunofluorescence analysis of CTCs 
(DAPI
+
/KRT
+
 and CD45
-
) trapped inside the device. Most CTCs expressing epithelial markers (pan-KRT in 
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green) are also positive for the STn antigen (in orange). The hematopoietic marker CD45 (in red) was used as 
negative control. In summary, these findings demonstrate, for the first time, that MIBC CTCs express the STn 
antigen.  
 
 
Figure 4. CTCs from metastasized MIBC patients express the STn antigen. As a proof of concept 
peripheral blood was collected from six metastasized MIBC patients presenting STn positive tumours. Blood 
from individuals without known neoplasia was used as a control. On average patients presented on average 59 
CTC/mL of blood (DAPI
+
/CK
+
/CD45
- 
or CD45
+
; however significant inter-individual variations were observed 
(CTC counts variations: 46-108 cells/mL;
 
data not presented in the graph). Nevertheless, STn was consistently 
found in approximately 94% of the isolated CTC in all studied patients. These findings suggest that STn may be 
a novel CTCs and metastasis marker.  
 
We have then extracted RNA from the cells entrapped in the microfluidics device and were 
able to amplify KRT14 but not KRT5 and KRT20 in all cases. These observations demonstrate that 
CTCs present a basal-like phenotype and high degree of undifferentiating, consistent with their highly 
aggressive nature. Likewise, patients showing STn positive tumours presented a decreased CSS in 
comparison to STn negative tumours (mean 74 months vs. 47 months; log rank, p=0.034, Figure 5), 
albeit STn expression was not associated with any particular molecular subtype. Notwithstanding, 
presence of STn allowed to discriminate sub-groups of patients facing worst CSS within luminal and 
basal-like phenotypes. Accordingly, presence of STn in luminal tumours was significantly associated 
with decreased CSS as compared to STn-negative tumours (log rank, p=0.027, Figure 6). Likewise, 
within the group of patients with basal-like lesions presence of tumour STn was related with decreased 
CSS compared to those lacking STn (mean 19 months vs.53 months, respectively; log rank, p=0.027). 
Moreover, it was expressed in CTC as well as in metastatic tissues, irrespective of their KRT-
phenotype. 
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Figure 5. Kaplan–Meier analysis showing the association between STn expression and decreased CSS in 
MIBC patients. Log-rank test (p=0.034); + censored STn negative tumors;  censored STn positive tumors. 
 
 
Figure 6 - Effect of STn expression in Cancer-specific survival (CSS) for luminal and basal-like subtypes. 
Kaplan-Meier analysis to evaluate the association between CSS and STn expression for (A) luminal and (B) 
basal-like subtypes. Log rank test, (A) p=0.047, (B) p=0.027. + censored STn negative tumours; ⧫ censored STn 
positive tumours. 
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5. Discussion and concluding remarks 
 
This work supports the potential of KRT-based molecular classification for prognostication of 
bladder tumours and its introduction in clinical setting. Moreover, we report that analysis of STn 
expression likely improves patient stratification and holds potential for pinpointing sub-populations 
facing worst prognosis. More importantly, by showing for the first time STn expression in both CTC 
and metastatic lesions, we present a strong link between the STn antigen, tumour dissemination and 
metastasis, providing key molecular information to target aggressive bladder cancer cells. These results 
are in agreement with previous reports showing that STn expression is associated cancer cell 
aggressiveness features in tumours from different organs and poor prognosis of the patients[14,15]. 
Given its influence on cell adhesion properties[5,8] cell and immune camouflage[10], STn-
positive cancer cells may be endowed with adaptive capabilities that ultimately contribute to establish 
metastases. However, further studies involving a higher number of patients are required to confirm 
these findings before application in the clinical practice. Particular attention should be devoted to 
exploring the molecular nature and the clinical relevance of STn-positive CTC populations, including 
the possibility of early detection of disseminated disease, prognosis, therapeutic monitoring and non-
invasive liquid biopsies on metastatic cells. Finally, the present study highlights the importance of 
understanding the role of glycans in bladder cancer, which remained poorly explored in comparison to 
other solid tumours. A comprehensive glycomic and glycoproteomic screening of bladder tumours 
may provide relevant molecular information envisaging true precision medicine settings. 
Glycomapping heavily glycosylated glycoproteins, such as CD44, CD49f, and other cancer stem cell 
biomarkers[1,2] known to carry STn[5,8], may provide key insights for designing more efficient 
targeted therapeutics. 
 
6. Abbreviations 
 
BSA: bovine serum albumin; CTC: circulating tumour cell; CSS: cancer-specific survival; FFPE: 
formalin-fixed, paraffin-embedded tissue sections; MIBC: muscle-invasive bladder cancer; PBS: 
phosphate buffered saline; KRT: keratin; RNA: ribonucleic acid; STn: sialyl-Tn. 
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1. Abstract  
 
Circulating tumour cells (CTC) detaching from the primary tumour, lymph nodes and distant metastasis hold 
tremendous potential for liquid biopsies by providing a molecular fingerprint for disease dissemination and its 
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temporal evolution through the course of disease management. Moreover, CTC enumeration, classically defined 
based on surface expression of epithelial cell adhesion molecule (EpCAM) and absence of pan-leukocyte 
marker CD45, has shown to correlate with clinical outcome. However, existing approaches introduce bias in the 
subsets of captured CTC, which may be excluding biologically and clinically relevant subpopulations. Here we 
explore the overexpression of the membrane protein O-glycan sialyl-Tn (STn) antigen in advanced bladder and 
colorectal tumours, but not in blood cells, to propose a novel CTC isolation technology. Using a size-based 
microfluidic device, we first show that the majority of CTC (>90%) isolated from the blood of metastasized 
bladder and colorectal cancers express the STn antigen, reinforcing its pancarcinomic link with metastization. 
More importantly, STn
+
CTC counts were significantly higher compared to EpCAM-based detection in 
colorectal cancer, providing a novel and more efficient cell-surface biomarker for CTC isolation. Exploring this 
concept, we have then built a glycan affinity-based microfluidic device for selective isolation of STn
+
CTC and 
propose an enzymatic-based strategy for the recovery of viable cancer cells for downstream biomedical 
research. Finally, clinically relevant cancer biomarkers (transcripts and mutations) in bladder and colorectal 
tumours were identified in microfluidic-isolated cells, confirming their malign origin and highlighting the 
potential of this technology in the context of precision oncology. 
 
Keywords: Circulating tumour cells, glycosylation, microfluidics, cancer, liquid biopsy, lab-on-a-chip 
 
2. Introduction 
 
Liquid biopsies constitute the cornerstone for real-time assessment of metastasis development 
and its molecular nature, while overcoming the detection limitations posed by invasive procedures and 
imaging techniques
1
. Particularly, several reports have demonstrated that circulating tumour cells 
(CTC) released from the primary tumour harbour genetic and molecular features found in metastatic 
sites
2, 3
. Despite being one of the driving force of metastasis and cancer-related deaths, CTC are rare, 
accounting for less than 0.004% of all mononucleated blood cells
4, 5
. Nevertheless, CTC were proven 
to better predict overall survival than other cancer biomarkers
6
, holding tremendous potential for 
aiding early intervention, therapeutic decision and predicting response to therapy
7
.  
The gold standard technique for CTC analysis involves affinity enrichment for cell-surface markers 
followed by detection by flow cytometry
5, 8-10
. Nevertheless, it requires expensive upfront investments 
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and maintenance, exhibits low recovery and sensitivity rates and does not guarantee the retrieval of 
viable populations for downstream molecular studies
5, 8-10
. Moreover, this strategy relies on the 
expression of epithelial proteins, as the epithelial cell adhesion molecule (EpCAM), which is often 
suppressed or downregulated in circulating and metastatic cancer cells
5, 10-12
. It is also estimated that 
more aggressive and relevant CTC populations remain uncovered by the use of current detection 
methods
13
. Moreover, EpCAM-expressing cells have been observed in the bloodstream of patients 
with benign lesions
14, 15
. As such, the introduction of alternative methods for isolation of these rare 
cells represents the critical step to generate advances in CTC research. The development of the first 
silicon-based microfluidic capture device (2007) constituted a break-through in CTC research, offering 
a unique opportunity to overcome the limitations of available methods, mainly related to cost, 
processing times and ease of use
16, 17
. Microchips allow the separation of CTC from other blood 
components based on their physicochemical characteristics, sometimes even without the need of prior 
processing, but also based on their cell-surface protein expression. In this case, the inner surfaces of 
the devices are functionalized with antibodies and other ligands, thereby improving binding specificity 
and CTC purity
4, 18, 19
. Microchips are also a versatile technology, endowing either in situ analysis
20, 21 
or the isolation of viable cells for downstream molecular studies
22-24
. Several studies, with different 
chip designs, demonstrated the potential of this technology for basic research and as a clinical tool, 
allowing to improve CTC counts while providing phenotypic analysis
25-27
. Nevertheless, positive 
selection of CTC in these devices continues to rely on EpCAM expression
28, 29
, and confirmation 
mostly depend on the DAPI+/CK+/CD45- molecular profile that contrasts with the DAPI+/CK-
/CD45+ phenotype of white blood cells28. This significantly diminishes the spectra of captured CTC
5, 
11, 12
, urging the development of more specific tools. Moreover, CTC identification relies mostly on 
CKs expression, which are not cancer specific biomarkers, and most studies do not present 
complementary molecular methods confirming the malignant nature of isolated cells. Similar 
approaches exploring other cell-surface markers (PSMA30, HER2
31
) have been attempted but 
significant contamination with blood cells is still common in microfluidic devices
32
, hampering their 
potential clinical application. More recently, the spectra of captured CTC has improved with the 
introduction of multitarget microchips
33-36
; however the development of microchips targeting more 
metastasis-specific biomarkers is warranted.  
Glycosylation, the most common post-translational modification of cell surface proteins, plays a key 
role in the modulation of protein functions
37, 38
. Altered protein glycosylation is a hallmark of cancer
37, 
39
 and, over the last years, the detailed mapping of protein glycosylation by mass spectrometry has 
increased the specificity and sensitivity of cancer biomarkers
40, 41
. Our group has demonstrated the 
biological and clinical significance of the cancer-associated glycan sialyl-Tn (STn), which results from 
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a premature stop in protein O-glycosylation in different cancer models
40, 42-44
. Accordingly, STn is 
expressed by most advanced stage bladder
43, 44
, gastrointestinal
40, 42 
and colorectal tumours
40
, being 
often related with metastasis
45
, while absent or marginally expressed on corresponding healthy 
tissues
43
. Moreover, the antigen affects cell adhesion, migration, invasion, metastasis and 
chemoresistance, while contributing to immune escape
40, 43, 46, 47
. Despite these evidences, the 
expression of STn by CTC, which constitute the driving force of metastasis, remains mostly 
unaddressed. Based on these insights, we aim to evaluate the potential of STn antigen as a novel cell-
surface biomarker for selective CTC detection and enrichment, as well as to propose the first glycan-
based microfluidic device for CTC discovery and downstream biomedical applications. 
 
3. Material and Methods 
 
3.1 Patient samples and processing 
 
CTC were isolated from whole blood collected from 17 cancer patients (5 bladder and 12 colorectal). 
Bladder cancer patients were enrolled at Urology Department, Porto Hospital Centre, St António Hospital 
(CHP-HSA) in Porto, Portugal, whereas colorectal cancer patients originated from the Portuguese Institute of 
Oncology—Porto (IPO-Porto) also in Portugal. All patients were under follow-up after surgery at these 
hospitals at the time of blood collection (2017). Amongst colorectal patients (4 colon and 8 rectum), 50% 
presented lymph node metastasis and 42% distant metastasis at the time of surgery. Regarding bladder cancer, 
all patients presented metastasis at the time of blood collection for CTC analysis. Table 1 summarizes available 
clinicopathological information at the time of diagnosis. Formalin fixed paraffin embedded (FFPE) tumour 
tissues from colorectal patients were also included. Blood donors matched in age and gender, and without 
known neoplasias, were included as controls. Peripheral blood samples were collected following the standard 
venipuncture technique in EDTA-coated tubes (BD
®
 biosciences, San Jose, CA, USA) for analysis by size-
based microfluidic devices. Alternatively, peripheral blood mononuclear cells (PBMC) were separated from the 
sample, using Ficoll-Paque™ (GE Healthcare, Little Chalfont, UK), density gradient centrifugation, and 
analysed in the glycan-affinity microfluidic device. All procedures were performed under patient’s informed 
consent, and after approval by the Ethics Committee at CHP-HSA and IPO-Porto. Clinicopathological 
information was obtained from patient’s clinical records.  
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Table 1. Summarized clinicopathological data for patients enrolled in this study. 
Patient Gender Age TNM 
Bladder cancer 
#1 M   
#2 M 82 T4N2M1 
#3 M 51 T1G3N0M0 
#4 M 41 TaG1N0M0 
#5 M 62 T3N0M0 
    
Colorectal cancer 
#1 M 70 T3N0M0 
#2 M 77 T3N0M1 
#3 F 73 T3N0M0 
#4 F 72 T3N2bM0 
#5 M 68 T3N1cM0 
#6 M 69 T3N1M1 
#7 F 89 T4N2aM0 
#8 M 74 T3N1M0 
#9 M 59 T2N0M0 
#10 M 69 T2N0M1 
#11 F 83 T3N1aM1 
#12 M 63 T3N0M1 
 
 
 
3.2. Cell models and culture 
 
Metastatic human bladder cancer cell models MCRSTn, overexpressing the STn antigen, and 
MCRmock, expressing residual levels of the glycan
43
, were used for this study. Cell lines were 
cultured in HyClone Dulbecco's High Glucose Modified Eagles Medium (DMEM; GE Healthcare) 
with 4,0 mM L-glutamine, and 1,0 mM sodium pyruvate, supplemented with 10% heat-inactivated 
FBS (Gibco, Life Technologies, Co Dublin, Ireland) and 1% penicillin-streptomycin (10,000 Units/mL 
penicillin; 10,000 mg/mL streptomycin; Gibco, Life Technologies). Cell lines were cultured as a 
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monolayer at 37°C in a 5% CO2 humidified atmosphere, and were routinely subcultured after 
trypsinization (Trypsin, Promega Corporation, Madison, WI, USA). 
 
3.3.Non-targeted microfluidic devices design and fabrication 
 
 The non-targeted microfluidic devices used for screening patients CTCs for STn expression 
were designed to split the sample equally in different analysis areas, containing each a set of filters that 
isolate CTCs according to their size and deformability, as previously described
48
. Silicon moulds were 
fabricated using photolithography and deep reactive ion etching to achieve highly anisotropic features, 
as well as hydrophobized with a vapor phase treatment in trichloro(1H,1H,2H,2H perfluoro 
octyl)silane (Sigma Aldrich). Replicas were fabricated in Polydimethylsiloxane (PDMS, Ellsworth 
Adhesives Iberica, Madrid, Spain) and bonded to glass slides using oxygen plasma. Once primed with 
ethanol, to enhance the wettability, devices were passivated to avoid unspecific attachment. More 
details on fabrication procedures may be found in a recent patent application
48
 
 
3.4. Glycan-affinity microfluidic devices design and fabrication 
 
An innovative glycan-affinity microfluidic device was specially designed to isolate STn-
expressing cells. These devices were fabricated in PDMS (Ellsworth Adhesives Iberica) and comprise 
an inlet, a cell enrichment area composed of micropillars functionalized with an anti-STn antibody, 
and an outlet. Masters for PDMS moulding were fabricated using standard photolithography 
techniques. Cylindrical features with diameters of 100 µm and interspacing of 100 µm were used in a 
geometric arrangement with a 100 µm shift in every row to maximise mixing. Silicon wafers were 
cleaned by subsequent sonication steps in acetone and isopropanol for 5 minutes each, dried with 
nitrogen and activated in oxygen plasma for 5 minutes. Upon activation, the wafers were immersed in 
5% GPTMS in ethanol for 1h, rinsed in ethanol and cured at 80ºC for 1 hour. SU8-50 was dispensed 
on the wafer and spun to achieve a 50 µm thick layer. The wafer was soft baked in 2 steps, first at 65ºC 
for 10 minutes and secondly at 95ºC for 30 minutes. The wafer was then exposed through a 
transparency mask (JD tools) to a UV lamp with a dose of 250 mJ/cm2, and postbaked at 55ºC 
overnight. The sample was developed for 20 minutes and hardbaked ramping from 65ºC to 200ºC. 
Prior to master replication, the wafer was hydrophobized with a vapour-phase treatment in trichloro 
1,1,2,2-perfluorooctyl-silane for 1 hour in a desiccator, and cured for another hour at 80ºC. PDMS was 
mixed at 1:10 ratio, degassed, poured over the master, degassed again and cured at 80ºC for 2 hours. 
After curing, the PDMS was unmoulded and the inlet and outlet were punched. Finally, clean glass 
slides and PDMS replicas were treated with oxygen plasma at low power for 15 seconds and 
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subsequently brought in contact to produce irreversible bonding. 
Upon activation with oxygen plasma, the microfluidic devices were connected to a syringe 
pump and filled with ethanol. All the functionalization steps were carried out at 100 µL.min−1. After 
stabilization in ethanol, 2% (3-Aminopropyl)triethoxysilane (APTES) in ethanol was withdrawn into 
the device for 30 minutes and rinsed in ethanol for 10 minutes. Then, the buffer was changed to MilliQ 
water and stabilized for 10 minutes prior to withdrawing 1% glutaraldehyde in water for another 30 
minutes and rinsing in water for 10 minutes. Sterile PBS was then withdrawn into the device and 
equilibrated for 10 minutes just before introducing 200 µL of anti-STn monoclonal antibody B72.3 
(1:33 in PBS-2% BSA, Abcam, Cambridge, UK) in PBS and left to react overnight at 4 °C. For 
optimization procedures, devices functionalized with different amount of antibody were produced (0, 
5, 15, 33, 50 μg). Unbound antibody was then rinsed with PBS for 10 minutes and the surface blocked 
with 2% bovine serum albumin (BSA) in PBS and 1% human serum albumin for 1 hour. All reagents 
were purchased to Sigma Aldrich unless indicated otherwise. 
The functionalization process was monitored using a Quartz Crystal Microbalance (OpenQCM, 
Novaetech, Italy) by measuring variations in frequencies caused by mass variations. A gold sensor was 
coated with a thin layer of SiO2 for this purpose and used to study the functionalization process. After 
exposure for 15 seconds in the Plasma cleaner, in low power, the sensor was placed in a flow chamber 
and subjected to a 100 µL.min-1 flow. After stabilizing with ethanol, 2% APTES in ethanol was 
pumped until a stability in the measurement was reached for at least 1 minute. After rinsing in ethanol, 
the buffer was changed to MilliQ water and 1% glutaraldehyde was pumped until stability was 
reached, them the system was rinsed with MilliQ water. In the final step, PBS was used as buffer and 
monoclonal antibody B72.3 was inserted in the system and then rinsed. 
 
3.5. CTC analysis using size-based microfluidics devices 
 
An innovative microfluidic device48 was used for CTC isolation based on their higher 
dimensions a low deformability compared to blood cells. Peripheral blood from metastatic bladder and 
colorectal cancer patients (3.5 mL) was collected in EDTA tubes (BD® biosciences) and unprocessed 
samples were run within two hours of collection. After surface passivation, 3.5 mL of unprocessed 
blood samples were injected though the system at a constant flow rate of 80 μL.min-1, according to 
previous optimization
48
, followed by a washing step with PBS at the same flow rate. Trapped cells 
were then fixed with formalin (approx. 4% paraformaldehyde, Sigma Aldrich) during 20 min at RT, 
washed again with PBS and incubated overnight at 4°C with anti-STn clone B72.3 mouse monoclonal 
antibody (Abcam; 1:33 in PBS-2% BSA), followed by labelling with a secondary goat anti-mouse 
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IgG-TRITC antibody (Thermo Fisher Scientific, Waltham, MA, USA; 1:500 in PBS-2%BSA) for 1h at 
RT. Cells were further stained for 1h with DAPI (1:1000, Sigma Aldrich), anti-pan CK-FITC (Sigma 
Aldrich; 1:50 in PBS-2% BSA) and anti-CD45-CY5 (Abcam; 1:50 in PBS-2%BSA) antibodies, used 
as nuclear, epithelial and hematopoietic markers, respectively. When appropriate, trapped cells were 
also probed with Alexa Fluor® 488 anti-human CD326 (EpCAM) antibody clone 9C4 (Biolegend; 
1:50 in PBS-2%BSA). Fluorescence microscopy analysis was performed using a Nikon Ti-E inverted 
fluorescence microscope equipped with a sCMOS camera (Andor Technology Ltd, Belfast, Ireland). 
Cells presenting DAPI+/CK+/CD45- profile were considered CTC while those presenting a 
DAPI+/CK-/CD45+ phenotype where identified as normal blood cells28. In addition, cells isolated 
from blood of a subgroup of colorectal cancer patients (#6-10) were also evaluated for DAPI, STn, 
EpCAM and CD45, and analysed by fluorescence microscopy as previously described. CTC were then 
lysed by injection of 300 μL TriPure isolation Reagent (Roche Diagnostics GmbH, Mannheim, 
Germany) at 80 µl.min-1 and incubated for 30 minutes at 4ºC envisaging nucleic acid isolation. 
Another 300 μL of TriPure were injected into the devices at higher flow rate (250 µl.min-1) and 
incubated for 10 min. Chloroform (Sigma Aldrich) was then added to Tripure, and the aqueous phase 
containing the nucleic acids was isolated for further processing. 
 
3.6.CTC analysis using glycan-affinity microfluidics devices 
 
Glycan-based microfluidic devices, described here for the first time, were validated using 
model cell lines, prior to the analysis of patient samples. Validation steps included: i) definition of 
optimal amounts of immobilized antibody; ii) identification of optimal solvent flow rates; iii) 
estimation of capture yield for STn-expressing cells in model conditions (PBS) and spiked blood. 
Validation assays were also conducted using peripheral blood from metastatic colorectal cancer 
patients. Prior to blood samples (3.5 mL) analysis, CTC were pre-enriched together with PBMCs. 
 For optimization experiments, calcein (Thermo Fisher Scientific) labelled MCRSTn cells were 
used to determine the ideal antibody amounts for downstream studies. Cell suspensions were injected 
at a flow rate of 30 μL.min-1, previously described as optimal for affinity microfluidic devices with 
similar architecture but targeting different antigens
49
. Microfluidic devices functionalized with 
different amounts of immobilized antibodies were tested (5, 15, 33, 50 μg). Non-functionalized devices 
were used as controls. Solvent flow rate was also varied to maximize cell isolation yields during 
washing steps (15, 30, 45 μL.min-1). The affinity of the microchips for STn-expressing cells was 
determined using MCRSTn and MCRmock cells. Briefly, 10
3
 cells were dispersed in 200 μL PBS and 
injected into the devices. Human PBMCs (10
6
 cells) that do not express STn were used as controls. 
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Cell entrapment was estimated by fluorescence microscopy. Then, PBMCs from donors without 
known neoplasias were spiked with different amounts of both MCRSTn and MCRmock (10
2
, 10
3
, 10
4
) 
cells, in an attempt to mimic CTC found in metastatic cancer patients. Cancer cells were isolated 
together with PBMCs from whole blood and processed as described above. Finally, the blood of a 
subset of colorectal cancer patients (#10-12) was also analysed according with the optimized 
conditions. Entrapped cells were probed for DAPI, panCK, STn and CD45, as previously described for 
non-functionalized microfluidic devices. Colorectal CTC were then released from the affinity device 
with a α-sialidase from Clostridium perfringens (10 U/mL, Sigma Aldrich) for 30 and 120 minutes at 
37°C, under stationary conditions or by continuous injection of the enzyme at a flow rate of 10 
μL.min-1. Released cells were lysed for DNA isolation for downstream mutation analysis by Droplet 
Digital™ PCR (ddPCR™) Technology (BioRad, Hercules, CA, USA). All experiments were 
performed in triplicate and presented results correspond to the average of at least two concordant 
replicates. 
 
3.7.Immunohistochemistry for the STn antigen 
 
Formalin-fixed, paraffin-embedded tissue sections (FFPE) were screened for STn by 
immunohistochemistry using the strepavidin/biotin peroxidase method, as described by Ferreira et 
al.43. Briefly, 3 μm sections were deparaffinized with xylene (VWR, Radnor, PA, USA), rehydrated 
with graded ethanol series (Merck Millipore, Burlington, MA, EUA), microwaved for 15 min in 
boiling citrate buffer (10mM Citric Acid, 0.05% Tween 20, pH 6.0; Vector Laboratories, Burlingame, 
CA, USA), and exposed to 3% hydrogen peroxide (Merck Millipore) for 20 minutes. STn expression 
was performed using clone B72.3 mouse monoclonal antibody (Abcam) at a dilution of 1:100 in PBS, 
after overnight incubation at 4°C. After blockage with BSA (5% in PBS), the antigens were identified 
with UltraVision HRP Detection System Kit (Thermo Fisher Scientific) followed by incubation with 
3,3-diaminobenzidine tetrahydrochloride (Impact Dab, Vector Laboratories) for colour development. 
Finally, the slides were counterstained with haematoxylin for 1 minute. Negative control sections were 
performed by adding BSA (5% in PBS) devoided of primary antibody. The immunoassayed sections 
were blindly assessed using light microscopy by two independent observers and validated by an 
experienced pathologist. Disaccording readings were re-analysed using a double-headed microscope 
and consensus was reached. Given the absence of STn in the healthy urothelium43, tumours were 
classified as positive for these antigens when membrane and/or cytoplasmic immunoreactivity were 
observed in more than 5% of the tumour. 
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3.8.Flow Cytometry for the STn antigen 
 
MCRSTn, MCRmock and blood cells were screened for STn expression by flow cytometry 
with anti-STn mouse monoclonal antibody clone B72.3, as described by Peixoto et al.
47
. 
Approximately 10
6
 adherent MCRSTn and MCRmock cells were converted into single cell 
suspensions using Versene (Gibco, Life Technologies) at 4ºC, followed by filtration using a 70 μm 
Nylon cell strainer (BD Falcon, BD® biosciences). A minimum of 10
5
 cells were analysed by flow 
cytometry. The cell population in this study was gated based in FSC and SSC features to avoid 
background and debris (corresponding to > 95% of the measured cells in each sample). Cells digested 
with α-sialidase from Clostridium perfringens (10 U/mL, Sigma Aldrich) for 90 min at 37°C, were 
used as negative controls. This procedure was responsible by hydrolysing the sialic acid in STn, 
impairing recognitions by B72.3 monoclonal antibody50. Experiments with mouse IgG1 [ICIGG1] 
Isotype Control (Abcam) were further included as negative controls. Polyclonal rabbit anti-mouse 
immunoglobulins/FITC (DAKO, Agilent technologies, Santa Clara, CA, USA; F0313) was used as 
secondary antibody. Two independent experiments were performed in triplicate for each cell line. 
Whole blood samples were used and labelled with anti- STn, CD45-PO (Life Technologies), CD3-
v450, CD14-APC (BD Biosciences), and CD19-PE Cy7 (Beckman Coulter) monoclonal antibodies, to 
assess different subpopulations of white blood cells. Samples were lysed in BD FACS Lysing solution 
(BD Biosciences) after staining and analysed in NAVIOS flow cytometry (Beckman Coulter). Results 
were analysed with the Infinicyt software (Cytognos S.L.). The percentage of STn positive cells was 
defined as cells with a fluorescence intensity above the Isotype Control. Blood samples from five 
healthy male individuals’ ages between 45 and 60 (median: 52 years) were analysed. 
 
3.9.Real-time PCR for KRT14, 5 and 20 expression in bladder CTC 
 
 Total RNA from bladder CTC entrapped in the microfluidics device was extracted from nucleic 
acid-enriched aqueous fractions using RNA FFPE kit (Agilent technologies). The purity and quantity 
of RNA extracts were determined based on the A260/A280 ratio using Nanodrop ND1000 (Nano Drop 
Technologies Inc., Wilmington, DE, USA). Only samples with ratios between 1.9 and 2.1 were 
considered for downstream molecular studies. RNA (2µg) was reverse transcribed with random 
primers, using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, 
CA, USA). The amplification conditions were the following: 25°C for 10 minutes, 37ºC for 120 
minutes and RT inactivation at 85°C for 5 minutes. Two non-template negative controls were used. 
The products were amplified in a Mycycler Thermal cycler (BioRad). Gene expression levels of KRT5 
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(Hs00934200_g1), KRT14 (Hs00559328_m1) and KRT20 (Hs00300643_m1), including three 
reference genes (B2M: Hs00984230_m1, HPRT: Hs99999909_m1, and ActB: Hs99999903_m1) were 
analysed using a TaqMan Gene Expression Master Mix and TaqMan assays (Applied Biosystems). 
Real-time PCR amplification of cDNA samples was performed in a ABIPRISM 7500 Real-Time PCR 
System (Applied Biosystems). Thermal cycling conditions were 10 minutes at 95°C followed by 45 
cycles of 15 sec at 95ºC and 1 minute at 60°C. All samples were run in duplicate. Relative mRNA 
gene expression was calculated with the 2
-ΔCt
 formula. 
 
3.10. ddPCR for APC mutation detection in colorectal CTC 
 
DNA from colorectal CTC, corresponding primary tumours and metastasis, whenever 
available, were screened for APC wild-type (WT) and APC c.4348C>T mutation (MT) DNA. CTC 
DNA was isolated from nucleic acid enriched fractions isolated from microfluidics devices, whereas 
DNA from primary tumours and metastasis was extracted from FFPE tissue sections available at IPO-
Porto biobank. DNA was isolated using QIAamp® DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) 
following the manufacturer's instructions and quantified on a Qubit fluorometer using the dsDNA HS 
(High Sensitivity) Assay Kit (Thermo Fisher Scientific). DNA was diluted up to 65 ng/μl using MilliQ 
water. For each assay, no template controls (NTC) were used, and wild-type-only (WT-only) samples 
were used in order to estimate false-positive rates. Each droplet of a PCR supermix (Bio-Rad) reaction 
contained: 1× droplet PCR supermix, 250 nM of each probe, 900 nM primers and 65 ng of non-
digested genomic and CTC DNA, in a total reaction volume of 20 μL. The following PrimePCR 
ddPCR™ Mutation Assay (BioRad) was used: APC WT for p. R1450* (assay ID: dHsaCP2500509) 
and APC p.1450* (assay ID: dHsaCP2500508). Droplets were generated and analysed using the 
QX100 system (Bio-Rad). Amplifications were performed using the following conditions: 1 cycle of 
95 °C for 10 minutes, 40 cycles of 94 °C for 30 s and 55 °C for 1 minutes, and 1 cycle of 98 °C for 10 
minutes. All samples were run in duplicates. QuantaSoft analysis software (Bio-Rad) enabled 
fractional abundance to be calculated for each sample. To ensure experiment quality, samples with 
total droplet counts lower than 10,000 were considered invalid and excluded from the analysis. 
Positive control samples were used to verify assay performance and facilitate the establishment of 
thresholds. Additionally, positive control samples were validated by comparing the fractional 
abundance (FA) in FFPE samples to NGS mutation frequencies. False-positive rate estimation was 
determined by performing 5 experiments for each assay using the WT-only samples, where total 
amounts of detected MT-positive droplets determined thresholds above which positive droplets in 
patient samples were to be considered as true positive. 
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3.11. Statistical Analysis 
 
Statistical data analysis was performed with IBM Statistical Package for Social Sciences—SPSS for 
Windows (version 20.0) and Graphpad prism 7 (GraphPad Software, Inc.). Differences between 
continuous variables among the evaluated groups were accessed by Mann-Whitney non-parametric test 
for independent samples. Spearman’s nonparametric bivariate test was used for correlation estimate. 
Differences were considered significant when p<0.05.  
 
4. Results and discussion  
 
 The identification of novel CTC biomarkers capable of overcoming the limitations presented by 
current CTC isolation technologies are warranted to pave the way for novel targeted technological and 
clinical applications. The STn antigen, expressed at the cell-surface of advanced stage tumours and 
generally associated with disease dissemination, may hold potential in this context; nevertheless, its 
expression by CTC has yet to be fully demonstrated. Herein, we have addressed the expression of STn 
in CTC from patients with distinct advanced cancers, envisaging the necessary molecular rational for 
precision medicine applications. A schematic representation of the experimental design used in this 
study is represented in Figure 1. 
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Figure 1. Schematic representation of the experimental design. A) Analysis of Total CTC using non-
targeted size-based microfluidics devices. Whole blood from metastatic bladder and colorectal cancer patients 
was processed in non-targeted, size-based affinity devices. The device is composed of an inlet, a separation 
section presenting a micropillar architecture capable of retaining cancer cells based on their higher dimensions 
in comparison to blood cells, and an outlet. Cells were stained with DAPI and analyzed in situ by 
immunofluorescence for CTC biomarkers (PanCK, STn) and hematopoietic cells (CD45). Cell enumeration was 
performed by immunofluorescence microscopy. In addition, entrapped cells were lysed and RNA or DNA 
isolated for downstream transcript (RT-PCR) and mutation analysis (ddPCR™), respectively. B) Analysis of 
STn-positive CTC using glycan-affinity microfluidic devices. MCRSTn bladder cancer model, overexpressing 
the STn antigen, and MCRmock, showing residual level of STn, were used for validation purposes. PBMCs 
were recovered from whole blood of metastatic bladder and colorectal cancer patients, mixed with MCR cells 
and processed in glycan-affinity microfluidic devices functionalized with anti-STn B72.3 monoclonal antibody. 
Cells were analyzed in situ by immunofluorescence as described above. In addition, STn-CTC were selectively 
released by sialidase treatment for downstream molecular analysis. Scale bar for microscopy images is 20 μm. 
 
Our group has previously demonstrated that all metastatic bladder tumours and corresponding 
metastasis overexpress the STn antigen
45
; however, such a correlation is not clear for colorectal cancer. 
Therefore, as a proof of concept, we have addressed STn antigen expression in colorectal (n=12) 
tumours and corresponding metastasis, where the prevalence of this antigen was found associated with 
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poor prognosis
40, 43, 44
. All histological sections presented malignant cells expressing the STn antigen at 
the plasma membrane (Figure 2). Cytoplasm staining was also observed, mostly likely derived from 
glycoproteins in secretory pathways, thus in accordance with previous observations
43, 51
. More 
importantly, all tumours presented STn positive lymph node and/or distant metastasis, irrespectively of 
their location (lung, liver). These observations support that STn expression in primary colorectal 
tumour sites are reflected in the metastasis, as previously reported for bladder cancer
45
. Moreover, it is 
in agreement with previous studies demonstrating that STn expression may play a key role in disease 
dissemination
41
. Together with previous reports
52
, these observations support the pancarcinomic nature 
of this glycan. 
 
Figure 2. STn expression in colorectal primary tumours and corresponding lymph node and 
distant metastasis. All metastatic cancer patients enrolled in this study (#1-12) presented STn positive 
tumours. Moreover, the corresponding locoregional and distant metastasis (whenever available) were 
also positive. This Figure highlights findings for patients #11 and #12 at a 100x magnification.  
 
In parallel, whole blood was collected from colorectal cancer patients (n=12) and the presence 
of STn at the membrane of isolated CTC investigated, as previously observed for bladder cancer
45
. To 
further validate our previous findings, peripheral blood from an independent set of bladder cancer 
patients (n=5) was also analysed. CTC were sorted from unprocessed blood using a label-free 
microfluidic device capable of retaining cells based on their size and deformability. These physical 
characteristics are distinct between CTC and blood cells, i.e. CTC display higher dimensions and are 
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less deformable
8
, allowing a successful isolation and enrichment of CTC in these systems, while 
minimizing leukocyte contamination8. Moreover, this non-targeted approach allows isolation of CTC 
irrespectively of their molecular profile, thus enabling the capture of distinct, heterogeneous and 
clinically relevant CTC subpopulations for downstream molecular studies. Captured cells were then 
probed in situ with DAPI and screened for panCKs, CD45, and STn antigen by immunofluorescence. 
The absence of CK expression and the presence of the hematopoietic marker CD45 was the criteria 
used to distinguish CTC (DAPI+/CK+/CD45-) from normal blood cells (DAPI+/CK-/CD45+), as 
reported in multiple studies
14, 53, 54
. Notably, CTC were detected in all patient samples regardless of 
their origin (Figure 3A); more importantly, CTC were not observed in the blood of controls without 
known neoplasia matched in age and gender, supporting the pathological nature of the cells found in 
cancer patient samples. Moreover, trapped CTC were found to be similar in size, displaying 
homogenous dimensions from 15 to 20 μm. A similar CTC size range was observed by others using a 
label-free microfluidic technology
55. Occasionally, few cells presenting a maximum diameter of 10 μm 
could also be detected, together with residual (<0.1% of total cells) white blood cells (DAPI+/CK-
/CD45+). Noteworthy, we have observed CTC in two colorectal cancer samples without imagiological 
evidences of metastasis, and several samples (n=5) showing just locoregional, but not systemic 
disease. Such findings suggest that this approach may be useful for detecting disease not yet fully 
disseminated, providing the necessary means for early intervention. Remarkably, the majority of 
CK+CTC also expressed the STn antigen (>95%; Figure 3A and 3B), in clear contrast to leukocytes; 
complementary analysis by flow-cytometry corroborated the absence of STn in blood cells (Figure 4). 
STn signal specificity was confirmed by the loss of fluorescence upon sialidase incubation (data not 
shown). In summary, our results demonstrate that STn antigen is highly expressed in CTC from 
distinct tumour types, in mimicry of the primary tumour and corresponding metastasis. Altogether, this 
data highlights the potential of STn as a novel CTC biomarker for improved CTC detection and 
targeting. 
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Figure 3. STn expression in bladder and colorectal CTC isolated using non-targeted size-based 
microfluidic devices. Whole blood from patients with metastatic bladder (n=5) and colorectal tumours (n=10) 
was processed using non-targeted size-based microfluidic devices, which sort CTC from blood cells based on 
their higher dimensions. Entrapped cells were then probed for DAPI (blue), panCK (green), STn antigen 
(orange), CD45 (red) and analyzed by immunofluorescence microscopy. A) Immunofluorescence staining 
pattern of isolated CTC for each type of tumour as well as blood cells. CTC were identified according to the 
following criteria: DAPI positive, panCK positive and CD45 negative. CTC were therefore distinguishable from 
blood cells, which presented a DAPI positive, panCK negative, CD45 positive phenotype (highlighted by a 
white arrow in the right panel). The left panel highlights the predominance of STn in relation to EpCAM-
positive CTC. The middle panel highlights STn+/EpCAM+ CTC subpopulations, whereas the right panel 
highlights STn+/EpCAM- CTC, which constitute the majority of isolated CTC. B) Total CTC/mL vs STn-
CTC/mL of blood enumeration plots for bladder and colorectal cancer patients. Total CTC for bladder cancer: 
36-140 CTC/mL of blood (median: 49 CTC/mL); Total CTC for colorectal cancer: 27-131 CTC/mL of blood 
(median: 53 CTC/mL). The vast majority of isolated CTC in both models expressed the STn (STn-CTC/Total 
CTC percentage is presented on top of each column). For bladder cancer: 83-100% (median: 95%).For 
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colorectal cancer: 68-98% (median: 96%). The results correspond to the average of at least two independent 
experiments and three measurements. “**” p < 0.01. Scale bar for microscopy images is 20 μm. 
 
 
Figure 4. A) STn antigen expression in MCRCSTn, MCRmock and PBMCs isolated from the blood of 
healthy donors. Approximately 75% of MCRSTn cells expressed the STn antigen, contrasting with the 11% 
presented by MCRCmock. PBMCs did not express STn. The MCRCSTn cells were significantly sensitive to 
sialidase treatment, confirming the specificity of the signal. B) STn expression in different populations of 
human blood cells. All cell populations (CD45
+
) were negative for the STn antigen using the B72.3 
monoclonal antibody. 
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4.1. STn vs EpCAM expression in colorectal CTC 
 
EpCAM remains the most explored biomarker of CTC and the basis for EpCAM-based CTC 
enrichment methods
28, 29
. This includes CellSearch, the only FDA-approved immunoaffinity method 
extensively explored for the use of CTC enumeration for colorectal cancer prognosis10. Prompted by 
our previous observations of high STn expression in CTC, we next investigated and compared the 
presence of STn and EpCAM at the surface of CTC on five colorectal cancer patients (#6-10). Of note, 
the percentage of STn
+
CTC was, on average, 3 times higher than EpCAM+CTC for all cases analysed 
(Figure 5B), suggesting that EpCAM
+
CTC may be a minor subset in relation to the total CTC 
population present in the blood of metastatic patients. Nevertheless, CTC positive for both STn and 
EpCAM could also be observed (Figure 5A, middle panel), which reinforces CTC plasticity and 
molecular heterogeneity
56, 57
. These findings further support the concept that targeting EpCAM may 
significantly hinder access to clinically relevant CTC subpopulations and decrease the sensitivity of 
current detection and isolation methods 
 
Figure 5. STn vs EpCAM expression in colorectal CTC isolated using non-targeted, size-based 
microfluidic devices. EpCAM has been the gold standard membrane biomarker for accessing and 
enriching for CTC in colorectal tumours whereas STn is showing to be widespread expressed in CTC. 
Accordingly, whole blood from patients with metastatic colorectal tumours (n=5; labelled #6-10) were 
processed using non-targeted size-based microfluidics devices, which sort CTC from blood cells based 
on their higher dimensions. Entrapped cells were then probed for DAPI (blue), STn antigen (orange), 
EpCAM (green) and CD45 (red) and analyzed by immunofluorescence microscopy. A) 
Immunofluorescence staining pattern of isolated CTC highlighting the predominance of STn-CTC in 
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relation to EpCAM-CTC. The left panel highlights the higher density of STn expressing CTC in 
relation to those expressing EpCAM. The middle panel shows the existence of CTC subpopulations 
expressing both STn and EpCAM, denoting heterogeneous populations. The right panel highlights 
STn+/EpCAM- CTC. B) Percentage of STn- vs EpCAM-CTC in relation to total CTC for colorectal 
cancer patients #6-10. The percentage of STn-CTC is, on average, 3 times higher than EpCAM-CTC, 
suggesting that EpCAM-CTC may be a minor subset in relation to total CTC present in the blood of 
metastatic patients. “**” p < 0.01; “***” p < 0.001 
 
4.2. Molecular characterization of bladder and colorectal CTC 
 
We have then devoted to confirming the malignant nature of CTC isolated in non-targeted 
microfluidic devices, based on complementary transcripts and genetics analysis.  
For bladder cancer, the STn antigen was shown to define worst prognosis in advanced tumours 
presenting a basal phenotype, characterized by KRT14 and/or KRT5 overexpression and KRT20 
downregulation, which was also mimicked by the metastasis
45
. This contrasted with better prognosis 
presented by STn- and luminal tumours (KRT14- and/or KRT5- and KRT20+ phenotype)
45
. Building 
on these findings, we have isolated RNA from bladder cancer CTC samples to assess KRT14, KRT5 
and KRT20 genes expression by RT-PCR. We observed that bladder cancer CTC significantly 
upregulated KRT14 in comparison to KRT5 and KRT20 (Figure 6A), similarly to CTC isolated from 
blood of an independent set of metastatic bladder cancer patients
45
. The KRT14+/KRT5-/KRT20- 
phenotype exhibited by CTC is characteristic of basal bladder cancer cells exhibiting a highly 
dedifferentiated, more aggressive nature, frequently associated to therapy resistance. 
A different strategy was pursued to confirm the malignant origin of CTC isolated from blood of 
colorectal cancer patients. In this case, colorectal CTC, the corresponding primary tumours and distant 
metastasis (whenever available) were screened for APC mutation c.4348C>T, a frequent early stage 
mutation in these cells
58
. Using a cohort of 11 metastatic cancer patients (#2-12), we found that the 
mutation was present in 58% of the primary tumours, 67% of CTC and 75% of available metastasis 
(Figure 6B). Moreover, there was a correlation between the mutation status in the primary tumour and 
CTC (p = 0.04). Likewise, a match between the CTC and metastasis was observed, although with no 
statistic correlation most likely due to the low number of samples analysed. These findings may reflect 
the molecular nature of STn
+
CTC, which constitute most of the isolated CTC, highlighting the 
potential of microfluidic chips for further downstream molecular analysis, including evaluation of 
CTC mutational status.  
In summary, these observations support the malignant phenotype of isolated bladder and 
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colorectal CTC, most likely expressing the STn antigen. Furthermore, our results reinforce the 
potential of exploring CTC-isolation microchips beyond cell enumeration towards molecular analysis. 
 
 
 
Figure 6. Transcripts and Mutation analysis in CTC isolated using non-targeted, size-based 
microfluidic devices. CTC isolated in microfluidic devices were hydrolyzed in situ for RNA (bladder 
CTC) and DNA (colorectal CTC) extraction and downstream molecular analysis. A) KRT14, KRT5 
and KRT20 transcripts in bladder cancer CTC. More aggressive and potentially metastatic bladder 
cancer cells generally present the KRT14+ and/or KRT5+, KRT20- phenotype (basal), which contrasts 
with the KRT14- and/or KRT5-, KRT20- phenotype (luminal) generally present by tumour cells in 
lesions facing better prognosis. Here, we demonstrate that bladder cancer CTC exhibit a basal 
phenotype, consistent with their more aggressive nature. It is possible that this may reflect the 
molecular nature of STn-CTC, which constitute the majority of the isolated CTC. Moreover, it 
demonstrates the potential of exploring microfluidic devices for CTC transcripts analysis. B) Analysis 
of APC c.4348C>T mutations in primary tumours, colorectal CTC and corresponding metastasis, 
whenever available. The analysis of APC c.4348C>T, a colorectal cancer driver mutation, in a cohort 
of 11 metastatic cancer patients (#2-12), demonstrates that the mutation is present in 58% of the 
primary tumours, 67% of CTC and 75% of available metastasis. There is a correlation between the 
mutation status in the primary tumour and CTC (p = 0.04; Spearman’s nonparametric bivariate 
correlation). There was also a match between the CTC and the metastasis; however, the low number of 
sample did not allow to determine a correlation. These findings may reflect the molecular nature of 
STn-CTC, which constitute the majority of the isolated CTC and the potential of exploring 
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microfluidic devices for CTC mutation analysis.  
 
 
 
4.3.Glycan-based immunoaffinity microfluidics for STn-CTC analysis 
 
Having established the STn antigen as a CTC biomarker in bladder and colorectal cancers, we 
have further devoted to the development of a glycan-affinity microfluidics device for specific 
enrichment of STn
+
CTC. Accordingly, we have prepared a high-surface area microfluidic device, 
containing thousands of microposts closely arranged to maximize cell-surface interactions, and 
functionalized its inner surfaces with anti-STn B72.3 monoclonal antibody. Based on the surface area 
of the device and the availability of binding sites created in our functionalization strategy, the 
minimum amount of antibody required to produce a monolayer was estimated to be 5 μg. Therefore, 
microchips were functionalized with 5, 15, 33, and 50 μg of antibody for subsequent optimization 
experiments aiming to maximize cell entrapment. Functionalization efficiency was confirmed using a 
quartz crystal Microbalance (Figure 7).  
 
 
Figure 7. Evaluation of the functionalization of Glycan-affinity microchips using Quartz Crystal 
Microbalance. After addition of each of the functionalization reagents, the frequency decreased, and remained 
in the surface upon washing steps, confirming the success of the functionalization strategy. 
 
Identification and Characterization of Glycobiomarkers in Bladder Cancer Stem Cells 
 
95 
 
 
Antibody-free devices were used as controls to provide insight on unspecific cell binding to the 
surface of the chips. Optimization tests were conducted using the bladder cancer cell model MCRSTn, 
transduced to overexpress the STn antigen (Figure 4). MCRSTn cells (10
3
 cells) were first labelled 
with calcein for better visualization and injected into the device at a flow-rate of 30 µl min
−1
, which 
had been previously reported to maximize the number of entrapped cells in similar applications
59
. 
Accordingly, we have concluded that 15 μg of antibody was the minimum amount required for 
achieving maximum cell yields (Figure 8).  
 
 
Figure 8. Optimization of the amount of antibody for glycan-affinity microfluidic devices 
functionalization. Briefly, glycan-affinity devices were functionalized with different amounts anti-STn 
entrapment (approximately 59%) 
was observed for 15 mg of immobilized antibody. “ns”: not significant; “*” p < 0.05; “***” p < 0.001. 
 
Moreover, we have observed significantly low percentages of cell entrapment in non-
functionalized devices (<2% of injected cells), suggesting the high specificity of cell to antibody 
binding. Similar results were found for systems functionalized with an IgG1 isotype control (data not 
shown), further reinforcing the chips specificity for STn-expressing cells. Therefore, devices 
functionalized with 15 μg of antibody were elected for subsequent experiments. Flow rates of 15, 30 
and 45 µL.min
−1
, were also tested for the washing step. Based on these experiments, the optimal flow 
for maximizing MCRSTn cells entrapment was 30 µL.min
−1
 (Figure 9).  
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Figure 9. Flow rate optimization for glycan-affinity microfluidic devices. Briefly, different flow 
rates (15, 30, 45 μL.min-1) were tested for the washing step in order to maximize MCRSTn cell yield. 
Maximum yield was observed for 30 mL.min
-1
 flow rate. “ns”: not significant; “**” p < 0.01 
 
We have then explored both MCRSTn and MCRmock (expressing low levels of STn antigen) 
cell models to assess the affinity of functionalized devices for cells expressing different levels of STn. 
Figure 10A illustrates that functionalized microchips primed with MCRSTn showed twice the number 
of captured cells in comparison to those with MCRmock, translating their higher STn levels. In 
addition, we observed that glycan-affinity devices were capable of capturing MCRSTn cells displaying 
a wide variation in size (<5-20 μm) (Figure 11). Such observations highlight the potential of this tool 
for accessing CTC subpopulations spanning considerably different dimensions, in contrast to size-
based microchips which frequently have underrepresented smaller CTC. In addition, we have isolated 
and injected 500,000 PBMC previously isolated from blood of healthy donors into glycan-affinity 
devices to evaluate possible unspecific binding of blood cells to the chip surface, as PBMC lack STn 
expression (Figure 4). Accordingly, we observed residual PBMC (<0.5%) inside the devices, 
supporting the higher affinity and specificity of these functionalized microfluidic chips for STn 
expressing cells. In an attempt to mimic conditions found in patients, PBMC were next spiked with 
different amounts of calcein-labelled MCRSTn and MCRmock cancer cells (10
2
,10
3
,10
4
 cells) and 
subsequently run through glycan-affinity microfluidic devices. The obtained results highlighted a 
significant increase in MCR cell entrapment with cell concentration (Figure 10B), and further confirm 
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the affinity of these chips for capturing malignant STn expressing cells.  
Finally, we have analysed in parallel the blood of three colorectal cancer patients (#10-12) with 
size-based and glycan-affinity microfluidics devices. Glycan-affinity microfluidics devices provided 
higher CTC counts in comparison to size-based devices for all cases (Figure 12), suggesting a higher 
sensitivity of glycan-affinity devices in comparison to size-based solutions. Moreover, we observed 
that captured STn+CTC on all studied cases presented highly heterogeneous dimensions, 10-20 μm 
diameter (Figure 12), in agreement with the observations for model solutions (Figure 11). This 
clearly contrasted with the higher and more homogenous range of diameters presented by CTC 
entrapped in size-based microfluidics devices (15-20 μm), and may account for the higher cell counts 
exhibited by glycan-affinity devices. Moreover, it is in agreement with previous reports demonstrating 
that the same patient may exhibit CTC spanning from 4-30 μm diameter60. These observations suggest 
that glycan-based microfluidic devices may further broaden the spectra of captured CTC by enabling 
capture of cells presenting smaller dimensions, which may ultimately be excluded by size-based 
microchips. 
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Figure 10. Percentage of MCR bladder cancer cells expressing different STn levels analyzed by glycan-
affinity devices. A) Percentage of MCRSTn (75% STn expression) and MCRmock (11% STn) bladder cancer 
cells and human PBMC (0% STn) retained in glycan-affinity devices. Briefly, MCRSTn (75% STn expression) 
and MCRmock (11% STn) calcein labelled cells were analyzed using microfluidic devices. Accordingly, a 
higher number of cells were recovered for MCRSTn cells in comparison to MCRmock, in accordance with STn 
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expression. Moreover, only residual PBMCs were observed, highlighting low levels of non-specific binding. B) 
Bladder cancer cells recovery from human blood spiked with different amounts of MCRSTn and MCRmock
(102, 
103, 104)
. Briefly, PBMC isolated from the blood of healthy donors was spiked with different amounts of 
MCRSTn and MCRmock bladder cancer cells, in an attempt to mimic CTC in the blood of metastatic cancer 
patients. Bladder cancer cells were then isolated together with PBMCs and injected into the devices. Higher 
cells yields could be observed for MCRSTn in comparison to MCRmock, irrespectively of the initial blood cells 
concentration. Nevertheless, the amount of captured cancer cells increased with blood cell concentration, but it 
was more pronounced from 102 to 103 cells (15 times increase) than the observed for 104 (2 times increase), 
suggesting device saturation beyond that point. “ns”: not significant; “*”:p < 0.05; “**” p < 0.01; “***” p < 
0.001.  
 
 
 
Figure 11. Glycan-affinity devices are capable of capturing MCRSTn cells of different dimensions. 
Briefly, glycan-affinity devices demonstrate the existence of a heterogeneous MCRSTn population in terms of 
dimensions. Accordingly, captured MCRSTn cells presented diameters spanning 5-20 μm. 
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Figure 12. CTC counts for colorectal cancer patients (#10-12) in size-based vs glycan-affinity microfluidic 
devices. Blood collected from metastatic colorectal cancer patients was analyzed in parallel by size-based and 
glycan-affinity microfluidic devices. Glycan-affinity microfluidic devices provided higher CTC counts in 
comparison to size-based devices for all cases. ns: not significant (yet showing a trend increase); “*” p < 0.05. 
 
 
Figure 13. STn-CTC subpopulations from colorectal cancer patient #11 presenting different dimensions 
(>10 μm - approximately 8 μm), 15 μm, 20 μm) captured by glycan-microfluidic devices. Similar 
observations were made for cases #10 and #12. 
 
4.4. Glycan-affinity microfluidics in precision oncology  
 
 While non-targeted microfluidics devices constitute an important starting point for accessing 
the CTC molecular landscape, glycan-affinity microfluidics devices provide the necessary platform for 
more specific downstream studies. This may be particularly important for cases were STn does not 
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constitute the majority of the entrapped CTC population, such as for bladder cancer patient #4 (83%) 
and colorectal cancer patient #2 (81%) and, specially, patient #12 (68%). Nevertheless, the specific 
recovery of STn-expressing cancer cells from the microchips is a critical matter. Envisaging this goal, 
a sialidase was injected into microfluidics devices with already entrapped MCRSTn and MCRmock 
cells and allowed to incubate under both stationary and dynamic conditions at a constant flow rate (10 
μL.min-1), for 30 and 120 minutes. This enzymatic treatment cleaves the glycosidic linkage between 
the sialic acid and the GalNAc residue of the STn antigen, releasing the cells expressing the Tn antigen 
(STn desialylated counterpart), without impacting on cell membrane integrity. As highlighted in 
Figure 14, minimum cell recovery was 15% for stationary incubation whereas a maximum recovery of 
approximately 35% of entrapped cells was observed for 120 minutes of dynamic incubation. Such 
yields may, in part, be related with the formation of extracellular matrix by cancer cells in contact with 
the device coating, leading to unspecific binding. Stearic hindrance provided by antibody binding may 
also affect enzymatic cleavage and account for these findings. Nevertheless, sialidase treatment 
provides an elegant strategy to specifically recover STn expressing cells for analysis, with minor 
impact on cell molecular nature.  
 
 
Figure 14. Percentage of MCRSTn and MCRSmock released from glycan-affinity devices after in situ 
sialidase treatment. Briefly, 10
3
 MCRSTn were injected into microfluidic devices, showing a retention profile 
similar to Figure 5 (main manuscript; 40% entrapment).  Entrapped cells were released by sialidase treatment at 
37ºC under stationary conditions or by constant flow of the enzyme (dynamic flow), for 30 and 120 min. Under 
stationary flow, 10% of entrapped cells were recovered, which did not vary over time. Similar results were 
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observed under dynamic flow for 30 min. However, a 3 times higher statistically significant increase was 
observed after 120 min.   
 
 We have then applied this strategy to selectively recover STn
+
CTC from colorectal case #10-
12, which were subsequently screened for APC mutation c.4348C>T. Sialidase released cells from all 
cases were positive for the mutation, in accordance with size-based microchips analysis (data not 
shown). Noteworthy, while matched results to be expected for cases #10 and #11 presenting STn
+
CTC 
counts that exceed 90% of the entrapped CTC, similar extrapolation could not be made for case#12, 
presenting only 68% STn
+
CTC. Nevertheless, based on this strategy, we could confirm that STn-
expressing cells on patient #12 mimicked the overall population. In summary, these observations set 
the necessary basis for a comprehensive study on STn
+
CTC, envisaging to understand their biological 
and clinical relevance.   
 
5. Concluding remarks 
 
  The identification of CTC cell-surface biomarkers remains a challenging topic in the context of 
liquid biopsies due to the scarce molecular information about these cells. In fact, the majority of 
studies presented to date explore the expression of epithelial marker EpCAM for CTC identification 
and isolation
28, 29
, which has been suggested to significantly underestimate the number of cancer cells 
in peripheral circulation
5, 11, 12
. Particularly, EpCAM expression is frequently downregulated in cells 
undergoing epithelial-to-mesenchymal transition, a crucial milestone for metastasis development11. 
Using a label-free microfluidics device, we demonstrated that metastasized colorectal cancer patients 
present significantly higher CTC counts than first expected through EpCAM, targeting, thus 
reinforcing these observations. More importantly, most isolated CTC also expressed the STn antigen, 
confirming preliminary findings for bladder cancer
45
. Nevertheless, to the best of our knowledge, this 
was the first report concerning the glycosylation of bladder and colorectal CTC. Interestingly, CTC 
derived from different tumours of distinct aetiologies share similar cell surface glycosylation features, 
suggesting a common molecular ground in metastasis development that warrants careful evaluation in 
future studies. Accordingly, the cell-surface overexpression of STn has been previously found to 
endow cancer cells with a more motile phenotype and drive invasion in both models
40, 43, 47
. In 
addition, STn expression is part of an array of molecular mechanisms enabling cancer cells to escape 
immune responses46, which is critical for survival and successful colonization of distant niches. 
Supporting its association with more malignant features, STn expression has been frequently 
associated with poor prognosis and metastatic risk in bladder
43, 44, 47 
and colorectal cancers
40
. Our 
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observations now set the necessary molecular rationale for exploiting the biological and functional 
significance of this antigen in metastasis development. Moreover, this study demonstrates that 
targeting the STn antigen may allow access to yet unknown CTC subpopulations, frequently 
overlooked by EpCAM-based detection methods. In addition, the membrane nature of this antigen also 
holds tremendous potential for selectively targeting CTC for downstream molecular characterization 
and ultimately the development of targeted therapies. 
Envisaging this goal, we have developed and optimized a glycan-affinity microfluidics device 
targeting the STn antigen. This analytical tool allowed selective enrichment and further release of rare 
STn-expressing CTC, following PBMC extraction from whole blood of cancer patients. Isolated CTC 
may be directly screened in situ for different antigens by immunofluorescence, lysed in situ or 
selectively released from the device by sialidase treatment. This not only enables more specific 
downstream molecular characterization but also allows the collection of intact and viable cells, which 
is crucial for subsequent functional studies. Moreover, preliminary findings support that this device 
may provide access to a broader population of CTC in comparison to size-based solutions, most 
probably by enabling the capture of smaller cells. By exploring CTC recovery by sialidase release, we 
have further demonstrated that bladder CTC exhibit a KRT14+/KRT5-/KRT20- phenotype, previously 
associated to highly dedifferentiated and more aggressive basal cells implicated in metastasis45. 
Regarding the isolated colorectal cancer CTC, which were found to express STn at high levels, we 
demonstrated that it harboured a frequent APC mutation c.4348C>T, in mimicry of the primary tumour 
and the corresponding metastasis. Overall, such findings support the importance of targeting STn+ 
CTC for molecular insights on the primary tumour and the metastasis.  
 In summary, we have identified a novel biomarker, which is not expressed by human blood 
cells but is widely present in CTC, for selectively capturing and/or targeting these cells. Moreover, our 
data supports that targeting STn may significantly improve on CTC detection sensitivity in comparison 
to conventional EpCAM-based methods, holding tremendous potential for improving on 
prognostication using CTC-based models. In addition, we have designed a glycan-affinity 
microfluidics device and a method to specifically recover STn
+CTC from patients’ blood for 
downstream molecular analysis and precision medicine applications. Nevertheless, while this is a 
proof-of-concept study, involving a small set of well characterized metastatic patients, showing 
consistent data, it now warrants validation in larger patient series. Particular emphasis should be 
devoted to exploiting the higher sensitivity provided by STn targeting, for early identification of 
patients with residual disseminated disease and/or exhibiting radiologically occult micrometastasis. 
Based on these preliminary findings, a clinical study is being setup to disclose the clinical relevance of 
STn
+
CTC and gain more insights on the molecular nature of these cells. Moreover, sialidase treatment 
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has allowed recovering viable CTC from microfluidics devices (preliminary data, not shown), which 
may now be expanded in vitro and/or xenotransplanted into relevant animal models enabling more in 
depth molecular analysis, personalization of therapeutic schemes and/or testing novel treatments. 
Therefore, we envisage that targeting STn may allow improving on CTC-based liquid biopsies and 
foster molecular based precision medicine. Our findings further support the potential of a 
comprehensive interrogation of the glycome and glycoproteome of both primary tumours, CTC and 
metastasis envisaging highly specific biomarkers for improving advanced patient’s management. 
These findings will likely pave the way for novel and improved microfluidics platforms for liquid 
biopsies applications. 
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Concluding remarks and future perspectives 
 
The management of advanced bladder cancer remains a gray zone for clinicians, in part due to 
its molecular heterogeneity, thereby calling for novel molecular tools that help to identify patients 
facing worst prognosis and at higher risk of disease progression. Moreover, it is imperative to identify 
biomarkers for targeting aggressive and chemoresistant cancer cells, often responsible by disease 
relapse and dissemination. Within this context, many glycoproteins, including CD44, integrins (αv 
integrins), and integrin-associated proteins (CD47) have been suggested to hold potential for targeting 
bladder cancer stem cells with the above-mentioned characteristics. However, these proteins lack 
organ-specificity, thus hampering the development of effective therapeutics.  
We hypothesized that the identification of specific cancer-associated glycoforms might help 
narrowing these glycoproteins to clinically relevant species and, as we highlighted in a recent review 
(Annex A), chemoresistant stem-cells often present distinct glycosylation patterns in comparison to 
other cancer cells. The identification of these glycoforms may be used to improve on sensitivity and 
specificity of cancer-associated glycoproteins-targeted therapeutics design. Building on these 
observations and previous reports(160), herein we disclosed that advanced bladder tumours 
significantly overexpress sialylated short-chain O-glycans compared to superficial lesions. Amongst 
these, STn was found to be the most relevant antigen, due to its cancer-specific nature and association 
with poor prognosis in both NMIBC and MIBC. Such observations are in accordance with previous 
reports supporting its influence on cell motility and as a promoter of invasion in bladder cancer(160). 
In addition, the STn antigen was found in basal-like lesions, phenotypically characterized by the 
overexpression of KRT14 and/or KRT5 in relation to KRT20 and enriched for chemoresistant cancer 
stem cells(180). Moreover, the presence of STn-positive cancer cell subpopulations has been 
associated with a significant reduction in the survival of patients exhibiting luminal tumours (KRT14
-
 
and/or KRT5
-
 and KRT20
+
 phenotype), which generally present better survival than basal lesions(180). 
Noteworthy, tumours relapsing after chemotherapy have also been found to be enriched for cells 
expressing this glycan as well as for stem-cell molecular characteristics suggesting an association 
between both events, as previously reported for other tumours(181). Interestingly, chemoresistant 
lesions have also been found to overexpress the stem-cell marker CD44 and STn
+
CD44 glycoforms, as 
well as a basal phenotype, strongly suggesting that this glycan could be used to specifically target 
cancer stem cells. These findings were further reinforced by studies in vitro using relevant cell models 
representative of different invasion pathways (T24: FGFR3/CCND1 pathway; HT1376: E2F3/RB1 
pathway) challenged with cisplatin. Cumulatively and notably, we described for the first time that most 
tumour cells found in peripheral blood circulation of metastatic bladder cancer patients also express 
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the STn antigen, mimicrying the primary tumour and the metastasis. Additionally, bladder STn
+
CTC 
presented a KRT14
+
, KRT5
-
, KRT20
- 
phenotype consistent with the most undifferentiated basal state 
and stem-cell ((180). While the functional role of STn in metastasis remains incompletely elucidated, 
these findings support a potential selective advantage for cells carrying this posttranslational 
modification. In agreement with these observations, STn expression has been described to endow 
cancer cells with the capacity to circumvent immune responses(162), which is a crucial step for cancer 
cells survival in circulation and to successfully colonize distant locations.  
Here, a reasonable amount of evidence is depicted supporting that bladder cancer stem cells, 
possibly endowed with chemoresistant traits, express the STn antigen. As such, the STn antigen is 
suggested as novel biomarker of bladder cancer aggressiveness that should be explored in the context 
of targeted therapies. Accordingly, future studies should focus on the validation of these preliminary 
findings, including a more comprehensive functional and molecular characterization of the STn-
glycoproteome, with emphasis also on O-glycosites mapping. Emphasis should also be given to CD44, 
which has been consensually reported as clinically relevant in bladder cancer and considered a cancer 
stem-cell marker(70, 182). Nevertheless, the identification of CD44 iso- and glycoforms expressed by 
more aggressive cancer cells compared to healthy cells, will be particularly crucial to increase 
specificity and avoid potential off-target effects of novel therapeutics based on this glycoprotein, as 
well as theragnostic applications. These ligands may be ultimately used to specifically guide drug 
loaded nanoparticles, genetically modified T cells expressing chimeric antigen receptors, or other 
cytotoxic/cytostatic agents to tumour sites and more aggressive cancer cells; thereby, boosting specific 
immune responses against cancer cells or inhibiting oncogenic pathways(183). 
The exploitation of STn-expression by circulating tumour cells is also demonstrated. In fact, 
this work not only supports STn as a novel and potentially widespread CTC biomarker, but also 
provides an innovative glycan-based microfluidics platform that may pave the way for molecular-
based precision medicine. It has also been demonstrated that STn antigen is expressed by colorectal 
cancer, suggesting a pan-carcinoma nature warranting future evaluation. Moreover, preliminary studies 
support that targeting the STn antigen may significantly improve on the sensitivity of current methods 
for CTC analysis. Clinical studies should now be undertaken to determine its potential for early 
detection of disease dissemination, therapy selection, follow-up and development of novel therapeutic 
strategies. In addition, these devices may be used for accessing the molecular nature of STn
+
CTC and 
may constitute important liquid biopsies platforms capable of improving advanced patient’s 
management. Finally, the possibility of recovering CTC from microfluidics devices by means of a 
simple sialidase treatment may allow expansion and xenografting in relevant animal models, enabling 
drug testing and development.  
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 This work presents a closer clinical link between STn expression, poor prognosis, and stem-cell 
phenotypes, characterized by chemoresistance and capability of regenerating tumour heterogeneity. 
Moreover, the widespread nature of STn
+
CTC and its prevalence in the corresponding metastasis 
supports a role in disease dissemination that warrants confirmation in future studies. The clinical 
rationale is now set to comprehensively address the STn-glycoproteome envisaging novel and highly 
specific bladder cancer ligands. Moreover, STn is presented as a novel CTC biomarker that should be 
carefully exploited envisaging to improve on advanced stage patient’s management. In addition, a 
novel glycan-affinity microfluidics tool is presented, which may now help paving the way for 
improved patient care. 
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Abstract 
Cisplatin-based chemotherapeutic regimens are the most frequently used (neo)adjuvant 
treatments for the majority of solid tumors. While platinum-based chemotherapeutic 
regimens have proven effective against highly proliferative malignant tumors, 
significant relapse and progression rates as well as decreased overall survival are still 
observed. Currently, it is known that sub-populations of chemoresistant cells share 
biological properties with cancer stem cells (CSC), which are believed to be responsible 
for tumor relapse, invasion and ultimately disease dissemination through acquisition of 
mesenchymal cell traits. In spite of concentrated efforts devoted to decipher the 
mechanisms underlying CSC chemoresistance and to design targeted therapeutics to 
these cells, proteomics has failed to unveil molecular signatures capable of 
distinguishing between malignant and non-malignant stem cells. This has hampered 
substantial developments in this complex field. Envisaging a novel rationale for an 
effective therapy, the current review summarizes the main cellular and molecular 
mechanisms underlying cisplatin resistance and the impact of chemotherapy challenge 
in CSC selection and clinical outcome. It further emphasizes the growing amount of 
data supporting a role for protein glycosylation in drug resistance. The dynamic and 
context-dependent nature of protein glycosylation is also comprehensively discussed, 
hence highlighting its potentially important role as a biomarker of CSC. As the 
paradigm of cancer therapeutics shifts towards precision medicine and patient-tailored 
therapeutics, we bring into focus the need to introduce glycomics and glycoproteomics 
in holistic pan-omics models, in order to integrate diverse, multimodal and clinically 
relevant information towards more effective cancer therapeutics. 
 
1. Introduction 
Cisplatin (cis-diamminedichloridoplatinum(II); cis-[Pt(NH3)2(Cl)2]) was first 
described by Michele Peyrone in 1845, but its structure was only determined in 1893 
(Trzaska S, 2005). After several years of investigation, Rosenberg realized its potential 
to induce tumor cells death (Rosenberg B, 1973) and finally in 1978 the drug was 
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approved by the FDA for the treatment of testicular and ovarian cancer (Trzaska S, 
2005). Nowadays, cisplatin-based regimens are widely used as (neo)adjuvant 
chemotherapy against a spectrum of solid tumors including gastric, non-small cell lung 
(NSCLC), head and neck, gallbladder, and urinary bladder cancer. However, cisplatin 
treatment exhibits severe side effects including immunosuppression, renal toxicity, 
gastrointestinal disorders and ototoxicity (Boussios S et al., 2012; Karasawa T et al., 
2015). It may also cause gonadal suppression resulting in amenorrhea or azoospermia, 
partial or irreversible infertility and embryo-toxicity (Brennemann W et al., 1997; 
Meistrich ML, 2009). 
Cisplatin is an alkylating agent capable of forming adducts with 
macromolecules, particularly with N7 atoms of purine nucleobases. This results in inter- 
and intra-strand DNA cross-links that bring induce cell cycle arrest mainly in the G2/M 
checkpoint (Yuan L et al., 2003). The inability to repair this DNA damage ultimately 
leads to programmed cell death. However, experimental evidence revealed that other 
mechanisms such as the production of reactive oxygen species (ROS) and the activation 
of inflammatory pathways, may also contribute to the induction of apoptosis (Casares C 
et al., 2012). Cisplatin has shown significant efficacy against rapidly proliferating tumor 
cells. However, despite a fairly acceptable intrinsic drug response rate, there is a 95% 
risk of tumor relapse in NSCLC patients. The 5-year survival rate is approximately 50% 
for muscle-invasive bladder cancer, (Nadal R et al., 2014) and 15-20% for ovarian 
cancer patients (Siddik ZH, 2003); similar survival rates have been reported for other 
solid tumors. It has been hypothesized that chemotherapy may either act as a selective 
pressure for more aggressive cell phenotypes (Freitas DP et al., 2014), or that tumor 
cells which are less drug sensitive may acquire mutations during the course of 
treatment, that enable them to evade drug-induced cell death (Crea F et al., 2011). The 
failure of cisplatin-based regimens is considered both life-threatening and a major 
burden to health care systems, as it requires the introduction of more expensive second 
line treatments. Therefore, deciphering the mechanisms underlying this treatment failure 
has been a primary goal of cancer research and, in the past two decades, some of the 
modalities underlying anticancer drug resistance have been identified; however the 
implications for improving drug therapy have been limited. 
Chemotherapy resistance results from a synergism of events that include tumor 
cell extrinsic factors (pharmacokinetic resistance and tumor microenvironment) as well 
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as intrinsic factors, namely alterations in drug transport and metabolism, relative 
dormancy/slow cell cycle kinetics, efficient DNA repair systems and inhibition of 
apoptosis (Martin LP et al.; Pommier Y et al., 2004; Raguz S and Yague E, 2008). In 
addition, some chemoresistant tumor cell clones may present self-renewal and 
pluri/multipotent differentiation capabilities, which are characteristics associated with 
cancer-stem cells (CSC) (Visvader JE and Lindeman GJ, 2008). Therefore, these cells 
constitute a small pool of CSC capable of generating more differentiated sub-
populations that, during subsequent divisions, form the vast majority of the tumor bulk. 
The remarkable longevity of CSC also renders them more susceptible to the 
accumulation of genetic damage and epigenetic alterations that may ultimately promote 
the proliferation of heterogeneous and aggressive cell phenotypes (Muñoz P et al., 
2012). Some subsets of CSC can be found in poorly vascularized hypoxic tumor niches, 
which favour the maintenance of stem-cell characteristics, and are consequently 
exposed to suboptimal drug concentrations (Lin Q and Yun Z, 2010). Furthermore, 
these cells may undergo epithelial-to-mesenchymal transition (EMT) in response to 
microenvironmental stimuli, namely prolonged exposure to low oxygen levels, and may 
acquire the capability to invade and metastasize to regional lymph nodes and distant 
organs (Jiang J et al., 2011). In summary, it became evident that cisplatin and other 
conventional chemotherapeutic drugs may ultimately contribute to the selection of a 
pool of slow dividing or quiescent CSC (Wang W et al., 2014). These cells are endowed 
with the capability of recapitulating tumor heterogeneity and undergo EMT, considered 
as one of the driving forces of cancer dissemination (Frank NY et al., 2010). As such, 
patients would greatly benefit from combined therapies including agents capable of 
selectively eliminating CSC. The ideal therapy should specifically recognize these cells 
from the tumor bulk, include means to inhibit resistance mechanisms, as well as include 
CSC-killing agents. However, the majority of membrane-bound CSC biomarkers known 
to date can also be found in normal stem- and non-malignant cells (Cojoc M et al., 
2015), which hampers the development of specific targeted therapeutics.  
More recently, several studies have demonstrated that profound alterations in 
protein glycosylation that often accompany malignant transformation may also 
influence resistance to chemotherapy. This rather neglected mechanism of drug 
resistance has been often associated with impaired function of membrane-bound 
glycoproteins, such as ATP-binding cassette efflux transporters, due to specific 
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alterations in their glycosylation patterns (Beers MF et al., 2013; Nakagawa H et al, 
2009). However, alterations in cell-surface protein glycosylation have also been shown 
to favor oncogenic signaling pathways associated with chemoresistance and CSC-like 
phenotypes (Dall’Olio F et al., 2014; Häuselmann I and Borsig L, 2014; Ju T et al., 
2008; Pinho SS et al., 2012). Therefore, cancer-associated glycans constitute markers of 
chemoresistance and bear potential promise for the identification and therapeutic 
targeting of CSC. 
Envisaging a rationale for an effective therapy, the present review discusses the 
main mechanisms of cisplatin resistance known to date, integrating key insights about 
the role of cancer-associated glycans. Although the current review focuses mainly on 
cisplatin, it is proposed here that many of these strategies mediate resistance to other 
drugs as well. The present paper also provides a comprehensive overview on the impact 
of the chemotherapeutic challenge in tumor biology, CSC selection and clinical 
outcome. Moreover, it aims to raise awareness for the fact that CSC harbor distinct 
glycosylation patterns that should be carefully explored towards the development of 
highly specific targeted therapeutics.  
 
2. Overview on drug resistance mechanisms and CSC selection 
Drug resistance is a multifactorial process which is based on both extrinsic and 
intrinsic factors in tumor cells (Raguz S and Yague E, 2008). Extrinsic factors such as 
unfavorable drug pharmacokinetics and abnormal tumor vasculature result in the 
delivery of suboptimal concentrations of cytotoxic agents to tumor sites (Rohwer N et 
al, 2011). Defective tumor vasculature also results in hypoxic and acidic niches that 
significantly modulate cell function in manners that favor chemoresistance (Wilson WR 
and Hay MP, 2011). Similarly, alterations in the extracellular matrix architecture and 
stromal cell paracrine signals have been found to influence chemotherapy outcome 
(Sherman-Baust CA et al, 2003; Tripathi M et al., 2012). In addition, tumor cells may 
either present, or develop during the course of treatment, various mechanisms to 
withstand and overcome chemotherapeutic challenges (Shen D et al., 2012). These 
mechanisms include for example: i) Alterations in drug transport and metabolism; ii) 
Enhanced DNA repair mechanisms; iii) Alterations in cell cycle regulation; and iv) 
Inhibition of apoptosis. Emerging evidences support the notion that chemoresistance, 
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driven by the above mentioned factors, is associated with CSC-like properties as well as 
the acquisition of EMT capability, thereby explaining the high relapse and progression 
rates presented by first line chemotherapy agents (Cojoc M et al., 2015). Based on these 
considerations, the following sections aim to illustrate the influence of the main tumor-
associated extrinsic and intrinsic properties in chemoresistance. 
 
2.1. The impact of the microenvironment on drug resistance 
2.1.1 Tumor vasculature and hypoxia 
Solid tumors often present tortuous, poorly differentiated and truncated 
vasculature, resulting in the delivery of suboptimal concentrations of cytotoxic drugs to 
certain niches (Minchinton AI and Tannock IF, 2006). This also accounts for the 
formation of a hypoxic environment that significantly influences cell metabolism and 
modulates gene expression, ultimately enhancing chemoresistance and maintenance of 
CSC (Rohwer N et al., 2011); discussed in detail in the following sections) (Figure 1). 
Furthermore, hypoxia modulates the expression of genes linked to EMT – (addressed in 
detail in subsequent sections) and drug resistance phenotypes (Adamaki M et al., 2012; 
Jiang J et al., 2011; Polyak K and Weinberg RA, 2009; Ruan K et al., 2009; Shannon 
AM et al., 2003). 
The primary transcription factor mediating the response to hypoxic challenge is 
hypoxia-inducible factor-1 (HIF-1) (Semenza GL, 2001). HIF-1 consists of a 
constitutively expressed subunit HIF-1β and a tightly oxygen-regulated subunit HIF-1α 
(or its paralogs HIF-2α and HIF-3α) (Brocato J et al., 2014). Under normoxia 
conditions, the HIF-1α protein is constitutively expressed but rapidly marked for 
proteosomal degradation, resulting in a very short cytoplasmic half-life (5-8 min). 
Under hypoxic conditions, HIF-1α is translocated to the nucleus where it binds to the 
co-activators HIF-1β and p300/CBP (Semenza GL, 2001), inducing an array of 
responses such as overexpression of angiogenic genes (i.e. VEGF, PDGF‐BB and NOS) 
and growth factors (i.e. IGF-II) (Brocato J et al., 2014; Denko NC et al., 2003; Harris 
AL, 2002), decreases mitotic and metabolic rates and adapts energy requirements to the 
hypoxic challenge (Hockel M et al., 2001; Shannon AM et al., 2003). In particular, HIF-
1α contributes to the dramatic shift of intracellular glucose metabolism from aerobic 
cellular respiration to anaerobic glycolysis through the transactivation of genes 
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encoding glucose transporters (i.e. GLUT-1) and several rate-limiting enzymes of 
glycolysis (Jose C et al., 2011; Mucaj V et al., 2012). It also suppresses the tricarboxylic 
cycle (TCA) via the PDK1 gene, encoding pyruvate dehydrogenase kinase 1, which 
inactivates pyruvate dehydrogenase, resulting in fueling the TCA cycle with acetyl-CoA 
(Shirato K et al., 2011). Moreover, HIF-1α has been shown to regulate the expression of 
cytochrome C oxidase (COX) allowing cancer cells to optimize the efficiency of 
respiration at different oxygen levels (Mucaj V et al., 2012). Ultimately, HIF-1α 
contributes to cellular adaptation to hypoxic stress which can culminate in 
mitochondrial autophagy (Zhang H et al., 2008). By modulating mitochondria activity, 
HIF-1α influences cell death mechanisms mainly by interfering with apoptotic and 
necrotic signaling (Greijer AE, Van der Wall E, 2004). Furthermore, HIF-1α has also 
been shown to act as apoptosis suppressor in cancer cells through the regulation of anti-
apoptotic target genes and additional molecular mechanisms that still remain largely 
elusive (Adamaki M et al., 2012; Harris AL, 2002). For instance, hypoxic regulation of 
p53 has been proposed to be HIF-dependent; however, controversy remains over this 
topic. Nevertheless, most reports point to the fact that hypoxia acts as a positive 
selective pressure for the positive selection of p53 mutant cells and hence inducing 
diminished apoptotic potential (Ruan K et al., 2009), thereby compromising the 
response to chemotherapy (Gogna R et al., 2012; Weisz L et al., 2007). HIF-1α also acts 
as a regulator of drug efflux through the activation of the MDR1 gene encoding the 
multidrug resistance efflux transporter P-glycoprotein (P-gp; ABCB1) (Comerford KM 
et al., 2002; Rohwer N et al., 2011; Shannon AM et al., 2003). P-gp belongs to the 
ATP-binding cassette (ABC) superfamily of transporters, however it does not recognize 
cisplatin as a transport substrate (Lockhart AC et al., 2003; Rohwer N et al., 2011), but 
is capable of markedly decreasing the intracellular concentration of a wide range of 
structurally and functionally distinct hydrophobic chemotherapeutic agents (Lockhart 
AC et al., 2003; Shapira A et al., 2011).  
Under hypoxic conditions an association between high levels of HIF-1α and 
cisplatin resistance has been widely reported for several representative tumor cell lines, 
including ovarian cancer (Su W et al., 2011), NSCLC (Fischer C et al., 2015), 
hepatocellular carcinoma and hepatic progenitor cell lines (Jiao M and Nan K, 2012). 
Supporting a role for HIF-1α in chemoresistance, elevated levels of this key 
transcription factor have been observed in tumors of different tissue origin and linked to 
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more resilient tumor cells, poor prognosis and resistance to radiotherapy and 
chemotherapy (Huang LA et al., 2007; Shannon AM et al., 2003; Wilson WR and Hay 
MP, 2011). Nevertheless, it should be noticed that, despite the pivotal role of HIF-1α, 
other independent mechanisms have been found to mediate hypoxia-related 
chemoresistance (Adamaki M et al., 2012; Scholten DJ et al., 2014). More detailed 
insights about the role of HIF in chemoresistance may be found in previous reviews by 
Rowner and Cramer (Rohwer N et al., 2011) and Raguz and Yagüe (Raguz S and Yague 
E, 2008). 
 
2.1.2. The tumor stroma 
The tumor stroma, mainly formed by the basement membrane, extracellular 
matrix, cancer-associated fibroblasts (CAFs), immune cells, and vasculature, is a 
complex structure whose interactions markedly affect tumor growth, invasion, and 
metastasis during the course of disease (Bremnes RM et al., 2011; Pietras K et al., 2010) 
(Figure 1). Over the recent years, the crosstalk between cancer cells and the tumor 
stroma has been progressively unveiled (see review Bremnes RM et al., 2011; Tripathi 
M et al., 2012). However, the dynamics of cancer cell death in response to cisplatin and 
the tumor microenvironment has yet to be fully characterized. Noteworthy, it has been 
shown that the presence of stroma in 574 breast cancer specimens from patients who 
underwent surgery combined or not with adjuvant radiotherapy, adjuvant chemotherapy 
or adjuvant endocrine therapy, was an independent prognostic factor for relapse-free 
period, particularly in the triple-negative subpopulation (de Kruijf EM, 2011). However, 
extracellular matrix components mediating resistance to chemotherapy are still poorly 
understood. Several in vitro studies have demonstrated that the extracellular matrix not 
only constitutes a physical barrier to drug dissemination (Choi I et al., 2013), but may 
also exert a protective effect against apoptosis induced by various anticancer drugs 
(Chen Y et al., 2010; Kouniavsky G et al., 2002; Sethi T et al., 1999). Miyamoto H and 
colleagues have further found that the grade of differentiation of pancreatic tumor cells 
affects the interaction with different ECM macromolecules (fibronectin, collagen I, and 
collagen IV) as well as the matrix-driven sensitivity to chemotherapeutic drugs, 
including cisplatin (Miyamoto H et al., 2004). The presence of fibronectin, type IV 
collagen, and laminin have also been linked to cisplatin-resistance and local recurrence 
Page 9 of 65
Ac
ce
pte
d M
an
us
cri
pt
9 
 
of uveal melanomas (Bérubé M et al., 2005). The authors observed that apoptosis was 
less frequent after cisplatin administration in the presence of ECM when compared with 
cells cultured on a non-permissive matrix (Bérubé M et al., 2005). Several studies also 
found that the overexpression of ECM-associated genes correlates with increased 
cisplatin resistance (Januchowski R et al., 2014; Sherman-Baust CA et al., 2011; 
Sherman-Baust CA et al., 2003). In this respect, the gene expression profile of a 
subpopulation of the human ovarian carcinoma cell line A2780 displaying cisplatin 
resistance revealed a significant upregulation of the COL6A3 gene, encoding for 
collagen VI (Varma RR et al., 2005). These findings suggest that chemoresistance may 
modulate ECM composition through altered regulation of gene expression in cancer 
cells. Moreover, cisplatin-sensitive cells cultured in the presence of collagen VI showed 
enhanced resistance in vitro and immunohistochemistry studies revealed an association 
between collagen VI overexpression, tumor grade and resistance to chemotherapy 
(Sherman-Baust CA et al., 2003). Furthermore, ovarian tumors with pronounced 
stromal/mesenchymal gene signatures exhibited the worst outcome when compared to 
groups with non-stroma-associated gene signatures (Verhaak RGW et al., 2012). In 
addition, ECM gene signatures were associated with chemotherapy resistance (Mintz 
MB et al., 2005). Altogether, these findings suggest that tumor cells may remodel their 
microenvironment in order to increase survival to chemotherapeutic challenges 
(Sherman-Baust CA, et al., 2003). Recent studies point towards the pivotal role of β1-
integrins in ECM-cancer cells interactions and chemoresistance (Aoudjit F and Vuori K, 
2012). According to Hodkinson PS et al., β1-integrin-mediated PI3K activation prevents 
caspase-3 activation, thereby protecting small cell lung cancer cell lines against 
chemotherapy-induced cell cycle arrest and apoptosis (Hodkinson PS et al., 2007). A 
more recent report on oral carcinoma cell lines has shown that adhesions within the 
carcinoma matrix create an environment in which exposure to cisplatin induces 
proliferation through the function of β1-integrin, talin and FAK pathways that regulate 
nuclear activity of NF-kB (Eberle KE et al., 2011). Based on these observations, it has 
been suggested that the inhibition of ECM-integrin interactions in combination with 
chemotherapy could have positive therapeutic implications (Mahadevan D and Von 
Hoff DD, 2007). Impaired binding of hyaluronan to transmembrane receptor CD44 has 
also been shown to influence multiple cell signaling pathways that stimulate tumor cell 
proliferation, migration, and matrix metalloproteinase secretion, and to promote CSC 
properties as well as cisplatin resistance (Bourguignon LY et al., 2013; Ohashi R et al., 
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2007; Torre C et al., 2010). Several metalloproteinases that are responsible for the 
proteolysis of ECM components during biological processes such as carcinogenesis, 
differentiation, apoptosis, migration and invasion, tumor angiogenesis and immune 
surveillance may also contribute to modulate response to treatment (Blons H et al., 
2004; Ertan E et al., 2011; Mahadevan D and Von Hoff DD, 2007). The balance 
between matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases 
(TIMPs) is crucial for ECM stability (Nagase H et al., 2006) and acts in a coordinated 
manner to drive cancer progression and metastasis (Hara I, 2001; Rodriguez FO et al., 
2012). Overexpression of TIMP-2, an inhibitor of MMP-2, in ovarian cancer stromal 
areas was found to be associated with better response to chemotherapy (Hałoń A et al., 
2012). Furthermore, in vitro studies of squamous cell carcinoma of the head and neck 
have shown significant correlations between resistance to cisplatin and the expression of 
TIMP-2, suggesting that TIMP-2-mediated chemoresistance is dependent on the 
physiological environment (Akervall J et al., 2004). However, studies using ovarian 
cancer cell lines failed to show any association between this MMP-2 inhibitor and 
cisplatin resistance (Hałoń A et al., 2012). Also, expression of MMP-7 and -13 was 
found to be associated with cisplatin resistance in head and neck cancer cell lines 
(Ansell A et al., 2009). Again, these observations suggest that the crosstalk between the 
microenvironment and cancer cells is essential in order to influence intrinsic cell 
characteristics and chemotherapy resistance. These findings imply that disruption of 
cell-matrix interactions may provide ways to block ECM-mediated upstream or 
downstream intracellular signaling cascades, which could result in the overcoming of 
cisplatin resistance. Taking into account the encouraging results from studies using 
matrix modulating agents in combination with chemotherapy (Hussain A et al., 2012; 
Kamaraj S et al., 2010; Pisano C et al., 2014), it is now important to fully clarify the 
role of ECM components in platinum resistance in order to design rational therapeutic 
approaches.  
Stromal changes also include the development of carcinoma-associated 
fibroblasts (CAFs) that play a crucial role in disease (Tripathi M et al., 2012). In the 
recent years, the crosstalk between cancer cells and CAFs has been unveiled and 
comprehensively reviewed by several groups (Brennen WN et al., 2012; Liu R et al, 
2012; Puré E, 2009). CAFs have been found to directly drive cancer development 
through multiple mechanisms, which include the promotion of angiogenesis, cellular 
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proliferation, invasion and inhibition of apoptosis in cancer cells (Brennen WN et al., 
2012; Hale MD et al., 2013). Numerous growth factors, cytokines, proteases, and 
extracellular matrix proteins, such as SDF-1, FGF2, VEGF, TGF-β, HGF, tenascin-c, 
LOX, and MMPs are among the key molecules mediating these processes. Growth 
factors and other proteins produced by activated fibroblasts not only act on cancer cells 
but also on other components of the stroma, including adipocytes, inflammatory and 
immune cells as well as in the remodeling of the ECM, hence creating intricate 
feedback loops mediated by paracrine and autocrine signaling that drives CAFs 
development, disease progression and dissemination (Brennen WN, 2012; Hale MD et 
al., 2013). Nevertheless, only limited data on the response of CAFs to chemotherapy 
and their potential impact on therapy outcome are available. Namely, Sonnenberg et al. 
addressed the influence of CAFs in lung and breast tumors as well as in primary 
cultures hence revealing that, similarly to cancer cells, the sensitivity of CAFs to 
cisplatin is highly variable and dependent on the cancer type and its microenvironment 
(Sonnenberg M et al., 2008). Moreover, studies have demonstrated that the presence of 
CAFs contributes to the decreased response to chemotherapy in prostate  (Franco OE et 
al., 2012), breast (Rong G et al., 2013) and lung (Sonnenberg M et al., 2008) cancers. 
Furthermore, strategies targeting CAFs components have proven capable of improving 
the response to chemotherapy (Elenbaas B et al., 2001; Loeffler M et al., 2006), 
suggesting a role for these cells in treatment outcome. Also, a recent systematic review 
by Hale et al., has highlighted the fact that stroma-derived biomarkers, with emphasis 
on molecules produced by CAFs, are useful biomarkers to predict response to therapy 
(Hale MD et al., 2013). Several studies also support the notion that CSC, known for 
their intrinsic resistance to chemotherapy, also receive critical maintenance cues from 
supportive stromal elements, including CAFs (Hasegawa T et al., 2014; Li L et al., 
2013; Liao CP et al., 2010). In this respect, the interplay between CSC and CAFs 
towards increased chemoresistance and CSC self-renewal and invasion, have been 
recently demonstrated for colorectal cancer; according to this study, chemotherapy 
induces the remodeling of the tumor microenvironment to support cellular hierarchy 
through secreted factors that include IL-17A (Lotti F et al., 2013). 
Overall, there is a growing amount of evidence supporting the notion that 
stromal components promote chemoresistance; hence, the mechanisms underlying this 
stromal based chemoresistance should be critically evaluated hence paving the way 
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rs12686377 polymorphisms and platinum resistance in NSCLC patients has also been 
described (Xu X et al., 2012). Nevertheless, more clinical studies are required to 
determine the prognostic value of hCtr1 and its genetic variants in the context of 
cisplatin treatment. The hCtr1 transporter protein is responsible by regulating 
intracellular copper homeostasis. In turn, the expression of hCTR1 is regulated at the 
transcriptional level by copper via the transcription factor Sp1 and at the post-
translational level by a mechanism involving copper-stimulated endocytosis and 
degradation of the transporter (Howell SB et al., 2010; Petris MJ et al., 2003). The 
exposure to copper-chelating agents has been proven to increase the expression of hCtr1 
and sensitize tumor cells to platinum (Galluzzi L et al., 2012; Ishida S et al., 2010; 
Liang ZD et al., 2012). Furthermore, a pilot clinical trial has shown that administration 
of a copper-lowering agent can partially resensitize platinum-resistant high-grade 
epithelial ovarian cancer patients to platinum chemotherapy (Fu S et al., 2012). 
Altogether, these observations suggest a role for hCtr1 in cisplatin resistance and 
support larger studies to assess the efficacy of this approach in platinum-resistant 
cancers treatment. Other transporters such as Solute Carrier Family 22 Members 1 and 2 
(Li Q and Shu Y, 2014; Yonezawa A et al., 2006) have also been implicated in cisplatin 
uptake; nevertheless, more studies are required to delineate their role in cisplatin 
resistance as well as their potential use as biomarkers for resistance to platinum 
cytotoxic agents.  
 
2.2.2. Cisplatin efflux 
The efflux of platinum-based drugs is believed to be mediated by Transporting 
P-type Adenosine Triphosphatases ATP7A and ATP7B (Drayton RM et al., 2012; 
Stewart DJ, 2007; Tadini-Buoninsegni F et al., 2014) (Figure 2). Unsurprisingly, the 
overexpression of these transmembrane carriers have been implicated in cisplatin 
resistance and poor patient survival in several cancers (Konkimalla VB et al., 2008; 
Tadini-Buoninsegni F et al., 2014; Yoshizawa K et al., 2007). Silencing ATP7A in 
cisplatin-resistant tumor cells restored cisplatin sensitivity to a certain extent and 
enhanced apoptosis, suggesting that ATP7A may also be a target to sensitize cancer 
cells to cisplatin (Li ZH et al., 2012). Resistance to cisplatin has also been associated 
with the overexpression of Multidrug resistance-associated proteins (MRP) 1, 2, 3 and 
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5, members of the superfamily of ABC transporters (Borst P et al., 2000; Guminski AD 
et al., 2006; Konkimalla VB et al., 2008; Song Y et al., 2015) (Figure 2). In particular, 
MRP2 expression seems to determine the efficacy of cisplatin-based chemotherapy in 
patients with hepatocellular carcinoma (HCC) (Korita PV et al., 2010). Furthermore, a 
reduction in MRP2 expression using ribozymes has been shown to restore cisplatin 
sensitivity in cisplatin-resistant adrenocortical carcinoma and melanoma cell lines 
(Materna V et al., 2005), further suggesting a role for this molecule in cisplatin 
resistance. Nevertheless, it has been demonstrated that cisplatin is not a substrate for 
MRP transporters and that its ability to transport the drug across the cell membrane 
requires the formation of glutathione- or metallothioneins-cisplatin conjugates 
(discussed in detail in the following section) (Chen ZS et al., 1998; Fujiwara Y et al., 
1990; Kelland L, 2007) (Figure 2). 
 
2.2.3. Detoxification by intracellular molecules 
Although purine nucleobases are the main therapeutic target for cisplatin, a vast 
majority of cisplatin molecules will react with other ligands before reaching the nucleus. 
In particular, cisplatin shows much higher affinity for thiols than for nitrogen groups, 
hence making intracellular cisplatin detoxification via these functional groups one of the 
main mechanisms of cisplatin scavenging (Dabrowiak JC et al., 2002). As such, 
resistance to cisplatin has been associated with the overexpression of metallothioneins, 
a class of low-molecular weight cysteine-rich proteins that promote intracellular 
homeostasis of physiological metals, providing protection against metal toxicity and 
oxidative stress (Knipp M, 2009) (Figure 2). This has been observed in different cancer 
models (Gansukh T et al., 2013; Peng B et al., 2012) as well as in bladder (Siu LL et al., 
1998; Wülfing C et al., 2007), colorectal (Hishikawa Y et al., 2001), esophageal 
(Yamamoto M et al., 1999), and breast (Bay BH et al., 2006; Lai Y et al., 2011) 
carcinomas, among other neoplasia.  
Glutathione (GSH), a thiol containing tripeptide (Glu-Cys-Gly), highly 
expressed in mammalian cells, also plays a key role in cisplatin scavenging (Rocha CR 
et al., 2014) (Figure 2). Glutathione-S-transferase 1 (GSTP1-1) conjugates the reduced 
form of glutathione (GSH) to xenobiotic substrates for the purpose of detoxification and 
catalyzes the formation of cisplatin-GSH conjugates (Peklak-Scott C et al., 2008; 
Sawers L et al., 2014). As such, increased expression of enzymes involved in GSH 
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2.3. Alterations in DNA repair systems 
Several DNA repair pathways interact to maintain accurate DNA replication, 
genomic integrity and normal cell functioning. These include: i) nucleotide excision 
repair (NER); ii) base excision repair (BER); iii) homologous recombination repair 
(HR); iv) mismatch repair (MMR); v) non-homologous DNA end-joining repair 
(NHEJ); vi) O6- alkylguanine DNA alkyl transferase (AGT) mediated repair. Increased 
efficiency of  DNA repair systems is considered essential for the maintenance and 
longevity of stem cell phenotypes and plays a key role in cytotoxic drugs resistance 
(Martin LP et al., 2008). This review will discuss the most studied DNA repair 
pathways involved in platinum response, i.e., nucleotide excision repair (NER) and 
mismatch repair (MMR), and will briefly refer the role of BRCA in DNA repair (Figure 
3). 
Several reports describe associations between the alterations in the XPF-ERCC1 
protein complex of the NER system and platinum-based treatment outcome (Kirschner 
K and Melton DW, 2010) (Figure 3). This complex is a structure-specific endonuclease 
involved in recombination, double strand break and inter-strand crosslink repair 
(Ahmad A et al., 2008). The impossibility to replace damaged nucleotide sequences 
promotes downstream activation of the mitochondrial BAX protein, inducing apoptosis 
(Pawlowski J and Kraft AS, 2000) (Figure 4). As such, XPF-ERCC1 overexpression has 
been found to promote resistance to platinum-based compounds in vitro (Arora S et al., 
2010; Kirschner K and Melton DW, 2010; McNeil EM and Melton DW, 2012), most 
likely due to overefficient DNA repair. In agreement with these observations, 
retrospective studies involving patient’s histological samples have highlighted an 
association between the overexpression of ERCC1, resistance to chemotherapy and poor 
outcome in squamous cell head and neck (Bauman JE et al., 2013) and bladder 
carcinomas (Sun JM et al., 2012). A recent clinical trial has also demonstrated that 
elevated expression of the ERCC1 gene is an independent prognostic factor for overall 
survival in first line treatment of advanced gastric cancer (Kwon HC et al., 2007). 
Furthermore, a phase II trial showed that single nucleotide polymorphisms of ERCC1 
gene (118T/C and 8092C/A) could be used to determine the response of NSCLC 
patients to cisplatin (Mazzoni F et al., 2013). Another study has demonstrated that 
8092C/A could be used as an independent predictive biomarker of better response in 
esophageal cancer patients treated with cisplatin-based regimens (Bradbury PA et al., 
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2009). An enhanced expression of ERCC1 has also been observed in esophageal (Zhao 
Y, Bao Q, Schwarz B, Zhao L, Mysliwietz J, Ellwart J, Renner A, Hirner H, Niess H, 
Camaj P, Angele M, Gros S, Izbicki J, Jauch KW, Nelson PJ, 2014) and ovarian 
(Abubaker K et al., 2013) platinum-resistant cancer-stem cell sub-populations. 
Cisplatin resistance has also been associated with somatic mutations in 
Mismatch Repair system-associated proteins (MMR), namely in MSH2 and MSH3 
proteins (Clodfelter JE et al., 2005; Karran P et al., 2003; Park JM et al., 2013) (Figure 
3). MSH2, together with MSH3, form the MutSβ heteroduplex which interacts with 
interstrand crosslinks induced by drugs such as cisplatin (Muniandy PA et al., 2010). 
Recognition of mismatched base pairs by MMR proteins may directly activate apoptotic 
pathways, thereby leading to cell death. As such, cisplatin-resistance is often 
accompanied by loss of expression of MMR proteins (Topping RP et al., 2009). 
Takahashi et al., has further demonstrated that MSH3 deficiency contributes to the 
cytotoxicity of platinum drugs through deficient repair of double strand breaks in the 
established colorectal cancer cell line HCT116 (Takahashi M et al., 2011). Moreover, 
Velasco A et al., demonstrated that decreased MMR expression in testicular tumors is 
associated with a shorter time to recurrence and death despite chemotherapy (Velasco A 
et al., 2008). 
Likewise, disruption of the homologous recombination (HR) system, responsible 
for DNA double-strand break repair during the S-phase of the cell cycle, has been 
shown to modulate response to cisplatin (Wang QE et al., 2011; Wiedemeyer WR et al., 
2014)  (Figure 3). In particular, breast cancer susceptibility proteins 1 and 2 (BRCA1/2) 
play an important role in DNA repair by interacting with components of DNA repair 
systems and through gene expression regulation of homologous recombination, non-
homologous end joining, and nucleotide excision repair intermediates. As such, BRCA 
proteins affect transcriptional regulation, cell cycle control, apoptosis, and 
ubiquitination (Deng CX and Wang RH, 2003; Mullan PB et al., 2006; Wu W et al., 
2008). Normally, cancer cells with BRCA1/2 deficiency present defective DNA repair 
by homologous recombination and are sensitive to interstrand DNA crosslinking agents, 
such as cisplatin. Therefore, these agents are natural choices for the treatment for 
BRCA1/2-deficient tumors and were shown to be clinically effective (Shah NP, 2008). 
In contrast, during tumor expansion or as a result of chemotherapy, genetic reversion of 
BRCA1 or BRCA2 mutations can occur mainly due to secondary mutations and 
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restoration of function, leading to cisplatin resistance (Dhillon KK et al., 2011; Peng G 
and Lin SY, 2011). Loss of function mutations in genes encoding HR system proteins, 
BRCA1/2 were associated with increased response to cisplatin in breast (Turner NC and 
Tutt AN, 2012) and ovarian tumors (Kwa M et al., 2014). Also, overexpression of 
BRCA1 in cisplatin-resistant human breast and ovarian carcinoma cell lines (MCF-7 
CDDP/R and SKOV-3 CDDP/R, respectively), resulted in increased resistance to 
cisplatin. In turn, antisense inhibition of BRCA1 expression enhanced cisplatin 
sensitivity associated with decreased DNA repair by NER and increased apoptosis in 
the ovarian carcinoma cell line (Husain A et al., 1998). Furthermore, BRCA1 mRNA 
expression levels were also inversely correlated with sensitivity to cisplatin in malignant 
pleural effusions of NSCLC patients and in ascites of gastric patients (Wang L et al., 
2008). In addition, several retrospective clinical studies have demonstrated that low 
BRCA1 mRNA expression was associated with longer survival of breast, ovarian, small 
cell lung cancer and esophageal squamous cell carcinoma (James CR et al., 2007; 
Margeli M et al., 2010; Quinn JE et al., 2007) subjected to cisplatin-based therapeutic 
regimens, and could be therefore used as predictive and prognostic marker. Moreover, 
several studies, recently comprehensively reviewed by Buckley et al., suggest a role for 
BRCA1 in stem cell regulation through activation of the p63 and Notch pathways 
(Buckley NE et al., 2012).Collectively, these studies suggest that functional mutations 
in BRCA1 as well as reduced BRCA1 mRNA levels may predict a benefit from DNA-
damage-based chemotherapy. Furthermore, they highlight a link between BRCA1, stem 
cell regulation and response to chemotherapy. More detailed information regarding the 
role of DNA repair systems in resistance to platinum-based treatment can be found in 
recent reviews by Martin LP et al., (Martin LP et al., 2008). 
Some of the above described DNA repair-associated effectors were found 
overexpressed in CSC, when compared with differentiated tumor cells (Maugeri-Saccà 
M et al., 2012). For instance, a significant increase in gene copy number of BRCA1 and 
RAD51 has been observed in prostatic CSCs compared with the adherent population 
isolated from the primary site (Maugeri-Saccà M et al., 2012). Therefore, it has been 
hypothesized that CSC are endowed with proficient DNA repair mechanisms which 
allow them to resist conventional chemotherapy and act as tumor initiators (Mathews 
LA et al., 2011), urging CSC-targeted therapeutics aimed at the elimination of these 
residual tumorigenic cell sub-populations. 
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RPA and displaces it to allow for Rad51 binding. BRCA2 binds to Rad51 until BRCA2 
becomes phosphorylated, releasing Rad51 and allowing it to localize to the DSB with 
Rad52. Rad51 then forms a nucleoprotein filament that invades a homologous sequence 
and activates strand exchange to generate a crossover between the juxtaposed DNA (not 
shown). BRCA. BReast CAncer genes; EXO1. Exonuclease 1; MLH. MutL 
homologues; MRN complex. This protein complex consists of Mre11, Rad50 andNbs1 
proteins; MSH. MutS protein homolog; PCNA. Proliferating-cell nuclear antigen; 
PMS2. Post-meiotic segregation 2; Pol δ/ε. DNA polymerase δ/ε; RAD. Checkpoint 
protein; RFC. Replication factor C; RPA. Replication protein A. 
 
2.4. Alterations in apoptosis-regulatory pathways 
The cytotoxic effect of cisplatin is primarily mediated by the activation of a 
multibranched pro-apoptotic signaling cascade in response to the impossibility to repair 
DNA damage. Details on these mechanisms have been extensively and 
comprehensively reviewed by several groups (Basu A and Krishnamurthy S, 2010; 
Siddik ZH, 2003). As such, the response to cisplatin is significantly dependent on 
functional apoptotic pathways. Furthermore, genetic and epigenetic alterations in genes 
encoding key mediators of these processes have been long recognized to be associated 
with drug resistance (Dasari S et al., 2014; Galluzzi L et al., 2012; Shen D et al., 2012). 
These events may either result in enhanced survival stimuli, diminished death stimuli or 
diminished sensibility to death signals. Perhaps the most common and well documented 
apoptosis-related deregulation associated with cisplatin resistance stems from the 
inactivation of the tumor suppressor protein p53 (Galluzzi L et al., 2012; Siddik ZH, 
2003) (Figure 4). Furthermore, several studies demonstrated that cancer patients 
harboring wild-type TP53 have a higher probability to benefit from cisplatin-based 
chemotherapy than patients with TP53 mutations (Gadducci A et al., 2002; Liang X et 
al., 2011). Consistently, mutations occur infrequently (< 3%) in germ cell tumors like 
testicular cancer, even though p53 protein is overexpressed in the vast majority of tumor 
samples (Guillou L et al., 1996), reinforcing the key role of p53 as a mediator of 
chemotherapy response. Other p53-related nuclear transcription factors including p63 
and p73, are also part of a network that together with p53, contribute to regulation of 
apoptosis and tumorigenesis (Flores ER et al., 2005; Flores ER et al., 2002) as well as to 
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chemotherapy-induced DNA damage response (Leong CO et al., 2007; Müller M et al., 
2006; Rocco JW et al., 2006; Yuan M et al., 2010). Multiple promoters and alternative 
splicing events result in the expression of several isoforms of these transcription factors, 
which include full-length isoforms with transactivation domains (TA) homologous to 
that of full-length p53, and amino-terminally truncated (DeltaN) isoforms, which lack 
the TA domains. The TA isoforms of p63 and p73 are able to activate downstream 
target genes and promote apoptosis. Conversely, the DeltaN isoforms may act as 
dominant inhibitors of the full-length forms of p53, p63 and p73, hence impairing the 
activation of target genes and inducing apoptosis upon chemotherapy challenge 
(Courtois S et al., 2002; Marcel V et al., 2012; Takahashi R et al., 2014) (Figure 4). 
Several studies have further demonstrated that interfering with the expression or 
function of DeltaNp63 and/or DeltaNp73 and/or mutant p53 in tumor cells contributes 
to the improvement of tumor response to chemotherapy (Müller M et al., 2005; Müller 
M et al., 2006). 
 Alterations in other proteins mediating apoptosis triggered either by DNA 
damage or oxidative stress, via the mitochondrial pathway or by the extrinsic route, may 
also influence sensitivity to cisplatin (Henkels KM and Turchi JJ, 1999; Tanida S, 
Mizoshita T et al., 2012). Several death receptors, cytoplasmic adaptors, pro- and anti-
apoptotic members of the Bcl-2 protein family, caspases, calpains, and mitochondrial 
intermembrane proteins are among the factors shown to modulate the response to 
cisplatin in vitro (Henkels KM and Turchi JJ, 1999; Park MS et al., 2002; van 
Oosterwijk JG et al., 2012). Moreover, some have been suggested to modulate clinical 
response (Aggarwal H et al., 2007; Muris JJ et al., 2005). Namely, high endogenous 
expression of anti-apoptotic members of the Bcl-2 family, such as Bcl-2 and Bcl-XL, 
were associated with increased cisplatin resistance (Michaud WA et al., 2009). 
Likewise, loss of Bax and Bak causes complete resistance to cisplatin (Qian W et al., 
2014) (Figure 4). Moreover, studies involving the combination of cisplatin with the Bcl-
2-inhibitor ABT-737 have shown an improvement in the response to cisplatin, through a 
synergistic effect mediated by Noxa, to promote cell death and loss of clonogenic 
survival (Li R et al., 2009). Overexpression of survivin, a caspase-inhibitory protein 
often upregulated in response to cisplatin by phosphoinositide-3-kinase (PI3K)/AKT1-
dependent mechanisms (Belyanskaya LL et al., 2005), has also been associated with 
lack of response to cisplatin and unfavorable outcome in gastric (Sun XP et al., 2014), 
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esophageal (Kato J et al., 2001), ovarian (Jiang L et al., 2013) and NSCLC tumors 
(Wang HQ et al., 2014). Moreover, the administration of survivin inhibitors (for 
example, YM155, LY2181308) have also been found to improve the outcome of several 
malignancies (Church DN et al., 2012).  
 Several of the abovementioned mechanisms have been found to endow CSC 
with the capability to evade death signals, hence compromising chemosensitivity (Fulda 
S, 2013; Signore M et al., 2013). More detailed insights on the mechanisms regulating 
apoptosis in CSC can be found in recent reviews (He YC et al., 2014; Medina V et al., 
2009). As recently revised by Signore et al., several strategies exploiting signaling 
pathways that govern self-renewal and survival of CSC are currently approved or are 
being tested in clinical trials (Signore M et al., 2013). Strategies to sensitize CSC to 
chemotherapy include the stimulation of death receptors using Apo2L/TRAIL inducers 
(Plasilova M et al., 2002; Ravi R et al., 2004). By promoting the activation of the 
apoptotic extrinsic pathway, this strategy has the potential to overcome drug resistance 
in many tumors harboring p53-inactivating mutations (Ashkenazi A et al., 2008). 
Several antibodies and small molecules targeting the mitochondria-associated apoptosis 
machinery have also been developed including the Bcl-2 inhibitor ABT-727 that was 
able to sensitize glioma CSC to TRAIL treatment both in vitro and in vivo (Tagscherer 
KE et al., 2008). The inhibition of EGF-R/Akt pro-survival signaling is also among the 
most explored strategies to indirectly induce apoptosis of CSC (Gallia GL et al., 2009; 
Signore M et al., 2013). Despite the significant success presented by these strategies, it 
is now consensual that sub-populations of CSC with distinct genetic features may co-
exist within the same tumor (He YC et al., 2014; Wang W et al., 2014) and significant 
molecular variations were also observed between CSC isolated from tumors of the same 
organ and different organs (Frank NY et al., 2010). This phenotypic heterogeneity 
accounts for significant variations in response to targeted strategies and highlights the 
need for a careful evaluation of the signal transduction pathways that drive each sub-
population of CSC to evade apoptosis, towards personalized cancer treatments. 
Furthermore, despite the encouraging reports with patient-derived xenografts capable of 
recapitulating CSC expression and tumor heterogeneity in immune deficient animals 
(Dobbin ZC et al., 2014; Whittle JR et al., 2015; Williams SA et al., 2013), more efforts 
should be devoted to the development of reliable clinical models able to support the 
development of new anti-cancer strategies.  
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and glycosidases in the endoplasmic reticulum (ER) and the Golgi apparatus (GA) 
(Pinho SS and Reis CA, 2015; Spiro RG, 2002). Glycans play a key role in protein 
folding, trafficking, stability, activity and act as mediators of cell-cell adhesion, cell 
differentiation, migration, modulation of cell signaling pathways, immune recognition 
and host-pathogen interactions (Haltiwanger RS et al., 2010; Ohtsubo K and Marth JD, 
2006; Pinho SS and Reis CA, 2015; Shental-Bechor D et al., 2009). Two main classes 
of glycans can be found at the cell-surface: i) O-glycans, initiated in the Golgi apparatus 
by the initial attachment of GalNAc moieties to the hydroxyl groups of Ser or Thr 
residues of a given polypeptide chain (forming the Tn antigen GalNAcα-Ser/Thr, the 
simplest form of O-glycosylation); ii) N-glycans, whose biosynthesis initiates in the ER 
by the addition of an oligosaccharide chain to an Asn residue within consensus peptide 
sequences of Asn-X-Ser/Thr (X denotes any amino acid except proline). Less abundant 
forms of protein glycosylation include O-Fucosylation, O-Glucosylation and C-
mannosylation of Thr residues (Pinho SS and Reis CA, 2015; Spiro RG, 2002). Protein 
glycan chains are often branched or elongated and may present sialic acids in blood 
group related antigens or ABO(H) blood group determinants as terminal structures 
(Dall’Olio F et al., 2012). Other modifications may include phosphorylation, O-
acetylation of sialic acid and O-sulfation of galactose and N-acetylglucosamine 
residues, thereby increasing the structural complexity of the glycophenotype (Muthana 
SM et al., 2012). Furthermore, protein glycosylation patterns do not obey a predefined 
template (Lazar IM et al., 2011), as it is regulated at the tissue level, and promptly 
responds to physiological changes and cues (Ohtsubo K and Marth JD, 2006; Palorini R 
et al., 2013; Shirato K et al., 2011b; Testa R et al., 2015). In fact, variations in glucose 
and oxygen levels, among other microenviromental stimuli and signaling molecules, 
have been shown to influence the transcription and activity of glycosyltransferases and 
glycosidases, the trafficking of these enzymes to the ER and the Golgi apparatus and the 
availability of sugar donors (Carvalho AS et al., 2010; Dall’Olio F et al., 2012; Gill DJ 
et al., 2013; Pinho SS and Reis CA, 2015; Shirato K et al., 2011b). Recent studies have 
challenged the classical view of protein glycosylation as an intracellular event by 
demonstrating that glycans may experience further structural remodeling by 
extracellular enzymes (Lee MM et al., 2014; Nasirikenari M et al., 2014). This makes 
the glycome a highly dynamic molecular entity that mirrors a particular biological 
milieu and the glycomic/glycoproteomic characterization, a challenging analytical 
enterprise. Detailed insights on the structure of these glycans and their biosynthesis are 
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available in several reviews and textbooks on the subject (Brockhausen I et al., 2009; 
Stanley P et al., 2009) and will not, therefore, be discussed in detail. 
Malignant transformation is often accompanied by the expression of 
glycosylated structures that promote tumor growth, cell survival, cell-to-cell 
detachment, migration, immune evasion and metastasis (Figure 5, Christiansen MN et 
al., 2014; Dall’Olio F et al., 2014, 2012; Gomes C et al., 2013; Pinho S et al., 2007; 
Radhakrishnan P et al., 2014). In some cases, malignant tissues recapitulate the 
glycosylated antigens expressed during fetal life (Feizi T, 1985; Hakomori S, 1989; 
Varki A et al., 2009). Perhaps the most studied cancer-associated glycans include 
variants resulting from a premature stop in protein O-glycosylation, namely the Tn 
antigen (the simplest O-glycan), its sialylated counterpart sialyl-Tn (sTn; Neu5Acα2-
6GalNAcα-O-Ser/Thr ) and the T or core 1 antigen that results from the addition of a 
Gal residue to the Tn antigen (Galβ1-3GalNAc-Ser/Thr) (Cazet A et al., 2010; Ju T, 
Lanneau GS et al., 2008; Julien S et al., 2012; Marcos NT et al., 2004). These antigens 
have been classically termed simple mucin-type O-glycans reflecting the abundance of 
O-glycosylation sites in mucins and stem from the incapability of the cellular 
glycosylation machinery to produce more elongated glycans. Recently, a precision 
mapping of the human O-GalNAc glycoproteome has revealed over 6000 glycosites in 
more than 600 O-glycoproteins, the majority of which were found at the cell surface 
(Campos D et al., 2015; Schjoldager KT and Clausen H, 2012; Steentoft C et al., 2013; 
Steentoft C et al., 2011), thereby greatly expanding the view of the O-glycoproteome 
and its functional role. Of note, several intracellular proteins, including cytoplasmic, 
mitochondrial and nuclear proteins, have also been found expressing this type of 
posttranslational modification (Steentoft C et al., 2013). Despite the need for further 
analytical validation, these observations may suggest a currently neglected role for O-
GalNAc glycosylation in intracellular physiological and pathological events. Similar 
subsequent studies have contributed to the notion that cells of different origins express a 
minor and unique O-glycoproteome that should be carefully explored when envisaging 
highly specific cancer biomarkers (Campos D et al., 2015; Campos D et al., 2015) 
While hindered by extended glycosylation in healthy and benign tissues, simple 
mucin-type O-GalNAc glycans are uncovered in the majority of human carcinomas, 
particularly in advanced stages of the disease (Figure 5, Dall’Olio F et al., 2012; Freire-
de-Lima L, 2014; Julien S et al., 2012; Marcos NT et al., 2004). The Tn, sTn and T 
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antigens have been associated with malignant cell phenotypes, disease progression, 
metastasis and poor prognosis in clinical settings for a variety of different solid tumors 
(Cazet A et al., 2010; Julien S et al., 2012; Marcos NT et al., 2011; Reis CA et al., 
2010a). Recently, we have reported the association between sTn, high-grade bladder 
cancer and muscle-invasion (Bernardo C et al., 2014; Ferreira JA et al., 2013; Lima L et 
al., 2013) as well as the capability of sTn+-bladder cancer cells to promote a tolerogenic 
immune response of dendritic cells (Carrascal MA et al., 2014), demonstrating the 
involvement of glycans in the mediation of cancer immune responses. The fact that 
these simple glycans are absent, significantly underexpressed or restricted to some cell 
types in healthy tissues, renders them potential diagnostic and therapeutic targets. 
Proteins carrying abnormal glycosylation are often released from the cell-surface, 
therefore increasing sTn concentrations in the serum (CA72-4 test) of gastric, colorectal 
and pancreatic carcinoma patients (Carpelan-Holmström M et al., 2004; Reis CA et al., 
2010b; Ychou M et al., 2000) as well as in pre-cancerous gastric lesions (Gomes C et 
al., 2013). The elevation of CA72-4 was shown to be an independent prognostic factor 
in gastric cancer (Louhimo J et al., 2004) and predictive of tumor recurrence in gastric 
(Ychou M et al., 2000) as well as pancreatic cancers (Louhimo J et al., 2004). 
Moreover, monoclonal antibodies have been developed for sTn-MUC1 glycopeptides 
(Sørensen AL et al., 2006) as well as the therapeutic vaccine Theratope that, despite 
promising initial results in pre-clinical and in early stage clinical trials for advanced 
breast tumors (Holmberg LA et al., 2000; Holmberg LA et al., 2004), it remains to be 
thoroughly assessed in other solid tumors known to overexpress sTn. 
Several evidences also point to an increase in the complexity of N-linked 
glycans and glycolipids through β−1,6 branching, mediated by β-1,6-N-
acetylglucosaminyltransferase V (Mgat5) in cancer (Figure 5, Fortuna-Costa A et al., 
2014; Liu H et al., 2015; Pinho SS et al., 2013; Pinho SS et al., 2011; Taniguchi N et al., 
2015). The β-1,6-N-acetylglucosamine-branched glycans are responsible to the high-
affinity binding of Galectin-3 to several membrane glycoproteins and glycolipids, with 
implications to angiogenesis, metastasis, and other tumor progression events (Fortuna-
Costa A et al., 2014; Funasaka T et al., 2014). For instance, lysosomal membrane-
associated glycoproteins such as (LAMPs)-1and -2, Mac-1 and Mac-3, CD-98, CD-45, 
and CD-7 as well as EGF, TGF-β, and VEGF are known ligands for Galectin-3. 
Galectin-3 also binds CEA and MUC-1, among other relevant cancer-associated 
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proteins (Fortuna-Costa A et al., 2014). Galectin-3 crosslinks cell surface glycoprotein 
receptors resulting in functional microdomains that regulate extracellular signal 
transduction (Boscher C et al., 2011; Lajoie P et al., 2009), glycoprotein receptor 
turnover and endocytosis (Lakshminarayan Ret al., 2014). As recently highlighted by 
several reports (Fortuna-Costa A et al., 2014; Liu FT and Rabinovich GA, 2005; 
Rabinovich GA and Toscano MA, 2009) galectin-3 mediates several hallmarks of 
cancer, including tumor growth(Peng W et al., 2008), anoikis resistance (Kim HR et al., 
1999), inhibition of apoptosis (Takenaka Y et al., 2004), angiogenesis (Nangia-Makker 
P et al., 2010), cell adhesion (Khaldoyanidi SK et al., 2003), cell motility (Boscher C 
and Nabi IR, 2013), cell invasion (Tsuboi K et al., 2007) as well as microenvironment 
modulation (Nangia-Makker P et al., 2008; Reticker-Flynn NE et al., 2015). Increased 
β-1,6-branching of cadherins, integrins and other cytokine/growth factor receptors has 
also been found to enhance and promote tumor growth and metastasis (Carvalho S et 
al., 2015; Granovsky M et al., 2000; Pinho SS et al., 2013; Zhao Y et al., 2008) while 
the Mgat5 knockout inhibited these phenomena in vitro and in vivo in different 
experimental cancer models (Carvalho S et al., 2015; Dall’Olio F et al., 2012; Fortuna-
Costa A et al., 2014; Lau KS and Dennis JW, 2008). 
Two other common cancer-associated antigens are the α−2,3-sialylated forms of 
type 1 and type 2 Lewis blood group determinants Lea and Lex, sLea and sLex , that may 
be found as terminal epitopes of glycan chains in both glycoproteins and glycolipids 
(Carvalho AS et al., 2010; Dall’Olio F et al., 2012; Julien S et al., 2011; Kannagi R, 
2007; Tozawa K et al., 2005). These glycans are specific ligands for E- and P-selectins 
in endothelial cells, two proteins that mediate leukocyte extravasation at sites of tissue 
injury in a sLea/sLex-dependent manner (Dall’Olio F et al., 2012). Similarly, these 
sialylated glycans are thought to act as regulators of the metastatic cascade by 
promoting endothelial adhesion (Kannagi R, 1997). In addition to a role in metastasis, 
selectin ligands are also thought to play a role in tumor growth and angiogenesis 
(Gomes C et al., 2013; Terraneo L et al., 2013). In particular, several reports associate 
the overexpression of sLea with decreased overall survival in digestive tract tumors 
(Kannagi R, 2007; Matsui T et al., 2004; Portela SV et al., 2011). Furthermore, 
serological detection of sLea on glycolipids and glycoproteins by the CA19-9 assay is 
used as a diagnostic tool to monitor clinical response to therapy for these tumors 
(Humphris JL et al., 2012; Kannagi R, 2007; Yang GY et al., 2013). Furthermore, the 
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Figure 5 A) Representation of protein N- an O-glycosylation in healthy tissues and 
malignant cells. Protein glycosylation plays a key role in the definition of protein 
folding and physiological functioning. Glycans contribute to cell-cell and cell-
extracellular matrix adhesion, immune cell recognition, among other key biologic 
processes. Glycosylation is a highly dynamic posttranslational modification resulting 
from the concerted and highly regulated action of several glycosyltransferases in 
secretory organelles that rapidly changes in response to physiological stimuli. Several 
N- (Asn residues) and O- (Ser/Thr residues) glycans may coexist in the same protein 
backbone, depending on available glycosites and conformational constrains. In 
comparison to healthy cells, malignant cells tend to present more complex and branched 
oversialylated and/or fucosylated N-glycans. N-glycans may also be more extended by 
LacNAc chains.  Conversely, more malignant clones present less complex and 
immature O-glycans, namely the Tn, sTn and T antigens that may be also found in 
oncofetal tissues. Some cancer cells may also express selectin ligands sLea/x as 
terminal structures of both N- and O-glycans. These structural alterations at the cell-
surface favor more motile and plastic cell phenotypes, invasion, lymphatic and 
hematogenous dissemination and immune evasion. By impairing normal functions of 
cell-surface receptors, cancer-associated glycans also interfere with normal intracellular 
signaling transduction pathways towards the activation of oncogenic features.  
 
3.2. Protein glycosylation: contribution to chemoresistance 
 Several studies have described that subpopulations of multidrug resistant (MDR) 
cancer cell lines of distinct tissue origin present altered glycosylation patterns, 
particularly at the N-glycosylation level, when compared with the parental cell lines 
(Beretta GL et al., 2010; Kudo T et al., 2007; Noda I et al., 1999; Schultz MJ et al., 
2013; Zhang Z et al., 2012; Zhao Y et al., 2014). Alterations in glycogene expression 
were also reported and, in most cases, have been found in agreement with the observed 
glycosylation patterns (Schultz MJ et al., 2013; Zhao Y et al., 2014). In particular, some 
studies have further associated the overexpression of cell-surface ATP binding cassette 
transporters (MRP1 and MRP4) and CD147 showing abnormal N-glycosylation patterns 
with drug resistance (Afonso J et al., 2014; Beretta GL et al., 2010). Furthermore, the 
exposure of chemoresistant cancer cells to tunicamycin, an N-glycosylation biosynthesis 
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inhibitor, has been shown to sensitize these cells to anti-cancer agents (Kramer R et al., 
1995; Noda I et al., 1999). Although these observations suggest that alterations in N-
glycosylation may alter the functional properties of cell-surface transporters involved in 
multidrug resistance, it should be noticed that tunicamycin is responsible by inducing 
significant ER stress leading to apoptosis (Han C et al., 2008). Several structural 
alterations, namely α-2,6-oversialylation of cell-surface molecules, have also been 
shown to significantly modulate downstream oncogenic signaling pathways towards 
enhanced cell survival, tumor growth and migration (reviewed in detail by Dall’Olio F, 
et al. and Park J and Lee M) (Dall’Olio F et al., 2014, 2012; Park J and Lee M, 2013). 
Yet, the contribution of these events to chemotherapy resistance remains to be 
determined. Adding to these findings, several studies associated elevation of serum sTn 
antigen (detected by the CA72-4 test) and sLea (detected by the CA19-9 test) levels in 
cancer patients with both recurrence after chemotherapy, metastasis and poor overall 
survival (Kim DH et al., 2015; Yang GY et al., 2013; Ziske C et al., 2003), suggesting 
that the presence of these glycans may be associated with drug resistance. However, this 
hypothesis warrants confirmation in future studies. Altogether, these findings support 
the notion that glycosylation may constitute a currently neglected posttranslational 
modification of proteins which may be associated with cancer chemoresistance. Given 
its cell-surface nature, in-depth studies of these glycans may allow the selective 
targeting of these aggressive malignant clones and glycosylation remodeling may 
constitute a novel approach to overcome chemoresistance. 
 
4. Chemotherapy challenge and CSC selection: exploring the role of glycosylation 
for guided therapeuti s 
During the last decade, CSC populations were described in various types of solid 
tumors, albeit their phenotypic and functional characteristics are still under intensive 
investigation (Tirino V et al., 2013; Visvader JE and Lindeman GJ, 2008). As a result, 
specific functional features such as self-renewal and long-term repopulation potential 
were identified in CSC and these characteristics were predominantly related to tumor 
initiation and maintenance of tumor growth (Al-Hajj M and Clarke MF, 2004). In 
addition, CSC exhibit a number of genetic and cellular adaptations that confer resistance 
to conventional chemotherapeutics such as relative dormancy/slow cell cycle kinetics, 
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efficient DNA repair, overexpression of multidrug resistance efflux transporters and 
resistance to apoptosis (Abdullah LN and Chow EK, 2013; Cojoc M et al., 2015), as 
outlined in detail in the previous sections. Furthermore, several reports suggest that 
conventional therapy often results in enrichment and maintenance of CSC pools that 
form the tumor after chemotherapy, triggering relapse as chemoresistant tumors. In 
particular, Levina et al., (Levina V et al., 2008) suggested that cisplatin-containing 
chemotherapy leads to propagation of human lung cancer stem cells and inhibition of 
cell differentiation. Moreover, these cells appear to activate an efficient cytokine 
network that favors their tumorigenic and metastatic potential (Levina V et al., 2008). 
Other research groups related lung cancer recurrence with maintenance of treatment-
selected CSC (Barr MP et al., 2013; Leung EL et al., 2010). For instance, using whole 
genome expression analysis, Hamilton et al., (Hamilton G and Olszewski U, 2013) 
demonstrated that small cell lung cancer (SCLC) cells express CSC markers (CD44, 
CD133, CD47, ALDH1A1, AKR1C), as well as WNT and Notch pathway 
intermediates after chemo-radiotherapy, compared to treatment-naïve cells. Bertolini et 
al., also reported that cisplatin treatment spares highly tumorigenic CD133+ NSCLC 
cells that display stem-like features (Bertolini G et al., 2009). Zhang Yi et al., found 
similar correlations in cisplatin-resistant bladder cancer cells, which displayed enhanced 
self-renewal and tumorigenicity as well as higher levels of sphere formation, a larger 
proportion of side population cells and stem cell marker expression (Zhang Y et al., 
2012). Regarding ovarian cancer, cisplatin-based chemotherapy also appears to preserve 
CSC-like cells, resulting in increased tumor burden (Abubaker K et al., 2013; Yasuda K 
et al., 2013).  
These findings support the notion that the combination of conventional 
chemotherapy directed to  bulk tumor cells and targeted strategies against CSC may 
hold promise to improve cancer management compared to monotherapies. Therefore, 
over the past decade many concentrated efforts have been put on the isolation and 
molecular characterization of CSC using chemotherapy selection approaches. In fact, 
the chronic or acute exposure of tumor cell lines, xenografts and patient samples to 
anticancer drugs has provided a simple strategy for CSC enrichment, as recently 
reviewed (Freitas DP et al., 2014). This has allowed the establishment of CSC-
biomarker panels, which include, for example, the following proteins: ALDH1, CD29, 
CD24, CD44, CD90, and CD133 (de Beça FF et al., 2013; Langan RC et al., 2013; 
Yang CH et al., 2014). Nevertheless, these biomarker molecules fall short to discern 
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cancer from normal adult stem cells, as previously reviewed in detail (Karsten U and 
Goletz S, 2013), hence prompting the introduction of more specific molecules for 
targeted therapeutics. Several authors now suggest that targeting oncofetal stem cell 
markers, normally not present in adult stem cells, may constitute a novel and more 
effective treatment strategy. 
Exploring cancer-associated glycans, which are often of oncofetal nature, presents 
a unique and highly specific opportunity to target CSC. In fact, several studies reported 
alterations in the glycopatterns of CSC of different tissue origins compared to other 
cancer cells. Many of these findings concern the overexpression of glycans commonly 
found in glycolipids (CD60a, CD77, GD2, Gb4) and proteins (CD147 or Ley, CD15 or 
Lex) (Karsten U and Goletz S, 2013). More recently cumulative evidences confirm that 
CSC resistant to gemcitabine (Terao N et al., 2015) and doxorubicin (Azuma K et al., 
2014) present distinct glycosylation patterns when compared to drug sensitive parental 
cell lines. Namely, Terao et al., described that CSC derived from the gemcitabine 
chemoresistant pancreatic cancer cell line Panc1 display significant overfucosylation 
and upregulation of fucosyltransferases, GDP-fucose synthetic enzymes, and GDP-
fucose transporters (Terao N et al., 2015). However, knockdown of GDP-fucose 
transporters did not improve gemcitabine response, suggesting that overfucosylation is a 
result of CSC transformation with little influence on chemoresistance. On the other 
hand, Azuma K et al., explored the oversialylation of doxorubicin-resistant 
hepatocellular CSC towards the identification of highly specific glycoprotein species 
(Azuma K et al., 2014). These approaches have contributed to highlight the importance 
of an in-depth assessment of the glycome and glycoproteome of different CSC 
populations towards more specific biomarkers. 
In this review we emphasize the growing amount of evidence supporting an 
association between the protein-specific cancer-associated O-glycans sTn and T and 
CSC proteins (Figure 6). The sTn and sialylated T antigens, which result from a 
premature arrest in protein glycosylation (as addressed in detail in the previous section), 
are absent from the majority of healthy tissues, but expressed in several solid tumors 
(Julien S et al., 2012; Marcos NT et al., 2011; Videira PA et al., 2009). Furthermore, 
many studies report an increased expression of these proteins in advanced stages of the 
disease (Julien S et al., 2012). Perhaps the most studied is the sTn antigen (CD72-4), 
whose presence in adult healthy tissues has been highly restricted to specific cells 
(Ferreira B et al., 2006; Julien S et al., 2012; Marcos NT et al., 2011). In contrast, the 
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sTn antigen has been found overexpressed in many advanced stage solid tumors, where 
it plays a key role in endowing cancer cells with a metastatic potential; furthermore it is 
also present in the metastatic lesions (Ferreira B et al., 2006; Julien S et al., 2006; 
Marcos NT et al., 2011; Pinho S et al., 2007). Although more evidence are required, 
these findings suggest that sTn-expressing cells may be capable of detaching from the 
primary tumor and colonize distant tissue locations. Moreover, the sTn antigen was also 
detected in several fetal organs of both genders (e.g. esophagus, stomach, pancreas, 
colon, lung, mammary gland, gonadal tissue) (Itzkowitz SH et al., 1989; Julien S et al., 
2012; Pistolesi S et al., 2001; Stanick D et al., 1988; Thor A et al., 1986). Although 
little is known about the biological role of sTn during embryonic development, these 
evidences suggest that cancer cells undergo, to some extent, similar mole ular events. In 
spite of the possibility of sTn being expressed by all proteins presenting O-
glycosylation sites, as demonstrated by several studies using engineered cancer cells to 
express this antigen (Campos D et al., 2015; Campos et al, 2015b; Julien S et al., 2012), 
few proteins have emerged from models that naturally express the antigen. Among these 
proteins are the heavily glycosylated MUC1 (Beatson R et al., 2015; Lakshminarayanan 
V et al., 2012) and CD44 (Campos D et al., 2015; Carrascal MA et al., 2014; Irimura T 
et al., 1999; Marcos NT et al., 2011), whose overexpression has been widely observed 
in CSC of different tumor models (Bourguignon LY et al., 2014; Curry JM et al., 2013; 
Nath S et al., 2015). Likewise, Karsten and Goletz discussed a similar role for the T 
antigen (CD176) in their recent review on this topic (Karsten U and Goletz S, 2013). 
Accordingly, this oncofetal antigen has been found in primary tumors and metastases, 
and detected in CD44 (Lin W et al., 2011; Singh R et al., 2001), CD45 (Baba M et al., 
2007), and CD34 (Cao Y et al., 2008) of CSC from different cancer models. 
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more specific biomarkers than the currently available panels and provide insights to the 
possible role of O-glycans in chemoresistance. 
 
5. Concluding Remarks 
Cancer cells show remarkable capability to resist chemotherapy treatments due 
to the synergistic effect of intrinsic, acquired as well as microenvironmental factors. 
Moreover, chemotherapy frequently acts as a positive selective pressure for the 
emergence of more aggressive cell subpopulations such as CSC, which are responsible 
for promoting disease relapse and progression. While many molecular mechanisms 
linking chemoresistance and CSC were already identified, CSC targeting remains a 
challenge, mostly due to the molecular similarities of CSC to non-malignant stem cells. 
We now comprehensively propose, for the first time, that alterations in protein 
glycosylation are amongst the key events accompanying and possibly driving 
chemoresistance. In fact, chemoresistant cancer cells supported by favorable 
microenvironments and endowed with intracellular mechanisms to evade cell death, 
present distinct N- and O-glycosylation patterns when compared to other cancer and 
non-malignant cells. Moreover, many studies have brought glycosylation into the 
spotlight by demonstrating that selective inhibition of N-glycosylation pathways may 
constitute an important therapeutic strategy to overcome chemoresistance. However, we 
argue that the influence of glycosylation extends beyond these events, given that it plays 
a pivotal role in the activation of several oncogenic pathways that sustain 
chemoresistance. Despite these insights, a direct link between protein glycosylation and 
chemoresistance remains to be established. Furthermore, the specific structural nature of 
CSC-associated glycans and glycoproteins, envisaging highly specific biomarkers has 
not yet been fully disclosed. Nevertheless, the context-dependent nature of glycans 
offers tremendous potential for the identification of unique CSC-glycoproteomes and 
clinically valuable biomarkers for cancer detection and targeted therapeutics. 
As cancer treatment is shifting towards precision medicine and patient-tailored 
strategies (Kohane IS, 2015), we emphasize the need to integrate the patients’ 
background, clinical history, tumor molecular features and the microenvironment in a 
single holistic perspective. Furthermore, we conclude that it will be imperative to 
address chemoresistance as a multifactorial and dynamic feature, considering many of 
the aspects discussed in the current review. Therefore, we come forward with a novel 
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way towards more specific targeted therapy. Focus should also be put on a careful and 
comprehensive glycoproteomic evaluation of chemoresistant clones and their 
microenvironmental context. These studies will greatly benefit from the tremendous 
advances, over the past two decades, in the development of highly sensitive mass-
spectrometry platforms and protocols specifically designed to address the complex 
structural nature of protein glycosylation (Almeida A et al., 2013; Zhang Y et al., 2013). 
Moreover, while tumor cell lines are important starting models for proof-of-concept 
studies, it will be important to expand studies towards models able to more accurately 
mimic the tumor microenvironment. Future approaches should include direct human 
cancer xenografts in animal models, the so-called avatar models, which have been 
shown to preserve the molecular features of human tumors, in luding tumor 
glycosylation (Aparicio S et al., 2015; Bernardo C et al., 2014; Hidalgo M et al., 2014). 
New bioengineering approaches such as 3D Lab-on-a-chip settings may also provide the 
necessary system complexity to address drug toxicity in cancer cells, as demonstrated in 
several recent publications (Kim C et al., 2015; Ruppen J et al., 2014; Su M et al., 
2014). 
As already mentioned, true improvements in patient care and chemoresistance 
require the introduction of multi-target patient-tailored therapeutics. In this context, 
altered protein glycosylation may constitute the necessary mean to selectively deliver 
emerging nanotherapeutic agents to cancer cells, thereby improving the efficacy and 
reducing the toxicity of the treatments (Fernandes E and Ferreira JA et al., 2015; Livney 
YD and Assaraf YG, 2013). These nanodelivery sytems may include conventional 
chemotherapy drugs, genetic-based strategies such as the siRNAs against key oncogenic 
proteins involved in chemoresistance (Ganesh S et al., 2013; Navarro G et al., 2012; 
QingShuo M et al., 2013) or the administration of genes capable of rescuing the 
expression of p53 and other cell cycle checkpoint proteins (Chen GX et al., 2014; 
Kamal A et al., 2014; Kim SS et al., 2014; Li D et al., 2013). The introduction of 
antibodies against cancer-associated glycoepitopes may also allow the selective 
inhibition of oncogenic pathways or the stimulation of immune responses against 
malignant cells (Azevedo R et al., 2015). Glycan-based therapeutic solutions should 
also be tested, for the first time, in the context of hematological malignancies that also 
pose significant chemoresistance issues (Assaraf YG et al., 2014; Assaraf YG, 2007; 
Gonen N and Assaraf YG, 2012). Nevertheless, the particular differences between blood 
and epithelial cells should be taken into consideration when designing such strategies. 
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In summary, exploiting altered glycosylation for targeted therapeutics is an 
emerging research topic that holds great potential for overcoming cancer 
chemoresistance phenomena. However, the roadmap for prototyping glycan-based 
therapeutics still requires a careful planning addressing the following research topics: i) 
comprehensive characterization of glycomic and glycoproteomic chemoresistant cells; 
ii) understanding the biological significance of altered glycosylation in 
chemoresistance; iii) development of glycan-specific ligands; and iv) establishment of 
cancer animal models mimicking human glycosylation. 
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ABSTRACT
The high molecular heterogeneity of bladder tumours is responsible for significant 
variations in disease course, as well as elevated recurrence and progression rates, 
thereby hampering the introduction of more effective targeted therapeutics. The 
implementation of precision oncology settings supported by robust molecular models 
for individualization of patient management is warranted. This effort requires 
a comprehensive integration of large sets of panomics data that is yet to be fully 
achieved. Contributing to this goal, over 40 years of bladder cancer glycobiology have 
disclosed a plethora of cancer-specific glycans and glycoconjugates (glycoproteins, 
glycolipids, proteoglycans) accompanying disease progressions and dissemination. 
This review comprehensively addresses the main structural findings in the field and 
consequent biological and clinical implications. Given the cell surface and secreted 
nature of these molecules, we further discuss their potential for non-invasive detection 
and therapeutic development. Moreover, we highlight novel mass-spectrometry-based 
high-throughput analytical and bioinformatics tools to interrogate the glycome in the 
postgenomic era. Ultimately, we outline a roadmap to guide future developments in 
glycomics envisaging clinical implementation.
INTRODUCTION
Bladder cancer, particularly muscle invasive 
bladder cancer (MIBC), is amongst the most common 
and deadliest genitourinary cancers [1]. The mainstay 
treatment for advanced stage tumours includes surgery 
and cisplatin-based chemotherapeutic regimens [1], 
which fail in avoiding tumour relapse and disease 
progression. Tremendous efforts have been put in the 
establishment of biomarker panels for early diagnosis, 
follow-up, patient stratification, prognosis, treatment 
selection and development of targeted therapeutics [2]. 
However, the highly heterogeneous molecular nature 
of bladder tumours has hampered true developments in 
this field [3]. Moreover, bladder cancer remains mostly 
an “orphan disease” in terms of targeted therapeutics, 
leading to few improvements in patient’s overall survival 
over the last decade [2, 4]. More detailed information on 
the clinicopathological nature of bladder tumours and 
critical aspects in disease management have been recently 
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reviewed [5]. A schematic illustration of bladder cancer 
staging and grading is shown in Figure 1.
Several decades of glycobiology research have 
disclosed the existence of profound alterations in the 
glycosylation patterns of bladder tumours, reflecting 
specific changes in glycan biosynthetic pathways, 
glycosyltransferases expression, amongst other factors 
[6]. These events often lead to novel protein and lipid 
glycoforms, either by incomplete or neo-synthesis of 
glycan epitopes, that cannot be found in the corresponding 
healthy tissues and preneoplastic lesions. These events 
play a key role in tumour progression by affecting ligand-
receptor interactions, and interfering with regulation 
of cell signaling, adhesion, migration, proliferation, 
angiogenesis, and immune responses [6]. Moreover, 
cancer-associated glycans may be actively secreted 
into bodily fluids (e.g. blood and urine) or shed from 
apoptotic and necrotic cancer cells [7]. As such, glycans 
and abnormally glycosylated molecules (e.g. proteins and 
lipids) hold tremendous value for non-invasive cancer 
detection, while membrane bound glycans may be used 
to selectively target tumour sites and specific cancer cells. 
Nevertheless, the structural complexity and heterogeneity 
of oligosaccharides, and the lack of analytical methods 
for elucidating structures still pose a major difficulty 
when addressing the glycome, glycolipidome and 
glycoproteome [8]. Still, a plethora of mass spectrometry-
based analytical approaches have been developed to 
address these challenges [8, 9] and the standardization 
of high-throughput glycomics is expected to boost our 
knowledge on bladder cancer glycobiology in the near 
future.
Based on these considerations, the present review 
comprehensively summarizes the clinical significance 
of the main biomarkers arising from over forty years of 
bladder cancer glycobiology research and establishes the 
milestones towards clinical applications. Ultimately, we 
discuss the need to integrate glycans in holistic panomics 
models for precision oncology, namely the molecular-
based individualization of patient care. 
Glycosylation signatures in bladder cancer: 
biological and clinical implications
Glycosylation is the most frequent, complex 
and plastic post-translational modification of secreted 
and membrane-bound proteins, as well as a common 
substitution in lipids at the cell membrane [10]. 
Glycans are secondary gene products resulting from 
the coordinated action of nucleotide sugar transporters, 
glycosyltransferases and glycosidases in the endoplasmic 
reticulum (ER) and Golgi apparatus (GA) of mammalian 
cells [10]. Glycans are involved in several structural, 
modulatory, molecular mimicry and recognition roles 
including protein folding, stability, adhesion and 
trafficking, as recently reviewed [11]. Alterations in 
glycosylation patterns are common features of solid 
tumours, being detected even in pre-malignant lesions 
[12]. Generally, the most frequently described cancer-
related glycosylation modifications include the synthesis 
of highly branched and heavily sialylated glycans, the 
premature termination of biosynthesis, resulting in the 
expression of short-chained forms, and the expression 
de-novo of glycosidic antigens of foetal type [13]. 
These structural motifs are mostly associated with: i) 
altered glycogenes expression [14, 15]; ii) impaired 
glycosyltransferases’ chaperone function [16]; iii) 
altered glycosidase/glycosyltransferase activity [15]; 
iv) reorganization of glycosyltransferases topology [17, 
18]; v) bioavailability of sugar nucleotide donors and 
cofactors [19]; vi) alterations on the conformation of 
peptide backbone or on the nascent glycan chain structure 
[19]. The resultant aberrant and cancer-associated glycans 
seem to be implicated in the activation of oncogenic 
pathways [20], establishment of tumour-tolerogenic 
immune responses [21], and in epithelial-to-mesenchymal 
transition (EMT), a crucial milestone towards invasion 
and metastasis [22, 23]. Thus, many glycoepitopes, and 
their related glycosidases/glycosyltransferases, can be 
considered relevant tumour-associated antigens [24, 25], 
with possible clinical significance in bladder cancer. 
Therefore, the following sections will focus on these key 
findings in bladder cancer glycobiology (summarized 
in Supplementary Table 1 - Supplementary material). 
Given their structural complexity and broad distribution, 
known cancer-associated glycogenes, glycosyltransferases 
and glycans will be presented in the context of specific 
classes of biomolecules (glycoproteins, glycolipids, 
proteoglycans). 
Protein glycosylation
Two main classes of glycans can be found altered in 
cancer cell-surface proteins, namely N-glycans, attached to 
the peptide sequence via an asparagine (Asn) residue, and 
O-glycans, attached by a N-acetylgalactosamine (GalNAc) 
residue to the hydroxyl group of a serine (Ser) or threonine 
(Thr) residue.
Cancer-associated N-glycans
Protein N-glycosylation takes place in the ER, 
where the oligosaccharide transferase complex (OSTase) 
scans nascent proteins for Asn-X-Ser/Thr “sequons” 
(“X” stands for any amino acid residue except proline), 
and transfers a precursor glycan (Glc
3
Man9GlcNAc2-) 
from dolichol pyrophosphate to Asn residues [26]. At 
this point, all N-glycans share a common core structure 
(Manα1-6(Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAcβ1-
Asn-X-Ser/Thr), which is further processed in the ER 
and GA by several glycosyltransferases and glycosidases, 
yielding mature core structures that may be classified into 
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three major N-glycan types (oligomannose, complex, and 
hybrid, Figure 2). The O-3 linked Man residues in hybrid 
and complex N-glycans may be further O-4 substituted 
with N-acetylglucosamine (GlcNAc) residues by 
GlcNAcT-III (GnT-III) to yield bisecting core structures. 
The introduction of the bisecting GlcNAc residue by 
GnT-III alters the composition and conformation of 
the N-glycan, resulting in the suppression of further 
processing and elongation [27, 28]. More highly branched 
N-glycans may be generated by the action of different 
GlcNActransferases (GnT-IV, -V, -VI). These structures 
may be further elongated with galactose, poly-N-
acetyllactosamine, sialic acid, and fucose residues. 
Particularly, N-glycans frequently exhibit Lewis (Le) 
blood group related antigens (Lea, Lex, Leb and Ley) and 
corresponding sialylated structures or ABO(H) blood 
group determinants as terminal epitopes. Similar terminal 
structures may also be found in O-glycans (Figure 2). 
Other sugar modifications may include phosphorylation, 
O-acetylation of sialic acids, and O-sulfation of galactose 
and N-acetylglucosamine residues, thereby increasing the 
structural complexity of the glycome [29]. 
Several N-glycan alterations have been described 
in bladder tumours, including changes in branching and 
terminal structures through oversialylation, fucosylation 
(Supplementary Table 1), which will be discussed in detail 
in the following sections.
N-glycans branching
Alterations in N-glycans branching resulting from 
impaired GnTs expression have been evaluated in the 
context of bladder cancer prognosis. Namely, increased 
GnT-III, N-glycans bisection and GnT-IV expression 
were associated with higher disease stage and grade in 
bladder cancer patients [30]. Conversely, decreased GnT-V 
expression, responsible by O-6 N-glycans branching, was 
found associated with higher bladder tumour grade and 
stage, shorter disease-free survival and bladder cancer 
recurrence [31, 32]. Moreover, low GnT-V expression 
was found to predict shorter cause-specific survival of 
bladder cancer patients while overexpression of O-6 
branched N-linked oligosaccharides was associated 
with lower tumour stage, suggesting that these findings 
could be applied to risk stratification [32]. The opposing 
associations of GnT-III and GnT-V in bladder cancer 
prognosis can be explained by the antagonistic effect of 
their enzymatic activity [28]. Contrasting with the findings 
for bladder cancer, reduced GnT-III and increased GnT-V 
Figure 1: Schematic representation of bladder cancer stage and grade. The stage of the primary tumour (T) is based on the 
extent of penetration or invasion into the bladder wall. Regarding tumour grading, bladder lesions can be classified as urothelial papilloma 
(a benign lesion), papillary urothelial neoplasm of low malignant potential (PUNLMP), low-grade papillary urothelial carcinoma and high-
grade papillary urothelial carcinoma. Of note, PUNLMP lesions do not have cytological features of malignancy and have a very low risk 
of progression. Nevertheless, they show high tendency to recur. Tis, Tumour in situ: ‘‘flat tumour’’; Ta, Non-invasive papillary carcinoma; 
T1, Tumour invades sub-epithelial connective tissue; T2, Tumour invades muscle; T2a, Tumour invades superficial muscle (inner half); 
T2b, Tumour invades deep muscle (outer half); T3, Tumour invades perivesical tissue; T4, Tumour invades any of the following: prostate, 
uterus, vagina, pelvic or abdominal wall.
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expressions have been found to promote metastasis in 
different cancer models [33-36] yet no consensus exists 
between GnT-V expression and prognosis in gastric [35, 
36], oral squamous cell [37] and endometrial cancers [38]. 
These observations suggest GnT-V/III evaluation may 
hold potential for bladder cancer prognosis and ultimately 
targeted therapeutics, which warrants confirmation in 
future studies. 
b) N-glycans terminal structures (also found in protein 
O-glycans and glycolipids)
Amongst the most common cancer-associated 
structural features are alterations of terminal glycan 
epitopes. In fact, the first reported glycosylation alterations 
in bladder cancer were the loss of ABO(H) blood group 
determinants in advanced stage carcinomas of secretor 
individuals [39, 40], as well as changes in Lewis antigens 
patterns. 
The ABO(H) blood group system consists of 
terminal oligosaccharide antigens carried by glycoproteins 
or glycolipids in hematopoietic or epithelial cells [41]. 
Their biosynthesis is presumed to be controlled by the 
ABO(H), Se, H, Le, and X blood group genes [41]. These 
antigens are present on normal bladder epithelium of 
secretor individuals but not on some low-grade and early-
stage papillary urothelial carcinomas [42]. Moreover, 
initially expressing tumours lose these cell surface 
antigens upon local recurrence, progression to invasion 
or metastization [42]. As such, the possibility that loss of 
genetically predicted blood group antigens precedes the 
development of recurrent, invasive or metastatic bladder 
cancer has been extensively explored [43]. Studies have 
shown that abnormally low or absent expression of these 
epitopes is frequently found in high grade and invasive 
bladder disease [44-46] and associated with bladder 
tumour progression and shorter recurrence-free survival 
Figure 2: Schematic representation of protein-associated glycan structures relevant in bladder cancer. The figure represents 
specific N-linked and O-linked glycan structures, as well as terminal Lewis and sialylated Lewis structures that have biological significance 
in bladder cancer. Key enzymes mediating the addition of specific sugars are also shown. Protein N-glycan alterations include the β1-6 
branching of N-glycans in result of GlcNAcT-V (GnT-V) overexpression, and the addition of bisecting GlcNAc branches by GlcNAcT-III 
(GnT-III) glycosyltransferases. Alterations in O-glycosylation pathways are also a common hallmark of malignant transformations of the 
bladder. Herein, we represent the overexpression of simple mucin-type O-glycans and their sialylated counterparts, T, sialyl T (ST), Tn and 
sialyl Tn (STn) antigens. Altered expression of terminal structures is also a common feature of bladder tumours. Namely, the abnormally low 
or absent expression of ABO(H) blood group determinants is frequently found in high grade and invasive disease. Carbohydrate terminal 
Lewis antigens are significantly under-expressed in healthy urothelium when compared to bladder tumours and are also highlighted here. 
Lewis type 1 antigens include Lewisa (Lea), and sialyl Lewisa (SLea), while the type 2 group includes Lewisx (Lex) and sialyl Lewisx (Slex). 
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[47]. Furthermore, loss of tissue ABO(H) antigens in 
the initial biopsy of bladder carcinomas predicts a much 
greater chance of subsequent invasion than in tumours 
with detectable ABO(H) antigens [44, 45, 47]. However, a 
significant number of patients whose initial tumours were 
reported as blood group antigen negative failed to develop 
an invasive tumour [47]. It is possible that these conflicting 
results may, at least in part, be explained by differences in 
methodology, interpretation, or both. Moreover, the loss 
of activity of the A and B gene-encoded transferases in 
bladder tumours from blood group A and B individuals 
was reported, which explains the deletion of these 
antigens in bladder tumours [48]. In addition, the loss of 
the ABO(H) gene and/or its promoter hypermethylation 
is a specific marker for urothelial carcinoma [39]. In 
summary, alterations in ABO(H) accompanying bladder 
malignant transformation and disease dissemination are 
well established surrogate markers of profound alterations 
in glycosylation pathways, constituting important starting 
points for more in depth structural studies. 
The ABO(H) determinants have biosynthetic and 
structural similarities with Lewis antigens, including the 
fucosylated type 1 Lewisa (Galβ(1-3)GlcNAc[Fucα(1-4)]) 
and type 2 Lewisx (Galβ(1-3)GlcNAc[Fucα(1-4)]). Several 
authors have associated Lewisa and Lewisx expression 
patterns with malignant transformations of the bladder, 
reporting significantly lower expression of this antigen in 
healthy urothelium when compared to invasive tumours 
[44, 46]. As such, reduced expression of Lewisa and Lewisx 
was associated with higher tumour grade and invasion [44] 
and shorter recurrence-free survival [49]. As such, the 
expression of these antigens can be associated with worse 
bladder cancer phenotypes. Moreover, Lewisa antigen 
expression patterns change at an early neoplastic stage, 
suggesting that Lewisa determination might be useful in 
the diagnosis of very early premalignant changes in the 
urothelium [49]. In addition, scoring Lewisa expression 
allows the sub-classification of histologically identical 
tumours into prognostically different groups, pointing to 
a relationship between the pathological grade and stage of 
Figure 3: Schematic representation of short-chained O-linked glycan structures. The addition of specific sugar monomers to 
Ser/Thr residues of a protein backbone begins with the action of polypeptide N-acetylgalactosamine transferases (ppGalNAc-Ts; a family 
of 20 enzymes, including GalNAc-T1, GalNAc-T2, GalNAc-T3, GalNAc-T4, GalNAc-T5 and GalNAc-T6) giving rise to the Tn antigen, 
which is generally extended with a Gal residue by C1Gal-T1, originating the Thomsen-Friedenreich or T antigen (core 1). Alternatively, 
Tn and T antigens can be sialylated by α2,3-sialyltransferases (ST3Gal-Ts) and α-GalNAc ST6Gal-I (ST6GalNAc-I), forming the sialyl-
Tn (STn), and sialyl-T antigens. On the other hand, core 1 may be extended originating cores 2-4 by the action of N-acetylglucosamine 
(GlcNAc) transferases (GnTs; such as GnT-III, GnT-V, core 2 GnTs (C2GnTs) and β3GnT).
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the evaluated tumours and a morphological and functional 
de-differentiation [49]. Given this, Lewisa antigen is a 
valuable functional marker of the malignant potential in 
superficial bladder cancer. In turn, the Lewisx antigen is 
not expressed in normal urothelium, except for occasional 
umbrella cells [46, 50], but has been found in the majority 
of invasive tumours, regardless of blood type and secretor 
status of the individuals studied [46]. Lewisy is expressed 
in both normal urothelium and bladder tumours, yet its 
expression was associated with bladder tumour invasion 
capability [46]. Nevertheless, the number of studies 
concerning Lewis antigens in bladder cancer is still scarce 
to withdraw conclusions about their biological and clinical 
significance.
c) Oversialylation and fucosylation (also occurring in 
protein O-glycans and glycolipids) 
Oversialylation of cancer cells often stem from the 
overexpression of sialylated Lewis antigens sialyl lewisa 
(SLea; the CA19-9 antigen) and sialyl lewisx (SLex), which 
can be found as terminal epitopes of N-glycans, O-glycans 
and glycolipids [51]. SLea/x are specific ligands for E- 
and P-selectins in endothelial cells, thereby promoting 
the adhesion of malignant cells to the endothelium and 
the metastatic cascade [50-52]. These antigens also 
thought to play a role in tumour growth, invasion, and 
angiogenesis [51, 53]. In line with these observations, the 
overexpression of SLea and SLex have also been associated 
with bladder cancer malignant potential. Particularly, 
serum overexpression of SLea was associated with higher 
Figure 4: Schematic representation of the main glycomolecules with biological relevance in bladder cancer. The figure 
represents specific proteoglycans that have one or more glycosaminoglycan (GAG) chains, consisting of linear co-polymers of acidic 
disaccharide repeating units such as chondroitin sulfate (DS), heparan sulfate (HS) and dermatan sulfate (DS). These glycomolecules can 
be found attached to the outer leaflet of the plasma membrane (Syndecan-1) or in the extracellular matrix (Versican, Chondroitin sulfate 
proteoglycan-6, decorin and biglycan). Particularly, some of these structures can bind to each other through their N-terminal globular 
domain (G1), therefore increasing extracellular matrix (ECM) complexity. Of note, hyaluronic acid is the only GAG primarily found as a 
free sugar chain in the extracellular matrix. Hyaluronic acid synthases (HAS) and Hyaluronidases (HAse) constantly degrade and remodel 
hyaluronic acid molecules largely affecting ECM dynamics. Some glycoproteins can also be found linked to the cell membrane through a 
glycosylphosphatidylinositol (GPI) anchor, an example is glypican-3.
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stage, grade and invasion [53] while tissue loss/reduction 
of SLea expression was associated with higher atypia grade 
[50]. SLex has been closely link to invasive and metastatic 
potential of primary bladder tumours and correlated with 
shorter 5-year and 7-year survival rates [54], but another 
study demonstrated no associations between SLex with 
grade or stage in urothelial carcinoma of the renal pelvis, 
ureter, and urinary bladder [50]. The disialylated form 
of Lea (termed disialyl-Lewisa, dSLea) was described 
as preferentially expressed in non-malignant cells, and 
may be useful for distinguishing benign from malignant 
diseases mostly expressing SLea [55]. Supporting these 
observations, the overall increase in cell-surface sialic 
acid content was shown to reduce the attachment of 
metastatic tumour cells to the extracellular matrix [56]. 
These observations support the need for a comprehensive 
interrogation of bladder cancer cells “sialome” towards 
understanding tumour progression and dissemination. 
Moreover, future studies should explore the biological and 
clinical relevance of structurally identical sialylated forms 
in the context of bladder cancer.
Fucosylation is another common modification 
involving oligosaccharides on glycoproteins and 
glycolipids [57]. Particularly, the quantitative glycome 
analysis of N-glycan patterns in bladder cancer cells often 
reveals significant differences in N-glycan fucosylation 
compared to normal cells. Namely, bladder cancer cells 
(KK47, YTS1, J82, T24) showed high expression of 
complex core-fucosylated N-glycans and low expression 
of terminally fucosylated N-glycans [58]. Nevertheless, 
the implications of these differential fucosylation patterns 
in bladder cancer malignancy have been so far poorly 
explored. The transcript levels of fucosyltransferase 
(FUT) VI (FUT-VI) and FUT-VII from invasive and non-
invasive bladder tumours were also explored using RT-
PCR. Particularly, bladder cancer cell lines from invasive 
tumours that maintained their metastatic properties 
showed high levels of both enzymes, and cell lines from 
non-invasive tumours (KK-47) or normal bladder epithelia 
(HCV-29) were negative for FUT-VI and FUT-VII [54]. 
These evidences suggest that FUT-VI/-VII expression 
associates with more malignant cancer cell phenotypes. 
Another study has described β1-integrin activation 
by alpha1,2-fucosyltransferase 1 (FUT-I)-mediated 
fucosylation in J82 human bladder cancer cells, thereby 
enhancing bladder cancer adhesion and subsequent 
metastasis [59]. As such, changes in bladder cancer 
fucosylation patterns seem to be associated with tumour 
invasion and progression to metastization in cancer cell 
lines, suggesting that these changes could provide novel 
strategies for cancer therapy. 
Cancer-associated O-glycosylation 
The most common form of cell-surface protein 
O-glycosylation results from the transfer of a GalNAc 
residue from a UDP-GalNAc donor to either serine 
or threonine in a given polypeptide chain (O-GalNAc 
glycosylation), originating the monosaccharide Tn 
antigen. This reaction is catalysed by several UDP-
GalNAc:polypeptide N-acetylgalactosaminyl transferases 
(ppGalNAc-Ts) in the ER, in a substrate dependent 
manner [60]. As opposed to N-glycosylation, no consensus 
sequence is required for ppGalNAc-Ts recognition. The 
Tn antigen is generally extended with a Gal residue by 
Gal-transferase (β(1-3)-galactosyltransferase, C1Gal-T1 
or T-synthase) and cosmc chaperone, originating 
the disaccharide Thomsen-Friedenreich or T antigen 
(Galβ1-3GalNAcα-O-Ser/Thr, core 1). Alternatively, Tn 
and T antigens can be sialylated by sialyltransferases, 
forming the sialyl-Tn (STn), sialyl-T and disialyl-T 
antigens. Sialylation stops any further processing of the 
oligosaccharide chain, prompting short-chain GalNAc-
type O-glycans expression [60]. Alternatively, core 
1 may be extended originating cores 2-4 (Figure 3), 
which are precursors for a vast array of more extended 
oligosaccharides and terminal structures, similar to the 
ones found in mature N-glycans. 
Recently, a precision mapping of human O-GalNAc 
glycoproteome has revealed over 6000 glycosites in 
more than 600 O-glycoproteins, the majority of which 
of membrane origin [61], greatly expanding our view on 
the O-glycoproteome and its functional role. Alterations 
in O-glycosylation pathways are a common hallmark of 
malignant transformations, frequently amplified at the cell-
surface as a result of the high number of O-glycosylation 
sites presented by mucins [62]. Such events are 
particularly pronounced in adenocarcinomas, due to the 
overexpression of these molecules [63]. While hindered 
by extended glycosylation in healthy and benign tissues, 
simple mucin-type O-GalNAc glycans are uncovered in 
most human carcinomas, including bladder cancer [45, 
64-67]. 
a) Premature stop in O-glycosylation
Perhaps the most studied cancer-associated 
O-glycans are the Tn antigen, its sialylated counterpart 
sialyl-Tn (STn) and the T antigen. They result from 
a premature stop in protein O-glycosylation and are 
classically termed simple mucin-type O-glycans, 
reflecting their overexpression in cancer-associated 
mucins [68]. Nevertheless, these alterations can also be 
significantly observed in other densely O-glycosylated 
proteins of relevant importance in bladder cancer, namely 
CD44 and different types of integrins [69, 70]. Several 
reports attribute the expression of simple mucin-type 
O-glycans to a disorganisation of secretory pathway 
organelles in cancer cells, mutations on Cosmc, a gene 
encoding a molecular chaperone of T-synthase [16, 71], 
and absence or altered expression and/or activity of 
glycosyltransferases [72]. In particular, the overexpression 
of ST6GalNAc-I has been found to promote the premature 
sialylation of the Tn antigen and consequent formation of 
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the STn antigen in bladder cancer [64, 69]. Specifically, 
the STn antigen is absent in the healthy urothelium, while 
being present in more than 70% of high-grade NMIBC 
and MIBC, denoting a cancer specific nature [64]. This 
post-translational modification of cell surface proteins 
is mostly expressed in non-proliferative tumour areas, 
known for their high resistance to cytostatic agents 
currently used to improve the overall survival of advanced 
stage bladder cancer patients [64]. Recently, a novel STn-
dependent mechanism for chemotherapeutic resistance 
of gastric cancer cells to cisplatin has been described, in 
which STn protects cancer cells against chemotherapeutic-
induced cell death by decreasing the interaction of cell 
surface glycan receptors with galectin-3 and increasing 
its intracellular accumulation [73]. Nevertheless, 
the relationship between chemoresistance and STn 
overexpression remains to be fully explored in bladder 
cancer. Furthermore, STn expression is significantly 
higher in MIBC when compared to NMIBC, denoting its 
association with muscle invasion and poor prognosis [20]. 
Studies in vitro have further demonstrated that this antigen 
plays an important role in bladder cancer cell migration 
and invasion through mechanisms so far unexplored [64, 
69]. Recent glycoproteomics studies of bladder cancer 
cell models highlighted that STn was mainly present in 
integrins and cadherins, further reinforcing a possible 
role for this glycan in adhesion, cell motility and invasion 
[69]. Also, recent work from our group has demonstrated 
the presence of STn in lymph node and distant 
metastasis, strengthening the notion that STn expression 
may influence cancer cell motility and metastization 
(unpublished data). Furthermore, STn-expressing bladder 
cancer cells have shown the ability to induce a tolerogenic 
microenvironment by impairing dendritic cells maturation, 
allowing cancer cells to evade innate and adaptive immune 
system responses [21]. Interestingly, the tolerogenic effect 
of short-chained O-glycans has also been correlated 
with bladder tumour metastasis through a mechanism 
Figure 5: Schematic representation of the main biologically relevant glycosphingolipids and glycosylphosphatidylinositol-
anchored proteins in bladder cancer. The figure represents certain glycosphingolipids, especially the sialic acid-containing 
glycomolecules, glycosylphosphatidylinositol-anchored proteins, and the enzymes implicated in the synthesis and hydrolysis of these 
conjugates have been implicate in bladder cancer malignancy.
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in which MUC1 carrying core 2 O-glycans functions 
as a molecular shield against NK cells attack, thereby 
promoting metastization [74]. In addition, STn expression 
in bladder cancer tissues has been used in combination 
with other surrogate markers of tumour aggressiveness 
envisaging patient stratification regarding disease stage 
and therapeutic benefit. Specifically, expression of STn 
and sialyl-6-T (s6T), a sialylated form of T antigen, 
are independent predictive markers of BCG treatment 
response and were found useful in the identification of 
patients who could benefit more from this immunotherapy 
[75]. Moreover, STn was found to be a marker of poor 
prognosis in bladder cancer and, in combination with 
PI3K/Akt/mTOR pathway evaluation, holds potential to 
improve disease stage stratification [20]. In turn, it was 
observed that the reduction of Tn antigen expression was 
associated with higher bladder cancer stage [67]. 
Several reports associated the presence of T antigens 
with higher grade, stage and poor prognosis in bladder 
cancer [66, 76], suggesting that these antigens may be 
surrogate markers of profound cellular alterations. Also, 
there is growing evidences linking the overexpression of 
ST3Gal.I, the enzyme responsible for T antigen sialylation, 
with higher stage and poor prognosis [65]. Moreover, 
Figure 6: Schematic representation of the glycomolecule-mediated metastization model and diagnostic value of 
glycans. Herein we represent the process of tumour cell invasion, dissociation and metastization in which glycans interfere with cell-cell 
adhesion and haematogenous tumour cell spread. We emphasize the modification of epithelial cadherin with β1,6-N-acetylglucosamine 
(β1,6GlcNAc)-branched N-glycan structures, the loss of ABO(H) blood group determinants, changes in Lewis antigens patterns, and the 
oversialylation of glycans resulting in the over-expression of simple mucin type O-GalNAc glycans. Furthermore, expression of glycolipids, 
proteoglycans and gangliosides in cancer cell membranes can modulate signal transduction, activating various cellular pathways that 
induce tumour growth and progression. As such, some of these relevant glycomolecules are represented as well. The diagnostic value of 
some of these macromolecules is also highlighted.
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the expression of T antigen is significantly associated 
with higher risk for subsequent recurrences with deep 
muscle invasion and metastatic involvement of regional 
lymph nodes [67]. In agreement with these observations, 
we have recently reported that short-chain O-glycans 
are preferentially accumulated in hypoxic tumour areas 
[69], known to harbor more malignant sub-populations. 
It has been suggested that HIF-1α directly or indirectly 
modulates the expression of glycosyltransferases involved 
in the initial steps of O-glycosylation while repressing 
core elongation, thereby promoting an accumulation 
of precursor structures [69]. The fact that these simple 
glycans are absent, significantly under-expressed or 
restricted to some cell types in healthy tissues, makes them 
ideal diagnostic and therapeutic targets for bladder cancer 
therapy [77].
Overexpression of cancer-associated membrane 
glycoproteins 
Alteration in N- and O-glycosylation and other types 
of protein glycans are often amplified in cancer cells by 
the overexpression of key cancer-associated glycoproteins. 
Namely, HER2 (also known as ErbB2 or HER2/neu) 
is an heavily glycoprotein [78], member of the EGF 
receptor (EGFR) family, that is overexpressed in several 
malignancies, including advanced stage bladder cancer 
[79-81]. Curiously, the incidence of HER2 overexpression 
in bladder cancer (12.4%) is even higher than that found 
in breast carcinomas (10.5%), where it is associated with 
tumour aggressiveness, prognosis and responsiveness to 
therapy [81]. In fact, HER2 expression is also associated 
with poor prognosis in bladder cancer [82]. Thus, HER2 
could serve as a useful biomarker for clinical prediction 
and trials of anti-HER2 agents are warranted in patients 
with advanced bladder cancer. Nevertheless, the 
glycosylation of HER2 in bladder cancer remains to be 
addressed, which would be critical for the establishment 
of a more sensitive and specific biomarker.
EpCAM, also known as CD326, is a glycoprotein 
predominantly located in intercellular spaces of 
epithelial, progenitor and normal stem cells [83, 84]. This 
transmembrane macromolecule regulates both normal 
and cancer-associated cellular adhesion, proliferation, 
differentiation, migration and invasion [84, 85]. Its 
expression is associated with increased tumour stage and 
grade, as well as with poor prognosis and decreased overall 
survival in bladder cancer patients [86, 87]. Despite these 
evidences, the glycosylation pattern of EpCAM in bladder 
cancer has also not yet been evaluated. 
Frequently, cancer cells also overexpress galectins, 
N-acetyllactosamine-binding glycoproteins yielding 
either one or two carbohydrate-recognition domains. 
Galectins cross-link glycoproteins depending on their 
glycan structures and concentrations, forming galectin-
glycan molecular lattices [88]. Particularly, the correlation 
between increased galectin expression and tumour 
progression is proposed to be linked to their interaction 
with poly-N-acetyllactosamines on matrix proteins such 
as laminin, aiding cellular invasion [89]. Moreover, 
these glycoproteins are known to modulate cell growth, 
differentiation, adhesion, and apoptosis [90-92]. The 
altered expression of galectins has been implicated in 
bladder cancer malignancy [93], and both galectin-1, 
-2, -3, and -8 were suggested as potential disease 
markers and possible targets for bladder cancer therapy 
[94]. Specifically, galectin-1 is a possible independent 
prognostic marker of urothelial carcinoma [95], with 
its positive immuno-expression being significantly 
correlated with tumour stage, grade, vascular invasion 
and nodal status [96]. Moreover, galectin-1 mRNA and 
protein levels are markedly increased in most high-grade 
bladder tumours compared with low-grade and normal 
bladder tissue [97, 98]. Furthermore, this glycoprotein 
is associated with bladder cancer cell invasion by 
mediating the activity of MMP9 through the Ras-Rac1-
MEKK4-JNK-AP1 signalling pathway [95]. Recently, a 
photodynamic therapeutic approach targeting galectin-1 in 
bladder cancer cells and xenografts has inhibited tumour 
growth and enabled selective cytotoxicity in cancer cells, 
preventing undesired phototoxicity in the surrounding 
healthy tissues [99]. This study ultimately suggests that 
galectin-1 constitutes a valid bladder cancer cell biomarker 
capable of being used in effective targeted therapies. 
In turn, galectin-3 mRNA and protein levels were also 
found increased in bladder tumours when compared with 
normal urothelium [94, 97, 98, 100]. Moreover, galectin-3 
levels are increased in invasive tumours compared with 
non-muscle invasive lesions [101-103]. Furthermore, its 
expression patterns are also correlated with tumour stage, 
grade, proliferation (Ki67), apoptosis (apopdetek and bcl-
2), and overall survival in patients with T1G3 tumours 
[101]. These observations suggest a role for galectin-3 as 
a biomarker for bladder cancer staging and prognosis. In 
succession, galectin-7 was pointed as a predictive marker 
of chemosensitivity to cisplatin in urothelial cancer [104]. 
Finally, the loss of galectin-8 in bladder tumours increases 
tumour recurrence, while decreased immunohistochemical 
staining is associated with higher tumour stage and grade 
[105]. As such, the loss of galectin-8 might be an early step 
in the development of malignant lesions of the bladder and 
is a significant independent predictor of recurrence [105]. 
Several studies have recently pointed out the unique 
biological properties of basal-like bladder tumour cell 
subpopulations in their anchorage-independent growth 
ability and their association to poorly differentiated 
bladder cancer [106]. In this context, CD44, a member 
of the transmembrane glycoprotein family commonly 
implicated in cell-cell and cell-matrix interactions, cell 
proliferation, differentiation, migration, angiogenesis, 
presentation of cytokines, chemokines, and growth 
factors to the corresponding receptors, docking of 
proteases at the cell membrane, and cell survival [107-
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109], has been implicated as a cancer stem cell (CSC) 
marker in several malignancies [110-114]. Particularly, 
both CD44 and its splicing variants have been involved 
in bladder cancer carcinogenesis and progression. CD44+ 
cells exhibit an enhanced capacity to form xenografts in 
immunocompromised mice as well as chemoresistance 
compared to CD44− cells [115, 116]. CD44v6, a CD44 
isoform containing the CD44v6 exon, has also been shown 
increased in bladder CSCs [117, 118]. CD44v6 expression 
on CSCs is supported by a study that correlates CD44v6 
expression on bladder cancer cell lines with stem cell 
properties [119]. Both expression levels of CD44 and 
CD44v6 were higher in invasive bladder tumours than 
in pre-invasive tumours and normal urothelium [120]. 
Also, CD44 and CD44v6 upregulation is associated with 
higher tumour grade and stage [120, 121]. However, other 
studies have demonstrated an inverse association between 
CD44v6 expression and bladder cancer grade and stage 
[121, 122]. Moreover, the loss of CD44v6 expression 
was demonstrated as an independent factor for increased 
recurrence and shorter overall survival [123]. Also, the 
loss of CD44 expression was associated with shorter 
progression-free survival [124]. These discrepancies can 
be explained by the lack of standard immunohistochemical 
assays, the use of antibodies with different specificities, 
and differences in the clinicopathological status of 
bladder tumours used in the different studies. Therefore, 
integrative and standardized studies are necessary to 
elucidate the role of CD44 and CD44v6 in bladder cancer, 
as they hold an important biological and clinical value and 
may serve as therapeutic targets. In turn, CD44 variant 9 
(CD44v9) overexpression has been associated with shorter 
progression-free and cancer-specific survival in bladder 
cancer [125], likely impacting invasion and migration via 
the epithelial-mesenchymal transition (EMT). Therefore, 
its expression might be a useful predictive biomarker in 
basal-type muscle invasive and high-risk NMIBC [125]. 
Nevertheless, the specific glycosylation patterns of CD44 
in the context of bladder cancer also remains an open 
research topic. 
Mucins are large membrane-bound 
glycophosphoproteins, commonly overexpressed in 
Figure 7. Schematic representation describing associations between (altered) expression of glycans and glycoconjugates and bladder 
tumour stage, grade, invasion/metastasis,  patients’ diagnosis and prognosis. The figure clusters using a gradient of colored circles and lines 
the biological and clinical role of the altered expression of glycans and glycoconjugates in bladder cancer.
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several malignancies [126], including bladder cancer 
[127-129]. Mucin 1 (MUC1) is restricted to the apical 
membranes of umbrella cells in normal urothelium, 
while there is an aberrant MUC1 expression in basal and 
intermediate layers of neoplastic epithelium [128, 130]. 
Additionally, the pattern, intensity and depth of MUC1 
immunostaining are correlated with bladder cancer grade 
[129]. Notwithstanding, other study reported no correlation 
of MUC1 expression with survival, tumour stage or grade 
[131]. Yet, patients overexpressing MUC1 only had a 
favourable survival when HER3 was also overexpressed 
[131]. This may be at least partially explained by the 
existence of several MUC1 glycoforms, including 
underglycosylated, sialylated, and fully glycosylated 
forms. As previously mentioned, several studies have been 
focusing on the identification of extracellular cell surface 
markers for urothelial CSCs, envisaging diagnosis and 
drug targeting. Of note, it has been shown that urothelial 
CSCs are enriched in an MUC1−CD44v6+ subpopulation 
of cells. This conclusion was based on the observation that 
MUC1− and CD44v6+ cells were only present in the basal 
layer of normal urothelium, which is thought to comprise 
urothelial stem cells. Subsequently, MUC1− and CD44v6+ 
cells were isolated, and a slightly increased clonogenicity 
was observed for these cells compared with unsorted 
bladder tumour cells [117]. Expression of other mucins 
such MUC2 and MUC6 were associated with a less 
aggressive behavior of bladder tumours and demonstrated 
to be useful predictors of better bladder cancer survival 
while MUC4 demonstrated an opposite role [129]. In 
addition, MUC16 STn+ glycoforms, characteristic of 
ovarian cancers, were recently described for the first time 
in bladder cancer and demonstrated to be expressed in a 
subset of advanced-stage bladder tumours facing worst 
prognosis [132]. Nevertheless, with the exception of 
MUC16, the specific glycosylation patterns of this class 
of glycoproteins also remains unknown in bladder cancer. 
Integrins are a family of transmembrane adhesion 
receptors for extracellular matrix components participating 
in the metastatic cascade. Particularly, normal urothelium 
presents a polarized expression of alpha6beta4 integrin 
(ITGA6) on basal cells, while neoplastic urothelium 
frequently overexpresses this receptor [133]. Moreover, 
the evaluation of alpha6beta4 integrin tumour expression 
may provide valuable prognostic information on 
bladder cancer patients clinical outcome, since patients 
with alpha6beta4 integrin overexpression hold a 
significantly worst survival [133]. Throughout EMT-
driven carcinogenesis, disseminated cancer cells often 
acquire a stem cell-like self-renewal capability [134, 
135]. Moreover, during EMT, epithelial markers such as 
ITGAV (αv integrin receptors) are upregulated in several 
solid tumours [136-138], including bladder cancer with 
a trend increase in ITGAV expression with disease stage 
and grade [139]. Furthermore, the functional inactivation 
of ITGAV (targeting with the integrin receptor antagonist 
GLPG0187 or knockdown of ITGAV) leads to a less 
malignant bladder cancer phenotype with significantly 
impaired migration, EMT response, clonogenicity and a 
reduction in the size of the stem/progenitor pool. In line 
with these in vitro observations, knockdown of ITGAV 
or treatment with GLPG0187 significantly inhibited 
metastasis and secondary tumour growth [140]. In turn, 
a central role was also suggested for the beta1-integrin 
subunit in forming the cell-cell and cell-matrix bonds 
necessary for adhesion, extravasation and migration of 
bladder cancer cells [141] through enhanced transmission 
and generation of contractile forces [142] and possible 
microenvironmental involvement [69]. Despite its role in 
bladder carcinogenesis there are also no reports about the 
specific glycosylation of this class of glycoproteins. 
In summary, increased levels of several 
glycoproteins have been associated with the severity 
of disease and as part of the molecular signature of 
more malignant bladder cancer sub-populations. These 
events not only amplify structural alterations that stem 
from deregulations in glycosylation pathways but also 
synergically contribute together with altered glycosylation, 
to a net effect favouring disease progression. Nevertheless, 
a comprehensive and context-oriented glycomapping of 
relevant glycoproteins has not been provided yet, which 
would be crucial for achieving highly specific cancer 
biomarkers holding true therapeutic potential. Moreover, 
the glycomic mapping of relevant glycoproteins may 
provide highly cancer-specific epitopes in comparison to 
glycans or glycoproteins alone. This would pave the way 
for designing more effective targeted therapeutics for more 
malignant bladder cancer cells.
Proteoglycan glycosylation
Proteoglycans are structurally and functionally 
complex glycoconjugates, exhibiting one or more high 
molecular weight glycosaminoglycan (GAG) chains 
covalently attached to a protein core [143]. These 
structures can be found as: i) transmembrane syndecans 
or glypicans, at the cell surface; ii) hyalectans (aggrecan, 
versican, brevican and neurocan) or small leucine-rich 
proteoglycans (decorin, biglycan and lumican) at the 
extracellular matrix (ECM); iii) basement membrane 
proteoglycans (perlecan, agrin and collagen XVIII) [144]. 
Serglycin is the only characterized proteoglycan found at 
intracellular level, normally in secretory compartments 
[145]. 
The biosynthesis and modification of proteoglycans 
occurs in the Golgi apparatus (GA) through the action 
of glycosyltransferases, sulfotransferases, epimerases, 
sulfatases, glycosidases, and heparanases, revealing 
multiple layers of regulation of these macromolecules 
[143]. The length and structure of each GAG chain may 
differ greatly within a certain proteoglycan molecule, 
while the number of chains linked to the protein core 
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is determined by the number of sugar attachment sites, 
marked by Ser-Gly dipeptide motifs [143, 146]. The 
biosynthesis of GAGs, such as chondroitin sulfate, 
heparan sulfate, dermatan sulfate, hyaluronic acid, and 
heparin is initiated by the sequential addition of four 
monosaccharides (Xyl, Gal and GlcA) to a Ser-Gly motif 
on the core protein. Then, the sugar chains are extended 
by the addition of two alternating monosaccharides 
containing an acetylated or sulfated hexosamine (GalNAc, 
GlcNAc) and uronic acid (GlcA acid or idoA) [143]. In the 
case of keratan sulfate, the GAG is initiated as N-linked 
or O-linked repeating disaccharides, and extended by the 
addition of N-acetyl-glucosamine and galactose residues 
[143]. Once synthesized, the GAGs are linked to a core 
protein and proteoglycans are transported from the GA to 
the cell surface or ECM [144, 147]. Notably, unlike all 
other GAGs, hyaluronic acid is primarily found as a free 
sugar chain at the ECM, and its synthesis is epigenetically 
regulated [148]. Interestingly, hyalectans have the ability 
to bind hyaluronic acid through their N-terminal globular 
domain (G1), therefore increasing ECM complexity 
[149]. Of note, proteins such as MHC class II invariant 
chain, transferrin receptor, thrombomodulin and CD44 
can be considered proteoglycans, since some of their 
alternative splicing variants present GAG-initiation sites 
[150]. Other proteoglycans like endocan and versican 
also present alternatively spliced forms with variable 
sugar modifications [150]. In particular, a versican variant 
without chondroitin sulphate attachment sites has been 
described,  [149]. 
Proteoglycans present high affinities for various 
ECM constituents and cell adhesion molecules, playing 
a crucial role in intercellular interactions [144]. These 
glycoconjugates can also bind growth factors, cytokines 
and chemokines, allowing them to escape proteolysis. 
Some can also act as co-receptors for growth factors 
and tyrosine kinase receptors, changing the duration 
of their signaling reactions or lowering their activation 
thresholds [143, 144]. Therefore, the altered expression 
of proteoglycans, including syndecan-1, neuropilins, 
versican, chondroitin sulfate proteoglycan 6, decorin, 
biglycan, endocan, hyaluronic acid and its metabolic 
enzymes, has been linked to several cancers and, 
specifically, with bladder cancer carcinogenesis, metastasis 
and prognosis (Figure 4, Supplementary Table 1). 
Cancer-associated transmembrane proteoglycans
Syndecans are a family of heparin sulfate 
proteoglycans, commonly presenting three to five heparin 
sulfate chains, and are known to modulate cellular 
adhesion, migration, proliferation, differentiation, and 
growth factor signaling [151]. These macromolecules 
are commonly found at bladder cancer cell surfaces, 
along with other transmembrane proteoglycans and 
glypicans [152, 153]. Syndecans can also be found 
in their soluble form, due to a post-translational 
modification causing the release of their ectodomains 
through juxtamembrane region proteolysis [154]. 
Particularly, syndecan-1 (CD138), frequently expressed 
in epithelial cells and some leukocytes [155], was found 
to be increased in bladder cancer patients serum and 
stroma, especially in muscle-invasive cases [156-158]. 
Serum overexpression of syndecan-1 was associated with 
lymph node metastasis, while stromal overexpression 
was related with poorer overall survival [158]. The loss 
of transmembrane syndecan-1 expression in tumour cells 
was related to higher tumour stage and grade [159, 160], 
as well as reduced recurrence-free survival in bladder 
cancer [160, 161]. Still, high-grade superficial, and deep 
invasive bladder carcinomas were also characterized 
by elevated expression of syndecan-1, while low-grade 
and non-invasive phenotypes do not [161]. Cytoplasmic 
overexpression of syndecan-1 in cancer cells, often 
accentuated close to the nucleus, was demonstrated in 
Ta tumours compared to normal urothelium, suggesting 
a failure in intracellular trafficking caused by the loss 
of functional syndecan-1 [162]. This directly affects 
carcinogenesis through the loss of cellular adhesion 
properties, thereby promoting more invasive phenotypes 
[160]. Also, syndecan-1 altered expression can affect 
tumour cells via junB-FLIP long signals, involving 
apoptosis resistance and increased proliferation [161]. 
Simultaneous loss of syndecan-1 expression in tumour 
cells and its overexpression in high-stage and high-grade 
bladder cancer patients serum suggest the importance of 
syndecan-1 in tumour progression; therefore, this molecule 
could be a new therapeutic target in human urinary bladder 
cancer [158]. 
Neuropilins are co-receptors of two structurally 
and functionally unrelated ligands classes, the class 
3 semaphorins and selected VEGF family members 
[163]. Neuropilin-1 has multiple heparan and/or 
chondroitin/dermatan sulfate GAG chains [163]. Recent 
reports demonstrate neuropilin-1 expression on non-
endothelial cells in bladder urothelium [164], as well as 
its overexpression in high grade/stage bladder tumours 
[165]. Moreover, neuropilin-1 upregulation was associated 
with shorter overall survival in bladder cancer patients 
[165]. In addition, neuropilin-2 is expressed in neural and 
endothelial cells and, upon ligand stimulation, induces 
neural development and the growth of newly formed 
blood and lymphatic vessels [163]. Overexpression of 
neuropilin-2 demonstrated to have prognostic value in 
bladder cancer, as it was associated with shorter overall 
and cancer-specific survival and earlier cancer-specific 
death after transurethral resection and radiochemotherapy 
[166]. Additionally, the co-expression of neuropilin-2 
and the family member VEGF-C is also a prognostic 
marker for overall survival of bladder cancer patients 
[166]. Therefore, syndecan-1 and neuropilins may play 
an important role in the progression of bladder cancer 
and their altered expression may serve as a biomarker for 
Oncotarget91747www.impactjournals.com/oncotarget
prognosis.
Cancer-associated extracellular matrix proteoglycans
Versican, also known as chondroitin sulfate 
proteoglycan 2, a central component of cancer-related 
inflammation, is highly expressed in metastatic bladder 
carcinomas and its overexpression is correlated with 
poor survival [167]. In tumour cell lines, versican 
overexpression was associated with increased cell 
migration and tumour stage [168]. A correlation between 
versican overexpression, RhoGTP dissociation inhibitor 
2 (RhoGDI2) underexpression, metastasis and poor 
clinical outcome was also demonstrated [167, 169]. 
Particularly, RhoGDI2 underexpression and versican 
overexpression are associated with metastasis through 
the involvement of macrophages and the CCL2/CCR2 
signaling axis [167, 169]. In fact, RhoGDI2 is a regulator 
of several Rho GTPases that play important roles in cell 
cycle progression, neovascularization, invasiveness, and 
metastasis [170]. Therefore, targeting this mechanism 
may provide novel therapeutic strategies for delaying the 
appearance of clinical metastasis [170].
The role of decorin, a key component of the 
tumour stroma, in cancer progression and its therapeutic 
potential has been the focus of several studies. Increased 
secretion of decorin in the MB49/MB49-I murine 
bladder cancer model and in muscle-invasive tumours 
was associated with the promotion of angiogenesis and 
tumour cell invasiveness [171]. Nevertheless, other 
studies demonstrate a possible tumour suppressor role 
for decorin, where bladder tumour tissues are entirely 
devoid of decorin expression while non-malignant stromal 
areas express this proteoglycan [172, 173]. A mechanism 
through which decorin exerts its tumour suppressor role 
has been proposed, where decorin may act as a natural 
antagonist of the oncogene insulin-like growth factor 
receptor I (IGF-IR) [173, 174]. Therefore, in bladder 
tumours, the loss of decorin expression eliminates IGF-
IR activity and signaling repression, promoting cellular 
motility, invasion, and cancer progression [173, 174]. 
Biglycan is a small leucine-rich proteoglycan with 
immune and growth factor activity modulating properties, 
as well as matrix assembly involvement [175]. This 
proteoglycan has been demonstrated to be overexpressed 
on invasive bladder cancer tissue [172, 176]. Interestingly, 
while biglycan overexpression is associated with higher 
tumour stages and muscle invasiveness, it’s up-regulation 
was related with tumour cell proliferation inhibition and 
increased patients’ 10-year survival [176].
Endocan, also known as endothelial cell-specific 
molecule 1, is a secreted proteoglycan that has a single 
dermatan sulfate side chain attached to serine 137 and 
demonstrated to be highly elevated on tumour vessels 
from invasive bladder cancer tissues [177]. Moreover, 
its expression correlated with stage, and invasiveness 
as well as predicted a shorter recurrence-free survival 
time in non-invasive bladder cancers [177]. Therefore, 
endocan expression impacts the prognosis of bladder 
cancer patients and, as described ahead, also is a possible 
diagnosis marker.
Hyaluronic acid (HA), an unsulfated anionic linear 
GAG, its implicated in cell adhesion, migration and 
angiogenesis [178]. Particularly, hyaluronidases (HAse) 
are enzymes that hydrolyze HA molecules into small 
angiogenic fragments, participating in the degradation 
of tumour surrounding ECM, and enabling cancer cells 
invasion and dissemination [178]. As such, HA, HAses 
(e.g. HYAL1), hyaluronic acid synthases (HAS) 1, 2 and 
3, as well as hyaluronic acid receptors (e.g. CD44 and 
receptor for hyaluronan-mediated motility, RHAMM) 
have been suggested as possible diagnosis and prognosis 
biomarkers. Also, both HAS, HYAL1, CD44 and 
RHAMM were found to be overexpressed in bladder 
cancer tissues [179, 180]. In addition, HYAL1 expression 
was also correlated with disease-specific mortality and 
recurrence [179, 181]. Finally, elevated expression of 
RHAMM was found in invasive bladder tumours and 
associated with poor prognosis, due to increased tumour 
cell proliferation and shorter overall and disease-specific 
survival [180].
Alterations in cancer-associated proteoglycans 
were demonstrated as associated with bladder cancer 
progression and may present prognosis value, yet more 
studies are necessary in order to confirm these associations 
and transpose these markers to clinical practice. 
Lipid glycosylation
Glycolipids are a major class of glycoconjugates 
that include glycosphingolipids (GSLs) and GPI anchors.
Alterations in sphingolipids’ glycosylation
Glycosphingolipids (GSLs) are neutral or anionic 
molecules composed by a hydrophilic glycan covalently 
β-linked via glucose (glucosylceramide) or galactose 
(galactosylceramide) to the terminal hydroxyl group of a 
hydrophobic ceramide backbone [182, 183]. Specifically, 
GSL biosynthesis is initiated in the ER with the 
condensation of sphingosine and acyl-CoA by a group of 
six ceramide synthases, giving rise to a long-chain amino 
alcohol base (sphingosine) in amide linkage to a fatty acid, 
namely a ceramide lipid [183, 184]. Ceramide can then be 
galactosylated by galactosylceramide synthase, to produce 
galactosylceramide, which in turn can be transported to 
the GA where it is sialylated to produce GM4 ganglioside, 
or sulfated to produce sulfogalactolipids [185-187]. 
Also, ceramide is frequently glucosylated in the GA by 
glucosylceramide synthase to form glucosylceramide, 
the core structure of 90% of GSLs [185-187]. 
Subsequently, the C-4 hydroxyl of glucosylceramide 
can be galactosylated by β4-galactosyltransferases V 
and VI, forming lactosylceramide [188]. Once produced, 
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lactosylceramide will serve as the metabolic precursor of 
more than 300 structurally different classes of complex 
GSLs through the action of specific glycosyltransferases 
and sulfotransferases, depending on nucleotide sugar 
donors availability [189]. Particularly, lactosylceramide is 
a template for: 1) GA2, through β,4-N-acetylgalactosylami
nyltransferase (B4GALNT1) activity; 2) GM3 ganglioside, 
through α-2,3-sialyltransferase (ST3GAL5Gb3); 3) Gb3, 
by α-1-4-galactosyltransferase (A4GALT) activity; and, 
4) Lc3, by the β-1,3-N-acetylglucosaminyltransferase 
(B3GNT5) [189]. GSLs glycan chains can be further 
extended and terminated with structural moieties similar 
to those found in glycoproteins, namely and Lewis blood 
type antigens. After synthesis, these structures leave the 
GA and are redirected to the plasma membrane [190], 
constituting approximately 5% of all membrane lipids
 GSLs are also implicated in key cellular functions, 
such as cell adhesion, proliferation, differentiation, 
apoptosis, motility and immune recognition [191-193]. 
Particularly, ceramide is implicated in apoptosis and 
regulates several cell cycle and senescence pathways 
[194]. Consequently, GSLs have received considerable 
attention as promising biomarkers for disease 
progression, as well as pharmacological targets for 
bladder cancer therapy. Pioneering studies demonstrated 
that glucosylceramide and glucosylceramide synthase 
are overexpressed in several multidrug resistant cancer 
cell lines, being related with drug resistance [195-197]. 
Particularly, in bladder cancer, glucosylceramide synthase 
overexpression was demonstrated to be associated 
with higher histologic grade [198]. In accordance, the 
overexpression of this enzyme is an indicator of poor 
prognosis, showing associations with lymph node 
metastasis, reduction in the 5-year overall and disease-
free survival [198]. The glycosphingolipid composition 
of human bladder cancer tissue has been assessed, 
showing large amounts of ganglioside GM3 in superficial 
bladder tumours, but not in invasive tumours [199]. 
This overexpression can be caused by the simultaneous 
overexpression of GM3 synthase and downregulation of 
both Gb3 and GD3 synthases [199]. Moreover, high levels 
of GM3 are associated with reduced invasive potential 
[199], proliferation, motility, tumour growth and increased 
apoptosis [200]. Since exposure to exogenous GM3 have 
been proved to inhibit tumour cell lines proliferation and 
adhesion, this approach was proposed as bladder cancer 
therapy. Also, the direct instillation of GM3 in orthotopic 
models inhibited tumour growth [201]. It has also been 
reported that the expression of GM2, GM3, or GM2/GM3 
complexes inhibited bladder cancer cell motility and 
growth [202] (Figure 5, Supplementary Table 1). 
Alterations in glycosylphosphatidylinositol-
anchored molecules
The anchoring of proteins and proteoglycans 
to cell membranes through the lipid portion of a GPI 
anchor is a conserved post-translational modification 
[203]. These anchors present conserved core structures 
consisting of ethanolamine phosphate, three mannose 
monomers, and a non-N-acetylated glucosamine attached 
to a inositol phospholipid (EtNP-6Manα-2Manα-6Manα-
4GlNα-6myoInositol-P-lipid) [204]. This backbone can 
be modified with phosphoethanolamine and/or various 
glycan side-branches. More detailed information about 
the biosynthesis of this class of glycans may be found in 
[204-206] and has been summarized in Figure 5.
Alterations in several enzymes involved in 
glycosylation of GPI-anchored molecules such the multi-
protein transaminase complex were first mentioned as 
relevant in cancer after the discovery of the oncogenic 
activity of PIG-U in bladder cancer [207, 208]. This was 
demonstrated through the induction of tumourigenesis 
mediated by PIG-U overexpression in mice [208]. In 
addition, PIG-U overexpression in vitro was correlated 
with increased cell proliferation and upregulation of GPI-
anchored proteins, such as urokinase receptor, increasing 
STAT-3 phosphorylation and subsequent cellular 
migration, and apoptosis [208]. PIG-U overexpression 
is also associated with higher tumour grade and muscle 
invasion, suggesting its role in tumour development and 
progression [209]. Moreover, overexpression of PIG-U 
is an independent predictor of recurrence for superficial 
bladder cancer [209]. Consequently, the expression of 
PIG-U and other multi-protein transaminase complex 
subunits was explored and confirmed in different cancer 
types using microarrays [210].
GPI-anchored proteins are almost exclusively 
located on cell surfaces, and are functionally diverse, 
presenting key roles in cell-cell interaction, adhesion, host 
defense, and signaling transduction [204, 211]. Thus, these 
proteins have been explored regarding their potential as 
biomarkers for carcinogenesis and metastatic potential in 
bladder cancer (Figure 5, Supplementary Table 1). The 
expression of GPI-specific phospholipase D, a highly 
specific GPI-anchored enzyme, is significantly increased 
in highly malignant murine bladder carcinoma cells when 
compared to less malignant controls [212]. In addition, 
CD109, a GPI-anchored glycoprotein that negatively 
regulates the transforming growth factor (TGF)-β/Smad 
signaling in vitro, is overexpressed in the basal layer of 
NMIBC and low-grade tumours. Interestingly, CD109 
shows a similar expression pattern to cancer stem cell 
marker CD44, and its overexpression was associated 
with better cancer-specific survival [213]. Prostasin, 
a GPI-anchored serine protease crucial for epithelial 
differentiation [214] and epidermal growth factor receptor 
(EGFR) proteolysis [215], was shown to be downregulated 
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in high-grade urothelial bladder cancer cell lines [216]. 
This loss of expression was associated with EMT, 
marked by a reduced E-cadherin expression and loss of 
epithelial morphology, which may have implications in 
the invasive potential and resistance to anti-EGFR therapy 
[216]. However, the clinical relevance of prostasin was 
not yet evaluated in bladder cancer. Notwithstanding, 
multi-protein transaminase complex subunits and GPI-
anchored proteins have potential to serve as markers of 
tumourigenesis and metastatic capability, being relevant 
targets for bladder cancer therapy. 
Beyond GPI-anchored proteins, alterations in 
glypicans, a class of GPI-anchored proteoglycans, also 
have been studied in cancer. Glypicans are a family of GPI-
anchored heparan sulfate proteoglycans known to interact 
with growth factors through heparan sulfate chains [217]. 
This class of proteoglycans is predominantly expressed 
during fetal development, being critical to organogenesis 
[218]. Moreover, glypicans were described in several 
cancers [219, 220], including bladder cancer. Particularly, 
glypican-3 is expressed in squamous cell and invasive 
urothelial carcinomas; however, it is not a good biomarker 
for diagnosis using tumour tissues [217]. Furthermore, 
glypican-3 expression was not associated with tumour 
stage, grade, lymph node metastasis, concomitant CIS, 
soft tissue surgical margins, disease recurrence or cancer 
specific mortality after radical cystectomy [221].
In conclusion, alterations in PIG-U and GPI-
anchored proteins seem to be promising regarding their 
prognosis value while GPI-anchored proteoglycans appear 
to be bad prognosis biomarkers. Notwithstanding, further 
studies are necessary to evaluate these GPI-anchored 
molecules and enzymes from multi-protein transaminase 
complex in bladder cancer biological and clinical context.
PROGNOSIS GLYCOMARKERS FOR 
BLADDER CANCER
The most challenging aspect in bladder cancer 
management stems from its highly heterogeneous nature, 
irrespectively of disease stage. This constitutes a true 
obstacle for individualized therapeutic decision, disease 
monitoring and prognosis with tremendously negative 
impact on patient care and life expectancy. In this 
context, several clinical studies have unveiled glycan-
associated signatures (glycans, glycan binding proteins, 
glycosyltranserases, heavily glycosylated proteins/lipids/
GPI-anchored molecules) associated with more aggressive 
cancer cell phenotypes, tumour recurrence, progression, 
metastization, or decreased overall survival. Particularly, 
in bladder cancer, the presence/overexpression of GnT-
III/IV, Lex, Ley, SLex, STn, ST6GalNAc.I, T-antigen, 
ST3Gal.I, HER2, EpCAM, galectin-1, galectin-3, 
CD44, CD44v9, MUC1, MUC4, ITGA6, ITGAV, 
neuropilin-1, neuropilin-2, versican, decorin, biglycan, 
endocan, HYAL1, hyaluronic acid synthase 1, RHAAM, 
glucosylceramide synthase, and PIG-U was associated 
with more aggressive phenotypes and/or poor prognosis 
[20, 30, 46, 50, 54, 64-67, 76, 82, 86, 87, 96, 97, 101-103, 
120, 121, 124, 125, 129, 133, 139, 165-168, 171, 172, 176, 
177, 179-181, 198, 208, 209]. By another hand, (over)
expression of β-1-6GalNAc antennae, galectin-7, CD44v6, 
MUC2, MUC6, glycolipid enzyme GM3, and CD109 
were linked to a less aggressive phenotype and/or better 
prognosis [32, 104, 121, 122, 129, 199, 213]. In turn, the 
loss of GnT-V, ABO(H) terminal structures, sLea, Tn, 
galectin-8 and prostasin is associated with more aggressive 
cancer phenotypes, making them potential markers of poor 
prognosis [31, 32, 44-47, 50, 67, 105, 158-160, 200, 216]. 
Yet, glypican-3 tissue expression was not associated with 
aggressive phenotype nor prognosis [217, 221] and studies 
for syndecan-1 demonstrated contradictory results [158-
162, 222], warranting elucidation of its prognostic and 
diagnostic role. For other molecules, the co-expression 
with another allowed to have or enhanced a significant 
prognostic and therapeutic outcome impact, such as Lea/
Leb antigens [44, 49], s6T/STn [75] neuropilin-2/VEGF-C 
[166], Gb3/GD3 synthases [199] and GPI-specific 
phospholipase D/H-ras oncogene [212] (Figure 6 and 7, 
Supplementary Table 1). 
While these studies support the potential of glycans 
for patient stratification significant bias hampers conclusive 
remarks to support introduction in clinical practice. 
Namely, most studies differ in cohort size and distribution 
of the cohort by bladder cancer type, stage and grade, 
which often translate into conflicting results. Moreover, 
most studies disregard patient ethnicity, lack endpoints 
standardization and rely on different biological samples, 
as well as in different sample processing and analysis 
techniques. Nevertheless, several molecular markers 
hold promise for becoming widely available and cost-
effective tools for a more reliable risk assessment. Thus, 
efforts need to be conducted to validate glycobiomarkers 
in larger series for prospective use, ideally in the context 
of prospective clinical multicenter randomized trials, using 
current clinicopathological parameters for risk assessment. 
The inclusion of relevant glycobiomakers in current 
patient stratification parameters may help accurately assess 
patient’s prognosis and response to different treatment 
options. Therefore, future studies should also evaluate the 
impact of glycomarkers in the therapeutic outcome and as 
novel targets for bladder cancer therapy. Finally, recent 
evidences support the need to integrate this knowledge 
in multiplex risk assessment tool combining standard 
clinicopathological factors with molecular markers [223] 
envisaging individualization of responses. Although 
much effort has been spent on glycobiomarkers research, 
clinicians and medicinal chemists rarely consider glycans 
as biological targets or drugs [224], hindering advances 
in bladder cancer management and in the development of 
targeted therapeutics. Notwithstanding, this unfamiliarity 
is beginning to change as improved methods for 
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carbohydrate synthesis [225-227], sequencing [228, 229], 
and biological analysis [230-232] become more sensitive 
and widely available. 
EXPLORING GLYCANS FOR NON-
INVASIVE BLADDER CANCER 
DETECTION
Non-invasive disease detection remains a major 
challenge despite the pressing need for tools capable 
of reducing the burden of disease-follow up, treatment 
monitoring and early detection [233]. The active secretion 
of cancer-associated glycoconjugates into bodily fluids, 
such as urine and blood, or shed from apoptotic and 
necrotic cancer cells holds tremendous potential to address 
this challenge [7, 51]. Accordingly, several FDA-approved 
cancer biomarkers for non-invasive cancer detection, 
follow-up and prognosis are either glycans, such as CA19-
9 (SLea), or heavily glycosylated glycoproteins, such as 
CA125 (MUC16), CA15-3 (MUC1), CA-72-4 (tumour-
associated glycoprotein 72, TAG-72), PSA (prostate-
specific antigen), and CEA (carcinoembryonic antigen) 
[233]. In bladder cancer, serum CA19-9 is a marker of 
aggressiveness and advanced stage disease, being almost 
invariably raised in patients with metastatic cancer. As 
such, it constitutes a valuable marker of poor prognosis 
[234]. Notwithstanding, its value as a screening tool 
has been opposed by its low sensitivity (29%) [234]. 
On the other hand, urinary CA19-9 is a better screening 
parameter, with optimum sensitivity and specificity, than 
its serum counterpart for diagnosis of low grade and early 
stage bladder cancer. Furthermore, it can be suggested that 
urinary CA19-9 can be used as better prognostic marker 
for low grade bladder cancer than its serum equivalent 
[235]. Moreover, urinary CA19-9 levels could be a new 
effective diagnostic tool for bladder cancer patients with 
both Le and Se alleles. Particularly, 70% of bladder 
cancer patients with both Le and Se alleles presented 
CA19-9 levels over the cut-off value, and only 16% of 
patients with other urological conditions were over the 
cut-off [236]. Furthermore, simultaneous elevation of 
CA19-9 and CEA serum levels correlated with tumour 
invasion and grade in patients with CA19-9-expressing 
urothelial carcinomas [53]. In addition, SLea antigen has 
been observed in bladder dysplasia, Tis, non-invasive, 
and invasive carcinomas of the bladder [53, 236, 237], 
suggesting that these patients may present elevated CA19-
9, which warrants confirmation in broad clinical studies. 
Considering the cancer-associated glycoproteins, 
galectins also hold potential for bladder cancer detection. 
In fact, bladder cancer patient’s serum levels of galectin-3 
are considerably higher than control groups, and are 
correlated with tumour type, stage and grade [98, 100, 
103]. Particularly, patients with high-grade urothelial 
carcinoma have higher serum levels of galectin-3 
than those with low-grade tumours [103]. Moreover, 
patients with muscle-invasive tumours also have higher 
serum levels of galectin-3 than those with Ta tumours 
[103], conferring to this glycoprotein a diagnostic and 
stratification value for bladder cancer patients. In addition, 
serum levels of galectin-3 also have diagnostic value 
for bladder squamous cell carcinoma (SCC) patients 
[103]. More recently, a multiplexed immunosensor has 
been developed for the detection of specific biomarkers 
galectin-1 and lactate dehydrogenase B present in different 
grades of bladder cancer cell lysates. This approach has 
allowed not only the identification of different grades 
of bladder cancer cells but also the real time detection 
of multiple analytes on a single chip, providing more 
practical benefits for clinical diagnosis [238].
Regarding proteoglycans, syndecan-1 was also 
explored as a diagnosis biomarker in a non-invasive 
urine-based assay, however with low predictive value 
(sensitivity of 70%, specificity of 48% and accuracy of 
59%) [222]. Therefore, further validation is warranted in 
larger and prospective studies. The chondroitin sulfate 
proteoglycan 6, also known as structural maintenance 
of chromosomes 3 (SMC3), has also been found 
overexpressed in bladder cancer. Moreover, when used in 
combination with six gene transcripts (insulin-like growth 
factor-binding protein 7, sorting nexin 16, cathepsin D, 
chromodomain helicase DNA-binding protein 2, nell-
like 2, and tumour necrosis factor receptor superfamily 
member 7), it could discriminate bladder cancer from 
control blood samples with a sensitivity of 83% (95% 
confidence interval, 67-93%) and a specificity of 93% 
(95% confidence interval, 76-99%), constituting a 
possible blood diagnosis biomarker [239]. Beyond the 
prognosis role of endocan, recently this proteoglycan 
also demonstrated non-invasive diagnosis potential for 
bladder cancer. In fact, serum expression of endocan could 
discriminated bladder cancer patients with a sensitivity of 
50% and specificity of 77% while the urinary endocan 
expression resulted in a sensitivity of 62% and specificity 
of 71% [240]. Moreover, HA and its related enzymes 
may have potential for detecting bladder cancer patients. 
In fact, increased HA levels are detected in all bladder 
cancer grades, while HAse levels are preferentially 
elevated in urothelial bladder cancer grades 2 and 3 [241, 
242]. Lokeshwar et al. and Passerotti et al. have reported 
an optimal sensitivity (91.9% and 81.9%, respectively) 
and specificity (92.8% and 80.5%, respectively) of the 
HA test for bladder cancer detection [243, 244]. Urinary 
HAse measurement demonstrated a 100% sensitivity and 
88.8% specificity to detect grade 2 and 3 bladder tumours 
[242]. Measurements of both urinary HA and HAse (the 
HA-HAse test) demonstrated an 89% sensitivity and 
83% specificity for detecting urothelial bladder cancer 
[241]. Similarly, other study evaluated this non-invasive 
method in urine samples, showing that the HA test has 
83.1% sensitivity, 90.1% specificity and 86.5% accuracy 
to detect bladder cancer [245]. Also, the urinary HAse test 
Oncotarget91751www.impactjournals.com/oncotarget
demonstrated 81.5% sensitivity, 83.8% specificity and 
82.9% accuracy in detecting grade 2 and 3 bladder cancer 
[245]. Other studies also reported high sensitivity and 
specificity for detecting bladder cancer using both urinary 
HA and HAse by a non-invasive approach [246-249]. 
In fact, the sensitivity of HA-HAse test demonstrated to 
be superior to ImmunoCyt® and cytology (83.3% versus 
63.3% and 73.0%, respectively), as well as to BTA 
STAT® test (94.0% versus 61.0%). In turn, specificity 
was comparable between HA-HAse and ImmunoCyt® or 
cytology (78.1% versus 75.0% and 79.7%, respectively) 
and between HA-HAse and BTA STAT® test (63.0% 
versus 74.0%) for detecting bladder cancer or bladder 
cancer recurrence [248, 249]. The evaluation of HAS1 
and HA expression resulted in a 79% and 88% sensitivity, 
as well an 83.3% and 100% specificity, respectively, for 
detecting bladder cancer. Moreover, both expressions 
correlated with a positive HA urine test [247]. In addition, 
the combined expression of HAS2-HYAL1 detected 
bladder cancer with overall sensitivity of 85.4% and 
79.5% specificity, predicting recurrence within 6 months 
[179] (Figure 6).
Despite significant research efforts and promising 
upfront results, neither glycans nor glycoconjugates 
have yet been approved for non-invasive bladder cancer 
detection. Again, reduced study dimensions, biased patient 
series and variations in detection methods are amongst the 
factors hampering the generalization of these approaches. 
As such, comprehensive clinical studies on the glycome, 
glycoproteome and glycolipidome of bodily fluids are 
warranted to broaden our understanding about alterations 
accompanying malignant transformations, disease 
progression and dissemination. Moreover, efforts should 
be undertaken to incorporate glycans in broad biomarker 
panels envisaging highly sensitive and specific detection 
methods. 
GLYCOMICS AND GLYCOPROTEOMICS: 
INSIGHTS TOWARDS PRECISION 
MEDICINE
The establishment of clinically useful glycan-based/
assisted molecular models have been significantly delayed 
by serious analytical limitations. In fact, the majority of 
the studies presented to this date are target-directed and 
based on immune assays with antibodies and/or lectins 
whose specificity for the target ligands has not been fully 
disclosed yet. These aspects delay the generalization of 
glycans biomarker potential. Moreover, most studies are 
one-dimensional, failing to provide a comprehensive 
overview of the glycome in clinical settings. The low 
abundance of relevant glycoforms in biological milieus 
also poses a major analytical difficulty, which adds to the 
significant structural diversity and complexity presented 
by this class of biomolecules. 
In the past decade, mass spectrometry has emerged 
as a core analytical technology to interrogate the glycome 
due to the rapid advance in resolution, mass accuracy, 
sensitivity, and reproducibility provided by modern hybrid 
mass analyzers. Currently, glycans and glycoconjugates 
analysis relies on hyphenated techniques comprehending 
separations by liquid chromatography or capillary 
electrophoresis, as well as detection by electrospray 
tandem mass spectrometry (ESI-MS) and matrix-
assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-MS). Complementary tandem 
experiments are required for unambiguous assignments. 
Even though, the identification of isomeric and/or 
isobaric species remains a challenging task. Nevertheless, 
it has been demonstrated that certain isomeric glycans 
produce characteristic product ion spectra that can be 
used for identification, irrespectively of the type of mass 
spectrometer [250, 251]. Moreover, the introduction of 
graphitized LC columns has significantly improved the 
analysis of native glycans by mass spectrometry [252]. 
More in depth insights on analytical advances in glycomics 
may be found in recent reviews on the subject [253-255]. 
Recent developments in matrix-assisted laser desorption/
ionization (MALDI) mass spectrometry imaging (MSI) 
on formalin-fixed paraffin-embedded (FFPE) tissue 
sections may also provid a key tool for evaluating spatio-
temporal investigation of glycosylation changes in cancer 
tissues. [269]. However, while the field still struggles 
with technical difficulties associated with variations in 
accuracy depending on analytical method and variety of 
mass spectrometry architectures, significant efforts are 
ongoing to standardize protocols and implement robust 
glycoanalytical platforms [256, 257]. In addition, rapid 
expansion of high-throughput mass spectrometry studies 
has generated significant amounts of experimental “omics” 
data that require more sophisticated bioinformatics 
tools and databases. In this context, several groups have 
started the development of algorithms for computerized 
annotation of mass spectra and fragmentation data, as 
revised by Hu et al. [258]. However, while significant 
advances have been observed for glycan analysis, 
glycopeptide data interpretation remains immature 
compared to proteomics data analysis. This is partly due 
to lack of consensus regarding the best way of estimate the 
false discovery rate, and the existence of multiple formats 
of data storage. Nevertheless, guidelines for reporting 
mass spectrometry-based glycoanalytic data are being 
developed [257, 259]. 
Despite the enormous potential of glycomics, few 
quantitative and comprehensive studies were conducted 
on bladder cancer. Yang et al. quantitatively analyzed 
and compared glycan expression patterns in normal and 
bladder cancer cells through an integrated methodology 
using lectin microarray and mass spectrometry [58]. It 
has been demonstrated that SLex and high mannose-type 
N-glycans were highly expressed in bladder cancer cells 
[58]. In addition, a high expression of core-fucosylated 
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N-glycans but a low expression of terminally fucosylated 
N-glycans was observed in bladder cancer cells [58]. In 
turn, Pocheć et al. determined the N-glycan patterns of 
integrin α3β1 in bladder cancer cells compared to normal 
bladder cells using an integrated methodology of lectin-
binding assays and mass spectrometry [260]. Accordingly, 
bladder cancer cell-associated integrins have been found to 
express high-mannose, hybrid and predominantly complex 
type N-oligosaccharides, as well as the sialylated tetra-
antennary complex type glycan Hex7HexNAc6FucSia4 
[260]. Weather by focusing on the whole proteome or in a 
single glycoprotein, both studies have given an important 
in vitro view of the glycome pattern of bladder tumour 
cells compared to a normal state, paving the way for new 
and more comprehensive studies. 
In summary, early glycan-based clinical studies 
have created the molecular basis to drive the emerging 
area of advanced glycomics in bladder cancer. We expect 
that the generalization of these approaches leads to the 
discovery of key glycan biomarkers with clinical and 
therapeutic potential in the near future. The incorporation 
of glycogenomics and glycoinformatics datasets are 
expected to accelerate a comprehensive understanding 
of the glycome. Furthermore, the integration with other 
“omics” will be crucial to deepen the understanding 
of glycosylation’s role in human systems and provide 
models capable of disclosing the polymorphic nature of 
disease and ultimately help tailoring medical decisions and 
achieve precision medicine settings. 
Concluding remarks and future perspectives
Bladder cancer is a heterogeneous disease 
encompassing distinct biological features and clinical 
outcomes. This is responsible for elevated recurrence rates, 
often accompanied by disease progression facing existing 
treatments. Moreover, it has hampered the establishment 
of precision medicine settings capable of molecular-based 
individualization of disease management. These aspects 
make bladder cancer one of the costliest malignancies 
to manage, constituting a burden to both patients and 
healthcare systems. We believe that true advances in this 
field will require an integrative panomics approach capable 
of providing robust models for molecular-based patient 
tailored clinical decisions. So far, most efforts have been 
put in genomics, transcriptomics and proteomics fields, 
with upfront enthusiastic results; however, over 40 years of 
glycobiology research has yet to retrieve solid evidences 
capable of boosting clinical implementation. Even though 
many studies have highlighted glycans and glyconjugates 
(glycoproteins, glycolipids and proteoglycans) holding true 
clinical potential, few have engaged in a comprehensive 
interrogation of the glycome. Notwithstanding, the 
relevance of these molecular entities for disease 
progression and dissemination suggests potential for 
more in depth targeted omics studies. Moreover, the 
standardization of glycomics protocols backed by high-
throughput analytical and novel bioinformatics tools 
opens now a unique opportunity for real advances in this 
area. Therefore, the field must now focus on large scale 
multicentric translational studies integrating glycomics 
data with novel molecular findings, including recently 
proposed models for bladder cancer risk-stratification 
[261-263]. Moreover, our understanding on the 
glycobiology of chemoresistance, formation of the pre-
metastatic and metastatic niches is still scarce and warrant 
careful evaluation on the near future. Complementary 
understanding of glycan biosynthesis pathways and 
the biological significance of these alterations will be 
warranted, envisaging theragnostic applications. Taking 
into consideration the glycome’s strong dependence on 
the microenvironment and physiological status, significant 
efforts should put on developing models capable of 
recreating tumour glycoheterogeneity. Patient derived 
xenografts have been proven useful in this context [264] 
and may constitute valuable tools for understanding the 
dynamics of glycosylation in malignancy as well as for the 
identification of prognostic glycobiomarkers. Ultimately, 
this will be of key importance for developing targeted 
therapeutics while exploring the cell-surface nature of 
glycans. Such approaches would strongly benefit from the 
identification of glycoconjugates (proteins, peptides or 
lipids) yielding cancer-associated carbohydrate antigens, 
which would significantly narrow biomarker specificity 
for malignant cells. While the development of novel high-
affinity glycan ligands, namely humanized monoclonal 
antibodies and antibody fragments, for theragnostics 
applications still poses a major task due to the complex 
structural nature of these molecules, several advances in 
cell glycoengeneiring and glycosynthesis [265-267] hold 
potential to overcome these limitations. Finally, it has 
been highlighted that glycans play a key role in immune 
modulation, especially by favoring tumour tolerogenic 
mechanisms [21, 268]. A deeper understanding of 
influence of glycosylation in immunological mechanisms 
is a hot research topic that will pave the way for 
circumventing these events and for more effective and 
less toxic immunotherapies. In summary, an intervention 
roadmap has been established to boost glycobiology 
towards omics settings capable of generating key data to 
improve the management of bladder cancer patients. 
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vinblastine, cisplatin and doxorubicin; NMIBC: non-
muscle invasive bladder cancer; PD-L1: programmed 
death-ligand 1; PGAP1: post-GPI attachment to 
proteins 1; ppGalNAc-Ts: UDP-GalNAc:polypeptide 
N-acetylgalactosaminyl transferases; NMP22: nuclear 
matrix protein; OSTase: oligosaccharide transferase 
complex; RHAMM: hyaluronan-mediated motility; 
RhoGDI2: RhoGTP dissociation inhibitor 2; SLea: 
sialyl lewisa; SLex: sialyl lewisx; STn: sialyl-Tn; TGF: 
transforming growth factor; TURBT: transurethral 
resection of the bladder tumour. 
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Bladder carcinogenesis and tumour progression is accompanied by pro-
found alterations in protein glycosylation on the cell surface, which may be
explored for improving disease management. In a search for prognosis
biomarkers and novel therapeutic targets we have screened, using immuno-
histochemistry, a series of bladder tumours with differing clinicopathology
for short-chain O-glycans commonly found in glycoproteins of human solid
tumours. These included the Tn and T antigens and their sialylated coun-
terparts sialyl-Tn(STn) and sialyl-T(ST), which are generally associated
with poor prognosis. We have also explored the nature of T antigen sialy-
lation, namely the sialyl-3-T(S3T) and sialyl-6-T(S6T) sialoforms, based on
combinations of enzymatic treatments. We observed a predominance of
sialoglycans over neutral glycoforms (Tn and T antigens) in bladder
tumours. In particular, the STn antigen was associated with high-grade dis-
ease and muscle invasion, in accordance with our previous observations.
The S3T and S6T antigens were detected for the first time in bladder
tumours, but not in healthy urothelia, highlighting their cancer-specific nat-
ure. These glycans were also overexpressed in advanced lesions, especially
in cases showing muscle invasion. Glycoproteomic analyses of advanced
bladder tumours based on enzymatic treatments, Vicia villosa lectin-affinity
chromatography enrichment and nanoLC-ESI-MS/MS analysis resulted in
the identification of several key cancer-associated glycoproteins (MUC16,
CD44, integrins) carrying altered glycosylation. Of particular interest were
MUC16 STn+-glycoforms, characteristic of ovarian cancers, which were
found in a subset of advanced-stage bladder tumours facing the worst
prognosis. In summary, significant alterations in the O-glycome and O-gly-
coproteome of bladder tumours hold promise for the development of novel
noninvasive diagnostic tools and targeted therapeutics. Furthermore,
abnormal MUC16 glycoforms hold potential as surrogate biomarkers of
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poor prognosis and unique molecular signatures for designing highly speci-
fic targeted therapeutics.
1. Introduction
Bladder cancer is the fifth most common cancer in Wes-
tern society and a growing concern in developing coun-
tries, as a result of demographic expansion, increased
life expectancy and, in some areas, Schistosoma haema-
tobium infection (Antoni et al., 2016; Burger et al.,
2013; Ploeg et al., 2009). At the time of clinical diagno-
sis, most cases are non-muscle-invasive bladder cancers
(NMIBC), conservatively treated by complete transure-
thral resection (TUR) (Babjuk et al., 2016; Bryan,
2011). In turn, high-grade tumours are generally charac-
terized by high recurrence rates and elevated risk of pro-
gression to muscle invasion (Babjuk et al., 2016; Bryan,
2011). Muscle-invasive bladder cancer (MIBC) is
amongst the most common and deadliest genitourinary
cancer (Witjes et al., 2013). The mainstay treatment
includes cisplatin-based regimens (Witjes et al., 2013),
which fail to avoid tumour relapse and disease dissemi-
nation (Chen et al., 2015; Weight et al., 2009), urging
the introduction of predictive biomarkers and novel
therapeutics (Azevedo et al., 2015; Ecke, 2015).
Glycosylation is the most common post-translational
modification of proteins, and more than 50% of
human proteins are thought to be glycosylated (Fer-
reira et al., 2016a; Spiro, 2002). The patterns of pro-
tein glycosylation are cell and tissue specific, closely
reflecting the physiological status of cells (Moremen
et al., 2012; Pinho and Reis, 2015; Spiro, 2002). There-
fore, glycosylation changes have been described for
several pathological conditions, including cancer
(Abou-Abbass et al., 2016; Maverakis et al., 2015;
Nardy et al., 2016). Taking advantage of their cell sur-
face nature, many cancer-associated glycobiomarkers
(CA72-4; CA19-9; CA125 which detects MUC16,
CEA) have been exploited for noninvasive cancer
detection, follow-up and therapy development (Bottoni
and Scatena, 2015; Santos et al., 2014; Silva, 2015).
Moreover, alterations in glycosylation often render
protein glycoforms holding tremendous potential for
targeted therapy (Azevedo et al., 2015; Fernandes
et al., 2015; Ferreira et al., 2016b). In this context, it
has also been long demonstrated that advanced-stage
tumours present significant deregulations in glycosyla-
tion pathways, translated by the loss of ABO blood
group determinants (Sheinfeld et al., 1992). Neverthe-
less, there are little insights on bladder cancer glycome
remodelling accompanying malignant transformation,
disease progression and dissemination. Still, few
reports have suggested that bladder cancer cells mimic
other advanced-stage solid tumours by promoting a
premature stop in protein O-glycosylation (Ferreira
et al., 2013; Langkilde, 1995; Yamada et al., 1988)
(biosynthesis pathway depicted in detail in Fig. S1).
This causes the accumulation of short-chain O-glycans
as a consequence of (a) altered glycosyltransferase
expressions (Vazquez-Martin et al., 2004); (b) muta-
tions in key enzymes involved in O-glycans biosynthe-
sis (Guda et al., 2009); (c) mislocalization of
glycosyltransferases in secretory organelles (Rivinoja
et al., 2009); (d) metabolic deregulations (Pinho and
Reis, 2015), amongst other factors. The accumulation
of short-chain O-N-acetylgalactosamine (O-GalNAc)
glycans at the cell surface of tumour cells affects their
adhesive properties while promoting their invasive,
metastatic and angiogenic potential, as well as immune
scape (Bapu et al., 2016; Carrascal et al., 2014; Fer-
reira et al., 2013). Moreover, it may modulate intracel-
lular signalling and activate key oncogenic pathways
(Bapu et al., 2016). Reinforcing these notions, we have
previously demonstrated that 70% of advanced-stage
bladder tumours express the cancer-associated carbo-
hydrate antigen sialyl-Tn (Costa et al., 2015; Ferreira
et al., 2013); conversely, the healthy urothelium and
most superficial tumours do not (Ferreira et al., 2013).
STn expression favours cell invasion, motility (Ferreira
et al., 2013; Peixoto et al., 2016) and immune toler-
ance (Carrascal et al., 2014) and has been associated
Abbreviations
CD44, cluster of differentiation 44; CEA, carcinoembryonic antigen; CID, collision-induced dissociation; CSS, cancer-specific survival; DAGR,
Database of Anti-Glycan Reagents; dST, disialylated sialyl-T; DTT, 1,4-dithiothreitol; ESI, electrospray ionization; FFPE, formalin-fixed,
paraffin-embedded tissue section; HRP, horseradish peroxidase; ITGB1, integrin beta 1; LTQ-Orbitrap XL, hybrid linear ion trap-Orbitrap
mass spectrometer; MIBC, muscle-invasive bladder cancer; MS/MS, tandem mass spectrometry; MS, mass spectrometry; MUC16, mucin-
16; nanoLC, nanoliquid chromatography; NMIBC, non-muscle-invasive bladder cancer; O-GalNAc, O-N-acetylgalactosamine; PLA, in situ
proximity ligation assay; S3T, sialyl-3-T; S6T, sialyl-6-T; STn, sialyl-tn; ST, sialyl-T; TUR, transurethral resection; WHO, World Health
Organization.
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with poor overall survival (Costa et al., 2015). In addi-
tion, solid tumours often accumulate the more com-
plex T antigen and its sialylated form ST, whose
overexpression has also been associated with poor
prognosis (Dow et al., 1989; Videira et al., 2009).
However, the ST antigen comprises a heterogeneous
group of mono- (sialyl-6-T: S6T; sialyl-3-T: S3T) and
disialylated glycoforms that remain to be individually
evaluated in cancer. Building on these insights, we
aimed to screen bladder tumours and corresponding
urine samples for the above-mentioned cancer-
associated short-chain O-glycoproteins, envisaging a
molecular rationale for the development of novel non-
invasive diagnostic tools and highly specific targeted
therapeutics towards precision medicine.
2. Materials and methods
2.1. Patient and sampling
The screening of cancer-associated short-chain
O-glycans (Tn and STn; T and ST, S6T and S3T) was
performed on 47 formalin-fixed, paraffin-embedded tis-
sue sections prospectively collected from 37 male and
10 female patients, mean age of 70 years (ranging 45–
89 years old), who underwent bladder surgery in the
Portuguese Institute for Oncology of Porto (IPO-
Porto, Portugal), between July 2011 and May 2012.
Based on urothelial carcinoma grading and staging cri-
teria of the World Health Organization (Eble et al.,
2004), three different groups were considered: low-
grade (LG; n = 17), high-grade (HG; n = 12) non-mus-
cle-invasive papillary bladder cancers (NMIBC) and
muscle-invasive (n = 18) bladder cancers (MIBC). For
molecular target validation, a larger subset of samples
was used, composed by a retrospective series of 176
bladder cancer cases (74 NMIBC and 102 MIBC). In
NMIBC, the male/female gender ratio was of 61 : 13
and the median age was 64 years. The male/female
gender ratio in MIBC was of 9 : 1 and the median age
was 71 years. Forty cases were considered stage Ta, 34
stage T1, 25 stage T2, 48 stage T3 and 29 stage T4
(for further analysis, T1- to T4-staged tumours were
compared against Ta-staged tumours). All MIBC
patients were treated with cystectomy, 27 of which
were also treated with adjuvant chemotherapy (cis-
platin+gemcitabine). All tumour samples were revised
by a pathologist (TA) according to 2004 WHO grad-
ing criteria. As such, 38 cases were considered low-
grade and 138 high-grade tumours. All procedures
were performed under the approval of Institutional
Ethics Committee of IPO-Porto after obtaining
informed patient’s consent. All clinicopathological
information was obtained from patient’s clinical
records.
2.2. Immunohistochemistry
FFPE urothelium sections were screened for the gly-
cans of interest by immunohistochemistry using the
avidin/streptavidin peroxidase method, as described by
Ferreira et al. (2013). The expression of the Tn, sialyl-
Tn and T antigens was directly evaluated using in-
house mouse monoclonal antibodies 1E3, TKH2 and
3C9, respectively (Clausen et al., 1988; Kjeldsen et al.,
1988; Marcos et al., 2004). All available information
on these antibodies including immunogens, specificity
and associated bibliography is deposited in the Data-
base of Anti-Glycan Reagents (https://ccr2.cancer.gov/
resources/Cbl/Tools/Antibody/About.aspx) (Sterner
et al., 2016). The expression of sialylated T antigens
(mono- and disialylated glycoforms) was determined
by comparing histological sections probed for the T
antigen before and after digestion with an a-neurami-
nidase from Clostridium perfringens (Sigma Aldrich,
St. Louis, MO, USA). The S3T antigen expression was
determined by comparing histological sections probed
for the T antigen before and after digestion with an a-
(2,3)-neuraminidase from Streptococcus pneumonia
(Sigma Aldrich) according to Fig. S1A. The S6T anti-
gen expression was accessed by comparing histological
sections probed for STn before and after digestion
with a recombinant b-(1,3)-galactosidase from Xan-
thomonas campestris (R&D systems, Minneapolis,
MN, USA) according to Fig. S1B. The chromogen
3,3-diaminobenzidine tetrahydrochloride (ImmPACT
DAB; Vector Laboratories, Burlingame, CA, USA)
was used to visualize antibody-binding sites, and sec-
tions were counterstained with Harris’s haematoxylin.
Negative controls were performed by replacing the pri-
mary antibody with 5% bovine serum albumin (BSA).
Positive controls were known positive tissues for the
antigens under study. Bladder tumours and metastasis
were also screened for MUC16 using rabbit anti-
human CA-125 monoclonal antibody EPR1020
(1 : 200 in PBS; Abcam, Cambridge, UK) at room
temperature for 1 h. Furthermore, tumour tissues were
screened for CD44 using anti-CD44 (1 : 150 in PBS;
EPR1013Y; Abcam) and anti-ITGB1 (1 : 100 in PBS,
A-4 clone; Santa Cruz Biotechnology, Dallas, TX,
USA). In addition, prior to glycoproteomics studies,
FFPE tissues were screened for blood group A deter-
minants using mouse monoclonal anti-human blood
group A antibody HE-195 (1 : 100 in PBS; Thermo
Fisher Scientific, Waltham, MA, USA) after 1-h incu-
bation at 37 °C. This approach aimed to elect negative
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cases for downstream glycoproteomics studies. The
immunoreactive tissue sections were assessed double-
blindly through light microscopy by two independent
observers (LL and DF) and validated by an experi-
enced pathologist (TA). Although the interobserver
agreement was high (k = 0.961, P < 0.001), discordant
readings were re-analysed using a double-headed
microscope (Olympus BX46; Olympus Corporation,
Tokyo, Japan), and consensus was reached. A semi-
quantitative approach was established to score the
immunohistochemical labelling based on the percent-
age of positively stained cells. For the evaluation of
glycans, the tissues were categorized as follows: nega-
tive (), when no staining was observed; positive (+),
1–19% of positive cells; positive (++), 20–49% of posi-
tive cells; positive (+++), 50–79% of positive cells; pos-
itive (++++), 80–100% of positive cells. Regarding
MUC16 evaluation, samples were classified as positive
whenever the antigen was present or negative in the
absence of the antigen.
2.3. Glycoprotein extraction and enrichment
Proteins were extracted from FFPE STn-positive blad-
der tumours of male MIBC patients (n = 5) using Qpro-
teome FFPE tissue kit (Qiagen, Hilden, Germany)
according to the supplier’s instructions. To avoid false
positives in downstream glycoprotein enrichment steps
based on GalNAc affinity chromatography, only Tn
and blood group A antigen-negative tumours were
included in this study. Five 10-lm-thick tumour sec-
tions from each patient were used for this propose. The
amount of protein in each extract was estimated with
RC DC protein assay kit (Bio-Rad, Hercules, CA,
USA). The extracted glycoproteins were then blotted
for STn as previously described (Peixoto et al., 2016) to
confirm the presence of glycoproteins yielding the STn
antigen. For proteomics analysis, 20 lg of the protein
pool was separated by 4–16% gradient SDS/PAGE
under reducing conditions; the bands were excised from
the gels; and proteins were reduced with 5 mM 1,4-
dithiothreitol (Sigma Aldrich) for 40 min at 60 °C,
alkylated with 10 mM iodoacetamide (Sigma Aldrich)
for 45 min in the dark and digested with trypsin (Pro-
mega, Madison, WI, USA) in situ for MS analysis (Fer-
reira et al., 2011) (according to Fig. S3A). For
glycoproteomics analysis, approximately 1 mg of total
protein was precipitated by the addition of four volumes
of 20 °C acetone to a sample extract and dried under
vacuum on a speedvac. The extract was resuspended in
0.05% RapiGest (Waters, Milford, MA, USA), digested
with PNGase F (10 U PNGase F from Eliza-
bethkingia meningoseptica; Sigma Aldrich) to remove
N-glycans, facilitating downstream trypsin digestion
and peptide identification. Subsequently, the extract
was subjected to neuraminidase treatment [10 U C. per-
fringens neuraminidase type VI (Sigma Aldrich)] to
remove neuraminic acids from STn, thereby exposing
the GalNAc residue (Tn antigen). The sample was then
loaded on 300 lL of agarose-bound Vicia villosa agglu-
tinin (VVA; Vector Laboratories) column to enrich the
extract in Tn-expressing glycoproteins. The column was
then washed with 10 column volumes of 0.4 M glucose
in LAC A buffer (20 mM Tris/HCl pH 7.4, 150 mM
NaCl, 1 M urea, 1 mM CaCl2, MgCl2, MnCl2 and
ZnCl2) followed by 1 mL 50 mM NH4HCO3 (all
reagents were purchased from Sigma Aldrich). The gly-
coproteins were then eluted by 4 9 500 lL 0.05%
RapiGest (Waters) with heating to 90 °C for 10 min.
The glycoprotein fraction was then directly reduced,
alkylated and digested with trypsin as previously
described (Ferreira et al., 2011) (according to Fig. S3B).
2.4. NanoLC-ESI-LTQ-Orbitrap-CID-MS/MS
A nanoLC system (3000 Ultimate nano-LC; Dionex,
Sunnyvale, CA, USA) was coupled online to a
LTQ-Orbitrap XL mass spectrometer (Thermo Scien-
tific, Waltham, MA, USA) equipped with a nano-
electrospray ion source (EASY-Spray source; Thermo
Scientific). Eluent A was aqueous formic acid (0.2%),
and eluent B was formic acid (0.2%) in acetonitrile.
Samples (20 lL) were injected directly into a trapping
column (C18 PepMap 100, 5 lm particle size) and
washed over with an isocratic flux of 95% eluent A
and 5% eluent B at a flow rate of 30 lLmin1. After
3 min, the flux was redirected to the analytical column
(EASY-Spray C18 PepMap, 100 A, 150 mm 9 75 lm
ID and 3 lm particle size) at a flow rate of
0.3 lLmin1. Column temperature was set at 35 °C.
Peptide separation occurred using a linear gradient of
5–40% eluent B over 117 min, 50–90% eluent B over
5 and 5 min with 90% eluent B. In order to favour
the separation and identification of peptides presenting
high hydrophobicity, samples were also analysed with
a two-step gradient protocol: 5–35% eluent B over
37 min, 35–65% eluent B over 80 min, followed by
65–90% eluent B over 5 min and 5 min with 90% buf-
fer B. The mass spectrometer was operated in the posi-
tive ion mode, with a spray voltage of 1.9 kV and a
transfer capillary temperature of 250 °C. Tube lens
voltage was set to 120 V. MS survey scans were
acquired at an Orbitrap resolution of 60 000 for an
m/z range from 300 to 2000. Tandem MS (MS/MS)
data were acquired in the linear ion trap using a
data-dependent method with dynamic exclusion: the
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top six most intense ions were selected for collision-
induced dissociation (CID). CID settings were 35%
normalized collision energy, 2-Da isolation window,
30-ms activation time, and an activation Q of 0.250. A
window of 90 s was used for dynamic exclusion. Auto-
matic gain control was enabled and target values were
1.00e+6 for the Orbitrap and 1.00e+4 for LTQ MSn
analysis. Data were recorded with XCALIBUR software
version 2.1 (Thermo Fisher Scientific).
2.5. MS/MS data curation
Data were analysed automatically using the SequestHT
search engine with the Percolator algorithm for valida-
tion of protein identifications (Proteome Discoverer
1.4; Thermo Scientific). Data were searched against the
human proteome obtained from the SwissProt data-
base on 22/11/2015, selecting trypsin as the enzyme
and allowing for up to two missed cleavage sites, a
precursor ion mass tolerance of 10 p.p.m. and 0.6 Da
for product ions. Carbamidomethylcysteine was
selected as a fixed modification, while oxidation of
methionine (+15.994u), modification of serine and thre-
onine with HexNac (+203.08u), and/or HexNacNeu-
Nac (STn) (+494.17u), considering the possibility of
partially inefficient a-neuraminidase treatment, and/or
T (+365.13u) were defined as variable modifications.
For whole tumour proteome analysis, only high confi-
dence peptides were considered. In glycoproteomics
studies, due to the high lability of the sugar moieties
under CID conditions, and the consequent difficulty in
identifying modified peptides, Sequest results of low
confidence peptides were also considered. Protein
grouping filters were thus set to consider glycosylations
with low confidence and DCn better than 0.05. The
strict maximum parsimony principle was applied. A
protein filter counting peptides only on top-scored pro-
teins was also set. Peptides were filtered for
Xcorr ≥ 1.0 and DCn ≤ 0.05. Cytoplasm membrane
proteins with at least one annotated glycosylation site
were selected and the modifications were validated
manually. Membrane proteins were sorted using NetO-
Glyc version 4.0 (http://www.cbs.dtu.dk/services/Ne
tOGlyc/) (Steentoft et al., 2013) to generate the final
protein list. Protein molecular and biological functions
were interpreted using Panther (Mi et al., 2016).
2.6. In situ proximity ligation assays on tissue
sections
The simultaneous detection of mucin-16 (MUC16),
ITGB1 and CD44 STn+-glycoforms was made by
in situ proximity ligation assays (PLA) using the
Duolink in situ detection reagents Brightfield and Red,
respectively (Olink Bioscience, Uppsala, Sweden)
according to the manufacturer’s instructions and based
on previous reports (Campos et al., 2015; Ricardo
et al., 2015). Briefly, FFPE tissues were deparaffinized,
rehydrated and subjected to acid- and heat-induced
antigen retrieval, followed by incubation with 3%
hydrogen peroxide and blocking solution in a humidity
chamber, as previously described (Ferreira et al.,
2013). MUC16 was detected by direct PLA using mon-
oclonal antibody CA125 (clone M11; DAKO, Santa
Clara, CA, USA) conjugated with PLA probe PLUS
(concentration of 0.005 mgmL1) and B72.3 mono-
clonal antibody against STn, which showed similar
recognition but lower background when compared
with TKH2 monoclonal antibody used for immunohis-
tochemistry, with PLA probe MINUS (concentration
of 5 ngmL1). Antibodies were conjugated according
to the instructions of Duolink in situ Probemaker and
were hybridized for 1 h at 37 °C. Next, ligation was
performed for 30 min at 37 °C and amplification was
carried out for 120 min at 37 °C to produce rolling
circle products, followed by incubation with horserad-
ish peroxidase (HRP)-labelled probes and addition of
the chromogen. Finally, sections were counterstained
with haematoxylin, dehydrated, cleared and mounted
for optical microscope analysis. Regarding the indirect
PLA for ITGB1 and CD44, FFPE tissues were incu-
bated with anti-CD44 (EPR1013Y; Abcam) and anti-
ITGB1 (A-4 clone; Santa Cruz Biotechnology) over-
night at 4 °C in a humidity chamber. Then, the PLA
probes anti-rabbit MINUS and anti-mouse PLUS were
both added and sections were incubated at 37 °C for
1 h. The following steps of ligation and amplification
were performed in the same conditions of the direct
PLA. Sections were incubated with 40,6-diamidino-2-
phenylindole for 10 min at room temperature and
mounted for fluorescence microscopy. PLA results
were evaluated by two observers and validated by an
experienced pathologist, who independently registered
cytolocalization of staining. PLA validation was con-
ducted using MUC16-expressing cell lines OVCAR3
wild-type which do not express STn (Kui et al., 2003)
and sequential ovarian cancer tissue sections showing
MUC16 and STn colocalization by immunohistochem-
istry (Ricardo et al., 2015).
2.7. MUC16 transcription in bladder tumours
RNA was isolated from FFPE tissue samples using the
Absolutely RNA FFPE Kit (Stratagene, San Diego,
CA, USA), as previously described (Lima et al., 2014).
Up to 2 mg of total RNA was reverse-transcribed with
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random primers, using the ‘High Capacity cDNA Rev-
erse Transcription Kit’ (Applied Biosystems, Foster
City, CA, USA). Real-time PCR amplification of
cDNA samples was performed in a StepOne Real-
Time PCR System (Applied Biosystems) using Taq-
Man Gene Expression Master Mix, primers and
probes provided by Applied Biosystems. MUC16
expression was measured with TaqMan expression
assay (ID: Hs01065189_m1) from Applied Biosystems.
The raw DCt was used to analyse MUC16 expression
and therefore used as an estimate of the mRNA rela-
tive levels. DCt stands for the difference between the
cycle threshold (Ct) of the amplification curve of the
target gene and that of the GAPDH (ID:
Hs03929097_g1). The efficiency of the amplification
reaction for each primer/probe is more than 95%, as
determined by the manufacturer.
2.8. Immunoprecipitation for CD44 and ITGB1
CD44 and ITGB1 were immunoprecipitated from total
protein extracts (IP) with anti-CD44 (EPR1013Y;
Abcam) and anti-ITGB1 (A-4 clone; Santa Cruz
Biotechnology) monoclonal antibodies using Pierce
Direct IP Kit (Thermo Scientific) according to the sup-
plier’s instructions. Protein samples were separated in
reducing SDS/PAGE gels, transferred to 0.45-mm
nitrocellulose membrane (GE Healthcare Life Sciences,
Uppsala, Sweden) and blotted for the CD44 and
ITGB1, respectively, as well as for STn with TKH2
monoclonal antibody. Protein extracts treated with a-
neuraminidase (Sigma Aldrich) were used as controls.
2.9. Statistical methods
Statistical data analysis was performed with IBM Sta-
tistical Package for Social Sciences – SPSS for Windows
(version 20.0; IBM, New York, NY, USA). Chi-square
analysis was used to compare categorical variables.
Kaplan–Meier survival curves were used to evaluate
correlation between MUC16-positive tumours and can-
cer-specific survival (CSS) and were compared using
log-rank statistical test. CSS was defined as the period
between the tumour removal surgery and patient death
from cancer and the last follow-up information.
3. Results and discussion
3.1. Expression of short-chain O-glycans in
bladder cancer
Despite the biological and clinical relevance of
altered O-glycosylation in cancer, few studies have
comprehensively addressed this matter in the context
of bladder malignancies. Herein, 47 bladder cancer
sections were screened by immunohistochemistry for
short-chain O-glycans, using specific monoclonal anti-
bodies. These included the Tn, STn and T antigens,
as well as sialylated T glycoforms (mono- and disia-
lylated forms) exposed after digestion of the histolog-
ical sections with a neuraminidase. Particular
emphasis was given to the expression of T antigen
monosialylated forms S3T and also S6T, which is
regarded as rare O-glycan, until now mostly observed
in vitro (Pinho et al., 2007) and more recently in
superficial bladder tumours (Lima et al., 2013).
Table 1 summarizes the expression of these glycans
in the studied samples according to their disease
subtype.
3.1.1. Expression of nonsialylated short-chain O-glycans
(Tn and T antigens)
Table 1 highlights that Tn and T antigens are poorly
expressed in bladder tumours (20–50% of total cases)
in comparison with their sialylated counterparts (62%
and 100%, respectively). More importantly, these
antigens are mostly found in high-grade tumours,
irrespective of the degree of invasion. Nevertheless,
the number of T antigen-positive cases largely exceeds
the Tn-positive cases (53% vs 23%), which was par-
ticularly notorious in advanced tumours when com-
pared to low-grade superficial lesions. These
observations suggest a possible overexpression of
C1GalT1 (core 1 synthase, T-synthase) or down-
regulation of other glycosyltransferases involved in
O-glycan extension in bladder tumours, which war-
rants careful evaluation in future studies. Possible
modulation by secreted galactosidases, sialidases are
also a possibility that should be investigated. Note-
worthily, we have previously observed that bladder
cancer cells exposed to hypoxia, a common microen-
vironmental feature in advanced tumours, promoted
a striking downregulation in C2GnT accompanied by
an increase in C1GalT1 (Peixoto et al., 2016). It is
possible that similar events may account for T anti-
gen accumulation in bladder tumours. More impor-
tantly, neither Tn nor T antigens were found in the
six studied healthy urothelia cases, demonstrating the
malignant nature of these molecular alterations.
Finally, our observations reinforce early studies in
bladder cancer glycosylation describing an association
between T antigen expression and tumour invasion
(Langkilde et al., 1992). Focus should now be set on
understanding the biological and clinical implications
of this profound alteration in O-glycosylation.
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3.1.2. Expression of sialylated short-chain O-glycans in
bladder (STn and mono- plus disialyl-T)
Contrasting with neutral short-chain O-glycans, sialy-
lated Tn and T antigens, including mono- and/or disia-
lyl-T, are widely detected in bladder tumours
irrespective of their grade and degree of invasion (62–
100%; Table 1). In agreement with previous studies
(Carrascal et al., 2014; Costa et al., 2015), the STn
antigen was found in high-grade and invasive tumours
(75 and 89%, respectively), whereas only 24% of low-
grade cases were positive. The majority of the positive
cases presented a low extension of expression (< 20%),
of focal and polydisperse nature, throughout the
tumour. STn was mostly found in cells of the basal
layer (Fig. 1A); yet in tumour areas presenting exten-
sive staining (> 50%) (Fig. 1B), it could also be
detected in papillary urothelium and invasive fronts
(Fig. 1B). Moreover, whenever present in the tumour,
STn was also detected in the adjacent but not in the
distal mucosa, also in agreement with previous reports
(Carrascal et al., 2014; Costa et al., 2015). Hence, cells
neighbouring the tumour are thought to carry signifi-
cant alterations that result in the expression of this
antigen. We also note that increase in STn is generally
accompanied by a loss of Tn, reinforcing the
association between increase in sialylation of O-glycan
precursors and the severity of the lesions (Table 1). On
the other hand, the sialylated forms of the T antigen,
including mono- and/or disialylated glycans, are dif-
fusely expressed by all studied bladder tumours
(Table 1 and Fig. 2). However, a significant increase
in the extension of sialylated T antigen could be
observed in more advanced cases, suggesting an over-
expression and/or increased activity of sialyltrans-
ferases (Fig. 2). In agreement with these observations,
it has been demonstrated that advanced-stage bladder
tumours overexpress ST3Gal-I (Videira et al., 2009),
the glycosyltransferase responsible for T antigen sialy-
lation. In summary, while superficial tumours mostly
present sialylated T antigens, more advanced-stage
tumours also co-express more immature O-glycans,
including the STn antigen (Table 1) that has been fre-
quently associated with more malignant phenotypes
and poor outcome (Bernardo et al., 2014; Cabral
et al., 2010; Costa et al., 2015; Ferreira et al., 2013).
3.1.3. Exploring the nature of T antigen sialylation
Despite the widespread nature of sialylated T antigens
in healthy and, particularly, malignant tissues, few
studies have focused on disclosing the nature of
Table 1. Expression of short-chain O-GalNAC glycans in bladder tumours of different clinicopathological natures determined by
immunohistochemistry
Tn STn T ST S6T S3T
Non-muscle invasive bladder cancer (NMIBC) (%)
Low Grade 17
 15 (88) 13 (76) 13 (76) 0 (0) 2 (12) 10 (59)
+ 2 (12) 4 (24) 4 (24) 5 (29) 11 (65) 6 (35)
++ 10 (59) 4 (24) 1 (6)
+++ 2 (12)
++++
Positive cases, n (%) 2 (12) 4 (24) 4 (24) 17 (100) 15 (89) 7 (41)
High Grade 12
 5 (42) 3 (25) 9 (75) 0 (0) 0 (0) 3 (29)
+ 7 (58) 7 (58) 3 (25) 3 (25) 5 (42) 7 (57)
++ 2 (17) 2 (17) 7 (58) 2 (14)
+++ 7 (58)
++++
Positive cases, n (%) 7 (58) 9 (75) 3 (25) 12 (100) 12 (100) 9 (71)
Muscle invasive bladder cancer (MIBC)
18
 16 (89) 2 (11) 0 (0) 0 (0) 5 (28) 7 (39)
+ 2 (11) 16 (89) 4 (22) 3 (17) 8 (44) 7 (39)
++ 6 (33) 5 (28) 6 (33) 4 (22)
+++ 5 (28) 6 (33)
++++ 3 (16) 4 (22)
Positive cases, n (%) 2 (11) 16 (89) 18 (100) 18 (100) 14 (78) 11 (61)
Total positive cases 47 11 (23) 13 (62) 25 (53) 47 (100) 38 (81) 27 (57)
Scoring: , negative; +: > 0–19%; ++: 20–49%; +++: 50–79%; ++++: ≥ 80%.
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T antigen sialylation, most likely due to the lack of
specific monoclonal antibodies and limitations in gly-
comics approaches. Facing these problems, we digested
bladder tumour sections with a b-(1-3)-galactosidase
prior to incubation with the anti-STn monoclonal anti-
body, to address the possibility of O-6 GalNAc sialyla-
tion (S6T). This procedure was responsible for the
removal of Ο-3-linked Gal residues from S6T antigens
exposing STn antigens for recognition (Fig. S2A).
Accordingly, we observed positive staining after enzy-
matic treatment in STn-negative tumours (Fig. S2A),
as well as an increased STn expression in several cases
(Table 1), suggesting the presence of the S6T antigen.
This glycan was found in approximately 80% of the
studied tumours, with similar percentage of positive
cases between NMIBC and MIBC. However, increased
extension of expression could be observed in advanced
tumour (Table 1 and Fig. 2). The S6T was further
evaluated in FFPE healthy urothelium from six
necropsied male individuals, which confirmed its can-
cer-associated nature. Recently, we have described that
the presence of S6T and STn in bladder tumours was
associated with a better response to BCG immunother-
apy for more aggressive NMIBC, suggesting that O-6
sialylation plays a key role in bacillus binding to the
epithelium (Lima et al., 2013). Such observations rein-
force the importance of including alterations in glyco-
sylation in panomics predictive molecular models.
Moreover, we have described an overexpression of
ST6GalNAc-I, a key glycosyltransferase involved in O-
6 sialylation of Tn antigens (Sewell et al., 2006) in
advanced-stage bladder tumours (Ferreira et al., 2013).
Future studies should be conducted to disclose the
transcription of ST6GalNAc-I/II and possibly ST6Gal-
NAc-IV, known to be involved in the O-6 sialylation
of Tn antigens (Spiro, 2002), gaining more insights on
the biological mechanisms underlying these molecular
alterations and its clinical relevance.
On the other hand, incubation with a a-neuramini-
dase specific for cleaving O-3-linked sialic acids
allowed T antigen detection in some negative tissues
(Fig. S2B) and increased the extension and intensity of
expression in T antigen-positive cases (Table 1),
strongly suggesting the presence of the S3T antigen.
Contrasting with the ubiquitous nature of S6T, the
S3T antigen was mostly found in high-grade NMIBC
(41% low-grade NMIBC; 71% high-grade NMIBC;
61% MIBC). Nevertheless, we should note that many
high-grade tumours co-express both T sialylated forms.
These observations support previous associations
between the overexpression of both sialyl-T and
ST3Gal-I, the sialyltransferase responsible for T anti-
gen O-3 sialylation, in high-grade tumours (Videira
et al., 2009). Moreover, similar to S6T, the S3T anti-
gen was also not detected in the healthy urothelium,
reinforcing the cancer-associated nature of these
antigens.
In summary, we have demonstrated that there are
minor subsets of advanced-stage tumours that co-
overexpress nonsialylated short-chain O-glycans (Tn
and T antigens) in association with their sialylated gly-
coforms. Moreover, we have highlighted the structural
diversity of T antigen sialylation in bladder tumours,
its cancer-associated nature and the prevalence of up
until now neglected O-6 sialoforms. Interestingly, this
mimics the sialylation of the Tn antigen, whose biolog-
ical and clinical significance has been extensively stud-
ied by our group. Furthermore, we have again
reinforced the association between STn antigen expres-
sion and aggressive disease, raising to over 300 the
number of evaluated tumour sections of different clini-
copathological classifications and aetiologies (Bernardo
et al., 2014; Cabral et al., 2010; Costa et al., 2015;
Ferreira et al., 2013; Lima et al., 2013; Peixoto et al.,
2016; Santos et al., 2014). Significant efforts should be
put on providing accurate quantification of these anti-
gens using high-throughput glycomics approaches and
on developing highly specific ligands. This would set
the necessary means for large-scale clinical studies and
targeted therapeutics. Moreover, it will be crucial for
A B
Fig. 1. Immunohistochemistry for sialyl-Tn (STn) antigen evidencing (A) expression in cells longing and invading the basal layer in high-grade
NMIBC and (B) extensive staining including in cells invading the muscle layer in MIBC.
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understanding the molecular mechanisms underlying
glycomic alterations, including (a) to determine the
events modulating the expression and activity of
glycosyltransferases and glycosidases in bladder
tumours; (b) to access the distribution of glycosyltrans-
ferases throughout the secretory organelles and
Fig. 2. Immunohistochemistry for sialylated T antigens (ST: corresponding to mono- and disialylated T glycoforms; S3T and S6T) for low-
and high-grade superficial papillary muscle-invasive bladder tumours. The figure highlights the increase in T sialylation with the severity of
the lesions. As the S6T antigen was determined based on comparisons with STn expression after b-(1,3)-galactosidase digestion, only STn-
negative tumour lesions are being presented in this figure. Moreover, because the S3T antigen expression was determined based on
comparisons with T antigen expression after a-(2,3)-neuraminidase treatment, only T-negative tissues are being presented.
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pathways; (c) to explore mutations in key enzymes
involved in O-glycans biosynthesis and its functional
impact. Such information will be crucial for accessing
the biological and clinical significance of altered O-gly-
cosylation in bladder cancer, providing relevant
insights for glycoproteomics studies and ultimately the
design of novel and more effective therapeutics (Fer-
reira et al., 2016a).
3.2. Bladder cancer-targeted glycoproteomics
Based on our previous and current observations, the
STn constitutes a key cancer-associated antigen highly
associated with advanced disease and poor prognosis
(Bernardo et al., 2014; Costa et al., 2015; Ferreira
et al., 2013; Lima et al., 2013; Peixoto et al., 2016).
Moreover, we have observed that STn expression sig-
nificantly favours cell motility and capacity to invade
(Ferreira et al., 2013; Peixoto et al., 2016) as well as
immune escape (Carrascal et al., 2014). Therefore,
mapping the STn-glycoproteome is crucial for develop-
ing highly specific targeted therapeutics against
advanced-stage bladder tumours. However, while the
majority of glycoproteomics studies presented so far
have focused mostly on body fluids and, to lower
extent, human tissues, none has attempted to address
protein glycosylation in FFPE tissues. Herein, we
extracted proteins from five MIBC tumours and
screened the samples for STn expression by western
blot, which retrieved similar expressions patterns
(Fig. S5A). These samples were then pooled and anal-
ysed by a conventional gel-based and nanoLC-MS/MS
proteomics approach (Fig. S3A), which allowed the
identification of 2578 peptides, corresponding to 294
proteins (Table S1). This illustrated that the feasibility
of using FFPE has starting material for retrospective
proteomic studies on clinical samples, despite the sig-
nificant modifications and degradation induced by
paraffin embedding. Gene ontology interpretation of
the results using Panther highlighted the presence of
proteins from all cell compartments, including plasma
membrane proteins known to yield the STn antigen
(4%; Fig. S4A); nevertheless, an overrepresentation of
cytoplasmic and cytoskeleton proteins could be
observed (Fig. S4A), in accordance with its higher
abundance in the cellular milieu. The main represented
molecular functions included binding, structural and
catalytic activities, whereas the main biological func-
tions were set on metabolic and cellular processes
(Fig. S4B,C), in accordance with the wide range of
identified proteins. Nevertheless, due to the low abun-
dance of STn-expressing membrane glycoproteins
potentially yielding the STn antigen, an enrichment
step was introduced based on affinity to VVA lectin
that selectively binds terminal GalNAc residues. To
render the glycoproteins with affinity for the chosen
lectin, the extracts were digested with a a-neuramini-
dase prior to the enrichment step, which removed sialic
acids from STn exposing the GalNAc residue (Tn anti-
gen). The absence of Tn and blood group A determi-
nants in the chosen cases ensured the specificity of the
enrichment for STn-expressing proteins (Fig. S3B).
Subsequent nanoLC-MS/MS analysis led to the identi-
fication of over 400 O-glycosites and 143 membrane
glycoproteins putatively expressing the STn antigen
(Table S2), which may be potential targets for targeted
therapies. These glycoproteins were found associated
with a wide array of molecular and biological func-
tions, as depicted in detail in Fig. 3. In particular,
STn-expressing proteins mostly mediate binding to
other proteins and have hydrolase catalytic activities.
They also mediate cell–cell communication and sig-
nalling and regulate primary metabolic processes.
These observations strongly suggest that altered glyco-
sylation may influence a wide array of cell functions,
thereby providing key preliminary insights to under-
stand the role of STn expression in bladder cancer.
Approximately half of the identified glycoproteins had
been previously studied in the context of bladder can-
cer and could be comprehensively distributed accord-
ing to its association with disease on an analysis
in silico with Oncomine (Rhodes et al., 2007) (Fig. 4).
This list included CD44, a typical bladder cancer stem-
cell associated glycoprotein also associated with drug-
resistant phenotypes and poor prognosis (Kobayashi
et al., 2016), and several integrins, in accordance with
previous observations (Peixoto et al., 2016). For vali-
dation purposes, we have immunoprecipitated CD44
and ITGB1 in these samples and confirmed the expres-
sion of STn by western blot (Fig. S5B). Furthermore,
immunohistochemistry showed the co-expression of
these antigens in the same tumour area, which was
confirmed by PL (Fig. S5C), which allows the simulta-
neous detection of the protein and the glycan when-
ever there is close proximity. In addition to these
glycoproteins, we have also identified, for the first
time, MUC16 and abnormal MUC16 glycoforms in
bladder tumours (Table S1). Interestingly, these high
molecular weight glycoproteins are generally found in
ovarian tumours facing poor prognosis, being fre-
quently used for serological monitoring and as diag-
nostic marker of ovarian cancer (CA125 test) (Duffy
et al., 2005; Felder et al., 2014; Vasudev et al., 2011).
Again, we have confirmed the presence of STn in
MUC16-derived glycopeptides based on characteristics
of CID-MS/MS fragmentation spectra (Fig. 5A).
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Moreover, we found glycopeptides carrying both Gal-
NAc and Gal-GalNAc substituents, highlighting the
complex antigenic glycoarray presented by bladder
cancer-associated glycoproteins (Fig. S6). In addition,
the analysis of consecutive bladder tumour sections
revealed that MUC16 expression is associated and
colocalized with STn expression in 95% of the cases,
irrespective of their histological classification (Fig. 5B).
Moreover, PLA confirmed the presence of MUC16
STn+ glycoforms in clinical samples (Fig. 5C). Despite
unequivocal data supporting the existence of MUC16
STn- glycoforms, we have further attempted to IP and
blot this glycoprotein as it has been done for CD44
and ITGB1; however, its high molecular weight
Fig. 3. Distribution of candidate STn-expressing glycoproteins in muscle-invasive bladder tumours (detailed in Table S2) comprehensively
integrated according to cellular localization (A), molecular (B) and cell functions (C) based on gene ontology analysis by Panther
bioinformatics tool. STn-expressing proteins were found to be associated with a wide array of molecular and biological functions as depicted
in detail in the figure. Accordingly, the identified glycoproteins were involved in nine main classes of molecular functions, with an
overrepresentation of catalytic activities (hydrolase, lyase and transferase activities) and protein binding mediation. Moreover, 13 main
biological functions were highlighted, being the most representative cellular processes such as cell communication and, to some extent, cell
cycle control. These observations suggest that altered glycosylation may influence a wide range of key cell events, which warrants
evaluation in future studies.
905Molecular Oncology 11 (2017) 895–912 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
S. Cotton et al. Targeted O-glycoproteomics in bladder cancer
(Mw < 2000 kDa) and the lack of suitable antibodies
for this procedure have posed as a significant analyti-
cal limitation that will be addressed in future studies.
Even though this is the first report regarding MUC16
expression in bladder cancer, CA125 elevation has
been previously observed in the serum of patients with
advanced pathological stage in comparison with lower-
stage disease, suggesting that this antigen may predict
advanced bladder cancer (Margel et al., 2007; Vasudev
et al., 2011). Furthermore, abnormal CA125 levels
have been associated with unresectable tumours, again
reinforcing its association with worse prognosis (Vasu-
dev et al., 2011).
3.3. Clinical significance of MUC16 expression in
bladder cancer
Given the key role of MUC16 in ovarian cancer
(Felder et al., 2014; Ricardo et al., 2015), and building
on the lack of clinical data for bladder cancer, we have
screened a retrospective series of 176 tumours
spanning different classifications (74 NMIBC and 102
MIBC). MUC16 was mainly expressed in the cell
membrane and cytoplasm, with moderated and focal
expression that did not exceed 20% of tumour cells
for the majority of the positive cases (Fig. 5B), irre-
spective of their histological/TNM classification. The
MUC16 antigen was observed in approximately 27%
of cases (48 of 176), mainly in tumours showing lamina
propria (T1; 30%) and muscularis propria (≥ T2; 20–
40%) invasion; conversely, the number of MUC16-
positive Ta tumours was lower than 15% (Fig. 6A;
P < 0.005). Concerning WHO criteria, MUC16-posi-
tive cells were mostly observed in the high-grade cases
(P = 0.008; Fig. 6B), reinforcing the association
between MUC16 expression and poor prognosis. In
agreement with these observations, we have also
observed an increased transcription of MUC16 gene in
MUC16-positive tumours in comparison with
MUC16-negative tumours (Fig. S7, P = 0.005). More-
over, we found that MUC16 expression associates with
lower CSS in MIBC patients treated with cisplatin and
Fig. 4. Candidate STn-expressing glycoproteins in muscle-invasive bladder tumours comprehensively distributed according to its association
with the severity of the lesions. Briefly, the identified glycoproteins were distributed according to associations with the type of lesion based
on an in silico analysis with Oncomine. Proteins identified for the first time in bladder tumours have not been included in the graph due to
the lack of associations with the type of disease.
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gemcitabine, suggesting a possible role in drug resis-
tance that is being currently evaluated. These observa-
tions are in agreement with the findings from
serological CA125 evaluation (Felder et al., 2014; Rao
et al., 2015) and strongly support the need for a dee-
per investigation on the biological and clinical signifi-
cance of MUC16 in bladder cancer.
4. Conclusions
It has been long known that advanced bladder
tumours present significant alterations in glycosylation
that relate to worst prognosis; however, there is a
lack of information on the structural nature of
cancer-specific glycans. This work highlights that
advanced bladder tumours overexpress and fre-
quently co-express an array of short-chain O-glycans
resulting from a premature stop in the glycosylation
of membrane and secreted proteins. Moreover, it
clearly demonstrates a predominance of sialylated
over neutral glycoforms, with emphasis on sialylated
Tn and T antigens. In addition, for the first time,
we provide key insights on the nature of the T anti-
gen sialylation, which will be crucial for guiding
Fig. 5. (A) Exemplificative annotated nanoLC-ESI-LTQ-Orbitrap-CID-MS/MS spectra for a MUC16 glycopeptide substituted with a HexNAc
residue evidencing the specific glycosite; (B) colocalization of MUC16 and STn in bladder tumours by immunohistochemistry; (C) expression
of MUC16 STn glycoforms in bladder tumours based on PLA analysis. This work identified for the first time MUC16 in bladder tumours and
its association with abnormal glycoforms such as the STn antigen. The mass spectrum shows a MUC16 glycopeptide substituted with a
HexNAc residue, strongly suggesting the presence of STn. The colocalization of MUC16 and STn (B) in bladder tumours also reinforces this
hypothesis. Finally, the red dots on the PLA image (C) in areas of colocalization result from the simultaneous detection of both antigens,
reinforcing this evidence.
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future glycomics and glycoproteomics studies and for
designing specific ligands against bladder cancer cells.
Moreover, we have highlighted a significant increase
in O-6 sialylation in bladder tumours, particularly
the STn antigen. Finally, we have mined the glyco-
proteome of advanced bladder tumours for STn-
expressing glycoproteins. This resulted in the identifi-
cation of MUC16 as a novel biomarker for a subset
of bladder tumours presenting poor prognosis. It
also highlighted a molecular link between bladder
and ovarian cancer, where abnormally glycosylated
MUC16 plays a key role in disease progression and
dissemination. Future studies should now be focusing
on the biological role of this glycoprotein in bladder
cancer. Our findings also reinforce the need to com-
prehensively address the CA125 antigen in the sera
and, possibly, also urine of patients with bladder
cancer. Furthermore, we augment that a careful
mapping of MUC16 and other cancer-associated gly-
coproteins may provide the necessary structural
information for highly specific biomarkers and tar-
geted therapeutics.
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Abstract
Muscle invasive bladder cancer (MIBC, stageT2) is generally associated with poor prog-
nosis, constituting the second most common cause of death among genitourinary tumours.
Due to high molecular heterogeneity significant variations in the natural history and disease
outcome have been observed. This has also delayed the introduction of personalized thera-
peutics, making advanced stage bladder cancer almost an orphan disease in terms of treat-
ment. Altered protein glycosylation translated by the expression of the sialyl-Tn antigen
(STn) and its precursor Tn as well as the activation of the PI3K/Akt/mTOR pathway are can-
cer-associated events that may hold potential for patient stratification and guided therapy.
Therefore, a retrospective design, 96 bladder tumours of different stages (Ta, T1-T4) was
screened for STn and phosphorylated forms of Akt (pAkt), mTOR (pmTOR), S6 (pS6) and
PTEN, related with the activation of the PI3K/Akt/mTOR pathway. In our series the expres-
sion of Tn was residual and was not linked to stage or outcome, while STn was statically
higher in MIBC when compared to non-muscle invasive tumours (p = 0.001) and associated
decreased cancer-specific survival (log rank p = 0.024). Conversely, PI3K/Akt/mTOR path-
way intermediates showed an equal distribution between non-muscle invasive bladder can-
cer (NMIBC) and MIBC and did not associate with cancer-specif survival (CSS) in any of
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these groups. However, the overexpression of pAKT, pmTOR and/or pS6 allowed discrimi-
nating STn-positive advanced stage bladder tumours facing worst CSS (p = 0.027). Further-
more, multivariate Cox regression analysis revealed that overexpression of PI3K/Akt/
mTOR pathway proteins in STn+ MIBC was independently associated with approximately
6-fold risk of death by cancer (p = 0.039). Mice bearing advanced stage chemically-induced
bladder tumours mimicking the histological and molecular nature of human tumours were
then administrated with mTOR-pathway inhibitor sirolimus (rapamycin). This decreased the
number of invasive lesions and, concomitantly, the expression of STn and also pS6, the
downstream effector of the PI3K/Akt/mTOR pathway. In conclusion, STn was found to be
marker of poor prognosis in bladder cancer and, in combination with PI3K/Akt/mTOR path-
way evaluation, holds potential to improve the stratification of stage disease. Animal experi-
ments suggest that mTOR pathway inhibition could be a potential therapeutic approach for
this specific subtype of MIBC.
Introduction
Bladder cancer is the second most deadly genitourinary tumour and presents significantly
worse prognosis uponmuscularis propria invasion [1]. Approximately 20–30% of the newly
diagnosed cases are muscle invasive bladder cancers (MIBC; T2-T4 stages), while 50% are non-
muscle invasive bladder tumours (NMIBC) with high potential to progress to invasion. MIBC
treatment includes cystectomy and (neo)adjuvant cisplatin-based chemotherapy regimens [2].
However, significant variations in the natural history of the disease and responses to treatment
can be observed between tumours with identical histological features, reflecting their high
molecular heterogeneity [3]. Furthermore, approximately 50% of cases develop metastasis
within 5 years, urging the identification of biomarkers to assist prognostication and the devel-
opment of more effective targeted therapeutics [4].
To meet this need, we have recently addressed the expression of the cancer-associated sia-
lyl-Tn antigen (STn) on a small prospective series of unselected bladder cancer patients [5].
STn is an abnormal post-translational modification that results from a premature stop in cell-
membrane proteins O-glycosylation by sialylation of the Tn antigen (Fig 1A). In bladder
tumours, STn it was mainly present in advanced stage cases, while absent from most low-grade
NMIBC [5]. Moreover, it was not expressed by the normal urothelium, denoting a cancer-spe-
cific nature [5]. Studies in vitro showed that STn expression endowed bladder cancer cells with
high invasion capability [5] and an immunotolerogenic phenotype, potentially favoring disease
dissemination [6]. Alterations in cell-surface protein glycosylation have be implicated in the
activation of intracellular oncogenic signalling pathways [7], including the phosphoinositide-3
kinase (PI3K)/Akt signalling pathway [8] which is thought to play a critical role in bladder can-
cer development. These preliminary observations support the hypothesis that STn expression
may play a key role in disease outcome, which warrants a deeper investigation. Several studies
also suggest that Tn antigen, which is a precursor of STn, may be also implicated in oncogenic
events [7]; however nothing is known about the expression of this glycan in bladder tumours.
The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin
(mTOR) pathways are interconnected signaling cascades essential for bladder cell growth and
survival (Fig 1B). The PI3K/Akt/mTOR or mTOR pathway integrates a multiplicity of extracel-
lular signals to regulate downstream signaling and protein synthesis, which ultimately leads to
Glycosylation and PI3K/Akt/mTOR Pathway in Bladder Cancer
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Fig 1. Schematic representation of membrane proteinO-glycosylation and the PI3K/Akt/mTOR pathways. A) Representation of membrane proteinO-
glycosylation with emphasis on the STn expression by cancer cells. This is a highly regulated process of critical importance for protein stability and function.
Briefly, newly synthesized proteins areO-glycosylated in the Golgi apparatus by the ppGalNAcTs-mediated addition of GalNAc moiety to Ser/Thr residues.
This originates the Tn antigen (GalNAc-O-Ser/Thr-protein backbone), which is the simplest O-glycan. In normal cells these chains are extended through the
sequential addition of other sugars first by CGALT-1 and then other enzymes. This culminates in highly complex, heterogeneous and elongated glycans
often terminated by ABO or Lewis blood group related antigens (left drawing). In cancer cells the Tn antigen is immediately sialylated by ST6GalNAc.I,
originating the STn antigen (Neu5Ac-GalNAc-O-Ser/Thr-protein backbone), thereby inhibiting further chain elongation (right drawing). The expression of STn
at the cell surface influences cell-cell adhesion and cancer cell recognition, favouring motility, invasion and immune escape. B) Schematic representation of
the PI3K/Akt/mTOR pathway, which is ubiquitously activated in bladder tumours. This is a highly conserved pathway regulated mainly by a wide variety of
extracellular signals, including mitogenic growth factors, hormones, nutrients, cellular energy levels, and stress conditions. These signals activate tyrosine
receptor kinases that recruit PI3K, which catalyses the conversion of membrane-bound PIP2 to PIP3. Then Akt and PDK-1 are activated through binding to
PIP3. PTEN preferentially dephosphorylates PIP3, inhibiting signalling progression. Full Akt activation requires double phosphorylation by PDK-1 itself and
PDK-2 (not shown). Akt phosphorylates mTOR directly or may also inactivate TSC1/TSC2 complex, inhibiting mTOR inactivation. mTORC1 triggers cell
growth and proliferation by phosphorylating eukaryotic translation regulators, among these p70S6 kinase (p70S6K or S6K1) that, in turn, phosphorylates the
Glycosylation and PI3K/Akt/mTOR Pathway in Bladder Cancer
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a competitive growth advantage, metastatic competence, angiogenesis, and therapy resistance
[9]. The signaling cascade begins with PI3K activation in the cell membrane followed by ser-
ine/threonine kinase Akt cell membrane translocation and activation. The best studied down-
stream substrate of Akt is the serine/threonine kinase mTOR, whose downstream effector is S6
kinase-1 (S6K1). In particular, a subset of mTOR pathway alterations have been shown to
occur in bladder cancer, such as mutations in PIK3CA gene, which culminates with increased
mTOR signaling and bladder cancer cells resistance to apoptosis [10]. Moreover, the pharma-
cological or biochemical inhibition of the PI3K pathway drastically reduced the invasive capac-
ity of bladder cancer cell lines. Furthermore, over half of primary human bladder tumours
present high Akt phosphorylation and the aberrant activation of this pathway has been sug-
gested to contribute to invasion [11]. Another event influencing mTOR pathway activation in
bladder tumours involves the loss of tumor suppressor PTEN (phosphatase and tensin homo-
log deleted on chromosome ten) function [12]. PTEN normally suppresses activation of the
PI3K/Akt/mTOR pathway antagonizing PI3K and preventing activation of Akt and PDK-1.
PTEN also functions to regulate chemotaxis and cell motility, thereby promoting tumor inva-
sion [13]. In summary, there are evidences that a comprehensive evaluation of PI3K/Akt/
mTOR pathway associated proteins may hold significant potential for value for patient stratifi-
cation. Moreover, many preclinical and clinical studies support that mTOR inhibitors, such as
sirolimus (rapamycin) and their derivatives may improve cancer treatment [13,14].
Based on these observations we hypothesize that Tn and/or STn may act synergistically with
the mTOR pathway to drive bladder cancer progression. As such, we have devoted to evaluat-
ing the expression of STn and proteins associated with the activation of the PI3K/Akt/mTOR
pathway activation in bladder tumours at different stages. We anticipate that the combination
of extracellular and intracellular oncogenic events may improve patient stratification and pro-
vide insights for novel therapeutics. Furthermore we have estimated the impact of sirolimus in
chemically-induced urothelial tumours in mice, envisaging the creation of a rationale for more
effective bladder cancer therapeutics.
Materials and Methods
Ethics Statement
This work involves experiences in tumour samples of patients diagnosed with bladder cancer
in the Portuguese Insitute of Oncology of Porto. All procedures were performed after patient’s
written informed consent and approved by the Ethics Committee of Portuguese Institute of
Oncology—Porto. All clinicopathological information was obtained from patients’ clinical
records.
It also involves animal experiments. All procedures involving animals were performed in
accordance with the European Directive 2010/63/EU. During the course of this study, the ani-
mals were fed ad libitum with standardized food (Tecklad Global Diet, Harlan, Spain). The fol-
lowing protocol was approved by the Portuguese Ethics Committee for Animal
Experimentation (Direção Geral de Veterinária, Approval no. 520/000/000/2003). All mice
used in the experiment were acclimatized for one week under routine laboratory conditions
before starting the experiments. They were housed randomly in groups of 4–5 in plastic cages,
with hard wood chips for bedding. The animals were maintained in a room with a controlled
ribosomal protein S6 (pS6), and the eukaryotic translation initiation factor 4E–binding protein 1 (4E-BP1). For the protein mTOR to activate its signalling
cascade, it must form the rapamycin-sensitive ternary complex mTORC1. Key PI3K/Akt/mTOR-pathway proteins pAkt, pmTOR and pS6 explored in this
studied are highlighted by orange circles.
doi:10.1371/journal.pone.0141253.g001
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temperature of 23±2°C, a 12-hour light/dark cycle and 55±5% humidity. The animals' drinking
solutions were changed once a week or earlier if necessary, and the volume drunk was recorded.
Weekly food intake was also noted. All mice were monitored throughout the experiment for
signs of distress and loss of body weight. The animals were sacrificed with 0.4% sodium pento-
barbital (1 ml/Kg, intraperitoneal).
Population
This study was performed in a retrospective series of 96 formalin-fixed paraffin-embedded
bladder tumours obtained from archived paraffin blocks at the Portuguese Institute of Oncol-
ogy—Porto (IPOP), Portugal. Bladder tumours were extracted from 82 men and 14 women,
ranging in age from 38 to 92 years (median of 69.5 years), admitted and treated at the IPOP
between 2005 and 2007. Forty seven of the examined tumours were histologically classified as
NMBIC (Ta and T1) and 49 as invasive lesions (T2-T4). Sixteen were low grade and 80 were
high grade tumours, according to the 2004 WHO grading criteria. Furthermore, carcinoma in
situ (CIS) was found concomitantly in 20.8% of the patients. The average follow up time period
was 45 months (1–134 months). Cystectomy was performed in 64 patients (66.7%) while the
other 32 (33.3%) were submitted to transurethral resection. Lymphadenectomy was performed
in approximately 47% of the patients and from those 37% presented metastasis. Fifty four
(56.3%) tumours were primary and 42 (43.7%) were recurrent tumors. From the recurrent
tumours, 38% had no prior treatment, 27% were treated with Mitomicin C, 11% with BCG and
19% were submitted to both treatments. Moreover 5% of these patients were treated with
neoadjuvant chemotherapy prior to the cystectomy. Table 1 summarizes the clinicopathologi-
cal information.
Cancer-specific survival (CSS) was defined as the period between the tumour removal by
surgery and either patient death by cancer or the last follow-up information. All procedures
were performed after patient’s informed consent and approved by the Ethics Committee of
IPO-Porto. All clinicopathological information was obtained from patients’ clinical records.
Immunohistochemistry
The expressions of STn antigen, its precursor Tn, and phosphorylated forms of Akt (pAkt),
mTOR (pmTOR), S6 (pS6) and PTEN in bladder tumours were accessed by immunohis-
tochemistry using the avidin/streptavidin peroxidase method, as described by Ferreira et al.
[5]. Information on the primary antibodies and dilutions used in this study are summarized in
Table 2. Immunoreactivity was revealed using diaminobenzidine (DAB, Thermo Scientific
LabVision) as chromogen and sections were counterstained with Harris’s hematoxylin. Nega-
tive controls were performed by replacing the primary antibody with 5% bovine serum albu-
min (BSA). Positive controls were known positive tissues for the antigens under study.
Immunohistochemistry scoring of human tumours
The immunostained sections were assessed double-blindly by light microscopy by two inde-
pendent observers (CC and SP) and validated by an experienced pathologist (TA). Disaccord-
ing readings were re-analyzed using a double-headed microscope (Olympus BX46; Olympus
Corporation), and consensus was reached. A semi-quantitative approach was established to
score the immunohistochemical labeling based on the extent and intensity of the staining.
Given the absence of Tn and STn in the healthy urothelium [5], tumours were classified as
positive for these antigens when membrane and/or cytoplasmic immunoreactivity were
observed in more than 5% of the tumour, as described by Ferreira et al. [5,15]. pAkt, pmTOR,
pS6 and PTEN expressions were scored according to the staining intensity (weak-1 point;
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moderate-2 points; strong-3 points) multiplied by the percentage of positive cells (0–5%-0
points;>5–25%-1 point;>25–50%-2 points;>50–75%-3 points;>75–100%-4 points). Based
on the classification proposed by Nishikawa et al. [16], tumours with a score<6 were consid-
ered negative, whereas those with a score6 were classified as positive (overexpression). pAkt
was evaluated based on nuclear immunoreactivity, pmTOR and pS6 based on cytoplasmic
expression and PTEN on both cytoplasmic and nuclear staining, as suggested by other publica-
tions [17,18].
Animal experiments with sirolimus and immunohistochemistry scoring
Histological sections of Imprinting Control Region (ICR) mice bearing N-butyl-N-(4-hydroxy-
butyl) nitrosamine (BBN)-induced bladder lesions, resulting from our previous work on the
impact of sirolimus on bladder cancer [19], were elected for this study. Briefly, four-week-old
male ICR mice (25g; Harlan, Barcelona, Spain) were randomly distributed into four groups, as
described in detail in a previous publication [18]. Group 1 (n = 6) included mice exposed to
0.05% BBN for 12 weeks followed by tap water for 8 weeks (total of 20 weeks). Group 2 (n = 7)
included mice treated with 0.05% BBN solution for twelve weeks, maintained with normal tap
water for another week, administrated intraperitoneally with mTOR-inhibitor sirolimus (1.5
mg/kg; Wyeth) for five days a week for six consecutively weeks, i.e. until the 19th week, followed
by another week of tap water (total of 20 weeks). Group 3 (n = 6) included mice exposed to
0.05% BBN for 12 weeks followed by tap water for 11 weeks (total of 23 weeks). Group 4
Table 1. Clinical-pathological data of the studied sample (n = 96).
Age, years
median [min—max] 69.5 [38–92]
Gender, n (%)
Male 82 (85.4%)
Female 14 (14.6%)
Stage, n (%)
Ta 27 (28.1%)
T1 20 (20.8%)
T2 9 (9.4%)
T3 20 (20.8%)
T4 20 (20.8%)
Grade, n (%)
Low 16 (16.7%)
High 80 (83.3%)
Recurrence status, n(%)
Primary 54 (56.3%)
Recurrent 42 (43.7%)
Associated Cis, n(%)
No 76 (79.2%)
Yes 20 (20.8%)
Metastasis, n(%)
No 19 (63.3%)
Yes 11 (36.7%)
Follow-up, n (%)
Alive, lost or death from other causes 67 (69.8%)
Death from cancer 29 (30.2%)
doi:10.1371/journal.pone.0141253.t001
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(n = 7) included mice treated with 0.05% BBN and sirolimus, as described for Group 2, but
with an exposure to tap water afterwards of 3 weeks (total of 23 weeks). Group 3 and 4 were
created to estimate the possibility of late relapse and/or molecular alterations resulting from
prolonged survival. All procedures were performed in accordance with the European Directive
2010/63/EU. During the course of this study, the animals were fed ad libitum with standardized
food (Tecklad Global Diet, Harlan, Spain). The histological changes induced by these experi-
ments included both preneoplastic and neoplastic lesions with invasive potential and invasive
tumours, as described in detail by Oliveira et al. [18]. Herein, lesions of high invasive potential
and muscle invasive tumours were screened for STn and pS6 by immunohistochemistry, as
described in detail for human tumours, since the antibodies used are reactive against both
human and mice. Both the intensity and the extension of immunostaining were taken into con-
sideration to score the expression of the antigens, as described in the previous section. The
bladder lesions and immunostaining were assessed double-blindly by two independent observ-
ers (CC and SP) and validated by an experienced veterinary pathologist (RMGC).
Statistical analysis
Statistical data analysis was performed with IBM Statistical Package for Social Sciences—SPSS
for Windows (version 20.0). Chi-square analysis was used to compare categorical variables.
Kaplan-Meier survival curves were used to evaluate correlation between STn expression and
cancer-specific survival (CSS) and were compared using log-rank test. Furthermore, multivari-
ate Cox regression analysis was performed to assess the individual effect of the evaluated mark-
ers on patient’s survival and adjust to potential confounders (variables that could affect CSS of
NMIBC and MIBC patients). The correlation between PI3K/Akt/mTOR pathway molecules
was performed using Spearman rho test.
Results
Altered protein glycosylation, translated by the expression of the STn antigen and its precursor
Tn, PI3K/Akt/mTOR pathway molecules (pAkt, pmTOR, pS6), and PTEN inactivation, are
salient features of bladder tumours. Herein we have devoted to a comprehensive analysis of
these molecular alterations in a series of bladder cancer patients at different stages of the dis-
ease, envisaging biomarkers of poor cancer-specific survival.
Our dataset was composed by 47 NMIBC and 49 MIBC patients, as showed in Table 1.
According to Fig 2, NMIBC presented a higher cancer-specific survival (CSS; mean CSS: 119
months) than MIBC patients (mean CSS: 43 months; log rank, p<0.001). These results
Table 2. Antibodies used in the immunohistochemical analysis.
Antibody Vendor Clone Dilution
Tn Non-commercial Hybridoma* IE3 1:5
STn Non-commercial Hybridoma* TKH2 1:20
Ki-67 Dako MIB-1 1:100
p53 Dako DO-7 1:100
Phos-AKT Cell Signaling Ser473 (736E11) 1:50
Phos-mTOR Cell Signaling Ser2448(49F9) 1:100
Phos-S6 Cell Signaling Ser240/244 polyclonal 1:75
PTEN Cell Signaling D4.3 XP 1:50
*Kindly provided by Prof. Celso Reis (IPATIMUP, UP, Portugal)
doi:10.1371/journal.pone.0141253.t002
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demonstrated that our series reflected the natural course of disease and highlighted the signifi-
cantly lower CSS of MIBC compared to NMIBC cases. Therefore, particular interest was set in
the identification of biomarkers for late stage disease based on the comparison between
NMIBC and MIBC.
Tn and STn antigen expressions in bladder cancer
The Tn antigen was observed in approximately 10% of NMBC and MIBC (Table 2) and its
expression was residual, did not exceeding 5% of the tumour area and without any defined pat-
tern. On the other hand, the STn antigen was detected in approximately 60% of the studied
bladder tumours, which is in accordance with our previous findings [5]. The antigen was pre-
dominately expressed at the cell membrane, although cytoplasmic staining could also be
observed. The STn antigen presented a focal expression that did not exceed 30% of the tumour
area for the majority of the positive cases, irrespectively of their histological origin. STn was
mainly expressed by dedifferentiated cells in tumours showing lamina propria (T1; 60%) and
muscularis propria ( T2; approximately 60–90%) invasion; conversely the percentage of posi-
tive Ta was lower than 30% (p<0.001; Fig 3A). Although without statistical significance, in Ta
tumours STn positive cells were mainly present in superficial tumour layers away from the ves-
sels. Conversely, STn positive cells in T1 tumours (Fig 3B) were observed accompanying and/
Fig 2. Association between disease groups and cancer-specific survival (CSS) in the studied patients.
Kaplan-Meier analysis showing the CSS of NMIBC (Ta and T1) and s of MIBC (T2,T3 and T4). Comparison
performed by log-rank test (p<0.001); + censored NMIBC patients; ^ censored MIBC patients.
doi:10.1371/journal.pone.0141253.g002
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or invading the basal layer (Fig 3B), while in MIBC these cells were mostly found in the inva-
sion fronts (Fig 3B) and invading and/or inside the vessels, which suggests a role in invasion
and disease dissemination. Reinforcing these observations, the presence of STn antigen was sta-
tistically higher in MIBC when compared to NMIBC (p = 0.001, Table 3).
PI3K/Akt/mTOR pathway in bladder cancer
The evaluation of the PI3K/Akt/mTOR/S6 pathway was done using antibodies for active phos-
phorylated forms of Akt (pAkt), mTOR (pmTOR), and S6 (pS6). PTEN, that negatively regu-
lates Akt signalling, was also evaluated.
pAkt was detected both in the cytoplasm and nucleus. In NMIBC cases several areas with
different intensity of expression were observed (Fig 4A), denoting a heterogeneous pattern that
was not evident in MIBC (Fig 4B). Furthermore, stromal cells of MIBC positive cases showed
enhanced staining intensity mainly in the areas close to the tumour. pmTOR immunoreactivity
Fig 3. STn expression in different bladder tumors stages. (A) Distribution of STn negative and positive tumors along the different stages of bladder
cancer; (B) Representative images of STn staining in NMIBC and MIBC. Left—NMIBC showing a predominance of STn positive cells in the superficial layers,
away from the fibrovascular support; note vessels without positive cells. Right—MIBC showing the invasion front with STn positively stained cells; note
positive STn urothelial cells in the vessels (arrow), suggesting possible involvement in metastasis.
doi:10.1371/journal.pone.0141253.g003
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was cytoplasmic and, in occasional cases, nuclear. In urothelium with apparent normal histol-
ogy pmTOR expression was restricted to superficial cell layers. In NMIBC pmTOR expression
was evenly distributed across the several layers of urothelial cells, although there was a more
intense staining in the superficial layers (Fig 4C). Moreover, several areas with variable staining
intensity were observed, denoting a heterogeneous expression. In MIBC positives cases,
pmTOR expression was focal and heterogeneous (Fig 4D). pS6 immunoreactivity was predom-
inantly cytoplasmic. In NMIBC pS6 expression was noted in all the superficial layers, both in
umbrella and differentiated cells (Fig 4E). The immunoreactivity of pS6 varied across the
tumour cells. In MIBC pS6 presented a diffuse expression throughout the tumour, being more
present in basal and mitotic cells (Fig 4F). Several positive cases presented increased pS6 stain-
ing intensity in the invasion front as well as pS6 expression in tumour infiltrating lymphocytes
and endothelial cells.
Taking into account the extension of staining and its intensity, 62/94 (66%), 33/96 (34%)
and 45/95 (47%) of the bladder tumours were considered positive for pAkt, pmTOR and pS6,
respectively. A Spearman rho test showed that pAkt, pmTOR, pS6 expressions were signifi-
cantly correlated (P<0.05) irrespectively of the tumour stage, thus in accordance with a fully
active pathway. Furthermore, despite histological differences, these markers presented an equal
distribution among the NMIBC and MIBC and could not be associated with muscle invasion
(Table 3).
On the other hand, 37/92 (40%) of the tumours were considered positive for PTEN. PTEN
was expressed in the cytoplasm and nucleus of the same cells, however with lower extension of
expression in MIBC (33%, Fig 4G) compared to NMIBC (83%; Fig 4H). Moreover, the PTEN-
negative phenotype was significantly associated with muscle invasion (Ta and T1; p<0.001,
Table 3), which may contribute to maintain an active PI3K/Akt/mTOR/S6 pathway in these
cases.
Table 3. Association between the evaluatedmarkers and the stage of disease.
Bladder Cancer
NMIBC MIBC P
n (%) n (%)
Tn
Negative 41 (87.2) 45 (91.8)
Positive 6 (12.8) 4 (8.2) 0.461
STn
Negative 27 (57.4) 12 (24.5)
Positive 20 (42.6) 37 (75.5) 0.001
pAKT
Negative 13 (28.9) 19 (38.8)
Positive 32 (71.1) 30 (61.2) 0.312
pmTor
Negative 30 (63.8) 33 (67.3)
Positive 17 (36.2) 16 (32.7) 0.717
pS6
Negative 22 (47.8) 28 (57.1)
Positive 24 (52.2) 21 (42.9) 0.183
PTEN
Negative 18 (38.3) 37 (82.2)
Positive 29 (61.7) 8 (17.8) <0.001
doi:10.1371/journal.pone.0141253.t003
Glycosylation and PI3K/Akt/mTOR Pathway in Bladder Cancer
PLOS ONE | DOI:10.1371/journal.pone.0141253 November 16, 2015 10 / 19
Fig 4. Expressions of pAkt, pmTOR, pS6 and PTEN in NMIBC and MIBC (40xmagnification). A and B)
pAKT nuclear and cytoplasmatic expression in NMIBC (A) and MIBC (B). In NMIBC cases pAkt presented a
heterogeneous pattern with areas of different intensity of expression. In MIBC, stromal cells mainly in the
areas close to the tumour showed higher expression. C and D) pmTOR cytoplasmic expression in NMIBC (C)
and MIBC (D). In NMIBC pmTORwas expressed across several layers, although there was a more intense
staining in the superficial ones. In MIBC positive cases pmTOR expression was focal. E and F) pS6
cytoplasmatic expression in NMIBC (E) and MIBC (F). In NMIBC pS6 expression was observed in all the
superficial layers both in umbrella and differentiated cells. In MIBC the immunoreactivity was diffuse, however
more present in basal and mitotic cells. pS6 expression was higher in the invasion front and in tumour
infiltrating lymphocytes and endothelial cells. G and H) PTEN cytoplasmic and nuclear expressions in NMIBC
(G) and MIBC (H). PTEN expression was higher in NMIBC compared to MIBC.
doi:10.1371/journal.pone.0141253.g004
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Tn, STn, PI3K/Akt/mTOR pathway and Cancer-specific Survival
A Kaplan-Meier analysis was used to evaluate associations between the addressed biomarkers
and the cancer-specific survival of patients. We observed that patients bearing STn expressing
tumours had a lower CSS, irrespectively of their stage (p = 0.024; Fig 5A). This was also
observed when evaluating NMIBC alone (p = 0.020; Fig 5B). More importantly, among
NMIBC, STn expressing T1 tumours presented lower CSS than negative tumours (p<0.05).
Moreover, multivariate Cox regression analysis adjusted to potential confounders, namely age,
gender, stage, grade, recurrence status, presence of concomitant CIS was performed. We found
that STn is an independent prognostic marker of worst CSS (HR = 11.836; 95%CI: [1.063–
131.7]; p = 0.044). Contrasting with STn, positive Tn, pAkt, pmTOR and pS6 tumours showed
no differences in CSS compared to negative lesions, irrespectively of their stage. We have also
observed that patients harbouring PTEN-negative tumours had lower CSS (p = 0.015, Fig 6).
More studies are necessary to determine if the lack of suppressive effect of PTEN over PI3K/
Akt/mTOR may account for these findings.
Based on these observations and aiming to improve the prognostic value of STn in the con-
text of late stage disease (MIBC), we have comprehensively integrated the information from
STn and PI3K/Akt/mTOR pathway biomarkers. According to Fig 7, the introduction of PI3K/
Akt/mTOR pathway molecules allowed discriminating STn positive MIBC tumours with worst
CSS (p = 0.027). Furthermore, multivariate Cox regression analysis (adjusted to age, stage,
recurrence status, presence of concomitant CIS and metastasis) revealed that the presence of
PI3K/Akt/mTOR pathway molecules in STn+ MIBC is independently associated with approxi-
mately 6-fold risk of death by cancer (HR = 5.662; 95%CI: [1.093–29.323]; p = 0.039). These
observations suggest, for the first time, that the combination of STn and mTOR pathway bio-
markers may hold potential to improve the stratification of advanced stage bladder tumours;
however corroboration in larger series is mandatory.
Inhibition of the PI3K/Akt/mTOR pathway in animal models
BBN-induced mice bladder tumours mimicking the histology and molecular nature of human
cancers [20,21], were screened for STn and pS6, the downstream effector of mTOR pathway.
We observed no STn expression in the healthy mice urothelium, in accordance with previous
observation for the healthy human bladder [5]. In mice healthy urothelium pS6 expression was
below 20%, thus underexpressed when compared with BBN-exposed mice (Fig 8). In the con-
trol groups (Group 1 and 3, Fig 8A), the exposure to BBN led to the development of invasive
tumours in 70–90% of the studied mice. Concomitantly, 83–100% of the invasive lesions over-
expressed the STn antigen and all significantly overexpressed pS6 (Fig 8B). This demonstrated
that BBN-induced lesions were able to recapitulate the association between altered glycosyla-
tion and an activated PI3K/Akt/mTOR pathway previously observed in advanced stage human
tumours. The STn antigen was mainly found in cells adjacent to the basal layer and in those
invading the stroma, as previously observed in human tumours (Fig 8B and 8C). Conversely,
pS6 presented a more diffuse expression, again in accordance with the pattern observed in
human lesions (Fig 8B and 8C). A comparison between groups 1 and 3 further highlighted that
extended lifespan did not alter the number of invasive lesions, but significantly increased STn
and pS6 overall expressions in each tumour (p<0.05; Fig 8B), highlighting the more aggressive
nature of Group 3 lesions.
In the sirolimus-treated groups (Groups 2 and 4; Fig 8A) a smaller number of mice devel-
oped invasive tumors (20–40%) when compared to the controls (Groups 1 and 3). Moreover,
only 43% of the mice treated with sirolimus overexpressed the STn antigen, irrespectively of
the experience periods. Still, the extension of STn expression was significantly decreased in
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STn-positive tumours when compared to the control groups (Fig 8B and 8C). Following the
same tendency, the pS6 protein was only overexpressed in 29% of the cases in Group 2 and the
extension of expression was also significantly decreased (Fig 8B and 8C). Contrastingly, the
expression of pS6 in Group 4 was higher than in Group 2, again translating the higher aggres-
sive nature of tumours obtained after longer lifespan. Despite these observations, sirolimus
treatment promoted a significant reduction in the percentage of positive pS6 cells in Group 4
mice when compared to Group 3 (p<0.05; Fig 8B and 8C). Altogether, sirolimus administra-
tion effectively reduced tumour burden and promoted a significant reduction in the expression
of STn and pS6 markers.
Discussion
Due to their high molecular heterogeneity, advanced stage bladder tumours present a signifi-
cant prognostication and treatment hurdle. In this context, much controversy exists regarding
the potential of conventional cancer biomarkers, urging the identification of novel molecules
capable of aiding disease personalization. Furthermore, advanced stage bladder cancer remains
an orphan disease in terms of therapeutics, as the only available options continue to be surgery
and conventional chemotherapy [22]. The introduction of targeted therapeutics is therefore
warranted.
In a previous explorative study we have observed that altered protein glycosylation trans-
lated by STn overexpression was a salient feature of a subset of advanced stage tumours [5].
Herein we have started by investigating the expression of STn precursor, the Tn antigen, in
bladder tumours. We observed that this antigen presented a very low expression in bladder
Fig 5. Effect of STn expression in cancer-specific survival (CSS). Kaplan–Meier analysis showing the association between STn and CSS in: (A) all
studied bladder cancer patients; (B) NMIBC patients. Comparison performed by log-rank test (A: p = 0.024; B: p = 0.020); + censored STn negative tumours;
^ censored STn positive tumours.
doi:10.1371/journal.pone.0141253.g005
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tumours and was not associated with any particular stage of the disease. These findings suggest
that the Tn antigen is rapidly sialylated or capped with more extended glycans in bladder
tumours. Moreover, we have confirmed that STn expression is more associated with muscle
invasive than non-muscle invasive disease in a larger patient set, suggesting that sialylation
plays a key role in stopping protein glycosylation in advanced stage bladder tumours. Further-
more, we have provided new insights regarding its correlation with decreased survival, as previ-
ously observed for digestive track tumours [23–25]. Accordingly, we and other authors have
shown that STn expression is responsible by the modulation of cell surface glycoprotein func-
tions in ways that favour malignant phenotypes in gastric [26], breast [27] and bladder [5] can-
cers. Namely, STn expression altered the adhesive properties of cancer cells, possibly by
impairing integrin function [26,27]. Furthermore, it enhanced cell motility, invasion [26,27]
and epithelial-to-mesenchymal transition, a key event leading to metastasis [28]. We have also
demonstrated that STn expression protects bladder cancer cells from adverse host immune
responses [6]. Namely, it impaired dendritic cell maturation inducing a tolerogenic phenotype
and limiting their capacity to trigger protective anti-tumour T-cell responses [6]. In resume, a
significant amount of data supports a key role of STn in disease progression and dissemination,
making of STn antigen, and in particular STn-glycoproteins, potential anti-cancer targets. Nev-
ertheless, there is scarce information about the molecular nature of this subset of STn-express-
ing aggressive tumours and consequently about the best therapeutic options.
Fig 6. Effect of PTEN expression and cancer-specific survival (CSS) in the studied patients. Kaplan-
Meier analysis showing the effect in CSS of PTEN expression in all studied bladder cancer patients.
Comparison performed by log-rank test (p = 0.013); + censored PTEN negative tumours; ^ censored PTEN
positive tumours.
doi:10.1371/journal.pone.0141253.g006
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Foreseeing a more accurate patient stratification we have also addressed the expression of
PI3K/Akt/mTOR pathway markers in bladder tumours. In our series the activation of mTOR
pathway proteins did not discriminate the stage of disease. Moreover it did not allow, by itself,
the identification of patients facing worst prognosis, which is in accordance with recent publica-
tions [29,30]. However, we found that PTEN expression, which exerts a suppressive effect over
the PI3K/Akt/mTOR pathway, was decreased in advanced stage tumours, in accordance with
previous observations [31–34]. Furthermore, PTEN-negative MIBC presented worst cancer-spe-
cific survival in comparison to PTEN-positive lesions. More studies are needed to determine if
the lack of suppressive effect over the PI3K/Akt/mTORmay account for poorer outcome. Inter-
estingly, we have also observed that the overexpression of PI3K/Akt/mTOR pathway biomarkers
decisively associated with worst CSS in STn positive advanced stage tumours, which currently
lack effective therapeutics. These findings lead us to hypothesize that this subset of more aggres-
sive bladder tumours may benefit frommulti-targeted approaches combining mTOR-inhibitors
and guided therapeutics against STn-expressing cells. However these are preliminary insights
from a relatively low number of patients. More studies involving a large population are war-
ranted to confirm these observations. It will also be important to evaluate other outcomes of
aggressiveness, namely response to conventional therapeutics and metastasis development.
Our study also reinforced that bladder tumours present extensive activation of the PI3K/Akt/
mTOR pathway irrespectively of their histological nature, as described in previous publications
[32,35]. Such findings contribute to support the idea that most bladder tumours may be good
candidates for mTOR-inhibitors therapeutics. Accordingly, mTOR-inhibitors have been
Fig 7. Effect of PI3K/Akt/mTOR pathway activation in cancer-specific survival (CSS) of patients with
STn positive MIBC. Kaplan–Meier analysis showing the association between pAKT, pmTOR and pS6
expressions in the CSS of STn positive tumors MIBC: Comparison performed by log-rank test (p = 0.027);
+ censored pAKT and pmTOR and pS6 negative tumours; ^ censored pAKT and/or pmTOR and/or pS6
positive tumours.
doi:10.1371/journal.pone.0141253.g007
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extensively explored in pre-clinical settings and two phase I/II clinical trials for bladder cancer
are ongoing [36]. In particular our group has demonstrated that the combination of everolimus
with cisplatin or gemcitabine decreased the proliferation of bladder cancer cell lines in compari-
son to the chemotherapy agent alone [14,37]. More recently we conducted studies in mice bear-
ing chemically-induced tumours mimicking the histological and molecular nature of human
tumours [20]. We concluded that administration of mTOR-pathway inhibitor sirolimus (rapa-
mycin) effectively reduced the frequency of invasive lesions. Using the same animal model, we
have now confirmed the anti-cancer activity of sirolimus in the context of aggressive bladder
disease. Namely, we observed a significant reduction in tumour burden accompanied by a loss
of pS6 expression, thus in accordance with the expected mechanism of action of the drug. More-
over, we are describing for the first time that chemically-induced bladder tumours expressed the
Fig 8. STn and pS6 expressions in bladder tumours from BBN-exposedmale ICRmice with or without the administration of mTOR-inhibitor
sirolimus (rapamycin). A) Experimental design to determine the sirolimus effect on STn and pS6 expressions in a model of urothelial carcinogenesis (male
ICRmice). B) Expression of STn and pS6 in BBN-derived urothelial tumours in the presence and absence of sirolimus. BBN-induced bladder tumours
(Groups 1 and 3) overexpressed STn and pS6, which was more pronounced in Group 3, after longer lifespan. Exposure to sirolimus decreased the number of
invasive lesions in groups 2 and 4 (data not shown) and, concomitantly, decreased the expressions of STn and pS6. C) Histological sections showing the
expressions of STn and pS6 in BBN-induced urothelial tumours before and after treatment.
doi:10.1371/journal.pone.0141253.g008
Glycosylation and PI3K/Akt/mTOR Pathway in Bladder Cancer
PLOS ONE | DOI:10.1371/journal.pone.0141253 November 16, 2015 16 / 19
STn antigen, thereby mimicking the glycosylation pattern of human cancers. These observations
are of particular importance due the lack of accurate models to access the biological role of this
antigen. In fact most established cancer cell lines express residual amounts of this antigen,
denoting a dependence on the tumours microenvironment. We believe that BBN-induced
tumours may now constitute key models to develop successful therapeutics against STn positive
bladder lesions. Moreover importantly, we have concluded that the administration of sirolimus
contributed to reduce the number of STn positive cells. These observations reinforce a possible
association between STn and an active PI3K/Akt/mTOR pathway in invasive tumours, as sug-
gested upon the evaluation of human cancers. It also points out that sirolimus may constitute a
valuable approach to manage STn and PI3K/Akt/mTOR-positive, which face worst OS. Still,
these preliminary evidences and more in depth studies are needed before progressing to clinical
phases. Namely, it will be important to support these findings in other models such as patient-
derived xenografts and compare the effect of sirolimus with conventional chemotherapeutics
for bladder cancer (cisplatin/gemcitabine-based regimens).
In resume, we have demonstrated that the STn antigen is a biomarker of poor prognosis,
particularly in MIBC. We also suggest the existence of potentially more aggressive subgroup of
STn positive MIBC characterized by an active mTOR-pathway. Such observations also provide
the first link between these two apparently unrelated events in bladder cancer (altered glycosyl-
ation and the PI3K/Akt/mTOR-pathway activation). Using animal models we have also con-
cluded that the administration of mTOR-pathway inhibitor sirolimus offers potential against
these highly malignant tumours. More validation studies are now warranted to set the pace for
clinical trials. Taking into consideration its cell-surface nature and key role played by STn
malignancy, specific antibody-based therapeutics can also be envisaged [22,38]. The combina-
tion of these approaches may provide novel ways to improve MIBC management, which
remains an orphan disease in terms of innovative treatments [22].
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